<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>a33887a1exv2w1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 2.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Execution Version</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;2.1
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV style="width: 100%; border-bottom: 3px double #000000; font-size: 1px">&nbsp;</DIV>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AGREEMENT AND PLAN OF MERGER</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>dated as of September&nbsp;18, 2007</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>by and among</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ALLERGAN, INC.,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ESMERALDE ACQUISITION, INC.,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ESPRIT PHARMA HOLDING COMPANY, INC.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>and</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ESCROW PARTICIPANTS&#146; REPRESENTATIVE</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV style="width: 100%; border-bottom: 3px double #000000; font-size: 1px">&nbsp;</DIV>

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE I DEFINITIONS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 1.01 Definitions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 1.02 Interpretation and Rules of Construction</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE II THE MERGER</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 2.01 The Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 2.02 Conversion of Capital Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 2.03 Treatment of Company Options in the Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 2.04 Treatment of Warrant in the Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 2.05 Net Working Capital Adjustment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 2.06 Certificate of Incorporation and Bylaws of the Surviving Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 2.07 Directors and Officers of the Surviving Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE III CLOSING; PAYMENT OF CONSIDERATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 3.01 Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 3.02 Establishment of Indemnification Escrow Fund and Net Working Capital Escrow
Fund</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 3.03 Deposit of Expense Amount</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 3.04 Surrender of Certificates</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 3.05 Transfer Books; No Further Ownership Rights in the Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 3.06 Termination of Fund; No Liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 3.07 Withholding Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 3.08 Lost, Stolen or Destroyed Certificates</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 3.09 Dissenting Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 3.10 Restricted Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 3.11 Further Action</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 3.12 Closing Deliveries by the Company and Escrow Participants&#146; Representative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 3.13 Closing Deliveries by Purchaser and Merger Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.01 Identity; Organization and Qualification</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.02 Organizational Documents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.03 Capitalization of the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.04 Subsidiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.05 Transaction Schedule</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.06 Authority Relative to Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.07 No Conflict; Required Filings and Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.08 Permits; Regulatory Compliance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.09 Financial Information; Books and Records</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.10 Bank Accounts; Receivables; Payables; Customers and Suppliers; Inventory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.11 Absence of Certain Changes or Events</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.12 Absence of Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.13 Employee Benefit Plans</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.14 Labor and Employment Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.15 Real Property; Title to Assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.16 Intellectual Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.17 Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.18 Environmental Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.19 Material Contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.20 Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">59</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.21 Certain Business Practices</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">60</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.22 Interested-Party Transactions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">60</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.23 Products Liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.24 Brokers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.25 Information Statement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 4.26 Disclosure</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE V REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 5.01 Corporate Organization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 5.02 Authority Relative to This Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 5.03 No Conflict; Required Filings and Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 5.04 Brokers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 5.05 Financing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VI ADDITAGREEMENTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.01 Indemnification of Officers and Directors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.02 Conduct of Business by the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.03 Written Consents; Information Statement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">67</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.04 Access to Information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.05 Confidentiality</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.06 Regulatory and Other Authorizations; Notices and Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.07 Notice of Developments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.08 No Solicitation or Negotiation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.09 Use of Intellectual Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.10 Company Divestiture</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.11 Transaction Expenses; Change of Control Payments; Closing Cash Balance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.12 Termination of the Stock Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.13 Termination of 401(k) Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.14 Employee Benefits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.15 Amendment of Severance Policy</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.16 General Release</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.17 Resignation of Officers and Directors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.18 Delivery of Financial Statements; Cooperation in Preparing Pro Forma Financial
Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.19 280G Payments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 6.20 Further Action</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VII TAX MATTERS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 7.01 Tax Periods Ending on or before the Closing Date</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 7.02 Tax Periods Beginning Before and Ending After the Closing Date</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 7.03 Tax Cooperation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 7.04 Contest Provisions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 7.05 Certain Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 7.06 Carrybacks</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">76</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VIII CONDITIONS TO CLOSING</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">76</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 8.01 Conditions to Obligations of the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">76</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 8.02 Conditions to Obligations of Parent and Merger Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">77</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IX INDEMNIFICATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">79</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 9.01 Survival of Representations and Warranties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">79</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 9.02 Indemnification of Parent Indemnified Parties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">79</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 9.03 Damages of Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">81</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 9.04 Limits on Indemnification</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">82</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 9.05 Notification of Certain Claims; Third Party Claims</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 9.06 Treatment of Adjustments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">85</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 9.07 No Right of Contribution from Parent, Merger Sub or the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">85</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 9.08 Investigation; No Company Recourse</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">85</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 9.09 Exclusivity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">85</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE X REPRESENTATIVE</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">86</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 10.01 Appointment of the Escrow Participants&#146; Representative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">86</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 10.02 Powers of the Escrow Participants&#146; Representative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">86</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 10.03 Escrow Participants&#146; Representative Discretion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">88</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 10.04 Notices to Escrow Participants&#146; Representative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">88</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 10.05 Payment of Costs and Liability of Escrow Participants&#146; Representative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">88</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 10.06 Reliance on Escrow Participants&#146; Representative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">89</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE XI TERMINATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">89</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 11.01 Termination Events</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">89</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 11.02 Effect of Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">91</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE XII GENERAL PROVISIONS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">91</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.01 Expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">91</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->iii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.02 Notices</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">91</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.03 Release</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">93</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.04 Public Announcements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">93</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.05 Severability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">94</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.06 Entire Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">94</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.07 Successors and Assigns</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">94</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.08 Amendment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">94</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.09 Waiver</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">95</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.10 No Third Party Beneficiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">95</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.11 Specific Performance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">95</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.12 Governing Law</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">95</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.13 Arbitration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">96</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.14 Cumulative Remedies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">96</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.15 Representation by Counsel</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">97</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">SECTION 12.16 Execution and Counterparts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">97</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>Schedules</B></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Schedule&nbsp;A &#150; Excluded Employees From Change of Control Payments

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Schedule&nbsp;B &#151; Escrow Participants

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Schedule&nbsp;C &#150; Transaction Awards

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Schedule&nbsp;D-1 &#150; Legal Opinion of Milbank, Tweed, Hadley &#038; McCloy LLP

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Schedule&nbsp;D-2 &#150; Legal Opinion of Steven Bosacki

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Schedule&nbsp;E &#150; Severance Policy

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Schedule&nbsp;F &#150; Consents

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>Exhibits</B></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;A &#150; Stockholders&#146; Written Consent

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;B &#150; Charter Amendment

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;C &#150; Indevus Agreement

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;D &#150; Escrow Agreement

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;E &#150; General Release

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;F &#150; Certificate of Incorporation of Surviving Corporation

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;G &#150; Letter of Transmittal for Company Stockholders

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;H &#150; Letter of Transmittal for Holder of Warrant

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->iv<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This AGREEMENT AND PLAN OF MERGER dated as of September&nbsp;18, 2007 is made and entered into by
and among Allergan, Inc, a Delaware corporation (&#147;<U>Parent</U>&#148;), Esmeralde Acquisition, Inc., a
Delaware corporation (&#147;<U>Merger Sub</U>&#148;), Esprit Pharma Holding Company, Inc., a Delaware
corporation (the &#147;<U>Company</U>&#148;), and Andrew J. Einhorn, solely in his capacity as the Escrow
Participants&#146; Representative. Capitalized terms not otherwise defined herein have the meanings set
forth in <U>Article&nbsp;I</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Board of Directors of the Company has unanimously (a)&nbsp;determined that the merger
of Merger Sub with and into the Company upon the terms and subject to the conditions set forth
herein (the &#147;<U>Merger</U>&#148;) is in the best interests of the Company and the Company Stockholders,
(b)&nbsp;approved, in accordance with Section&nbsp;251 of the DGCL, this Agreement and each of the
transactions contemplated hereby, including the Merger and (c)&nbsp;recommended that the Company
Stockholders approve this Agreement and each of the transactions contemplated hereby, including the
Merger; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Boards of Directors of Parent and Merger Sub have each determined that it is
advisable and in the best interests of Parent and Merger Sub for Merger Sub to consummate the
Merger;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Company has agreed to deliver to Parent and Merger Sub, within one Business Day
after the execution and delivery of this Agreement, a written consent duly executed by (a)&nbsp;the
holders of at least 60% of the outstanding shares of Series&nbsp;A Convertible Preferred Stock, par
value $0.0001 per share, of the Company (&#147;<U>Series&nbsp;A Stock</U>&#148;) and the outstanding shares of
Series&nbsp;B Convertible Preferred Stock, par value $0.0001 per share, of the Company (&#147;<U>Series&nbsp;B
Stock</U>&#148; and together with the Series&nbsp;A Stock, the &#147;<U>Preferred Stock</U>&#148;),voting together as
a single class, (b)&nbsp;the holders of at least a majority of the outstanding shares of the common
stock, par value $0.0001 per share, of the Company (the &#147;<U>Common Stock</U>&#148;), and (c)&nbsp;the
holders of at least a majority the outstanding shares of Preferred Stock (on an as-converted
basis), voting together as a single class with the outstanding shares of Common Stock (the
approvals specified in the foregoing clauses (a), (b)&nbsp;and (c)&nbsp;being referred to collectively as the
&#147;<U>Requisite Stockholder Approval</U>&#148;), in the form of <U>Exhibit&nbsp;A</U>, adopting this
Agreement and approving the Merger and approving an amendment (the &#147;<U>Charter Amendment</U>&#148;) in
the form of <U>Exhibit&nbsp;B</U> to the Amended and Restated Certificate of Incorporation of the
Company, as in effect on the date of this Agreement (the &#147;<U>Stockholders&#146; Written Consent</U>&#148;);
<I>provided, however</I>, such Stockholder Written Consent shall be executed by each of the Escrow
Participants; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, prior to or concurrently with the execution of this Agreement, the Company is
entering into the Amended and Restated License, Commercialization and Supply Agreement with Indevus
Pharmaceuticals, Inc., a Delaware corporation (&#147;<U>Indevus</U>&#148;) in the form attached hereto as
<U>Exhibit&nbsp;C</U> (the &#147;<U>Indevus Agreement</U>&#148;) that will become automatically effective upon
the Closing.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the mutual covenants and promises contained
in this Agreement and for other good and valuable consideration, the receipt and adequacy of
which are hereby acknowledged, and intending to be legally bound hereby, the Company, Parent and
Merger Sub hereby agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE I</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>DEFINITIONS</B></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 1.01</U> <U>Definitions</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;For purposes of this Agreement:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Acquired Companies</U>&#148; means (a)&nbsp;the Company and (b)&nbsp;each Subsidiary of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Acquired Company IP</U>&#148; means the combination of all the Acquired Company Owned IP and
all of the Acquired Company Licensed IP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Acquired Company Licensed IP</U>&#148; means all Intellectual Property licensed to each of the
Acquired Companies (other than off-the-shelf shrink-wrap software that is so licensed solely in
executable or object code form pursuant to a nonexclusive, internal use software license).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Acquired Company Owned IP</U>&#148; means all Intellectual Property that is related to the
business of the Acquired Companies and in which an Acquired Company has (or purports to have) an
ownership right or interest, but not including Acquired Company Licensed IP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Action</U>&#148; means any claim, action, suit, arbitration, proceeding or investigation by or
before any Governmental Authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Adverse Drug Reaction Report</U>&#148; means an adverse drug experience reported to the FDA or
other corresponding Governmental Authority associated with the use of a drug, whether or not
considered drug related, including the following: an adverse event occurring in the course of the
use of a drug product in professional practice; an adverse event occurring from drug overdose
whether accidental or intentional; an adverse event occurring from drug abuse; an adverse event
occurring from drug withdrawal; and any failure of expected pharmacological action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Affiliate</U>&#148; of a specified Person means a Person who, directly or indirectly through
one or more intermediaries, controls, is controlled by, or is under common control with, such
specified Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Affiliated Group</U>&#148; means any consolidated, affiliated, combined or unitary group of
corporations for Tax purposes with respect to which an Acquired Company is or has been a member on
or prior to the Closing.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Aggregate Proceeds Contribution Fraction</U>&#148; means, with respect to each share of
Company Stock held by an Escrow Participant (not including shares of Common Stock issuable upon the
exercise of In-the-Money Options or the Warrant), the fraction:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;having a numerator equal to, as the case may be, the amount specified in <U>Section
2.02(c)(i)</U> in respect of such share of Preferred Stock or <U>Section&nbsp;2.02(d)(i)</U> in respect
of such share of Common Stock; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;having a denominator equal to the aggregate total of all amounts specified in <U>Section
2.02(c)(i)</U> in respect of Preferred Stock held by the Escrow Participants and <U>Section
2.02(d)(i)</U> in respect of Common Stock held by the Escrow Participants.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of calculating the foregoing fraction in this definition of &#147;Aggregate Proceeds
Contribution Fraction&#148;, in no event shall Dissenting Shares or shares to be cancelled at the
Effective Time in accordance with <U>Section&nbsp;2.02(b)</U> be included in such calculation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Ancillary Documents</U>&#148; means the Escrow Agreement, Indevus Agreement, General Release,
Charter Amendment, the Letter of Transmittal for Company Stockholders and the Letter of Transmittal
for the holder of the Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Applicable Merger Consideration</U>&#148; means, with respect to a share of Common Stock, the
Closing Date Common Per Share Consideration and with respect to a share of Preferred Stock, the
Closing Date Preferred Per Share Consideration applicable to such share of Preferred Stock, in each
case plus the amount determined by <I>dividing </I>(a)&nbsp;the Post-Closing Cash Consideration, if any, <I>by </I>(b)
the Fully Diluted Common Share Number.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Benefit Plan</U>&#148; means any plan, policy, program, practice, agreement, understanding or
arrangement (whether written or oral) maintained, sponsored or contributed to by any of the
Acquired Companies, or under which any of the Acquired Companies has any Liability, whether actual
or contingent, for providing any current or former director, officer, employee or consultant (or to
any dependent or beneficiary thereof) with (i)&nbsp;pension, profit sharing, stock bonus, deferred
compensation or retirement benefits, (ii)&nbsp;medical, dental, cafeteria or other health and welfare
benefits, (iii)&nbsp;life or death benefits, insurance benefits, workers&#146; compensation, disability or
accident benefits, supplemental unemployment benefits, vacation or holiday benefits or (iv),
incentive or bonus compensation, stock, stock option, stock appreciation, phantom stock, restricted
stock or other stock-based compensation or benefits.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Business Day</U>&#148; means any day (other than a Saturday or Sunday) on which banks are not
required or authorized to close in the City of Los Angeles, California or in the City of New York,
New York.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Change in Control Payments</U>&#148; means (a)&nbsp;any amounts that become payable to any current
or former director, officer, employee or consultant of the Acquired Companies (except for the
payments identified on <U>Schedule&nbsp;A</U> to be made to those employees of the Acquired Companies
identified on <U>Schedule&nbsp;A</U>), in whole or in part, as a result of the execution and delivery
of this Agreement or the consummation of the Merger, whether pursuant to a severance policy of any
Acquired Company or an individual employment, severance or change-in-control Contract or otherwise
(but in no event the payments in respect of shares of Common Stock subject to In-the-Money Options)
and (b)&nbsp;any Indebtedness owed to an Acquired Company that is forgiven at or prior to the Effective
Time as a result of the Merger.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Closing Cash Balance</U>&#148; means the Company&#146;s good faith estimate of the sum of all cash
and cash equivalents of the Acquired Companies as of the Closing and reflected in the Transaction
Schedule, as updated by the Company not less than two (2)&nbsp;Business Days prior to the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Closing Change in Control Payments</U>&#148; means the Company&#146;s good faith estimate of Change
in Control Payments reflected in the updated Transaction Schedule to be delivered to Parent and
Merger Sub not less than two Business Days prior to the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Closing Company Debt</U>&#148; means the Company&#146;s good faith estimate of Company Debt
reflected in the updated Transaction Schedule to be delivered to Parent and Merger Sub not less
than two (2)&nbsp;Business Days prior to the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Closing Date</U>&#148; means the second (2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP>) Business Day following the later of
(A)&nbsp;the day on which the waiting period under the HSR Act with respect to the Transactions has been
terminated or expired and (B)&nbsp;the day on which the other conditions set forth in <U>Article
VIII</U> have been satisfied (excluding conditions that, by their terms, are to be satisfied at the
Closing, but subject to the satisfaction or waiver of such conditions), or such other date as
Parent and the Company agree upon in writing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Closing Date Common Per Share Consideration</U>&#148; means the quotient obtained by <I>dividing</I>
(a)&nbsp;an amount equal to (i)&nbsp;the Closing Date Total Cash Consideration <I>minus </I>(ii)&nbsp;the aggregate of
all Preferred Per Share Preference Amounts payable upon the Merger to holders of Preferred Stock
outstanding immediately prior to the Effective Time <I>by </I>(b)&nbsp;the Fully Diluted Common Share Number.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Closing Date Preferred Per Share Consideration</U>&#148; means, with respect to each share of
Preferred Stock, an amount equal to the sum of (a)&nbsp;the Preferred Per Share Preference Amount <I>plus</I>
(b)&nbsp;the lesser of (i)&nbsp;the Closing Date Common Per Share Consideration and (ii)&nbsp;the applicable
Participation Cap.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Closing Date Total Cash Consideration</U>&#148; means an amount (payable in cash in
immediately available United States funds) equal to the sum of (a)&nbsp;Three Hundred Seventy Million
Dollars ($370,000,000) <I>plus </I>(b)&nbsp;the Closing Cash Balance <I>plus </I>(c)&nbsp;the aggregate exercise price of
all In-the-Money Options outstanding as of immediately prior to the Effective Time <I>minus </I>(d)&nbsp;the
outstanding amount of Closing Company Debt <I>minus </I>(e)&nbsp;the amount of the Closing Transaction Expenses
<I>minus </I>(f)&nbsp;the Excess Change of Control Payments (if any) <I>minu</I>s (g)&nbsp;the Estimated Closing Net
Working Capital Shortage (if any).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Closing Transaction Expenses</U>&#148; means the Company&#146;s good faith estimate of Transaction
Expenses reflected in the updated Transaction Schedule to be delivered to Parent and Merger Sub not
less than two (2)&nbsp;Business Days prior to the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Code</U>&#148; means the United States Internal Revenue Code of 1986.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Debt</U>&#148; means any Indebtedness of the Company outstanding as of immediately
prior to the Closing, including amounts outstanding pursuant to the Loan Agreement and the
Subordinated Notes.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Disclosure Schedule</U>&#148; means the Disclosure Schedule, dated as of the date
hereof, delivered by the Company to Parent and Merger Sub in connection with this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Divestiture</U>&#148; means the Company&#146;s sale or other disposition of its assets and
liabilities relating to Prosed to be completed prior to the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Options</U>&#148; means options (including commitments to grant options) to purchase
shares of Common Stock issued pursuant to the Stock Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Securityholders</U>&#148; means the Company Stockholders, holders of In-the-Money
Options and the holder of the Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Stock</U>&#148; means the Common Stock and the Preferred Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Stockholders</U>&#148; means the holders of Company Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Consolidated Financial Statements</U>&#148; means the audited consolidated financial
statements of the Company for the years ended December&nbsp;31, 2005 and 2006, comprising a consolidated
balance sheet, a profit and loss account, a cash flow statement, the notes and the relevant audit
reports, all of which are included in Section&nbsp;4.09(a) of the Company Disclosure Schedule.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147; <U>Contract </U>&#148; means, with respect to any Person, any agreement,
understanding, contract, note, bond, deed, mortgage, lease, sublease, license, sublicense,
instrument, commitment, promise, undertaking or other binding arrangement, whether written or oral:
(a)&nbsp;to which such Person is a party; (b)&nbsp;by which such Person or any of its assets is or may become
bound or under which such Person has, or may become subject to, any obligation; or (c)&nbsp;under which
such Person has or may acquire any right or interest.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>control</U>&#148; (including the terms &#147;controlled by&#148; and &#147;under common control with&#148;) means
the possession, directly or indirectly, or as trustee or executor, of the power to direct or cause
the direction of the management and policies of a Person, whether through the ownership of voting
securities, as trustee or executor, by Contract or arrangement or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Damages</U>&#148; means the amount of any loss, claim, deficiency, lost profits, demand,
damage (including consequential damages but excluding indirect, punitive and special damages),
injury, Liability, demand, settlement, judgment, award, fine, penalty, fee (including attorneys&#146;
fees and consultants&#146; and experts&#146; fees), charge, cost (including costs of investigation), Tax, or
expense of any nature, whether or not involving an Action, including any costs of defending any
Actions or enforcing a Parent Indemnified Party&#146;s rights under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>DGCL</U>&#148; means the General Corporation Law of the State of Delaware.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Entity</U>&#148; means any corporation (including any non-profit corporation), general
partnership, limited partnership, limited liability partnership, joint venture, estate, trust,
company (including any limited liability company or joint stock company), branch office, firm or
other enterprise, association, organization or entity.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Environmental Laws</U>&#148; means any and all applicable U.S. or foreign laws, statutes,
ordinances, regulations, policies, guidance, rules, judgments, orders, court decisions or rule of
common law, Permits, restrictions and licenses, which (a)&nbsp;regulate or relate to the protection or
clean up of the environment; the use, treatment, storage, transportation, handling, disposal or
release of wastes, pollutants, contaminants or similar substances, the preservation or protection
of waterways, groundwater, drinking water, air, wildlife, plants or other natural resources; or the
health and safety of persons or property, including protection of the health and safety of
employees; or (b)&nbsp;impose Liability or responsibility with respect to any of the foregoing,
including the Comprehensive Environmental Response, Compensation and Liability Act (42 U.S.C. &#167;
9601 et seq.), or any other Law of similar effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Equity Participations</U>&#148; means any (a)&nbsp;share, quota, security, participation right and
any other present or future right entitling the holder, absolutely or contingently (through the
exercise of any subscription, conversion, exchange, option or similar right), to participate in the
revenues, dividends or equity appreciation of another Person, including capital stock, membership
interests, units, performance units, options, warrants, company appreciation rights, interests in
&#147;phantom&#148; stock plans, restricted or contingent stock or profits interests, voting securities,
stock appreciation rights or equivalents, stock loan purchase plans, convertible debentures or
stock bonus plans and (b)&nbsp;commitments to issue any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Escrow Agent</U>&#148; means the escrow agent to be reasonably agreed to by the parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Escrow Agreement</U>&#148; means an escrow agreement in the form of <U>Exhibit&nbsp;D</U> attached
hereto, subject to any amendments to such form requested by the Escrow Agent and mutually agreed to
by Parent and the Escrow Participants&#146; Representative.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Escrow Participants</U>&#148; means each of the Company Stockholders set forth on <U>Schedule
B</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Estimated Closing Net Working Capital Shortage</U>&#148; means the amount, if any, by which
the Estimated Closing Net Working Capital is less than the Target Net Working Capital.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Estrasorb</U>&#148; means any topically- or transdermally-administered product containing no
other active ingredient other than 17<FONT style="font-family: Symbol">&#098;</FONT> estradiol which is marketed under NDA No.&nbsp;21-371.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Excess Change in Control Payments</U>&#148; means the amount by which the Change in Control
Payments exceed Seven Million Five Hundred Thousand dollars ($7,500,000).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended, together with
the rules and regulations of the United States Securities and Exchange Commission promulgated
thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Expense Amount</U>&#148; means an amount equal to Five Hundred Thousand Dollars ($500,000).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Expense Fund</U>&#148; means the fund established by deposit of the Expense Amount with the
Escrow Participants&#146; Representative in accordance with the terms of this Agreement, which funds are
to be administered by the Escrow Participants&#146; Representative pursuant to the provisions of this
Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>FDA Act</U>&#148; means the Food Drug and Cosmetic Act, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>FDA</U>&#148; means the United States Food and Drug Administration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Financial Statements</U>&#148; means the Consolidated Financial Statements and the Interim
Financial Statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Fully Diluted Common Share Number</U>&#148; means the sum of (a)&nbsp;the number of shares of
Common Stock outstanding as of immediately prior to the Effective Time <I>plus </I>(b)&nbsp;the number of
shares of Common Stock subject to In-the-Money Options that are outstanding and unexercised as of
immediately prior to the Effective Time <I>plus </I>(c)&nbsp;the number of shares of Common Stock issuable upon
automatic exercise of the Warrant in accordance with its terms at the Effective Time to the extent
the Warrant has not been exercised as of immediately prior to the Effective Time <I>plus </I>(d)&nbsp;the
number of shares of Common Stock into which all shares of Preferred Stock outstanding as of
immediately prior to the Effective Time would be converted were such shares of Preferred Stock
converted into shares of Common Stock pursuant to Article&nbsp;IV.B.3 of the Company&#146;s Certificate of
Incorporation in effect as of the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>GAAP</U>&#148; means generally accepted accounting principles in the United States,
consistently applied throughout the specified period and in the immediately prior comparable
period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>General Release</U>&#148; means a General Release in the form attached hereto as <U>Exhibit
E</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Good Clinical Practice</U>&#148; means the ethical and scientific quality standard for
designing, conducting, recording, and reporting trials that involve the participation of human
subjects, including the regulations at 21 C.F.R. Parts 50, 54 and 56.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Good Laboratory Practice</U>&#148; means the good laboratory practices for conducting
nonclinical laboratory studies that support or are intended to support applications for research or
marketing permits for products regulated by the FDA or other corresponding Governmental Authority,
and which assures the quality and integrity of the safety data filed with the FDA or other
corresponding Governmental Authority, including the regulations at 21 C.F.R. Part&nbsp;58.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Good Manufacturing Practice</U>&#148; means the current good manufacturing practice for
methods to be used in, and the facilities or controls to be used for, the manufacture, processing,
packing, or holding of a drug to assure that such drug meets the requirements of Healthcare Laws as
to safety, and has the identity and strength and meets the quality and purity characteristics that
it purports or is represented to possess, including the regulations at 21 C.F.R. Parts 210 and 211.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Governmental Authority</U>&#148; means any United States or supranational, foreign,
provincial, state, municipal or local government, governmental, regulatory or administrative
authority, agency, body, branch or bureau, instrumentality or commission or any court, tribunal, or
judicial or arbitral body.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Hazardous Substances</U>&#148; means (a)&nbsp;any wastes, pollutants, contaminants or other
substances (including electromagnetic fields, radioactive substances, liquids, solids, gases,
noise, heat and vibration) that are materially harmful to the environment by virtue of their toxic,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">explosive, radioactive, corrosive, noisy, caustic or noxious properties, (b)&nbsp;petroleum and
petroleum products, including crude oil and any fractions thereof; (c)&nbsp;natural gas, synthetic gas,
and any mixtures thereof; (d)&nbsp;polychlorinated biphenyls, asbestos in any form, formaldehyde and
radon; and (e)&nbsp;any other contaminant, substance, material or waste regulated by any Governmental
Authority pursuant to any Environmental Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Healthcare Laws</U>&#148; means the FDA Act, the Controlled Substances Act (21 U.S.C. &#167; 801 et
seq.), Medicare (Title XVIII of the Social Security Act) and Medicaid (Title XIX of the Social
Security Act), the federal Anti-kickback Statute (42 U.S.C. &#167; 1320a-7b(b)), the Stark
Anti-Self-Referral Law (42 U.S.C. &#167;&#167; 1395nn), the Anti-Inducement Law (42 U.S.C. &#167; 1320a-7a(a)(5)),
the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the administrative False Claims Law (42
U.S.C. &#167; 1320a-7b(a)), the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167;
1320d et seq.), the exclusion laws (42 U.S.C. 1320a-7), all regulations or guidance promulgated
pursuant to such Laws, and any other Law which regulates the design, development, testing ,
studying, manufacturing, processing, storing, importing or exporting, licensing, labeling or
packaging, distributing or marketing of pharmaceutical products, or related to kickbacks, patient
or program charges, recordkeeping, claims process, documentation requirements, medical necessity,
referrals, the hiring of employees or acquisition of services or supplies from those who have been
excluded from government health care programs, quality, safety, privacy, security, pharmacy
practice and compounding, licensure, accreditation or any other aspect of providing health care or
pharmacy services.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>HSR Act</U>&#148; means Section&nbsp;7A of the Clayton Act (Title II of the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended) and the rules and regulations promulgated
thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>In-the-Money Option</U>&#148; means a Company Option having a per share exercise price less
than the Closing Date Common Per Share Consideration (it being understood that whether a Company
Option is an In-the-Money Option shall be determined on an iterative basis by initially calculating
the Closing Date Common Per Share Consideration without taking account of outstanding Company
Options, recalculating the Closing Date Common Per Share Consideration taking into account the
outstanding Company Options with a per share exercise price that is less than the initially
calculated Closing Date Common Per Share Consideration and then repeating this process until no
additional Company Options become In-the-Money Options as a result of such calculation).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Indebtedness</U>&#148; means, with respect to an Acquired Company, (a)&nbsp;all indebtedness of
such Acquired Company, whether or not contingent, for borrowed money, (b)&nbsp;all obligations of such
Acquired Company for the deferred purchase price of property or services (other than current trade
liabilities incurred in the Ordinary Course of Business and recorded on the Financial Statements),
(c)&nbsp;all obligations of such Acquired Company evidenced by notes, bonds, debentures or other similar
instruments, (d)&nbsp;all indebtedness created or arising under any conditional sale or other title
retention agreement with respect to property acquired by such Acquired Company (even though the
rights and remedies of the Acquired Company or lender under such agreement in the event of default
are limited to repossession or sale of such property), (e)&nbsp;all obligations of such Acquired Company
as lessee under leases that have been or should be, in accordance with GAAP, recorded as capital
leases, (f)&nbsp;all obligations, contingent or otherwise,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of such Acquired Company under acceptance, letter of credit or similar facilities, (g)&nbsp;all
obligations of such Acquired Company to purchase, redeem, retire, defease or otherwise acquire for
value any capital stock of such Person or any warrants, rights or options to acquire such capital
stock, valued, in the case of redeemable preferred stock, at the greater of its voluntary or
involuntary liquidation preference plus accrued and unpaid dividends (but, in the case of the
Company, excluding amounts included in the Preferred Share Consideration), (h)&nbsp;all Indebtedness of
others referred to in clauses &#147;(a)&#148; through &#147;(g)&#148; above guaranteed directly or indirectly in any
manner by such Acquired Company and (i)&nbsp;all Indebtedness referred to in clauses &#147;(a)&#148; through &#147;(g)&#148;
above secured by any encumbrance on property (including accounts and Contract rights) owned by such
Person, even though such Acquired Company has not assumed or become liable for the payment of such
Indebtedness.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Indemnification Escrow Amount</U>&#148; means an amount equal to Twenty Seven Million Seven
Hundred Fifty Thousand Dollars ($27,750,000).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Indemnification Escrow Fund</U>&#148; means the escrow fund established by deposit of the
Indemnification Escrow Amount with the Escrow Agent in accordance with the terms of this Agreement,
which funds are to be administered by the Escrow Agent pursuant to the provisions of this Agreement
and the Escrow Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Indevus License Agreement</U>&#148; means the License, Commercialization and Supply Agreement
by and between Indevus and Odyssey Pharmaceuticals, Inc., dated April&nbsp;6, 2004, Amendment No.&nbsp;1
thereto, dated April&nbsp;30, 2005, and the Amendment and Consent Agreement by and between Indevus,
Odyssey Pharmaceuticals, Inc. and Saturn Pharmaceuticals, Inc., dated May&nbsp;14, 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Intellectual Property</U>&#148; means all (a)&nbsp;United States and all other foreign patents,
patent applications and invention registrations of any type, (b)&nbsp;trademarks, service marks, domain
names, trade dress, logos, trade names, corporate names and other source identifiers, and
registrations and applications for registration thereof, (c)&nbsp;copyrightable works, copyrights, and
registrations and applications for registration thereof, (d)&nbsp;software, (e)&nbsp;confidential and
proprietary information, including inventions, trade secrets and know-how, (f)&nbsp;data collections,
development tools, diagrams, formulae, methods, network configurations and architectures,
processes, specifications, works of authorship and other forms of technology (whether or not
embodied in any tangible form and including all tangible embodiments of the foregoing, such as
instruction manuals, laboratory notebooks, prototypes, samples, studies and summaries), and (g)&nbsp;all
past, present, and future rights of the following types, which may exist or be created under the
laws of any jurisdiction in the world: (i)&nbsp;rights associated with works of authorship, including
exclusive exploitation rights and moral rights; (ii)&nbsp;trademark and trade name rights and similar
rights; (iii)&nbsp;trade secret rights; (iv)&nbsp;patent and industrial property rights; (v)&nbsp;other
proprietary rights in the items identified in subclause &#147;(a)&#148; through &#147;(f)&#148; above; and (vi)&nbsp;rights
in or relating to registrations, renewals, extensions, combinations, divisions and reissues of, and
applications for, any of the rights referred to in subclauses &#147;(i)&#148; through &#147;(v)&#148; above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Interim Balance Sheet</U>&#148; means the unaudited consolidated balance sheet of the Company
as of June&nbsp;30, 2007, which is included in the Interim Financial Statements.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Interim Financial Statements</U>&#148; means the Interim Balance Sheet and the related
unaudited consolidated statements of operations, stockholders&#146; equity and cash flows for the
portion of the fiscal year then ended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>IRS</U>&#148; means the United States Internal Revenue Service.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Key Stockholder</U>&#148; means collectively, each of the Company Stockholders set forth on
<U>Schedule&nbsp;B</U>, which Company Stockholders are also Escrow Participants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Knowledge</U>&#148; by a Person of a particular fact or other matter means (a)&nbsp;if the Person
is an individual, that such individual is aware of such fact or other matter or such individual
would reasonably be expected to discover or otherwise become aware of such fact or other matter in
the course of conducting a reasonable investigation concerning the existence of such fact or other
matter, and (b)&nbsp;if the Person is an Entity, a member of the board of directors or other governing
body or any officer of such Person is aware of such fact or other matter or such member or officer
would reasonably be expected to discover or otherwise become aware of such fact or other matter in
the course of conducting a reasonable investigation concerning the existence of such fact or other
matter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Law</U>&#148; means national, super national, state, provincial, municipal or local statute,
law, constitution, ordinance, code, regulation, rule, notice, court decision, interpretation,
agency guidance, Order, resolution, corporate integrity agreement, stipulation, determination,
requirement or rule of law (including common law), code or edict issued, enacted, adopted,
promulgated, implemented or otherwise put into effect by or under the authority of any Governmental
Authority, including Healthcare Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Liabilities</U>&#148; means any and all liabilities, obligations and Indebtedness, whether
accrued or fixed, absolute or contingent, matured or unmatured or determined or determinable,
including those arising under any Law, Action or any Order entered by or with any Governmental
Authority, and those arising under any Contract.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Liens</U>&#148; means any lien, pledge, hypothecation, charge, mortgage, security interest,
encumbrance, claim, option, right of first refusal, preemptive right, community property interest,
conditional or installment sale agreement, encumbrance, charges or other claims of third parties of
any kind, or restriction of any nature (including any restriction on the voting of any security,
any restriction on the transfer of any security or other asset, any restriction on the receipt of
any income derived from any asset, any restriction on the use of any asset and any restriction on
the possession, exercise or transfer of any other attribute of ownership of any asset).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Liquidation Amount</U>&#148; means, with respect to each share of Series&nbsp;A Stock, $0.54, and,
with respect to each share of Series&nbsp;B Stock, $0.65.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Loan Agreement</U>&#148; means the Loan Agreement, dated as of August&nbsp;10, 2007, as amended,
supplemented and otherwise modified from time to time, by and among Pharma (as borrower
thereunder), the Company (as guarantor thereunder) and Parent (as lender thereunder).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Material Adverse Effect</U>&#148; means any event, circumstance, change or effect that,
individually or when considered with any other events, circumstances, changes and effects, is or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">could reasonably be expected to (a)&nbsp;be materially adverse to the business, assets,
liabilities, condition (financial or otherwise) or results of operations of the Acquired Companies
taken as a whole (b)&nbsp;be adverse to Parent&#146;s right to own, or to receive dividends or other
distributions with respect to, the Surviving Corporation&#146;s capital stock or (c)&nbsp;prevent or
materially delay the consummation of the Transactions; <I>provided, however</I>, that the term
&#147;<U>Material Adverse Effect</U>&#148; shall not include any event, circumstance, change or effect
arising from (i)&nbsp;general economic and market conditions in or affecting the Company&#146;s industry,
(ii)&nbsp;general economic or market conditions in or affecting the United States economy or the credit
or financial markets, (iii)&nbsp;acts of terrorism or war (whether or not declared), that in the case
of clauses (i), (ii)&nbsp;and (iii)&nbsp;above, do not disproportionately affect the Acquired Companies
relative to other industry participants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Material IP Contracts</U>&#148; means the Contracts listed or required to be listed in Section
4.16(a)(ii)-(iv) of the Company Disclosure Schedule.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Net Working Capital</U>&#148; means the difference between (a)&nbsp;the current assets of the
Company and its consolidated Subsidiaries, including cash and cash equivalents, the value of
inventory, accounts receivable (less any reserves for uncollectibility and payment discounts) and
current prepaid expenses <I>and </I>(b)&nbsp;the current liabilities of the Company and its consolidated
Subsidiaries, including accounts payable (including amounts payable under Contracts of the Acquired
Companies) and all accrued expenses, including accrued commissions and incentive compensation,
rebates, chargebacks, product returns and all other pricing allowances, with each amount determined
in accordance with GAAP applied on a basis consistent with the past practices of the Company. For
purposes of this Agreement, Net Working Capital shall, in all events, exclude (i)&nbsp;cash and cash
equivalents to the extent such cash and cash equivalents have been included in the Closing Cash
Balance, fixed assets, deferred tax assets, goodwill, intangible assets, long term debt, the
current portion of Company Debt to the extent included in the Closing Company Debt (including the
current portion of the Loan Agreement and the Subordinated Notes), Change in Control Payments,
Transaction Expenses, assets relating to the Prosed products and assets relating to the products
acquired by Pharma pursuant to the Stock Purchase Agreement by and among Pharma and the
stockholders of Metagen Pharmaceuticals, Inc., dated September&nbsp;18, 2005 and (ii)&nbsp;liabilities
(including products returns and rebates) relating to the ProQuinXR Agreements for which the Parent
Indemnified Parties are receiving indemnification pursuant to <U>Section&nbsp;9.02(j)</U> and
liabilities relating to reserves established in respect of returns of Prosed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Net Working Capital Escrow Amount</U>&#148; means One Million Dollars ($1,000,000).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Net Working Capital Escrow Fund</U>&#148; means the escrow fund established by deposit of the
Net Working Capital Escrow Amount with the Escrow Agent in accordance with the terms of this
Agreement, which funds are to be administered by the Escrow Agent pursuant to the provisions of
this Agreement and the Escrow Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>NDA</U>&#148; means new drug application.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Order</U>&#148; shall mean any order, writ, judgment, injunction, decree, determination or
award.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Ordinary Course of Business</U>&#148; means the ordinary course of business consistent with
past practice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Parent Indemnified Party</U>&#148; means Parent, Merger Sub, their respective Affiliates
(including, following the Closing, the Company) and their respective directors, officers,
employees, agents, representatives, successors and assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Participation Cap</U>&#148; means, with respect to each share of Series&nbsp;A Stock, $1.62, and
with respect to each share of Series&nbsp;B Stock, $1.95.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Permit</U>&#148; means all permits, registrations, franchises, grants, authorizations
(including marketing and testing authorizations), concessions, licenses, easements, variances,
exceptions, exemptions, consents, certificates, clearances, approvals and Orders of any
Governmental Authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Person</U>&#148; means any individual, Entity or Governmental Authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Pharma</U>&#148; means Esprit Pharma, Inc., a Delaware corporation and wholly-owned
Subsidiary of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Post-Closing Cash Consideration Fraction</U>&#148; means, with respect to (i)&nbsp;each share of
Company Stock, (ii)&nbsp;each Share of Common Stock subject to In-the-Money Options that are outstanding
and unexercised as of immediately prior to the Effective Time and (iii)&nbsp;each share of Common Stock
issuable upon automatic exercise of the Warrant in accordance with its terms at the Effective Time
to the extent the Warrant is outstanding and unexercised immediately prior to the Effective Time,
the fraction:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;having a numerator equal to, as the case may be, the amount specified in <U>Section
2.02(c)(i)</U> in respect of such share of Preferred Stock, <U>Section&nbsp;2.02(d)(i)</U> in respect
of such share of Common Stock, <U>Section&nbsp;2.03(a)(i)</U> in respect of each share of Common Stock
subject to an In-the-Money Option that is outstanding and unexercised as of immediately prior to
the Effective Time, or <U>Section&nbsp;2.04(a)</U> in respect of such share of Common Stock issuable
upon the automatic exercise of the Warrant in accordance with its terms at the Effective Time; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;having a denominator equal to the aggregate total of all amounts specified in <U>Section
2.02(c)(i)</U> in respect of Preferred Stock, <U>Section&nbsp;2.02(d)(i)</U> in respect of Common
Stock, <U>Section&nbsp;2.03(a)(i)</U> in respect of Common Stock subject to In-the-Money Options that
are outstanding and unexercised as of immediately prior to the Effective Time, and <U>Section
2.04(a)</U> in respect of Common Stock issuable upon the automatic exercise of the Warrant in
accordance with its terms at the Effective Time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of calculating the foregoing fraction in this definition of &#147;Post-Closing Cash
Consideration Fraction&#148;, in no event shall Dissenting Shares or Company Stock cancelled prior to
the Effective Time in accordance with <U>Section&nbsp;2.02(b)</U> be included in such calculation.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Preferred Per Share Preference Amount</U>&#148; means, with respect to each share of Preferred
Stock, the sum of (a)&nbsp;the applicable Liquidation Amount <I>plus </I>(b)&nbsp;the amount of accrued and unpaid
dividends in respect of such share immediately prior to the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Products</U>&#148; means the Sanctura products, the Estrasorb products, the Prosed products
and the products acquired by Pharma pursuant to the Stock Purchase Agreement by and among Pharma
and the stockholders of Metagen Pharmaceuticals, Inc., dated September&nbsp;18, 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Proprietary Names</U>&#148; means trademarks, service marks, trade names, brand names, domain
names or the like, whether registered or unregistered.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>ProQuinXR Agreements</U>&#148; mean (a)&nbsp;the Exclusive License and Marketing Agreement by and
between the Company and Depomed, Inc., dated July&nbsp;21, 2005 and Amendment Number 1 thereto, dated
July&nbsp;24, 2006, (b)&nbsp;the Supply Agreement by and between the Company and Depomed, Inc., dated July
21, 2005 and (c)&nbsp;the Co-Promotion Agreement by and between the Company and Depomed, Inc., dated
July&nbsp;24, 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>ProQuinXR</U>&#148; means the extended release ciprofloxacin HCl pharmaceutical ingredient
product known as ProQuinXR composed of Depomed, Inc.&#146;s proprietary GR System and the active
ingredient, ciprofloxacin hydrochloride.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Prosed</U>&#148; means a multi-ingredient product with analgesic, antispasmodic and mild
antiseptic effects used to relieve lower urinary tract discomfort (i.e., irritative voiding
symptoms such as urgency, frequency and dysuria) as a result of hypermotility or spasm due to
inflammation or as a result of instrumentation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Registered IP</U>&#148; shall mean all Intellectual Property that is registered, filed or
issued under the authority of, with or by any Governmental Authority, including all patents,
registered copyrights, registered trademarks, registered Internet domain names owned by any of the
Acquired Companies or to which any of the Acquired Companies has a valid right and license and any
other Intellectual Property that is the subject of an application, certificate, filing,
registration or other document issued, filed with, or recorded by any Governmental Authority owned
by, registered or filed in the name of, any of the Acquired Companies, and all applications for any
of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Related Party</U>&#148; means: (a)&nbsp;each Key Stockholder; (b)&nbsp;each individual who is, or who
was at the time of the entry into the transaction or the creation of the interest in question an
officer or director of an Acquired Company; (c)&nbsp;each member of the immediate family of each of the
Persons referred to in subclause &#147;(b)&#148; above; (c)&nbsp;each Person that is, or that was at the time of
the entry into the transaction or the creation of the interest in question an Affiliate of any Key
Stockholder; and (d)&nbsp;any Entity (other than the Acquired Companies) in which, to the Knowledge of
the Acquired Companies, any one of the Persons referred to in subclauses &#147;(a)&#148; through &#147;(d)&#148; above
holds (or in which more than one of such Persons collectively hold), beneficially or otherwise, at
least ten percent (10%) of the voting interest or class of any outstanding Equity Participation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Sanctura</U>&#148; means any pharmaceutical preparation in final form (or, where the context
so indicates, the form under development) containing the chemical compound known as trospium
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">chloride whose specific chemical name is 3-alpha-benziloyloxynortropane-8-spiro-1&#146;-pyrrolidinium
chloride, also known as spiro &#091;8-azoniabicyclo &#091;3,2,1&#093; octane
-8,1&#146;-pyrrolidinium&#093;-3-&#091;(hydroxydiphenyl-acetyl)-oxy&#093; chloride (1<FONT style="font-family: Symbol">&#097;</FONT>, 3<FONT style="font-family: Symbol">&#098;</FONT>, 5<FONT style="font-family: Symbol">&#097;</FONT>)-(9CI)
and any related analogues, homologues, derivative and other pharmaceutically active salts as a
primary therapeutic ingredient, which is the subject of subject of FDA NDA No.&nbsp;21-595 and IND No.
71305.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Serious Adverse Event Report</U>&#148; means an adverse drug experience reported to the FDA or
other corresponding Governmental Authority occurring at any dose that results in any of the
following outcomes: death; a life-threatening adverse drug experience; inpatient hospitalization or
prolongation of existing hospitalization; a persistent or significant disability and/or incapacity;
a congenital anomaly and/or birth defect; or any other important medical event that, based upon
appropriate medical judgment, may jeopardize the patient or subject and may require medical or
surgical intervention to prevent one of the other outcomes listed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Stock Plan</U>&#148; means the 2005 Stock Plan of the Company, as amended from time to time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Subordinated Notes</U>&#148; means unsecured subordinated promissory notes issued by the
Company to certain stockholders of the Company in order to fund payments required to terminate the
ProQuinXR Agreements or for other general corporate purposes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Subsidiary</U>&#148; means, with respect to a Person, any other Entity which such Person
(either alone or through or together with any other subsidiary), owns, directly or indirectly,
fifty percent (50%) or more of the capital stock or other Equity Participations, the holders of
which are generally entitled to vote for the election of the board of directors or other governing
body of such Entity, or of which such Person is the managing member or general partner, or which
such Person is otherwise contractually entitled to direct and control.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Target Net Working Capital</U>&#148; means a Net Working Capital of negative Seven Million
Five Hundred Thousand Dollars ($-7,500,000).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Tax Returns</U>&#148; means any return, declaration, report, estimate, election, claim for
refund or information return or other statement or form relating to, filed or required to be filed
with any taxing Governmental Authority, including any schedule or attachment thereto, and including
any amendment thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Taxes</U>&#148; means any federal, state, local or foreign income, gross receipts, license,
payroll, employment, excise, severance, stamp, occupation, premium, windfall profits,
environmental, customs duties, capital stock, franchise, profits, withholding, social security,
unemployment, disability, real property, personal property, sales, use, transfer, registration, ad
valorem, value added, alternative or add-on minimum or estimated tax or other tax of any kind
whatsoever, including any interest, penalty, or addition thereto, whether disputed or not.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Transaction Expense</U>&#148; means any fee, cost, expense, payment, expenditure or Liability
of the Company (including legal fees and expenses, accounting fees and expenses and financial
advisory fees and expenses), whether incurred prior to the date of this Agreement, from the date
of this Agreement through the Closing or at or after the Closing, that relates to: (a)&nbsp;the
participation in or response to the investigation, review and inquiry conducted by Parent, Merger
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Sub, any other Person and their agents, representatives and advisors with respect to the business
of the Company in connection with the potential acquisition of an Acquired Company, the acquisition
of all or substantially all of the assets of an Acquired Company or the co-promotion or
co-marketing of Sanctura (and the furnishing of information to Parent, Merger Sub, any other Person
and their agents, representatives and advisors in connection with such investigation and review);
(b)&nbsp;the negotiation, preparation, drafting, review, execution, delivery or performance of this
Agreement (including the Company Disclosure Schedule) and the Ancillary Documents (except with
respect to the performance of the Indevus Agreement) or any other certificate, opinion, Contract or
other instrument or document delivered or to be delivered in connection with any of the
Transactions; (c)&nbsp;subject to the provisions of <U>Section&nbsp;12.01</U>, the preparation and
submission of any filing or notice required to be made or given in connection with any of the
Transactions, or the obtaining of any consent, waiver or approval required to be obtained in
connection with any of the Transactions; (d)&nbsp;the consummation of the Transactions; but excluding
the Change in Control Payments. Without limiting the generality of the foregoing, &#147;<U>Transaction
Expenses</U>&#148; shall (x)&nbsp;include (A)&nbsp;the Transaction Awards and (B)&nbsp;any fees that are payable or may
become payable by the Company in connection with the Transactions for services that were performed
at or prior to the Closing, even if the invoice for such fees is not issued until after the
Closing, and (y)&nbsp;not include any fee, cost, expense, payment, expenditure or Liability incurred by
Parent or any of its Affiliates (but with respect to the Surviving Corporation, only to the extent
incurred after the Closing).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Transaction Awards</U>&#148; means the total of all cash payments to be made to Persons at,
and subject to the occurrence of, the Effective Time, as set forth on <U>Schedule&nbsp;C</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Transactions</U>&#148; means the Merger and the other transactions contemplated by this
Agreement and the Ancillary Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Treasury Regulations</U>&#148; means the United States Treasury regulations promulgated under
the Code.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>WARN</U>&#148; means the Worker Adjustment and Retraining Notification Act of 1988, as
amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Warrant</U>&#148; means that certain warrant to purchase 5,377,488 shares of Common Stock (as
may be adjusted in accordance with the terms of the Warrant, including upon the automatic exercise
of the Warrant pursuant to the terms thereof and in connection with the Merger) issued on March&nbsp;9,
2006 to Drawbridge Special Opportunities Fund LP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The following terms have the meaning set forth in the Sections set forth below:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Defined Term</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Location of Definition</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accounting Firm</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 2.05(c)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Certificate of Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 3.01(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Charter Amendment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 3.01(a)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Defined Term</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Location of Definition</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Closing Net Working Capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 2.05(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Closing Net Working Capital Shortage</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 2.05(e)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Common Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Cure Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 11.01(c)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Indemnified Persons</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 6.01(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Confidential IP Information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 4.16(c)(v)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Confidentiality Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 6.05(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dissenting Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 2.02(e)(i)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Effective Time</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 3.01(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Environmental Permits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 4.18</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ERISA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 4.13(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Escrow Participants&#146; Representative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 10.01(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Escrow Participants&#146; Representative Costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 10.05(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Estimated Closing Net Working Capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 2.05(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Final Net Working Capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 2.05(c)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Indevus</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Indevus Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Information Statement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 6.03</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">JAMS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 12.13(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Lease Documents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 4.15(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Material Contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 4.19(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Merger Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Notice of Disagreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 2.05(c)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Option Closing Payment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 4.05(a)(vii)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Organization Documents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 4.02</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Parent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Parent Claim</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 9.02</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Parent Cure Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 11.01(d)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Paying Agent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 3.04(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Payment Fund</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 3.04(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Post-Closing Cash Consideration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 2.05(e)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Post-Closing Tax Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 7.04</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Preferred Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Requisite Stockholder Approval</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Secretary of State</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 3.01(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;A Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;B Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Social Security</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 4.13(c)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Statement of Closing Net Working Capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 2.05(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Statement of Estimated Closing Net Working
Capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 2.05(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stock Closing Payment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 4.05(a)(vi)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stockholder Written Consent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Surviving Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 2.01</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Defined Term</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Location of Definition</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tax Contest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 7.04</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Transfer Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 7.05</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Transaction Schedule</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 4.05(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Third Party Claim</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 9.05(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Warrant Closing Payment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#167; 4.05(a)(viii)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 1.02</U> <U>Interpretation and Rules of Construction</U>. In this Agreement,
except to the extent otherwise provided or that the context otherwise requires:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) when a reference is made in this Agreement to an Article, Section, Exhibit or Schedule,
such reference is to an Article or Section of, or a Schedule or Exhibit to, this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the table of contents and headings in this Agreement are for reference purposes only and
do not affect in any way the meaning or interpretation of this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) whenever the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they
are deemed to be followed by the words &#147;without limitation&#148;;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the words &#147;hereof,&#148; &#147;herein&#148; and &#147;hereunder&#148; and words of similar import, when used in
this Agreement, refer to this Agreement as a whole and not to any particular provision of this
Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) all terms defined in this Agreement have the defined meanings when used in any
certificate or other document made or delivered pursuant hereto, unless otherwise defined therein;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) whenever the context requires: the singular number shall include the plural, and vice
versa; the masculine gender shall include the feminine and neuter genders; the feminine gender
shall include the masculine and neuter genders; and the neuter gender shall include the masculine
and feminine genders;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) when calculating the period of time before which, within which or following which any act
is to be done or step taken pursuant to this Agreement, the date that is the reference date in
calculating such period is excluded. If the last day of such period is a non-Business Day, the
period in question ends on the next succeeding Business Day.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) any Law defined or referred to herein or in any agreement or instrument that is referred
to herein means such Law or statute as from time to time amended, modified or supplemented,
including by succession of comparable successor Laws, prior to or as of the Effective Time;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) references to a Person are also to its successors and permitted assigns;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) the use of &#147;or&#148; is not intended to be exclusive unless expressly indicated otherwise; and
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) all references to monetary amounts in this Agreement refer to U.S. dollars unless
otherwise indicated.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE II</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>THE MERGER</B></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 2.01</U> <U>The Merger</U>. Upon the terms and subject to the conditions of this
Agreement, at the Effective Time, Merger Sub shall be merged with and into the Company in
accordance with the DGCL, whereupon the separate existence of Merger Sub shall cease and the
Company shall continue as the surviving corporation (the &#147;<U>Surviving Corporation</U>&#148;) and a
wholly-owned Subsidiary of Parent. Subject to the foregoing and to the other sections of this
<U>Article&nbsp;II</U>, the effects of the Merger shall be as provided in the applicable provisions of
the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 2.02</U> <U>Conversion of Capital Stock</U>. By virtue of the Merger and without
any action on the part of Parent, Merger Sub, the Company or any Company Stockholder:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Capital Stock of Merger Sub</U>. Each share of the common stock, par value $0.001
per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall be
converted into and exchanged for one fully paid and nonassessable share of common stock, par value
$0.001 per share, of the Surviving Corporation. From and after the Effective Time, each stock
certificate of Merger Sub evidencing ownership of any such shares shall continue to evidence
ownership of such shares of common stock of the Surviving Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Capital Stock of the Company owned by Parent, Merger Sub or the Company</U>. Each
share of Company Stock owned by Parent, Merger Sub, the Company or any direct or indirect
wholly-owned Subsidiary of Parent, Merger Sub or the Company immediately prior to the Effective
Time, shall be canceled and retired without payment of any consideration with respect thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Preferred Stock</U>. Each issued and outstanding share of Preferred Stock (other
than those to be cancelled in accordance with <U>Section&nbsp;2.02(b)</U> and Dissenting Shares) shall
be converted into the right to receive:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;an amount in cash equal to the Closing Date Preferred Per Share Consideration; <I>minus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;for a share of Preferred Stock held by an Escrow Participant, the product of (A)&nbsp;the
Aggregate Proceeds Contribution Fraction with respect to such share of Preferred Stock <I>multiplied
by </I>(B)&nbsp;the Indemnification Escrow Amount; <I>minus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;for a share of Preferred Stock held by an Escrow Participant, the product of (A)&nbsp;the
Aggregate Proceeds Contribution Fraction with respect to such share of Preferred Stock <I>multiplied
by </I>(B)&nbsp;the Net Working Capital Escrow Amount; <I>minus</I>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;for a share of Preferred Stock held by an Escrow Participant, the product of (A)&nbsp;the
Aggregate Proceeds Contribution Fraction with respect to such share of Preferred Stock <I>multiplied
by </I>(B)&nbsp;the Expense Amount; <I>plus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;for a share of Preferred Stock held by an Escrow Participant, the product of (A)&nbsp;the
Aggregate Proceeds Contribution Fraction with respect to such share of Preferred Stock <I>multiplied
by </I>(B)&nbsp;the aggregate amount of any cash required to be released from the Indemnification Escrow
Fund to the Escrow Participants in accordance with the Escrow Agreement (as and when such cash is
required to be released); <I>plus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;for a share of Preferred Stock held by an Escrow Participant, the product of (A)&nbsp;the
Aggregate Proceeds Contribution Fraction with respect to such share of Preferred Stock <I>multiplied
by </I>(B)&nbsp;the aggregate amount of any cash required to be released from the Net Working Capital Escrow
Fund to the Escrow Participants in accordance with this Agreement and the Escrow Agreement (as and
when such cash is required to be released); <I>plus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;for a share of Preferred Stock held by an Escrow Participant, the product of (A)&nbsp;the
Aggregate Proceeds Contribution Fraction with respect to such share of Preferred Stock <I>multiplied
by </I>(B)&nbsp;the aggregate amount of any cash released from the Expense Fund to the Escrow Participants
(as and when such cash is released); <I>plus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)&nbsp;the product of (A)&nbsp;the Post-Closing Cash Consideration, if any, <I>multiplied by </I>(B)&nbsp;the
Post-Closing Cash Consideration Fraction with respect to such share of Preferred Stock (as and
when such cash is required to be released in accordance with <U>Section&nbsp;2.05</U>).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Common Stock</U>. Each issued and outstanding share of Common Stock (other than
those to be cancelled in accordance with <U>Section&nbsp;2.02(b)</U> and Dissenting Shares) shall be
converted into the right to receive:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;an amount in cash equal to the Closing Date Common Per Share Consideration; <I>minus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;for a share of Common Stock held by an Escrow Participant, the product of (A)&nbsp;the
Aggregate Proceeds Contribution Fraction with respect to such share of Common Stock <I>multiplied by</I>
(B)&nbsp;the Indemnification Escrow Amount; <I>minus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;for a share of Common Stock held by an Escrow Participant, the product of (A)&nbsp;the
Aggregate Proceeds Contribution Fraction with respect to such share of Common Stock <I>multiplied by</I>
(B)&nbsp;the Net Working Capital Escrow Amount; <I>minus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;for a share of Common Stock held by an Escrow Participant, the product of (A)&nbsp;the
Aggregate Proceeds Contribution Fraction with respect to such share of Common Stock <I>multiplied by</I>
(B)&nbsp;the Expense Amount; <I>plus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;for a share of Common Stock held by an Escrow Participant, the product of (A)&nbsp;the
Aggregate Proceeds Contribution Fraction with respect to such share of Common Stock <I>multiplied by</I>
(B)&nbsp;the aggregate amount of any cash required to be released from
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the
Indemnification Escrow Fund
to the Escrow Participants in accordance with the Escrow Agreement (as and when such cash is
required to be released); <I>plus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;for a share of Common Stock held by an Escrow Participant, the product of (A)&nbsp;the
Aggregate Proceeds Contribution Fraction with respect to such share of Common Stock <I>multiplied by</I>
(B)&nbsp;the aggregate amount of any cash required to be released from the Net Working Capital Escrow
Fund to the Escrow Participants in accordance with this Agreement and the Escrow Agreement (as and
when such cash is required to be released); <I>plus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;for a share of Common Stock held by an Escrow Participant, the product of (A)&nbsp;the
Aggregate Proceeds Contribution Fraction with respect to such share of Common Stock <I>multiplied by</I>
(B)&nbsp;the aggregate amount of any cash released from the Expense Fund to the Escrow Participants (as
and when such cash is released); <I>plus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)&nbsp;the product of (A)&nbsp;the Post-Closing Cash Consideration, if any, <I>multiplied by </I>(B)&nbsp;the
Post-Closing Cash Consideration Fraction with respect to such share of Common Stock (as and when
such cash is required to be released in accordance with <U>Section&nbsp;2.05</U>).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Dissenting Shares</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Notwithstanding anything in this Agreement to the contrary, any shares of Company Stock
outstanding immediately prior to the Effective Time eligible under the DGCL to exercise appraisal
rights and held by a holder who has not voted in favor of the Merger or consented thereto in
writing and who has exercised and perfected appraisal rights for such shares in accordance with
Section&nbsp;262 of the DGCL and has not effectively withdrawn or lost such appraisal rights
(collectively, the &#147;<U>Dissenting Shares</U>&#148;) shall not be converted into or represent the right
to consideration for Company Stock set forth in <U>Section&nbsp;2.02(c)</U> or <U>Section&nbsp;2.02(d)</U>,
and the holder or holders of such shares shall be entitled only to such rights as may be granted to
such holder or holders in Section&nbsp;262 of the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Notwithstanding the provisions of <U>Section&nbsp;2.02(e)</U>, if any holder of Dissenting
Shares shall effectively withdraw or lose (through failure to perfect or otherwise) such holder&#146;s
appraisal rights under Section&nbsp;262 of the DGCL, then, as of the later of the Effective Time and the
occurrence of such event, such holder&#146;s shares shall automatically be converted into and represent
only the right to receive the consideration for such shares set forth in <U>Section&nbsp;2.02(c)</U> or
<U>Section&nbsp;2.02(d)</U>, without interest, in accordance with an at the time specified in
<U>Section&nbsp;2.02(c)</U> or <U>Section&nbsp;2.02(d)</U>, and after surrender of the certificate
representing such shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;The Company shall (A)&nbsp;comply with the requirements of Section&nbsp;262 of the DGCL, (B)&nbsp;give
Parent prompt notice of any written demand received by the Company pursuant to Section&nbsp;262 of the
DGCL and of withdrawals of such demands, and provide copies of any documents or instruments served
pursuant to the DGCL received by the
Company and (C)&nbsp;give Parent the opportunity to participate in all negotiations and proceedings
with respect to any such demands. Prior to the Effective Time, the Company shall not make any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">payment or settlement offer with respect to any such demand unless Parent shall have consented in
writing to such payment or settlement offer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Any amounts that become payable in respect of Dissenting Shares shall be satisfied first
from the Payment Fund up to the Applicable Merger Consideration, as if such Dissenting Shares were
not Dissenting Shares, and thereafter from the Indemnification Escrow Fund.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 2.03</U> <U>Treatment of Company Options in the Merger</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>In-the-Money Options</U>. The Company and the board of directors of the Company
shall take all necessary and appropriate action so that all In-the-Money Options that are
outstanding and unexercised immediately prior to the Effective Time, whether or not immediately
exercisable, shall, at the Effective Time, be cancelled, terminated and extinguished and converted
into the right to receive, in respect of each share of Common Stock subject to such In-the-Money
Option immediately prior to the Effective Time and subject to the terms and conditions of this
Agreement, an amount in cash equal to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;the excess of the Closing Date Common Per Share Consideration over the per share exercise
price of such In-the-Money Option; <I>plus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;the product of (A)&nbsp;the Post-Closing Cash Consideration, if any, <I>multiplied by </I>(B)&nbsp;the
Post-Closing Cash Consideration Fraction with respect of each share of Common Stock subject to such
In-the-Money Option (as and when such cash is required to be released in accordance with
<U>Section&nbsp;2.05</U>); provided any payment made under this <U>Section&nbsp;2.03(a)</U> shall be made
in compliance with the requirements of Treasury Regulation&nbsp;Section&nbsp;1.409A-3(i)(s)(iv).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Out of the Money Company Options</U>. The Company shall take all necessary and
appropriate action, including providing reasonable notice to the holders thereof, so that all
Company Options that are not In-the-Money Options shall, at the Effective Time, be cancelled,
terminated and extinguished.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 2.04</U> <U>Treatment of Warrant in the Merger</U>. To the extent outstanding
and unexercised immediately prior to the Effective Time, the Warrant shall, at the Effective Time,
be terminated and, upon termination thereof, converted into the right to receive, in respect of
each share of Common Stock issuable upon automatic exercise of the Warrant in accordance with its
terms at the Effective Time and subject to the terms and conditions of this Agreement, an amount in
cash equal to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;the Closing Date Common Per Share Consideration; <I>plus</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;the product of (A)&nbsp;the Post-Closing Cash Consideration, if any, <I>multiplied by </I>(B)&nbsp;the
Post-Closing Cash Consideration Fraction with respect to such share of Common Stock (as and when
such cash is required to be released in accordance with <U>Section&nbsp;2.05</U>).
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 2.05</U> <U>Net Working Capital Adjustment</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Not more than five (5)&nbsp;Business Days nor fewer than two (2)&nbsp;Business Days before the
Closing Date, the Company shall provide Parent with a written and detailed statement of the Net
Working Capital (the &#147;<U>Statement of Estimated Closing Net Working Capital</U>&#148;) dated as of the
Closing Date (the &#147;<U>Estimated Closing Net Working Capital</U>&#148;), including the resulting
Estimated Closing Net Working Capital Shortage (if any), which Statement of Estimated Closing Net
Working Capital shall be prepared in good faith and in accordance with GAAP on a basis consistent
with the preparation of the Interim Financial Statements and shall be accompanied by a written
certificate to Parent, executed by the Chief Financial Officer on behalf of the Company,
certifying that the Statement of Estimated Closing Net Working Capital was so prepared.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Within sixty (60)&nbsp;days after the Closing Date, Parent shall review the Statement of
Estimated Closing Net Working Capital and deliver to the Escrow Participants&#146; Representative a
statement of Net Working Capital as of the Closing Date, signed by an executive officer or the
Controller of Parent (the &#147;<U>Statement of Closing Net Working Capital</U>&#148;). The Statement of
Closing Net Working Capital shall set forth the Net Working Capital as of the Closing Date (the
&#147;<U>Closing Net Working Capital</U>&#148;), including a detailed breakdown of the various amounts of
each component of Net Working Capital and taking into account additional information that becomes
available or events occurring after the Closing Date and prior to the preparation of the Statement
of Closing Net Working Capital.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Within thirty (30)&nbsp;days following Parent&#146;s delivery of the Statement of Closing Net
Working Capital, the Escrow Participants&#146; Representative shall deliver a written notice (the
&#147;<U>Notice of Disagreement</U>&#148;) to Parent of any dispute the Escrow Participants&#146; Representative
has with respect to the preparation or content of the Statement of Closing Net Working Capital and
the Closing Net Working Capital. The Notice of Disagreement shall describe in reasonable detail
the items contained in the Statement of Closing Net Working Capital that the Escrow Participants&#146;
Representative disputes and the basis for any such dispute. If the Escrow Participants&#146;
Representative does not notify Parent of a dispute with respect to the Statement of Closing Net
Working Capital within such 30-day period or notifies Parent that it does not have any dispute
with the information reflected in the Statement of Closing Net Working Capital, such Statement of
Closing Net Working Capital shall be final, conclusive and binding on the parties and the Closing
Net Working Capital reflected thereon shall become the &#147;<U>Final Net Working Capital</U>.&#148; In
the event a Notice of Disagreement is delivered to Parent, the Escrow Participants&#146; Representative
and Parent shall negotiate in good faith to resolve such dispute and agree upon the &#147;<U>Final Net
Working Capital</U>.&#148; If the Escrow Participants&#146; Representative and Parent, notwithstanding such
good faith effort, fail to resolve such dispute within ten (10)&nbsp;Business Days after the Escrow
Participants&#146; Representative delivers the Notice of Disagreement, then the Escrow Participants&#146;
Representative and Parent jointly shall engage a U.S. accounting firm of national reputation as is
reasonably acceptable to
the Escrow Participants&#146; Representative and Parent that has not provided services to either
of Parent or its Affiliates or the Acquired Companies or their Affiliates during the prior three
(3)&nbsp;years (the &#147;<U>Accounting Firm</U>&#148;) to resolve such dispute in accordance with the standards
set forth in this <U>Section&nbsp;2.05</U>. Parent and the Escrow Participants&#146; Representative shall
use commercially reasonable efforts to cause the Accounting Firm to render a written decision
resolving the matters submitted to the Accounting Firm within thirty (30)&nbsp;days after the making of
such submission. The Accounting Firm shall address only those items in dispute. The
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">Accounting
Firm shall determine, on such basis, whether and to what extent, the Closing Net Working Capital
requires adjustment, which determination shall be consistent with either the position of the
Escrow Participants&#146; Representative or the position of Parent or between the positions of the
Escrow Participants&#146; Representative and Parent and the amount determined by the Accounting Firm
shall become the &#147;<U>Final Net Working Capital</U>.&#148; Judgment may be entered upon the
determination of the Accounting Firm in any court having jurisdiction over the party against which
such determination is to be enforced. All determinations made by the Accounting Firm will be
final, conclusive and binding on the parties. The Escrow Participants&#146; Representative and/or
Parent shall share the fees and expenses of the Accounting Firm proportionately based on which
party&#146;s position was closer to the determination by the Accounting Firm. For purposes of
complying with the terms set forth in this <U>Section&nbsp;2.05</U>, each party shall cooperate with
and make available to the other parties and their respective representatives all information,
records, data and working papers, and shall permit reasonable access to its facilities and
personnel, as may be reasonably required in connection with the preparation and analysis of the
Statement of Closing Net Working Capital.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Following the determination of the Final Net Working Capital, the following payments, if
any, shall be made:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;If the Final Net Working Capital is greater than or equal to the Target Net Working
Capital and there was not an Estimated Closing Net Working Capital Shortage, then no additional
amounts will be owed by Parent or the Company Securityholders to the other.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;If the Final Net Working Capital is greater than or equal to the Target Net Working
Capital and there was an Estimated Closing Net Working Capital Shortage, then Parent shall be
required to pay an amount equal to the Estimated Closing Net Working Capital Shortage.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;If the Final Net Working Capital is less than the Target Net Working Capital and there
was not an Estimated Closing Net Working Capital Shortage, then Parent shall be entitled to receive
an amount equal to the amount by which the Final Net Working Capital is less than the Target Net
Working Capital.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;If the Final Net Working Capital is less than the Target Net Working Capital and there
was an Estimated Closing Net Working Capital Shortage, then:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;If the Final Net Working Capital is greater than the Estimated Closing Net Working
Capital, Parent shall be required to pay an amount equal to the
difference between the Final Net Working Capital and the Estimated Closing Net Working
Capital; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;If the Final Net Working Capital is less than the Estimated Closing Net Working Capital,
Parent shall be entitled to receive an amount equal the difference between the Estimated Closing
Net Working Capital and the Final Net Working Capital.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) If Parent is obligated to pay any amount pursuant to <U>Section&nbsp;2.05(d)(ii) </U>or
<U>Section&nbsp;2.05(d)(iv)(A)</U> (such amount, the &#147;<U>Post-Closing Cash Consideration</U>&#148;),
Parent shall,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">within five (5)&nbsp;Business Days after the Final Net Working Capital has been
established (i)&nbsp;pay the Post-Closing Cash Consideration to the Escrow Participants&#146; Representative
in immediately available funds, and such payment, when made, shall be deemed to have been paid in
full satisfaction of the rights of the Escrow Participants under <U>Sections&nbsp;2.02(c)(viii)</U>,
<U>2.02(d)(viii)</U>, <U>2.03(a)(ii)</U> and <U>2.04(b)</U>, and (ii)&nbsp;execute written
instructions to the Escrow Agent, instructing the Escrow Agent to disburse all of the funds in the
Net Working Capital Escrow Fund to the Escrow Participants&#146; Representative and such payment, when
made, shall be deemed to have been paid in full satisfaction of the rights of the Escrow
Participants under <U>Sections&nbsp;2.02(c)(vi)</U> and <U>2.02(d)(vi)</U>. If Parent is entitled to
receive any amount pursuant to any provision of <U>Section&nbsp;2.05(d)</U> (such amount, the
&#147;<U>Closing Net Working Capital Shortage</U>&#148;), Parent and the Escrow Participants&#146;
Representative shall, within five (5)&nbsp;Business Days after the Final Net Working Capital has been
established, execute joint written instructions to the Escrow Agent, instructing the Escrow Agent
to disburse the Closing Net Working Capital Shortage to Parent from the Net Working Capital Escrow
Fund and, to the extent the amount in the Net Working Capital Escrow Fund is less than the Closing
Net Working Capital Shortage, from the Indemnity Escrow Fund, and immediately thereafter to
disburse any amount remaining in the Net Working Capital Escrow Fund to the Escrow Participants&#146;
Representative and such payment, when made, shall be deemed to have been paid in full satisfaction
of the rights of the Escrow Participants under <U>Sections&nbsp;2.02(c)(vi)</U> and
<U>2.02(d)(vi)</U>. If Parent is neither required to pay any amount nor entitled to receive any
amount under <U>Section&nbsp;2.05(d)</U>, then within five (5)&nbsp;Business Days after the Final Net
Working Capital has been established, Parent and the Escrow Participants&#146; Representative shall
execute joint written instructions to the Escrow Agent, instructing the Escrow Agent to disburse
the Net Working Capital Escrow Fund to the Escrow Participants&#146; Representative and such payment,
when made, shall be deemed to have been paid in full satisfaction of the rights of the Escrow
Participants under <U>Sections&nbsp;2.02(c)(vi)</U> and <U>2.02(d)(vi)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 2.06</U> <U>Certificate of Incorporation and Bylaws of the Surviving
Corporation</U>. At the Effective Time, (a)&nbsp;the Certificate of Incorporation of the Surviving
Corporation shall be amended and restated in its entirety to conform to <U>Exhibit&nbsp;F</U> attached
to this Agreement and, as so amended, shall become the Certificate of Incorporation of the
Surviving Corporation, until the same shall be amended in accordance with its terms and applicable
Law, and (b)&nbsp;the Bylaws of Merger Sub as in effect immediately prior to the Effective Time shall be
the Bylaws of the Surviving Corporation until thereafter amended as provided by Law, the
Certificate of Incorporation of the Surviving Corporation and such Bylaws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 2.07</U> <U>Directors and Officers of the Surviving Corporation</U>. The
directors and the officers of Merger Sub immediately prior to the Effective Time shall, from and
after the Effective Time, be the directors and officers, respectively, of the Surviving Corporation
until their successors shall have been duly elected or appointed and qualified or until their
earlier death, resignation or removal in accordance with the Surviving Corporation&#146;s Certificate of
Incorporation and Bylaws.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE III</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>CLOSING; PAYMENT OF CONSIDERATION</B></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 3.01</U> <U>Closing</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Unless this Agreement shall have been terminated and the transactions herein contemplated
shall have been abandoned pursuant to <U>Article&nbsp;XI</U>, and subject to the satisfaction or
waiver (where applicable) of the conditions set forth in <U>Article&nbsp;VIII</U>, the closing of the
Merger (the &#147;<U>Closing</U>&#148;) will take place at the offices of Latham &#038; Watkins LLP, 650 Town
Center Drive, 20<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor, Costa Mesa, California, at 10:00&nbsp;a.m., local time, on the
Closing Date, or at such other place and time as is agreed to in writing by Parent and the
Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) At the Closing, a certificate of merger (the &#147;<U>Certificate of Merger</U>&#148;) shall be
duly prepared and executed by the Surviving Corporation and thereafter delivered to the Secretary
of State of the State of Delaware (the &#147;<U>Secretary of State</U>&#148;) for filing, as provided in
Section&nbsp;251 of the DGCL, as soon as practicable on the Closing Date. The Merger shall become
effective at the time of the filing of the Certificate of Merger with the Secretary of State (the
date and time of such filing being referred to herein as the &#147;<U>Effective Time</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 3.02</U> <U>Establishment of Indemnification Escrow Fund and Net Working Capital
Escrow Fund</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) At the Effective Time, Parent shall fund the Indemnification Escrow Fund by delivering or
causing to be delivered the Indemnification Escrow Amount to the Escrow Agent pursuant to the
provisions of the Escrow Agreement. The Indemnification Escrow Amount (or any portion thereof)
shall be distributed from the Indemnification Escrow Fund to the Escrow Participants and Parent at
the times, and upon the terms and conditions, set forth in this Agreement and the Escrow
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) At the Effective Time, Parent shall fund the Net Working Capital Escrow Fund by
delivering or causing to be delivered the Net Working Capital Escrow Amount to the Escrow Agent
pursuant to the provisions of the Escrow Agreement. The Net Working Capital Escrow Amount (or any
portion thereof) shall be distributed from the Net
Working Capital Escrow Fund to the Escrow Participants and Parent at the times, and upon the
terms and conditions, set forth in this Agreement and the Escrow Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The terms and provisions of the Escrow Agreement and the transactions contemplated
thereby are specific terms of the Merger, and the approval and adoption of this Agreement and
approval of the Merger by the Escrow Participants pursuant to the Stockholders&#146; Written Consent
and the delivery of the letters of transmittal pursuant to <U>Section&nbsp;3.04</U> shall constitute
approval by such Escrow Participants, as specific terms of the Merger, and the irrevocable
agreement of such Escrow Participants to be bound by and comply with the Escrow Agreement and all
of the arrangements and provisions of this Agreement relating thereto, including the deposit of
the Indemnification Escrow Amount and the Net Working Capital Escrow Amount into escrow, the
indemnification obligations set forth in <U>Article&nbsp;IX</U> hereof and the appointment and sole
authority to act on behalf of the Escrow Participants of the Escrow Participants&#146; Representative,
as provided for herein and in the Escrow Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 3.03</U> <U>Deposit of Expense Amount</U>. At the Effective Time, Parent shall
fund the Expense Fund by delivering or causing to be delivered, the Expense
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Amount to the Escrow
Participants&#146; Representative by wire transfer of immediately available funds to an account
designated by the Escrow Participants&#146; Representative prior to the Closing. The Escrow
Participants&#146; Representative shall hold the Expense Fund in trust solely for the purpose of
reimbursing the Escrow Participants&#146; Representative for expenses incurred by it on behalf of the
Escrow Participants in accordance with <U>Article&nbsp;X</U>. The payment of the Expense Amount by
Parent to the Escrow Participants&#146; Representative shall discharge Parent&#146;s obligations with respect
to such amount, and Parent shall not have responsibility or Liability for the manner in which the
Escrow Participants&#146; Representative administers the Expense Fund, or for causing or ensuring that
all or any portion of the Expense Amount is ultimately paid or distributed to the Escrow
Participants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 3.04</U> <U>Surrender of Certificates </U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Paying Agent</U>. At the Effective Time, Parent or Merger Sub shall deposit, or
cause to be deposited, with a reputable bank or trust company (the &#147;<U>Paying Agent</U>&#148;) for the
benefit of the Company Securityholders cash in an amount (the &#147;<U>Payment Fund</U>&#148;) equal to (i)
the Closing Date Total Cash Consideration <I>minus </I>(ii)&nbsp;the Indemnification Escrow Amount <I>minus </I>(iii)
the Net Working Capital Escrow Amount <I>minus </I>(iii)&nbsp;the Expense Amount <I>minus </I>(iv)&nbsp;the sum of the
Option Closing Payments payable in respect of each In-the-Money Option <I>minus </I>(v)&nbsp;the sum of the
aggregate exercise price of all In-the-Money Options. Such funds shall be invested as directed by
Parent or the Surviving Corporation pending payment thereof by the Paying Agent to the applicable
Company Securityholders. Earnings from such investments shall be the sole and exclusive property
of the Surviving Corporation, and no part of such earnings shall accrue to the benefit of the
Company Securityholders.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Surrender and Payment Procedures</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;With respect to the Key Stockholders, within three (3)&nbsp;Business Days prior to the Closing,
and with respect to all other Company Stockholders, promptly after the Effective Time, Parent shall
deliver or instruct the Paying Agent to deliver to each Company Stockholder at the address provided
by the Company in the Transaction Schedule (A)&nbsp;a letter of transmittal in substantially the form
attached hereto as <U>Exhibit&nbsp;G</U> and (B)&nbsp;instructions for use in effecting the surrender of
certificate(s) representing all of the shares of Company Stock held by such Company Stockholder in
exchange for the Stock Closing Payment that is payable in respect of the shares of Company Stock
formerly represented by such certificate(s). The payment of the Stock Closing Payment with respect
to each such certificate(s) is conditioned upon (1)&nbsp;the execution and delivery of such letter of
transmittal and (2)&nbsp;the delivery of such certificates. Promptly after receipt by the Paying Agent
of such certificate(s), properly endorsed or otherwise in proper form for transfer, for
cancellation, together with such duly executed letter of transmittal, the Paying Agent shall, in
exchange therefor, pay to such Company Stockholder the Stock Closing Payment payable in respect of
the shares of Company Stock formerly represented by the certificate(s) surrendered, but without
interest, and the certificate(s) so surrendered shall forthwith be canceled. If payment of any
portion of the applicable Stock Closing Payment is to be made to a Person other than the Person in
whose name the surrendered certificate(s) are registered, it shall be a condition of payment that
the Person requesting such payment (x)&nbsp;shall have paid any transfer and other Taxes required by
reason of the payment of those amounts to a Person other than the registered holder of the
certificate(s) surrendered, and shall have
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">established to the satisfaction of the Surviving
Corporation that such Tax has been paid, or (y)&nbsp;shall have established to the satisfaction of the
Surviving Corporation that such Tax is not applicable. From and after the Effective Time, until
surrendered as contemplated by this <U>Section&nbsp;3.04(b)</U>, each certificate formerly representing
shares of Company Stock shall be deemed to represent for all purposes only the right to receive the
consideration payable in respect of the shares of Company Stock formerly represented thereby in
accordance with the terms hereof and in the manner provided herein. Notwithstanding the foregoing,
Parent shall use commercially reasonable efforts to cause the Paying Agent to deliver the Stock
Closing Payment to each Key Stockholder and the Warrant Closing Payment to the holder of the
Warrant on the Closing Date and, in any event, promptly after the Effective Time for (A)&nbsp;any Key
Stockholder that delivers the fully completed and duly executed letter of transmittal, together
with wire instructions and the applicable Tax forms, and (B)&nbsp;the holder of the Warrant (to the
extent the Warrant is outstanding and unexercised as of the Effective Time) if the holder delivers
wire instructions and the applicable Tax forms, each within one (1)&nbsp;Business Day prior to the
Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Parent shall or shall cause the Surviving Corporation to, as soon as reasonably
practicable after the Effective Time, in accordance with its customary payroll practices, pay to
the holder of In-the-Money Options, the Option Closing Payment payable in respect of each
In-the-Money Option, but without interest and subject to applicable withholding and other Taxes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;Parent shall instruct the Paying Agent to, as soon as reasonably practicable after the
Effective Time, mail to the holder of the Warrant as of the Effective Time at the address provided
by the Company in the Transaction Schedule (A)&nbsp;a letter of transmittal in substantially the form
attached hereto as <U>Exhibit&nbsp;H</U> and (B)&nbsp;instructions for use in effecting the surrender of all
rights in and to the Common Stock subject to the Warrant in exchange for the Warrant Closing
Payment. The payment of the Warrant Closing Payment in respect of the
Warrant is conditioned upon the execution and delivery of such transmittal letter. Promptly
after receipt by the Paying Agent of such duly executed letter of transmittal, the Paying Agent
shall, in exchange therefor, pay to such Participating Warrant Holder the Warrant Closing Payment
in respect of the Warrant so surrendered, but without interest.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;For the purpose of releasing funds to Company Securityholders pursuant to this
<U>Section&nbsp;3.04(b)</U>, the Payment Agent shall round the aggregate amount of all Stock Closing
Payments, Option Closing Payments and Warrant Closing Payments payable to each Company
Securityholder to the nearest cent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 3.05</U> <U>Transfer Books; No Further Ownership Rights in the Shares</U>. At
the Effective Time, the stock transfer books of the Company shall be closed, and thereafter there
shall be no further registration of transfers of the shares of Company Stock on the records of the
Company. From and after the Effective Time, the holders of certificates formerly evidencing
ownership of the shares of Company Stock outstanding immediately prior to the Effective Time shall
cease to have any rights with respect to such shares, except as otherwise provided for herein or by
applicable Law. After the Effective Time, the Surviving Corporation or the Paying Agent shall
cancel and exchange, as provided in Section&nbsp;3.04, any presented certificate representing shares of
Company Stock outstanding immediately prior to the Effective Time.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 3.06</U> <U>Termination of Fund; No Liability</U>. At any time following the
first (1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>) anniversary of the Effective Time, the Surviving Corporation shall be
entitled to require the Paying Agent to deliver to it any funds (including any earnings received
with respect thereto) that had been made available to the Paying Agent and that have not been
disbursed to Company Securityholders and thereafter such Company Securityholders shall be entitled
to look only to the Surviving Corporation (subject to abandoned property, escheat or other similar
Laws) and only as general creditors thereof with respect to the Applicable Merger Consideration
payable to them, without any interest thereon. Notwithstanding the foregoing, none of Parent, the
Surviving Corporation or the Paying Agent shall be liable to any holder of a certificate formerly
representing shares of Company Stock for any amounts delivered to a public official pursuant to any
applicable abandoned property, escheat or similar Law. Any amounts remaining unclaimed by Company
Securityholders three (3)&nbsp;years after the Effective Time (or such earlier date, immediately prior
to such time when the amounts would otherwise escheat to or become the property of any Governmental
Authority) shall become, to the extent permitted by applicable Law, the property of the Surviving
Corporation, free and clear of any claims or interest of any Person previously entitled thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 3.07</U> <U>Withholding Rights</U>. Each of Parent, the Surviving Corporation
and the Paying Agent shall be entitled to deduct and withhold from payment of any amounts (or any
portion thereof) payable pursuant to this Agreement to, or on behalf of, any Company
Securityholder, and the Escrow Agent shall be entitled to deduct and withhold from payment of any
amounts payable pursuant to the Escrow
Agreement to, or on the behalf of, any Company Securityholder, such amounts as may be required
to be deducted and withheld with respect to the making of such payment under the Code, or any other
Law. To the extent that amounts are so withheld by Parent, the Surviving Corporation, the Paying
Agent or the Escrow Agent, such withheld amounts shall be treated for all purposes of this
Agreement and the Escrow Agreement as having been paid to the Company Securityholder to whom such
amounts would otherwise have been paid.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 3.08</U> <U>Lost, Stolen or Destroyed Certificates</U>. In the event any
certificate(s) which formerly represented shares of Company Stock shall have been lost, stolen or
destroyed, upon the making and delivery of an affidavit of that fact by the Company Stockholder
thereof in form reasonably satisfactory to Parent, Parent shall instruct the Paying Agent to pay
such Company Stockholder such Company Stockholder&#146;s Stock Closing Payment as provided in
<U>Section&nbsp;3.04(b)</U>; <I>provided</I>, <I>however</I>, that Parent may, in its sole discretion and as a
condition precedent to issuing such instruction to the Paying Agent, require the owner of such
lost, stolen or destroyed certificate(s) to deliver an agreement of indemnification in form
reasonably satisfactory to Parent and a bond in such sum as Parent may reasonably direct, as
indemnity against any claim that may be made against Parent, the Surviving Corporation or the
Paying Agent with respect to the certificate(s) alleged to have been lost, stolen or destroyed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 3.09</U> <U>Dissenting Shares</U>. The provisions of <U>Section&nbsp;3.04(b)</U>
shall also apply to Dissenting Shares that lose their status as such, except that the obligations
of Parent under <U>Section&nbsp;3.04(b)</U> shall commence on the date of loss of such status and the
holder of such shares shall be entitled to receive in exchange for such shares the applicable
amounts provided in <U>Section&nbsp;3.04(b)</U>.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 3.10</U> <U>Restricted Shares</U>. As provided in the Stock Purchase and Stock
Restriction Agreements dated as of May&nbsp;3, 2005, by and between Pharma and each of the following
individuals: John T. Spitznagel, John T. Spitznagel, Jr., Greg Stokes, Ernest Biczak, Andrew J.
Einhorn and Louis P. Berardi, and stock purchase agreements entered into pursuant to the Stock Plan
pursuant to which the Company granted to certain employees restricted shares of its Common Stock as
indicated in the Transaction Schedule, immediately prior to the Effective Time, each outstanding
restricted share shall vest and the restrictions thereon shall lapse and such restricted share
shall represent the right to receive the Applicable Merger Consideration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 3.11</U> <U>Further Action</U>. If, at any time after the Effective Time, any
further action is necessary or desirable to carry out the purposes of this Agreement and to vest
the Surviving Corporation with full right, title and possession to all assets, property, rights,
privileges, powers and franchises of the Acquired Companies and Merger Sub, the officers and
directors of the Acquired Companies and Merger Sub immediately prior to the Effective Time are and
will remain fully authorized in the name of such Acquired Company and Merger Sub or otherwise to
take such action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 3.12</U> <U>Closing Deliveries by the Company and Escrow Participants&#146;
Representative</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Closing, the Company and Escrow Participants&#146; Representative shall deliver or cause to
be delivered to Merger Sub and Parent:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) counterparts of the Escrow Agreement, duly executed by the Escrow Participants&#146;
Representative and the Escrow Agent;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) counterparts to the Indevus Agreement, duly executed by the Company and Indevus;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) a General Release, dated as of the Closing Date, executed by each Key Stockholder and
each officer and director of each of the Acquired Companies;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) a receipt for the Closing Date Total Cash Consideration, <I>minus </I>the Indemnification Escrow
Amount, <I>minus </I>the Net Working Capital Escrow Amount, <I>minus </I>the Expense Amount, <I>minus </I>the sum of
the Option Closing Payments payable in respect of the In-the-Money Options, <I>minus </I>the sum of the
aggregate exercise price of all In-the-Money Options, duly executed by the Escrow Participants&#146;
Representative;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) a certificate executed on behalf of the Company by the Chief Executive Officer and Chief
Financial Officer of the Company certifying the satisfaction of the conditions set forth in
<U>Section&nbsp;8.02</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) a certificate of the Secretary of the Company certifying the names and signatures of the
officers of the Company authorized to sign this Agreement and the Ancillary Documents and the
other documents to be delivered hereunder and thereunder;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) a legal opinion of Milbank, Tweed, Hadley &#038; McCloy LLP, special counsel to the Company,
dated as of the Closing Date and addressed to Parent and the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">Company, addressing the matters set
forth in <U>Schedule&nbsp;D-1</U> and a legal opinion of Steven M. Bosacki, General Counsel of the
Company, dated as of the Closing Date and addressed to Parent and the Company, addressing the
matters set forth in <U>Schedule&nbsp;D-2</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) evidence in form and substance reasonably acceptable to Parent to the effect that the
consents referred to in <U>Section&nbsp;8.02(f)</U> have been obtained;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) (A)&nbsp;a copy of the certificate of incorporation of the Company, as amended through the
Effective Time (including the Charter Amendment) certified by the Secretary of State of the State
of Delaware; (B)&nbsp;a certified copy of the bylaws of the Company; (C)&nbsp;certified minutes of the Board
of Directors of the Company approving the Merger and the transaction related thereto; and (D)&nbsp;a
certified copy of the Stockholders&#146; Written Consent;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) written evidence in a form and substance reasonably acceptable to Parent that the Company
has completed the Company Divestiture;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) The original certificates, assignments, share registers and resolutions evidencing the
direct or indirect ownership by the Company in each other Acquired Company;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) good standing certificates for each Acquired Company from the Secretary of State of the
State of its incorporation or formation and, in the case of Pharma only, from the Secretary of
State of the State of New Jersey, in each case dated as of a date not earlier than five (5)
Business Days prior to the Closing Date and accompanied by bring-down telegrams dated as of the
Closing Date; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) a certificate from the Company (in a form reasonably satisfactory to Parent) certifying
that no Acquired Company is a &#147;United States real property holding corporation&#148; for purposes of
Sections&nbsp;897 and 1445 of the Code.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 3.13</U> <U>Closing Deliveries by Purchaser and Merger Sub</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) At the Closing, Parent or Merger Sub shall deliver to the Escrow Participants&#146;
Representative:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;the Expense Amount in accordance with <U>Section&nbsp;3.03</U>;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;counterparts of the Escrow Agreement, duly executed by Parent and the Escrow Agent;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;a certificate of the Secretary or an Assistant Secretary of Parent certifying the names
and signatures of the officers of Parent and Merger Sub authorized to sign this Agreement and the
Ancillary Documents and the other documents to be delivered hereunder and thereunder; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;a certificate of the Secretary or an Assistant Secretary of Parent certifying the
satisfaction of the conditions set forth in <U>Section&nbsp;8.01(a) &#150; (d)</U>.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) At the Closing, Parent shall deliver or cause to be delivered the Indemnification Escrow
Amount to the Escrow Agent, in accordance with the Escrow Agreement and <U>Section&nbsp;3.02</U>.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IV</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</B></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company hereby represents and warrants to Parent and Merger Sub that, except as set forth
in the Company Disclosure Schedule (it being understood and agreed that each item of disclosure in
a particular section or subsection of the Company Disclosure Schedule provides an exception only to
the corresponding section or subsection of this Agreement, except that the disclosure set forth in
a section or subsection of the Company Disclosure Schedule shall be deemed to qualify other
sections or subsections of the Company Disclosure Schedule to the extent that it is reasonably
apparent from the text of such disclosure that such disclosure is applicable to such other sections
or subsections of the Company Disclosure Schedule), the
statements contained in this <U>Article&nbsp;IV</U> are true and correct as of the date hereof
and as of the Closing (unless the particular statement speaks expressly as of a particular date, in
which case it is true and correct only as of such date):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.01</U> <U>Identity; Organization and Qualification</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) A true and complete list of the Acquired Companies, together with the jurisdiction of
organization, incorporation or formation of each Acquired Company and the names of the directors
and officers (or members of similar governing bodies), together with their titles, of each
Acquired Company is set forth in Section&nbsp;4.01(a) of the Company Disclosure Schedule.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each Acquired Company is an Entity duly organized, incorporated or formed, validly
existing and in good standing under the laws of the jurisdiction of its organization,
incorporation or formation and has the requisite power and authority to own, lease and operate its
properties and to carry on its business as it is now being conducted and as it is proposed to be
conducted, and to perform its obligations under all of its Contracts. No Acquired Company has
been dissolved or is in the process of being dissolved by any corporate resolutions or other
action by its directors (or members of similar governing bodies) or equity holders, any
Governmental Authority, or by the occurrence of any event or otherwise. Section&nbsp;4.01(a) of the
Company Disclosure Schedule sets forth each jurisdiction where each Acquired Company is qualified,
licensed or admitted to do business and separately lists each other state, province or country in
which each Acquired Company owns, uses, licenses or leases its assets or properties, conducts
business, has employees or engages independent contractors. Each Acquired Company is duly
qualified, licensed or admitted to do business as a foreign corporation, or otherwise, and is in
good standing, in each jurisdiction where the character of the properties owned, leased or
operated by it or the nature of its business makes such qualification, licensing or admission
necessary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.02</U> <U>Organizational Documents</U>. The Company has delivered to Parent
accurate and complete copies of: (a)&nbsp;the articles of association, certificate of incorporation and
bylaws or certificate of formation, as applicable, and other charter and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">organizational documents
of each Acquired Company, including all amendments thereto (with respect to each Acquired Company,
such Acquired Company&#146;s &#147;<U>Organizational Documents</U>&#148;); (b)&nbsp;the stock or Equity Participation
records of each Acquired Company; and (c)&nbsp;the minutes and other records of the meetings and other
proceedings (including any actions taken by written consent or otherwise without a meeting) of the
stockholders or members, as applicable, of each Acquired Company, the board of directors or similar
governing body of each Acquired Company and all committees of the board of directors or similar
governing body of each Acquired Company. There have been no formal meetings or other proceedings
of the stockholders, members or partners, as applicable, of any Acquired Company, the board of
directors or similar governing body of any Acquired Company or any committee of the board of
directors or similar governing body of any Acquired Company that are not fully reflected in such
minutes or other records. Such Organizational Documents are in full
force and effect and there has not been any violation of any of the provisions of any Acquired
Company&#146;s Organizational Documents. No Acquired Company has taken any action that is inconsistent
in any material respect with any resolution adopted by such Acquired Company&#146;s stockholders or
members, as applicable, or board of directors or similar governing body or any committees thereof.
The books of account, stock or other equity records, minute books and other records of each
Acquired Company are accurate, up-to-date and complete in all material respects, and have been
maintained in accordance with prudent business practices. All of the foregoing books and records
are in the possession of the Acquired Companies. Except as set forth in Section&nbsp;4.02 of the
Company Disclosure Schedule, the Company does not have any prior names, and since the date of its
incorporation has not conducted business under any name other than the current name of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.03</U> <U>Capitalization of the Company</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) As of the date hereof, there are issued and outstanding (a)&nbsp;210,994,205 shares of Series
A Stock, (b)&nbsp;178,138,463 shares of Series&nbsp;B Stock, and (c)&nbsp;40,898,189 shares of Common Stock. As
of the date hereof 210,994,205 shares of Common Stock are issuable upon conversion of all
outstanding shares of Series&nbsp;A Stock, 178,138,463 shares of Common Stock are issuable upon
conversion of all outstanding shares of Series&nbsp;B Stock, 5,377,488 shares of Common Stock are
issuable upon exercise of the Warrant and 11,604,520 shares of Common Stock are issuable upon
exercise of all outstanding Company Options. Each Company Option was granted under the Stock
Plan. All of the outstanding shares of Company Stock are, and all of the shares of Common Stock
that may be issued upon conversion of the Series&nbsp;A Stock or Series&nbsp;B Stock or upon exercise of the
Warrant or pursuant to outstanding Company Options will, when issued, be, duly authorized, validly
issued, fully paid and nonassessable. The Company does not hold any shares of its capital stock
in its treasury.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except as reflected on the Transaction Schedule, there are no Equity Participations of
the Company. Except for the Company Stock, Company Options, Company Warrants and except as set
forth in Section&nbsp;4.03(b) of the Company Disclosure Schedule, there is no:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Contract with respect to the issuance, sale or transfer of Equity Participations of the
Company;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Contracts with respect to the voting of any capital stock of the Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;preemptive right, right of participation, right of maintenance or any similar right with
respect to the Equity Participations of the Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Equity Participation of the Company that is subject to any right of first refusal or
similar right; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;Contract relating to the voting or registration of, or restricting any Person from
purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right
with respect to), any Equity Participation of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) There is no Contract requiring an Acquired Company to repurchase, redeem or otherwise
acquire any Equity Participations of another Entity or to provide funds to, or make any investment
(in the form of a loan, capital contribution or otherwise) in, any Person. All outstanding Equity
Participations of the Acquired Companies have been issued and granted in compliance with (i)&nbsp;all
applicable Laws and (ii)&nbsp;all requirements set forth in applicable Contracts of the issuer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Except as set forth in Section&nbsp;4.03(d) of the Company Disclosure Schedule, none of the
Acquired Companies has ever repurchased, redeemed or otherwise reacquired any of its Equity
Participations. All securities so reacquired by the Company or any other Acquired Company were
reacquired in compliance with (i)&nbsp;applicable Law, and (ii)&nbsp;all requirements set forth in
applicable Contracts of such Acquired Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.04</U> <U>Subsidiaries</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company has no Subsidiaries except for the Entities set forth in Section&nbsp;4.01(a) of
the Company Disclosure Schedule; and no Acquired Company owns, beneficially or otherwise, any
Equity Participation in, any other Entity, other than an Acquired Company. None of the Acquired
Companies has, at any time, been a general partner of, or has been responsible or liable for any
of the debts or other obligations of, any Entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each issued and outstanding Equity Participation in each Acquired Company (other than the
Company) has been validly issued and fully paid and are nonassessable and free from preemptive
rights, rights of first refusal, rights of first offer or similar rights, and are wholly owned
beneficially and of record by the Company or an Acquired Company, free and clear of all Liens of
any kind or any rights of another Person to vote, sell or otherwise dispose of such Equity
Participation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) There is no:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Contract with respect to the issuance, sale or transfer of Equity Participations of such
Subsidiary;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Contracts with respect to the voting of any capital stock of such Subsidiary;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;Contract relating to the voting or registration of any Equity Participation of a
Subsidiary; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;certain or contingent Liability to make additional payments or contributions to any
Acquired Company as holder of Equity Participations in such Acquired Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.05</U> <U>Transaction Schedule </U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Section&nbsp;4.05 of the Company Disclosure Schedule (the &#147;<U>Transaction
Schedule</U>&#148;), sets forth the following, which information is true, complete and accurate, as of
the date hereof and, as updated prior to the Closing:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;the name and the mailing address (as set forth in the Company&#146;s records) of each Company
Securityholder and indicating which Company Securityholders are Escrow Participants;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;the Closing Cash Balance;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;the total amount of Closing Company Debt;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;the total amount of Closing Change in Control Payments, including the amount of the
Excess Change in Control Payments, if any;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;the total amount of Closing Transaction Expenses;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;with respect to each Company Stock certificate held by a Company Stockholder, (A)&nbsp;the
number and class or series of shares of Company Stock represented by such certificate, (B)&nbsp;the
gross consideration payable to such Company Securityholder in respect of such shares of Company
Stock pursuant to <U>Section&nbsp;2.02(c)(i)</U> or <U>Section&nbsp;2.02(d)(i)</U>, as applicable, (C)&nbsp;the
amount, if any, to be deposited into the Indemnification Escrow Fund as specified in <U>Section
2.02(c)(ii)</U> or <U>Section&nbsp;2.02(d)(ii)</U>, as applicable, (D)&nbsp;the amount, if any, to be
deposited into the Net Working Capital Escrow Fund as specified in <U>Section&nbsp;2.02(c)(iii)</U> or
<U>Section&nbsp;2.02(d)(iii)</U>, as applicable, (E)&nbsp;the amount to be deposited into the Expense Fund
as specified in <U>Section&nbsp;2.02(c)(iv)</U> or <U>Section&nbsp;2.02(d)(iv)</U>, as applicable (the
amount determined by subtracting the foregoing amounts specified in subclauses (C), (D)&nbsp;and (E)
from the amount specified in subclause (B)&nbsp;with respect to each Company Stock certificate, the
&#147;<U>Stock Closing Payment</U>&#148;), (F)&nbsp;the Aggregate Proceeds Contribution Fraction applicable to
the shares of Company Stock represented by such certificate, (G)&nbsp;the Post-Closing Cash
Consideration Fraction applicable to the shares of Company Stock represented by such certificate
and (H)&nbsp;the aggregate amount of withholding and other Taxes, if any, to be deducted pursuant to
applicable Law from the amount set forth above in subclause (A)&nbsp;and (I)&nbsp;the net consideration
payable to such Company Stockholder at the Closing in respect of such shares of Company Stock;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;with respect to each Company Option, (A)&nbsp;the date of the issuance of such Company
Option, (B)&nbsp;the total number of shares of Common Stock subject to such Company Option, (C)&nbsp;the per
share exercise price of such Company Option, (D)&nbsp;the consideration, if any, specified in
<U>Section&nbsp;2.03(a)</U> ( the <U>&#147;Option Closing Payment&#148;)</U>, (E)&nbsp;the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">aggregate amount of
withholding and other Taxes, if any, to be deducted pursuant to applicable Law from the amount set
forth above in subclause (D), (F)&nbsp;the Post-Closing Cash Consideration Fraction applicable to the
shares of Common Stock represented by such Company Option and (G)&nbsp;the net cash consideration, if
any, payable to the holder of such Company Option in respect of such Company Option;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)&nbsp;with respect to the Warrant (A)&nbsp;the total number of shares of Common Stock subject to
the Warrant, (B)&nbsp;the per share exercise price of the Warrant, (C)&nbsp;the consideration, if any,
specified in <U>Section&nbsp;2.04(a)</U> (the &#147;<U>Warrant Closing Payment</U>&#148;), (D)&nbsp;the Post-Closing
Cash Consideration Fraction applicable to the shares of Common Stock issuable upon the automatic
exercise of the Warrant in accordance with its terms at the Effective Time, (E)&nbsp;the aggregate
amount of withholding and other Taxes, if any, to be deducted pursuant to applicable Law from the
amount set forth above in subclause (C)&nbsp;and (F)&nbsp;the net cash consideration payable to the holder of
the Warrant in respect of the Warrant;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The calculations performed to compute the information reflected in the Transaction
Schedule are, and will be, accurate and performed in accordance with the terms of this Agreement,
the Company Organizational Documents and all other Contracts and instruments among the Company and
the Company Securityholders.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) From and after the Closing, no Company Securityholder or any holder of Equity
Participations of an Acquired Company will have the right to any consideration with respect to the
Equity Participations of the Acquired Companies, except as set forth in the Transaction Schedule.
The Company has taken or prior to the Closing will take, all necessary and appropriate actions so
that each share of Company Stock, each Company Option and the Warrant will be treated in the
Transaction in accordance with <U>Article&nbsp;II</U> and <U>Article&nbsp;III</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.06</U> <U>Authority Relative to Agreement</U>. The Company has all necessary
power and authority to execute and deliver this Agreement and each Ancillary Document to which it
is a party, to perform its obligations hereunder and thereunder and to consummate the Transactions.
Except for the Requisite Stockholder Approval, the execution, delivery and performance by the
Company of this Agreement and each Ancillary Document to which it is a party and the consummation
by the Company of the Transactions have been duly and validly authorized by all necessary corporate
action on the part of the Company, and no other corporate proceedings on the part of the Company or
the Company Securityholders are necessary to authorize this Agreement or the Ancillary Documents to
which the Company is a party or to consummate the Transactions. This Agreement and each Ancillary
Document to which the Company is a party has been duly and validly executed and delivered by the
Company and, assuming the due authorization, execution and delivery by the other parties to this
Agreement, constitutes legal, valid and binding obligations of the Company, enforceable against the
Company in accordance with its terms, except as such enforceability may be limited by bankruptcy,
insolvency, reorganization, moratorium and similar laws relating to or affecting creditors
generally and by general equity principles. The Board of Directors of the Company has unanimously
determined that the Merger is in the best interests of the Company and the Company Stockholders,
has approved, in accordance with Section&nbsp;251 of the DGCL, this Agreement and declared its
advisability, and has unanimously recommended that the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Stockholders approve this Agreement
and each of the Transactions, including the Merger and such approval has not been amended,
rescinded or modified.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.07</U> <U>No Conflict; Required Filings and Consents</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The execution and delivery by the Company of this Agreement and the Ancillary Documents
to which the Company is a party do not, and the performance by the Company of its obligations
under this Agreement and the Ancillary Documents to which the Company is a party and the
consummation of the Transactions do not and will not, (i)&nbsp;conflict with, or result in any
violation or breach of, any provision of the Organizational Documents of any Acquired Company,
(ii)&nbsp;result in any violation or breach of, or constitute (with or without notice or lapse of time,
or both) a default (or give rise to a right of termination, cancellation, modification or
acceleration of any obligation or loss of any benefit) under, result in a Lien under, or require a
consent or waiver under, any of the terms, conditions or provisions of any Contract to which any
Acquired Company is a party or is otherwise bound, (iii)&nbsp;result in or give any Person any
additional right or entitlement to any increased, additional, accelerated or guaranteed payment or
performance under any of the terms, conditions or provisions of any Contract to which any Acquired
Company is a party, or (iv)&nbsp;conflict with or violate any Permit, concession, franchise, license or
Law applicable to any Acquired Company or any of the properties or assets of any Acquired Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except as may be required by the HSR Act, the execution and delivery by the Company of
this Agreement and the other Ancillary Documents to which the Company is a party do not, and the
performance of this Agreement and the other Ancillary Documents to which the Company is a party by
the Company do not and will not, require any consent, approval, authorization or Permit of, or
Order of, action by, filing with or notification to, any Governmental Authority, any Law to which
any of the Acquired Companies, or any asset owned or leased by any of the Acquired Companies, is
subject. No &#147;business combination,&#148; &#147;fair price,&#148; &#147;moratorium,&#148; &#147;control share acquisition&#148; or
other similar anti-takeover statute or regulation, including, but not limited to, Section&nbsp;203 of
the DGCL, is applicable to this Agreement, the Merger or any of the other transactions
contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Requisite Stockholder Approval is the only vote of the holders of any of the
Company&#146;s capital stock necessary to approve this Agreement and the transactions contemplated
hereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.08</U> <U>Permits; Regulatory Compliance</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each of the Acquired Companies is, and has at all times been, acting or operated in
compliance with any Law or Order applicable to the Acquired Companies and their assets and
properties. None of the Acquired Companies or any Person acting on their behalf has (i)&nbsp;received
any notice, notification or communication from any Governmental Authority or other Person
regarding any actual or possible violation of, or failure to comply with any provision of, any Law
or Order applicable to the Acquired Companies or their assets or properties, or (ii)&nbsp;filed or
otherwise provided any notice, notification or communication to any Governmental Authority or
other Person regarding any actual or possible material violation of,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">or failure to comply with any
material provision of any Law or Order applicable to the Acquired Companies or their assets or
properties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Without limiting the generality of <U>Section&nbsp;4.08(a)</U>, none of the Acquired
Companies (including any of their officers, directors, agents, employees or other Person
associated with or acting on their behalf) has, directly or indirectly, taken any action which
would cause it to be in violation of the U.S. Foreign Corrupt Practices Act, as amended, or any
rules or regulations thereunder, including by offering or conveying, directly or indirectly (such
as through an agent), anything of value to obtain or retain business or to obtain any improper
advantage, including any bribe, rebate, payoff, influence payment, kickback or other similar
unlawful payment to a foreign government official, candidate for office, or political party or
official of a political party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Each Acquired Company is and has at all times been in possession of all Permits necessary
for it to own, lease and operate its properties or to carry on its business as it is now being
conducted, and as the same has been conducted or as it is proposed to be conducted. A true and
complete list of each such Permits is set forth on Section&nbsp;4.08(c) of the Company Disclosure
Schedule, and each such Permit is valid and in full force and effect, and accurate and complete
copies of such Permits have been delivered to Parent. No Acquired Company or any Person acting on
their behalf, is or has been in conflict with, or in default, breach or violation of any Permit of
such Acquired Company to operate its business or by which any property or asset of such Acquired
Company is bound. No suspension or cancellation of any Permit of an Acquired Company is pending
or, to the Knowledge of the Acquired Companies, threatened. None of the Acquired Companies has
received any notice from any Governmental Authority regarding (i)&nbsp;any actual or possible violation
of or failure to comply with any term or requirement of any such Permit, or (ii)&nbsp;any actual or
possible revocation, withdrawal, suspension, cancellation, termination or modification of any such
Permit. No Governmental Authority is challenging or has challenged the right of any of the
Acquired Companies to own, lease or operate its properties or to carry on its business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) (i)&nbsp;With respect to the Products, (A)&nbsp;each Acquired Company that designs, develops,
tests, studies, manufactures, processes, stores, imports or exports, licenses, labels or packages,
distributes, or markets any of its products or services, including the Products, and each company
that conducts such activity on behalf of each Acquired Company has obtained, unless otherwise
exempt, all necessary and applicable Permits to permit such design, development, testing ,
studying, manufacturing, processing, storing, importing or exporting, licensing, labeling or
packaging, distribution, or marketing any of its products or services, including of the Products,
to the extent necessary according to Law and applicable to the Acquired Company&#146;s business to
date; and (B)&nbsp;each site at which the Products are designed, developed, tested, studied,
manufactured, processed, stored, imported or exported, licensed, labeled or packaged, distributed
or marketed is in compliance with all Laws regarding registration, licensure, and certification;
(ii)&nbsp;with respect to all manufacturing operations relating to the Products performed by, or on
behalf of, the Acquired Companies, (A)&nbsp;such manufacturing operations have been and are being
conducted in all material respects in compliance with applicable Good Manufacturing Practices, or
equivalent such practices, in the all countries where such compliance is required; (B)&nbsp;the
Products have been
manufactured in accordance with the Acquired Company&#146;s specifications; and (C)
the Products have not been
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">adulterated or misbranded within the meaning of the FDA Act or any
comparable Law in other jurisdictions; (iii)&nbsp;all non-clinical and clinical studies of the Products
under development, sponsored by the Company and intended to be used to support regulatory
clearance or
approval, have been and are being conducted (A)&nbsp;to the extent applicable, in compliance with
accepted professional standards and Law, including the Good Laboratory Practice and Good Clinical
Practices and regulations or guidances of Governmental Authorities and, if applicable, the
requirements of the FDA Act and its applicable implementing regulations at 21 C.F.R. Parts 11, 50,
54, 56, 58, and 312, 314, and (B)&nbsp;to the extent applicable, counterpart regulations in all other
countries; and (C)&nbsp;in compliance with protocols approved by an institutional review board. To the
Knowledge of the Company, there has been no notice or communication from any Governmental
Authority, or any institutional review board, requiring the termination, suspension, or material
modification of any non-clinical or clinical study; and (iv)&nbsp;the Acquired Companies are in
compliance with all applicable reporting requirements for all Permits or plant registrations
described in subclause &#147;(i)&#148; above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Each Acquired Company is in compliance with all Laws and all Orders applicable to the
maintenance, compilation and filing of reports, including, but not limited to, periodic or annual,
or other reports, with regard to the Products. Each Acquired Company has filed with the
applicable Governmental Authority all applicable adverse event or product safety reports required
to be filed in relation to the Products, including any Serious Adverse Event reports or Adverse
Drug Reaction Reports to the extent applicable to the business of the Acquired Companies and as
required to be submitted under applicable Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Except as disclosed in Section&nbsp;4.08(f) of the Company Disclosure Schedule, the Products
have not been recalled, withdrawn, suspended or discontinued by any Acquired Company or any
Governmental Authority (whether voluntarily or otherwise). No Governmental Authority has required
revision of the Product labeling or indication for use. No proceedings in the United States or
outside the United States seeking the recall, withdrawal, suspension, seizure or discontinuance of
the Products, or suspension or termination of any study, or revision of the Product labeling are
pending against any Acquired Company or, to the Knowledge of the Acquired Companies, Person acting
on their behalf, or any licensee or distributor of the Products, nor have any such proceedings
been pending at any prior time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) The Acquired Company has not received any notice or communication from any Governmental
Authority or other Person (i)&nbsp;contesting the pre-market clearance or approval of, the clinical or
non-clinical testing of, the uses of or the labeling, promotion, or distribution of the Products
or (ii)&nbsp;otherwise alleging any violation of Laws by the Company. As to any Products for which a
new drug application or an investigational new drug application, or any similar state or foreign
Governmental Authority application has been submitted or approved, the Acquired Companies are in
material compliance with all applicable Laws. As to each such Product, the Acquired Companies
have included in the application, where required, the certification regarding use of debarred
persons in connection with application, described in 21 U.S.C. Section&nbsp;335a(k)(1), and the list of
all convictions described in 21 U.S.C. Section&nbsp;335a(k)(2), and each such certification and list
was true, complete and correct in all material respects when made. In addition, the Acquired
Companies are in substantial compliance with all applicable registration and listing requirements
set forth in 21 U.S.C. Section&nbsp;360. To the Knowledge of the Acquired Companies, no communication,
filing
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">or submission to any Governmental Authority or third party insurer with regard to the
Products that is or is intended to be the basis for any approval contains any material omission or
any false information.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) None of the Acquired Companies or, to the Knowledge of the Acquired Companies, any
director or employee of any Acquired Company (i)&nbsp;has been convicted of, charged with or, to the
Knowledge of the Acquired Companies, investigated by a Governmental Authority for violation of, or
non-compliance with applicable Healthcare Laws, or any regulations promulgated pursuant to such
Laws, including offenses relating to the United States Medicare or Medicaid programs or comparable
foreign Law or applicable codes or programs, (ii)&nbsp;has been convicted of, charged with or, to the
Knowledge of the Acquired Companies, investigated for a violation of Healthcare Law related to
fraud, theft, embezzlement, financial misconduct, billing third party payors, obstruction of an
investigation or participation in any Governmental Authority health-care programs, (iii)&nbsp;has been
excluded or suspended from participation in any federal or foreign health program of a
Governmental Authority, including the United States Medicare, or Medicaid programs, (iv)&nbsp;the
Acquired Companies have not been subject to any Order or any criminal or civil fine or penalty
imposed by any Governmental Authority with respect to any such health care program or applicable
Heathcare Law of a Governmental Authority, or (v)&nbsp;has Knowledge of any circumstances which could
reasonably be expected to give rise to any action described in items &#147;(i)&#148; through &#147;(iv)&#148; above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) None of the Acquired Companies has engaged in or received notice or communication of any
arrangement providing for any rebates, discounts, kickbacks or other forms of compensation to be
paid to any Person or entity in return for the referral of business or for the arrangement for
recommendation of such referrals that is unlawful in any material respect; and none of the
Acquired Companies has any financial arrangement which renders any of its claims for payment of
its Products and services unlawful pursuant to any Healthcare Law in any material respect. No
communication, filing or submission by or on behalf of the Acquired Company to any Governmental
Authority or third party insurer with regard to the Products that is or is intended to be the
basis for any reimbursement contains any material omission or any false information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.09</U> <U>Financial Information; Books and Records</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Section&nbsp;4.09(a) of the Company Disclosure Schedule contains a true, correct and complete
copy of the Financial Statements. The Company represents and warrants that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;the Financial Statements have been prepared in accordance with GAAP applied on a basis
consistent throughout the periods indicated and consistent with each other (except as may be
indicated in the notes thereto as delivered to Parent prior to the date hereof);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;the Financial Statements present fairly and accurately in all material respects the
financial condition and operating results of the Company and its Subsidiaries (including, assets,
liabilities, income, expenses, and cash-flows) as of the dates and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">during the periods indicated
therein, subject, in the case of the Interim Financial Statements, to
normal year-end adjustments, which adjustments will not be material in amount or significance;
and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;the Financial Statements were prepared in accordance with the books of account and other
financial records of the Acquired Companies, which books of account and other financial records are
accurate, complete and current.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The relevant auditors have issued unqualified audit reports in respect of each of the
Consolidated Financial Statements, subject to a note indicating that the auditors had substantial
doubt about the Company&#146;s ability to continue as a going concern due to its requiring additional
debt or equity financing to fund ongoing operations in 2007 and to satisfy certain milestone
payment commitments. There are no other written communications of the auditors to the Company
covering the periods reflected in the Financial Statements, other than those listed in Section
4.09(b) of the Company Disclosure Schedule. The Company has not withheld any information from the
auditors, which, if disclosed would have caused the auditors to qualify their audit report or to
refuse to issue their report with respect to any of the audited Consolidated Financial Statements.
No auditor to an Acquired Company has ever declined or indicated its inability to issue an
opinion with respect to any financial statements of such Acquired Company or its Subsidiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Each of the Acquired Companies maintains adequate internal accounting controls that are
reasonably designed to ensure that: (i)&nbsp;transactions are executed with management&#146;s general or
specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of the
Financial Statements in accordance with GAAP and to maintain accountability for the assets of the
Acquired Companies; (iii)&nbsp;access to the assets of the Acquired Companies is permitted only in
accordance with management&#146;s general or specific authorization; and (iv)&nbsp;accounts, notes,
inventories and receivables are recorded accurately and appropriate action is taken with respect
to any differences. There have been no instances of fraud, whether or not material, that occurred
during any period covered by the Financial Statements. None of the Acquired Companies or any
director, or officer, or, to the Knowledge of the Acquired Companies, any employee, accountant or
auditor of any Acquired Company, has received or otherwise had or obtained Knowledge of any
complaint, allegation, assertion or claim, whether written or oral, regarding the accounting or
auditing practices and procedures of any Acquired Company or their respective internal accounting
controls.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) None of the Acquired Companies has any Liabilities (whether or not required to be
reflected in Financial Statements in accordance with GAAP, and whether due or to become due),
except for: (i)&nbsp;Liabilities identified as such in the &#147;liabilities&#148; column of the Interim Balance
Sheet; (ii)&nbsp;normal and recurring current liabilities that have been incurred by the Acquired
Companies since December&nbsp;31, 2006 in the Ordinary Course of Business; (iii)&nbsp;liabilities incurred
in connection with the performance of (and not the breach by any Acquired Company or the
incurrence of any Acquired Company of indemnification obligations under) Contracts to which the
Acquired Companies are Parties, including the Material Contracts set forth in Section&nbsp;4.19 of the
Company Disclosure Schedule. No event has occurred, and no circumstance or condition exists, that
has resulted in, or that will or would reasonably be expected to result in, any claim for
indemnification or reimbursement by any employee of any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">Acquired Company (other than a claim for
reimbursement by an employee, in the Ordinary
Course of Business, of travel expenses, accrued vacation or other out-of-pocket expenses of a
routine nature incurred by such employee in the course of performing such employee&#146;s duties)
pursuant to (A)&nbsp;the terms of the Acquired Companies&#146; Organizational Documents, (B)&nbsp;any
indemnification agreement or other Contract between an Acquired Company and any such employee, or
(C)&nbsp;any applicable Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.10</U> <U>Bank Accounts; Receivables; Payables; Customers and
Suppliers; Inventory</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Section&nbsp;4.10(a) of the Company Disclosure Schedule sets forth (i)&nbsp;a true and complete
list of the names and locations of all banks, trust companies, securities brokers and other
financial institutions at which any of the Acquired Companies has an account or a safe deposit box
or maintains a banking, custodial, trading or other similar relationship (ii)&nbsp;a true and complete
list and description of each such account, box or relationship, indicating in each case the number
of each account (including the passwords and the codes associated with each account) and the
respective officers, employees, agents or other similar representatives of the Acquired Companies
having signatory power with respect thereto, and (iii)&nbsp;a list of each Equity Participation,
debenture, note, mortgage, certificate or other assets, the name of the record and beneficial
owner thereof, the location of such, the maturity date (if any) and any stock or bond powers or
other authority for transfer granted with respect thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Section&nbsp;4.10(b) of the Company Disclosure Schedule sets forth a list and aging of all
accounts and notes receivable of the Acquired Companies as of June&nbsp;30, 2007. All existing accounts
receivable of the Acquired Companies (including those accounts receivable reflected on the Interim
Financial Statements that have not yet been collected and those accounts receivable that have
arisen since June&nbsp;30, 2007 and have not yet been collected) (i)&nbsp;represent valid obligations of
customers of the Acquired Companies arising from bona fide transactions entered into in the
Ordinary Course of Business and (ii)&nbsp;are current and, to the Knowledge of the Acquired Companies,
will be collected in full (subject to the bad debt reserve reflected on the Interim Financial
Statements) without any counterclaim or set off.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Section&nbsp;4.10(c) of the Company Disclosure Schedule sets forth a list of all outstanding
loans and advances made by any of the Acquired Companies to any stockholder, employee, director,
consultant or independent contractor, other than advances made to employees, directors,
consultants or independent contractors for business expenses in the Ordinary Course of Business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Section&nbsp;4.10(d) of the Company Disclosure Schedule sets forth an accurate and complete
breakdown of amounts paid to, each supplier that received more than $100,000 from the Acquired
Companies during the fiscal year ended December&nbsp;31, 2006 and lists the amounts paid by the
Acquired Companies to each such supplier during such period. None of the Acquired Companies has
received any written notice from any such supplier indicating that any such supplier identified on
Section&nbsp;4.10(d) of the Company Disclosure Schedule plans to cease dealing with any of the Acquired
Companies or may otherwise materially reduce the volume of business transacted by such supplier
with any of the Acquired Companies below historical levels.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Section&nbsp;4.10(e) of the Company Disclosure Schedule sets forth an accurate and complete
list of each customer of the Acquired Companies as of the date of this Agreement. None of the
Acquired Companies has received any written notice indicating that any customer or other Person
identified on the list referred to in the preceding sentence may cease dealing with any of the
Acquired Companies or may otherwise materially reduce the volume of business transacted by such
Person with any of the Acquired Companies below historical levels.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) All inventory of the Company reflected on the Interim Financial Statements consisted, and
all inventory acquired since the date of the Interim Balance Sheet consists, of a quality and
quantity usable and salable in the Ordinary Course of Business, subject to the applicable reserve
reflected on the Interim Financial Statements. All items of Inventory have been produced or
manufactured and stored in accordance with the Company&#146;s specifications established for the
manufacture and storage thereof. All items included in the inventory of the Company are the
property of the Company free and clear of any Lien, have not been pledged as collateral (except
under the Loan Agreement), are not held by the Company on consignment from any Person and conform
in all material respects to all standards applicable to each inventory or its use or sale imposed
by any Governmental Authority or Law and, as of the Closing and except as otherwise set forth on
Section&nbsp;4.10(f) of the Company Disclosure Schedule, do not have an expiration dates prior to
twelve (12)&nbsp;months following the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.11</U> <U>Absence of Certain Changes or Events</U>. Since December&nbsp;31, 2006
the Acquired Companies have operated their business in the Ordinary Course of Business and there
has not been any Material Adverse Effect. Without limiting the generality of the foregoing, since
December&nbsp;31, 2006, none of the Acquired Companies has:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) experienced any material loss, damage or destruction to, or any material interruption in
the use of, any of the assets of such Acquired Company (whether or not covered by insurance);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) amended any of the Organizational Documents of such Acquired Company, or effected or been
a party to any acquisition transaction, recapitalization, reclassification of shares, stock split,
reverse stock split or similar transaction;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) declared, accrued, set aside or paid any dividend or made any other distribution in
respect of any shares of capital stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) sold, issued or authorized the issuance of any Equity Participations (except for shares
of Common Stock issued upon the exercise of outstanding Company Options);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) formed any Subsidiary or acquired any Equity Participation in any other Entity;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) incurred, or entered into any Contract with respect to, any Indebtedness or subjected any
of its properties or assets to any Lien;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) amended or waived any of its rights under, or permitted the acceleration of vesting
under, (i)&nbsp;any provision of the Stock Plan or (ii)&nbsp;any provision of any agreement evidencing any
outstanding Company Option;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) adopted, amended or terminated any Benefit Plan, other than as may have been required by
applicable Law;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) increased any compensation or fringe benefits, paid any bonus, other than in the Ordinary
Course of Business, granted or increased any severance or termination pay or otherwise changed any
of the terms of employment or service for any of its directors or officers or its employees,
consultants or agents;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) made any payment of any nature to any employee, director, officer, consultant or Company
Securityholder, other than compensation as an employee of the Company or the payment of benefits
pursuant to a Benefit Plan, in each case payable in the Ordinary Course of Business, or payment in
reimbursement or advancement of reasonable business expenses;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) forgiven or canceled any Indebtedness owed to it or claims held by it, or waived or
relinquished any right having a value in excess of $25,000 individually or in the aggregate;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) (i)&nbsp;acquired, leased or licensed any right or other asset from any other Person in excess
of $25,000 individually or $100,000 in the aggregate, (ii)&nbsp;sold or otherwise disposed of, or
leased or licensed, any right or other asset to any other Person in excess of $25,000 individually
or $100,000 in the aggregate, in each case except for the acquisition of supplies in the Ordinary
Course of Business, the acquisition of capital assets subject to <U>Section&nbsp;4.10(o)</U> below,
the sale of products in the Ordinary Course of Business, the disposal of obsolete equipment in the
Ordinary Course of Business and the Company Divestiture;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) incurred a capital expenditure or made a commitment to incur a capital expenditure
exceeding $50,000 in the aggregate;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) revalued any of its properties or assets (whether tangible or intangible), including
writing down the value of inventory, writing off accounts receivable as uncollectible, or
establishing any extraordinary reserve with respect to any account receivable;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) failed to pay its obligations or satisfy its Liabilities as the same have become due and
payable or requested an extension for the payment of obligations or satisfaction of Liabilities
that would have otherwise become due and payable;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) sold its products outside of the Ordinary Course of Business, including selling products
that it reasonably believe are in excess of market demand;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) changed any of its methods of accounting or accounting practices in any respect, other
than as required by GAAP;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) changed any election in respect of Taxes, adopted or changed any accounting method in
respect of Taxes, agreed or settled any claim or assessment in respect of Taxes, filed any amended
Tax Return, entered into any tax allocation agreement, tax sharing agreement, tax indemnity
agreement or closing agreement relating to any Tax, surrendered any right to claim a material Tax
refund, or extended or waived the limitation period applicable to any claim or assessment in
respect of Taxes;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) commenced or settled any Action or obtained Knowledge of the commencement, settlement,
notice or threat of any Action against the Acquired Company, or any reasonable basis for any of
the foregoing;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) changed or modified its credit, collection or payment policies, procedures or practices,
including accelerating collections or receivables (whether or not past due) or failed to pay or
delayed payment of payables or other Liabilities;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) entered into any material transaction or taken any other material action outside the
Ordinary Course of Business, except for the Company Divestiture; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) agreed or committed to take any of the actions referred to in subclauses &#147;(b)&#148; through
&#147;(u)&#148; above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.12</U> <U>Absence of Litigation</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) There is no Action pending or, to the Knowledge of the Acquired Companies, threatened
against any Acquired Company, or any property or asset of an Acquired Company. None of the
Acquired Companies nor any property or asset of any Acquired Company is subject to any continuing
Order of, settlement agreement or similar written agreement with, or, to the Knowledge of the
Acquired Companies, continuing investigation by, any Governmental Authority. There is no fact or
circumstance known to the Company that, either alone or together with other facts and
circumstances, could reasonably be expected to give rise to any Action against, relating to or
affecting any Acquired Company or any of their assets or properties. None of the Key Stockholders
are subject to any Order of any Governmental Authority that relates to the business of any
Acquired Company or to any of the assets owned or used by any Acquired Company. To the Knowledge
of the Acquired Companies, no officer or key employee of any of the Acquired Companies is subject
to any Order of any Governmental Authority that prohibits such officer or employee from engaging
in or continuing any conduct, activity or practice relating to the business of any of the Acquired
Companies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) No Acquired Company has threatened, initiated or taken any steps towards the commencement
of any Action against any other Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.13</U> <U>Employee Benefit Plans</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Section&nbsp;4.13(a) of the Company Disclosure Schedule sets forth and true and complete list
of all Benefit Plans. The Company has delivered to Parent a true and complete copy of each
Benefit Plan and has delivered to Parent a true and complete copy of the following items (in each
case, only if applicable) (i)&nbsp;each trust or other funding arrangement,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">(ii)&nbsp;each summary plan
description and summary of material modifications, (iii)&nbsp;the most recently filed annual reports on
IRS Form&nbsp;5500 for each such Benefit Plan, (iv)&nbsp;the most recently received IRS determination letter
for each such Benefit Plan, and (v)&nbsp;for each Benefit Plan that is not in writing, a written
description of the material terms of such Benefit Plan. Except as provided for in this Agreement
or the Benefit Plans listed in Section&nbsp;4.13(a) of the Company Disclosure Schedule, none of the
Acquired Companies has any express or implied commitment, whether legally enforceable or not, (A)
to create, incur any Liability with respect to or cause to exist any other employee benefit plan,
program or arrangement, (B)&nbsp;to enter into any Contract to provide compensation or benefits to any
individual or (C)&nbsp;to modify, change or terminate any Benefit Plan, other than with respect to a
modification, change or termination required by applicable Laws, including the United States
Employee Retirement Income Security Act of 1974, as amended (&#147;<U>ERISA</U>&#148;) or the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except for the Stock Plan, no Acquired Company has any stock option, stock incentive,
stock award, equity compensation or other plan pursuant to which an Acquired Company has granted
Equity Participations.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) All Company Options that have been granted to any person who is subject to taxation in
the U.S. upon the exercise of the Company Options have been granted or issued at an exercise price
equal to the fair market value of the underlying Common Stock at the date of grant or issuance, as
determined in accordance with Section&nbsp;409A of the Code and the temporary regulations and notices
promulgated thereunder, if applicable, and none of such Company Options or any other Equity
Participations of an Acquired Company or agreements constitute &#147;deferred compensation&#148; under
Section&nbsp;409A of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) None of the Acquired Companies has now or at any time contributed to, sponsored, or is
(i)&nbsp;an employee pension benefit plan (within the meaning of Section&nbsp;3(2) of ERISA), which is or
has been subject to Section&nbsp;412 of the Code or Title IV of ERISA, (ii)&nbsp;a multiemployer plan
(within the meaning of Section&nbsp;3(37) or 4001(a)(3) of ERISA) or (iii)&nbsp;a single employer pension
plan (within the meaning of Section&nbsp;4001(a)(15) of ERISA) for which any Acquired Company could
incur Liability under Section&nbsp;4063, Section&nbsp;4064, Section&nbsp;4069 or Section 4212(c) of ERISA.
Except as disclosed in Section&nbsp;4.13(d) of the Company Disclosure Schedule, none of the Benefit
Plans (A)&nbsp;provides for the payment of separation, severance, termination or similar-type benefits
to any person, (B)&nbsp;obligates any Acquired Company to pay separation, severance, termination or
similar-type benefits solely or partially as a result of any Transaction or (C)&nbsp;obligates any
Acquired Company to make any payment or provide any benefit as a result of a &#147;change in control&#148;,
within the meaning of such term under Section&nbsp;280G of the Code. Except as required under Part&nbsp;6
of Title 1 Subtitle B of ERISA or similar state Law, none of the Benefit Plans provides for or
promises retiree medical, retiree disability or retiree life insurance benefits to any current or
former employee, officer or director of any Acquired Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Each Benefit Plan is now and always has been operated in all material respects in
accordance with its terms and the requirements of all applicable Laws. Each Acquired Company has
performed all material obligations required to be performed by it under, is not in any material
respect in default under or in violation of, and has no Knowledge of any material default or
material violation by any party to, any Benefit Plan. No Action is
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">pending or threatened with
respect to any Benefit Plan (other than claims for benefits in the ordinary course) and, to the
Knowledge of the Acquired Companies, no fact or event exists that could reasonably be expected to
give rise to any such Action.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Each Benefit Plan that is intended to be qualified under Section 401(a) of the Code or
Section 401(k) of the Code has timely received a favorable determination letter from the IRS
covering all of the provisions applicable to the Benefit Plan for which determination letters are
currently available that the Benefit Plan is so qualified and , to the Knowledge of the Acquired
Companies, no fact or event has occurred since the date of such determination letter or letters
from the IRS to adversely affect the qualified status of any such Benefit Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) All employer or employee contributions, premiums or payments required by Law or pursuant
to the terms of any Benefit Plan to be made with respect to any Benefit Plan, have been made or,
if applicable, accrued in accordance with normal accounting practices, and, to the extent required
by the terms of such Benefit Plan, a pro rata contribution for the period prior to and including
the date of this Agreement has been made or accrued.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) None of the Acquired Companies is or at any time has been a member of any &#147;controlled
group of corporations,&#148; under &#147;common control,&#148; or a member of an &#147;affiliated service group,&#148; as
such terms are defined in Section&nbsp;414(b), (c), (m)&nbsp;or (o)&nbsp;of the Code, with any Person other than
the Company Securityholders and their Subsidiaries and none of the Acquired Companies has incurred
any Liability with respect to any Benefit Plan, or under any other compensation or employee
benefit plan, agreement, program, policy or other arrangement maintained by any Person other than
one or more of the Acquired Companies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) None of the Acquired Companies has made any payments, is obligated to make any payments,
or is a party to any Contract that under certain circumstances could obligate it to make any
payments, that will not be deductible under Code Section&nbsp;280G.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.14</U> <U>Labor and Employment Matters</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Section&nbsp;4.14(a) of the Company Disclosure Schedule sets forth a complete and accurate
list of all employees of the Acquired Companies, their current annualized base salary, their
expected or target bonus to be paid in 2007 and their state, province and country of employment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each of the Acquired Companies is in compliance, in all material respects, with all
contractual, legal, regulatory and other obligations relating to the employment of labor,
including those related to wages, hours, immigration and naturalization, insurance
coverage, Social Security, pension plans, data protection, Tax, prohibition of discrimination
due to age, gender, race, national origin or disability, religion, occupational safety and health
requirements and collective bargaining, WARN and any similar state or local &#147;mass layoff&#148; or
&#147;plant closing&#148; Laws. There has been no &#147;mass layoff&#148; or &#147;plant closing&#148; (as defined by WARN)
with respect to the Company within the six (6)&nbsp;months prior to Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Except as disclosed in Section&nbsp;4.14(c) of the Company Disclosure Schedule, there are no
claims relating to unfair labor practices or labor issues pending or, to the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">Knowledge of the
Acquired Companies, threatened between any Acquired Company and its employees or any trade union
or any other similar organization.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Except as disclosed in Section&nbsp;4.14(d) of the Company Disclosure Schedule, there is no
charge or proceeding with respect to a violation of any occupational safety or health standards
that has been asserted or is now pending or, to the Knowledge of the Acquired Companies,
threatened with respect to any Acquired Company. There is no charge of discrimination in
employment or employment practices, for any reason, including age, gender, race, religion or other
legally protected category, which has been asserted or is now pending or, to the Knowledge of the
Acquired Companies, threatened with respect to any Acquired Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) None of the Acquired Companies is a party to any collective bargaining agreement or other
labor union Contract applicable to persons employed by any Acquired Company, nor, to the Knowledge
of the Acquired Companies, are there any activities or proceedings of any labor union to organize
any such employees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Each Acquired Company has, to the extent required by GAAP, paid in full to all employees
or adequately accrued for in accordance with GAAP consistently applied all wages, salaries,
commissions, bonuses, benefits and other compensation due to or on behalf of such employees and
there is no claim with respect to payment of wages, salary or overtime pay that has been asserted
or is now pending or, to the Knowledge of the Acquired Companies, threatened before any
Governmental Authority with respect to any persons currently or formerly employed by any Acquired
Company. None of the Acquired Companies are a party to, or otherwise bound by, any consent decree
with, or citation by, any Governmental Authority relating to employees or employment practices.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.15</U> <U>Real Property; Title to Assets</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) None of the Acquired Companies owns or formerly owned any real property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Section&nbsp;4.15(b) of the Company Disclosure Schedule sets forth a true and complete list
each parcel of real property currently or formerly leased or subleased by any Acquired Company,
with the name of the lessor and the date of the lease, sublease, assignment of the lease, any
guaranty given or leasing commissions payable by any Acquired Company in connection therewith and
each amendment to any of the foregoing and all ancillary documents
pertaining thereto (collectively, the &#147;<U>Lease Documents</U>&#148;). True, correct and complete
copies of all Lease Documents have been delivered to Parent. All such current leases and
subleases are in full force and effect, are valid and effective in accordance with their
respective terms, and there is not, under any of such leases, any existing default or event of
default (or event which, with notice or lapse of time, or both, would constitute a default) by any
Acquired Company or, to the Knowledge of the Acquired Companies, by the other party to such lease
or sublease. To the Knowledge of the Acquired Companies, each parcel of real property leased by
any Acquired Company is neither subject to any Order of a Governmental Authority to be sold nor is
being condemned, expropriated or otherwise taken by any Governmental Authority, nor, to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">the Knowledge of the Acquired Companies, has any such condemnation, expropriation or taking been
proposed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Lease Documents grant to the tenant thereunder the exclusive right to use and occupy
the premises demised thereunder, and the Company has not entered into any lease or sublease
granting any Person the right to occupy or use (or the option to exercise the right to occupy or
use) all or any portion of such premises.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Except with respect to Intellectual Property, the tangible and intangible assets used by
the Acquired Companies in the operation of their business:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;belong to or may be lawfully used by the Acquired Companies, free and clear of any Lien,
other than (A)&nbsp;Liens for current Taxes and assessments not yet past due, (B)&nbsp;inchoate mechanics&#146;
and materialmen&#146;s Liens for construction in progress, (C)&nbsp;workmen&#146;s, repairmen&#146;s, warehousemen&#146;s
and carriers&#146; Liens arising in the Ordinary Course of Business, and (D)&nbsp;Liens and other
imperfections of title and encumbrances that do not materially reduce the value of the asset
subject thereto or impair its use by the Acquired Companies; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;are sufficient for the continuation of the business of the Acquired Companies after the
Closing in substantially the same manner as it is currently conducted.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Acquired Companies have taken all commercially reasonable efforts to maintain the
rights of the Acquired Companies to their assets, whether tangible or intangible.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The tangible assets owned or used by the Acquired Companies are in good operating
condition and repair taking into account normal wear and tear.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) There has been no termination of, or threat to terminate, the right of any Acquired
Company to use or possess any of its assets, whether tangible or intangible, that are necessary
for the continuation of the business of the Acquired Companies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.16</U> <U>Intellectual Property</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Section&nbsp;4.16(a) of the Company Disclosure Schedule accurately and completely sets forth:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;in Section&nbsp;4.16(a)(i) of the Company Disclosure Schedule: (A)&nbsp;each item of Registered IP
and each Proprietary Name in which any of the Acquired Companies has an ownership interest of any
nature (whether exclusively or jointly with another Person); (B)&nbsp;the jurisdiction in which such
item of Registered IP has been registered or filed and the applicable registration or serial
number; and (C)&nbsp;any other Person that has an ownership interest in such item of Registered IP or
Proprietary Name and the nature of such ownership interest;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;in Section&nbsp;4.16(a)(ii) of the Company Disclosure Schedule: (A)&nbsp;all Acquired Company
Licensed IP and (B)&nbsp;the corresponding Contract or Contracts pursuant to which such Intellectual
Property is licensed to such Acquired Company;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;in Section&nbsp;4.16(a)(iii) of the Company Disclosure Schedule, each Contract pursuant to
which any Person other than an Acquired Company has received or been granted a license or other
right (other than an ownership interest) in or to any of the Acquired Company IP, including
covenants-not-to-sue, cross-licenses and development licenses; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;in Section&nbsp;4.16(a)(iv) of the Company Disclosure Schedule, each Contract pursuant to
which any Intellectual Property was developed by an Acquired Company or by a third party, where the
terms of such Contract expressly contemplate (A)&nbsp;the development of any Acquired Company IP by such
third party, where the Acquired Company exclusively owns the Acquired Company IP (excluding
employee proprietary inventions and assignment agreements and any agreements pursuant to which a
individual consultant or independent contractor performed services on a full-time basis on behalf
of such Acquired Company while onsite at the Acquired Company&#146;s facilities); (B)&nbsp;the development of
any Intellectual Property by the Acquired Company on behalf of such third party, where the third
party exclusively or jointly owns the resulting Intellectual Property; or (C)&nbsp;the collaborative
development of Intellectual Property by the Acquired Company and such third party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except for any licenses and rights granted in the Acquired Company Contracts expressly
identified in Section&nbsp;4.16(a)(ii) and (iii)&nbsp;of the Company Disclosure Schedule, none of the
Acquired Companies is bound by, and no Acquired Company IP is subject to, any Contract containing
any covenant or other provision that in any material way limits or restricts the ability of any of
the Acquired Companies to use, exploit, assert, or enforce any Acquired Company IP anywhere in the
world. None of the Acquired Companies has transferred any portion of ownership of any Acquired
Company Owned IP to any third party, or knowingly permitted any Acquired Company IP to enter the
public domain or, with respect to any Acquired Company IP for which any of the Acquired Companies
has submitted an application or obtained a registration, to lapse (other than through the
expiration of an item of Registered IP at the end of its maximum statutory term). None of the
Acquired Companies has an explicit or implied legal obligation, absolute or contingent, to any
other Person to license, sell, transfer or assign any of the Acquired Company IP.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Acquired Companies exclusively own all right, title and interest to and in, or have a
valid and enforceable right to use, the Acquired Company IP (other than Intellectual Property set
forth in Section&nbsp;4.16(a)(i)-(iv) of the Company Disclosure Schedule as being subject to the
ownership interest of another Person) free and clear of any Lien (other than licenses granted
pursuant to the Contracts set forth in Section&nbsp;4.16(a)(ii) and (iii)&nbsp;of the
Company Disclosure Schedule). Without limiting the generality of the foregoing, except as
set forth in Section&nbsp;4.16(c) of the Company Disclosure Schedule:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;each Person who is or was an employee, consultant or independent contractor of any of the
Acquired Companies and who is or was involved in the creation or development of any Acquired
Company Owned IP, or who is or was named as an inventor on any patent application filed or owned by
any Acquired Company, has signed one or more valid and enforceable agreements containing an
irrevocable assignment of that Person&#146;s rights in Intellectual Property to the Acquired Company for
which such Person is or was an employee, consultant or independent contractor, and confidentiality
provisions protecting the Acquired Company Owned IP, and, no current or former employee, consultant
or independent contractor
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of any of the Acquired Companies: (A)&nbsp;is in violation of any term or
covenant of any Contract relating to employment, invention disclosure, invention assignment,
non-disclosure or non-competition or any other Contract with any other party (including academic or
medical institutions) by virtue of such employee, consultant or independent contractor being
employed by, or performing services for, any of the Acquired Companies or using trade secrets or
proprietary information of others without permission; or (B)&nbsp;has developed any technology, software
or other copyrightable, patentable or otherwise proprietary work for any of the Acquired Companies
that is subject to any Contract under which such employee, consultant or independent contractor has
assigned or otherwise granted, or is obligated to assign or otherwise grant, to any third party any
rights in or to such technology, software or other copyrightable, patentable or otherwise
proprietary work;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;no current or former employee, consultant or independent contractor of any Acquired
Company has any claim, license, right (whether or not currently exercisable) or interest to or in
any Acquired Company Owned IP;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;to the Knowledge of the Acquired Companies, no current or former employee, consultant,
or independent contractor who has performed services onsite at the Acquired Companies&#146; facilities
for any of the Acquired Companies is in breach of any Contract with any former employer or other
Person concerning Intellectual Property or confidentiality, where the cause or nature of the breach
arises out of the performance of any services related to the development of any Acquired Company
Owned IP by such employee, consultant, or independent contractor on behalf of any Acquired Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;no funding, facilities or personnel of any Governmental Authority or any university or
other educational institution were used to develop or create, in whole or in part, any Acquired
Company Owned IP or, to the Knowledge of the Acquired Companies, any Acquired Company Licensed IP,
and no funding from any Person (other than funds received in consideration for purchase of the
capital stock of the Acquired Companies) was used in the development of the Acquired Company Owned
IP or, to the Knowledge of the Acquired Companies, any Acquired Company Licensed IP. To the
Knowledge of the Acquired Companies, no current or former employee, consultant or independent
contractor of any of the Sellers, who was involved in, or who contributed to, the creation or
development of any Acquired Company IP, was employed by or has performed services for any
government, university, college or other educational or medical institution or research center
during a period
of time during which such employee, consultant or independent contractor was also performing
services for such Acquired Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;each of the Acquired Companies has taken reasonable steps to maintain the confidentiality
of and otherwise protect and enforce its rights in all confidential or non-public information
included in the Acquired Company IP (&#147;<U>Confidential IP Information</U>&#148;). To the Knowledge of
the Acquired Companies, all use, disclosure or appropriation of Confidential IP Information by or
to a third party has been pursuant to the terms of a written Contract between an Acquired Company
and such third party. To the Knowledge of the Acquired Companies, all use, disclosure or
appropriation of Confidential IP Information not owned by any or all of the Acquired Companies has
been pursuant to the terms of a written Contract between an Acquired Company and the owner of such
Confidential IP Information, or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">is otherwise lawful. All current and former employees and
consultants of each of the Acquired Companies having access to Confidential IP Information or
proprietary information of any of its respective customers or business partners have executed and
delivered to such Acquired Company an agreement regarding the protection of such Confidential IP
Information or proprietary information (in the case of proprietary information of the customers and
business partners of any of the Acquired Companies, to the extent required by such customers and
business partners); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;none of the Acquired Companies has assigned or otherwise transferred ownership of, or
agreed to assign or otherwise transfer ownership of, any Intellectual Property that is material to
the business of the Acquired Companies to any other Person, other than an Acquired Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) All rights in Intellectual Property sufficient to conduct the business of the Acquired
Companies as currently conducted and as is proposed to be conducted are either (i)&nbsp;owned by an
Acquired Company or (ii)&nbsp;licensed to an Acquired Company pursuant to the Contracts listed in
Section&nbsp;4.16(a)(ii) of the Company Disclosure Schedule. To the extent that any third party
Intellectual Property is incorporated into, integrated or bundled with, or used by any of the
Acquired Companies in the development, manufacture or compilation of any of the Products, such
Acquired Company has a written agreement with such third party pursuant to which such Acquired
Company either (A)&nbsp;has obtained complete, unencumbered and unrestricted ownership of, and is the
exclusive owner of, such Intellectual Property or (B)&nbsp;has obtained perpetual, non-terminable
licenses to such third party Intellectual Property sufficient for the conduct the business of the
Acquired Companies as currently conducted and as is proposed to be conducted.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) (A)&nbsp;all Acquired Company Owned IP that is Registered IP and, to the Knowledge of the
Acquired Companies, all Acquired Company Licensed IP that is Registered IP is valid, subsisting
and enforceable (or in the case of applications, applied for) in all material respects, all
registration, maintenance and renewal fees necessary for maintaining the Acquired Company Owned IP
and, to the Knowledge of the Acquired Companies, the Acquired Company Licensed IP, have been paid
and all documents, recordations and certificates in connection with such Acquired Company Owned IP
and, to the Knowledge of the Acquired Companies, such Acquired Company Licensed IP, have been
filed with the relevant patent, copyright, trademark or other authorities in the United States or
non-U.S. jurisdictions, as the
case may be, for the purposes of prosecuting, maintaining and perfecting the Acquired Company
Owned IP and, to the Knowledge of the Acquired Companies, the Acquired Company Licensed IP; and
(B)&nbsp;all Acquired Company Owned IP that consists of a material copyright (whether registered or
unregistered) is valid, subsisting, and enforceable in all material respects. No inequitable
conduct has been committed in the prosecution of any patents applications or patents in the
Registered IP, and no material information was withheld from any entity requiring disclosure of
such information during prosecution of such patent applications or patents. Without limiting the
generality of the foregoing:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;to the Knowledge of the Acquired Companies, no Proprietary Name owned by any Acquired
Company conflicts with any Proprietary Name owned, used or applied for by any other Person in any
jurisdiction where any Acquired Company currently
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">markets or promotes or presently plans to market
or promote, through the use of such Proprietary Name, any of the Products;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;except as set forth in Section&nbsp;4.16(e)(ii) of the Company Disclosure Schedule, each item
of Acquired Company Owned IP that is Registered IP is in compliance with Law, and all filings,
payments and other actions required to be made or taken to maintain each item of Acquired Company
Owned IP that is Registered IP in full force and effect have been made by the applicable deadline;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;except as set forth in Section&nbsp;4.16(e)(iii) of the Company Disclosure Schedule, the
Company has delivered to Parent complete and accurate copies of all applications, material
correspondence and other material documents related to each such item of Registered IP referenced
in subsection (e)(ii) above; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;except as set forth in Section&nbsp;4.16(e)(iv) of the Company Disclosure Schedule, no
interference, opposition, reissue, reexamination or Action of any nature is pending or threatened
in any jurisdiction in which the scope, validity or enforceability of any Acquired Company Owned IP
or, to the Knowledge of the Acquired Companies, any Acquired Company Licensed IP, is being, has
been or would reasonably be expected to be contested or challenged.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Neither the execution, delivery or performance of this Agreement or any of the Ancillary
Documents nor the consummation of any of the Transactions will, with or without notice or the
lapse of time, result in or give any other Person the right or option to cause or assert: (i)&nbsp;a
loss of, or Lien on, any Acquired Company IP; (ii)&nbsp;the release, disclosure or delivery of any
Acquired Company Owned IP by any escrow agent or to any other Person; (iii)&nbsp;the grant, assignment
or transfer to any other Person of any license or other material right or interest, such as an
ownership interest or covenant-not-to-sue, under, in or to any of the Acquired Company Owned IP;
or (vi)&nbsp;the forfeiture or termination of, or give rise to a right of forfeiture or termination of
any Acquired Company IP, or impair the right of such Acquired Company or Parent to use, possess,
sell or license any Acquired Company IP or portion thereof. Following the Closing, Parent will be
permitted to exercise all of the rights of any of the Acquired Companies under the Acquired
Company Licensed IP to the same extent such Acquired Company would have been able had the
transactions contemplated by this Agreement not occurred and without the payment of any additional
amounts or consideration
other than ongoing fees, royalties or payments that such Acquired Company would otherwise be
required to pay. There are no royalties, honoraria, fees or other payments payable by any of the
Acquired Companies to any Person (other than salaries payable to employees, consultants and
independent contractors not contingent on or related to use of their work product) as a result of
the ownership, use, possession, license-in, license-out, sale, marketing, advertising or
disposition of any Acquired Company IP by such Acquired Company, and the consummation of the
transactions contemplated by this Agreement will not result in any such royalties, honoraria, fees
or other payments being payable by Parent. Following the Closing, all Acquired Company IP will be
fully transferable, alienable or licensable by Parent without restriction and without payment of
any kind to any third party.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) To the Knowledge of the Acquired Companies, (i)&nbsp;no Person has infringed, misappropriated,
or otherwise violated, and (ii)&nbsp;no Person is currently infringing, misappropriating or otherwise
violating, any Acquired Company IP.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) None of the Acquired Companies, and no use of the Acquired Company IP, has infringed
(directly, contributorily, by inducement or otherwise), misappropriated or otherwise violated any
rights in Intellectual Property of any other Person. Except as set forth in Section&nbsp;4.16(h) of
the Company Disclosure Schedule and without limiting the generality of the foregoing:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;no infringement, misappropriation or similar Action is pending or threatened against any
of the Acquired Companies with respect to Acquired Company IP, and, to the Knowledge of the
Acquired Companies, no infringement, misappropriation or similar Action relating to the Acquired
Company IP is pending or threatened against any licensee, customer, vendor or supplier of an
Acquired Company who may be entitled to be indemnified, defended, held harmless or reimbursed by
any of the Acquired Companies with respect to such Action;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;none of the Acquired Companies has received any notice relating to any actual, alleged or
suspected infringement, misappropriation or violation of any Intellectual Property of another
Person by any of the Acquired Companies or any of the Acquired Companies&#146; employees, consultants,
or independent contractors who have performed services onsite at the Acquired Companies&#146; facilities
for any of the Acquired Companies, where the cause or nature of the alleged infringement,
misappropriation, or violation arises out of the performance of any services performed by such
employee, consultant, or independent contractor on behalf of any Acquired Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;none of the Acquired Companies is bound by any Contract to indemnify, hold harmless or
reimburse any other Person with respect to, or has assumed, pursuant to any Contract any existing
or potential Liability of another Person for, any infringement of Intellectual Property,
misappropriation or similar claim;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;to the Knowledge of the Acquired Companies, none of the Acquired Company IP is subject to
any pending or threatened outstanding Order, Contract, stipulation, proceeding, or notification,
including any pending interference, opposition, cancellation, reissue, reexamination, or other
challenge or adversarial proceeding, restricting in any manner the use, transfer, or licensing by
any of the Acquired Companies of any Acquired
Company IP, or which may affect the validity, use or enforceability of any Acquired Company
IP; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;to the Knowledge of the Acquired Companies, there is no substantial basis for a claim that
the design, development, manufacturing, reproduction, marketing, licensing, sale, offer for sale,
importation, distribution, provision and/or use of any of the Products or the operation of the
business of any of the Acquired Companies is infringing or has infringed on or misappropriated any
Intellectual Property of any third party.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.17</U> <U>Taxes</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Filing of Tax Returns</U>. Each of the Acquired Companies has duly and timely filed
with the appropriate Governmental Authorities all Tax Returns required to be filed. All such Tax
Returns are complete and accurate in all respects. All Taxes due and owing by any of the Acquired
Companies on or before the date hereof (whether or not shown on any Tax Returns) have been paid.
None of the Acquired Companies currently is the beneficiary of any extension of time within which
to file any Tax Return. No written claim has ever been made by a Governmental Authority in a
jurisdiction where any Acquired Company does not file Tax Returns that it is or may be subject to
taxation by that jurisdiction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Payment of Taxes</U>. The unpaid Taxes of the Acquired Companies did not, as of the
date of the Interim Financial Statements, exceed the reserve for Tax Liability (excluding any
reserve for deferred Taxes established to reflect timing differences between book and Tax income)
set forth on the face of the Interim Balance Sheet (rather than in any notes thereto). Since the
date of the Interim Financial Statements, no Acquired Company has incurred any Liability for Taxes
outside the ordinary course of business or otherwise inconsistent with past custom and practice,
other than any such Liability resulting from the Company Divestiture.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Audits, Investigations or Claims</U>. No deficiencies for Taxes with respect to any
of the Acquired Companies have been claimed, proposed or assessed by a Governmental Authority, in
each case in writing. There are no pending or, to the Knowledge of the Acquired Companies,
threatened audits, assessments or other actions for or relating to any Liability in respect of
Taxes of any of the Acquired Companies, and to the Knowledge of the Acquired Companies there are
no matters under discussion with any Governmental Authority, or Known to the Acquired Companies,
with respect to Taxes that are likely to result in an additional Liability for Taxes with respect
to any of the Acquired Companies. The Company has delivered or made available to Parent complete
and accurate copies of federal, state and local income Tax Returns of each of the Acquired
Companies for the years ended December&nbsp;31, 2005 and 2006, and complete and accurate copies of all
examination reports and statements of deficiencies assessed against or agreed to by any of the
Acquired Companies with respect to Taxes of any type. None of the Acquired Companies has waived
any statute of limitations in respect of Taxes or agreed to any extension of time with respect to
a Tax assessment or deficiency, nor has any request been made in writing for any such extension or
waiver. No power of attorney (other than powers of attorney authorizing employees of any Acquired
Company to act on behalf of such Acquired Company, respectively) with respect to any Taxes of
any Acquired Company is currently in effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Liens</U>. There are no Liens for Taxes (other than current Taxes not yet due and
payable) on any of the assets or properties of any Acquired Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>No Withholding.</U> Each of the Acquired Companies has withheld and paid all Taxes
required to have been withheld and paid in connection with amounts paid or owing (including any
gifts made) to any employee, independent contractor, creditor, stockholder or other third party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Other Entity Liability</U>. None of the Acquired Companies has any Liability for the
Taxes of any other Person (other than the Company, any Company Subsidiary
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->54<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">or any Entity disposed
of pursuant to the Company Divestiture) under Treasury Regulation&nbsp;Section&nbsp;1.1502&#150;6 (or any similar
provision of state, local, or foreign Law), as a transferee, by Contract, or otherwise. None of
the Acquired Companies has been a member of an Affiliated Group filing a consolidated federal
income Tax Return (other than a group the common parent of which is the Company).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Tax Sharing Agreements</U>. There are no Tax sharing agreements or similar
arrangements (including indemnity arrangements) with respect to or involving any of the Acquired
Companies, and, after the Closing Date, none of the Acquired Companies shall be bound by any such
Tax sharing agreements or similar arrangements or have any Liability thereunder for amounts due in
respect of periods prior to the Closing Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>Spin-Offs</U>. None of the Acquired Companies has distributed the stock of any
corporation in a transaction satisfying the requirements of Section&nbsp;355 of the Code, and no stock
of any Acquired Company has been distributed in a transaction satisfying the requirements of
Section&nbsp;355 of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Tax Elections</U>. None of the Acquired Companies (i)&nbsp;has agreed, or is required,
to make any adjustment under Section 481(a) of the Code by reason of a change in accounting method
or otherwise; (ii)&nbsp;has made an election, or is required, to treat any of its assets as owned by
another Person pursuant to the provisions of former Section 168(f) of the Code or as tax&#150;exempt
bond financed property or tax&#150;exempt use property within the meaning of Section&nbsp;168 of the Code;
(iii)&nbsp;has acquired or owns any assets that directly or indirectly secure any debt the interest on
which is tax exempt under Section 103(a) of the Code; (iv)&nbsp;has made or will make a consent
dividend election under Section&nbsp;565 of the Code; (v)&nbsp;has elected at any time to be treated as an S
corporation within the meaning of Sections&nbsp;1361 or 1362 of the Code; or (vi)&nbsp;made any of the
foregoing elections or is required to apply any of the foregoing rules under any comparable state
or local Tax provision.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <U>Partnerships, Single Member LLCs, CFCs, PHCs, and PFICs</U>. None of the Acquired
Companies (i)&nbsp;is a partner for Tax purposes with respect to any joint venture, partnership, or
other arrangement or Contract which is treated as a partnership for Tax purposes, (ii)&nbsp;owns a
single member limited liability company which is treated as a disregarded
entity, or (iii)&nbsp;is a &#147;personal holding company&#148; as defined in Section&nbsp;542 of the Code (or
any similar provision of state, local or foreign Law).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <U>Permanent Establishments</U>. None of the Acquired Companies has or has had a
permanent establishment in any foreign country, as defined in any applicable Tax treaty or
convention between the United States of America and such foreign country.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <U>Tax Shelters</U>. None of the Acquired Companies has entered into any transaction
identified as a &#147;listed transaction&#148; for purposes of Treasury Regulation&nbsp;Section&nbsp;1.6011-4(b)(2).
If any of the Acquired Companies has entered into any transaction such that, if the treatment
claimed by it were to be disallowed, the transaction would constitute a substantial understatement
of federal income tax within the meaning of Code Section&nbsp;6662, then it either (x)&nbsp;believes that it
has substantial authority for the tax treatment of such transaction or (y)&nbsp;disclosed on its Tax
Return the relevant facts affecting the tax treatment of such transaction.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->55<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) <U>Net Operating Losses</U>. As of December&nbsp;31, 2006, the Acquired Companies have the
net operating losses set forth in Section&nbsp;4.17(n) of the Company Disclosure Schedule, which
identifies the net operating losses and the Tax jurisdiction(s) applicable to such net operating
losses. There are no limitations on the utilization of the net operating losses of the Company
under Section&nbsp;382 or Section&nbsp;384 of the Code (or any corresponding or similar provisions of
applicable Law) or the separate return limitation year rules under the consolidated return
provisions of the Treasury Regulations (or any corresponding or similar provisions of applicable
state Law), other than any such limitation arising as a result of the consummation of the
transactions contemplated by this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.18</U> <U>Environmental Matters</U>. None of the Acquired Companies is in
violation of, or has violated, any Environmental Law. None of the properties currently or formerly
leased or operated by any Acquired Company (including soils and surface and ground waters) is or
has been contaminated with any Hazardous Substance as a result of releases of Hazardous Substances
by any Acquired Company or, to the Knowledge of the Acquired Companies, is or has been contaminated
with any Hazardous Substance as a result of releases of Hazardous Substances by any Person. None of
the Acquired Companies is actually, potentially or allegedly liable for any off-site contamination
by Hazardous Substances as a result of releases of Hazardous Substances by any Acquired Company,
nor is any Acquired Company aware of any information which might form the basis of any such
Liability. There is no site to which any Acquired Company has transported or arranged for the
transport of Hazardous Substances which to the Knowledge of the any Acquired Companies is or may
become the subject of any environmental action. None of the Acquired Companies is actually,
potentially or allegedly liable under any Environmental Law (including pending or threatened liens)
as a result of releases of Hazardous Substances by any Acquired Company, nor is any Acquired
Company aware of any information which might form the basis of any such Liability. Each Acquired
Company has all Permits required under any Environmental Law (&#147;<U>Environmental Permits</U>&#148;) for
the conduct and operation of the businesses as now being conducted, and all such Environmental
Permits are in good standing. Each Acquired Company has always been and is in compliance in all
material respects with its Environmental Permits. Neither the execution of this Agreement nor the
consummation of the
Transactions will require any Acquired Company to undertake any investigation, remediation or
other action with respect to Hazardous Substances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.19</U> <U>Material Contracts</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Section&nbsp;4.19 of the Company Disclosure Schedule sets forth the following types of
Contracts to which any Acquired Company is a party (such Contracts together with the Material IP
Contracts, being the &#147;<U>Material Contracts</U>&#148;):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;each Contract, whether or not made in the Ordinary Course of Business, that contemplates
an exchange of consideration with a value of more than $25,000, in the aggregate, over the term of
such Contract;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;all Contracts evidencing Indebtedness in excess of $10,000;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->56<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;all joint venture, partnership, strategic alliance and business acquisition or
divestiture agreements (and all letters of intent, term sheets and draft agreements relating to any
such pending transactions);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;all Contracts (other than Contracts evidencing Company Options or Company Warrants) (A)
relating to the acquisition, issuance, voting, registration, sale or transfer of any Equity
Participations of the Acquired Companies, (B)&nbsp;providing any Person with any preemptive right, right
of participation, right of maintenance or similar right with respect to any Equity Participations
of an Acquired Company, or (C)&nbsp;providing an Acquired Company with any right of first refusal with
respect to, or right to repurchase or redeem, any Equity Participations;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;all exclusive distribution Contracts to which any Acquired Company is a party;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;all leases of real property leased for the use or benefit of any Acquired Company and all
leases of personal property involving annual payments by the Acquired Companies in excess of
$25,000;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;all Contracts pursuant to which any Acquired Company obtains from any third party the
right to manufacture any product;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)&nbsp;all Contracts pursuant to which any Acquired Company grants to any third party the
right to manufacture any Product;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix)&nbsp;all distributor, dealer, reseller, agency, sales promotion, market research, marketing
consulting and advertising Contracts to which any Acquired Company is a party and any other
Contract that compensates any Person based on any sales by any Acquired Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)&nbsp;each employment agreement and any other Contracts (A)&nbsp;relating to the employment of, or
the performance of services by, any employee, consultant or independent contractor providing for
aggregate payments to any such Person in any calendar year in excess of $100,000, (B)&nbsp;pursuant to
which an Acquired Company is or may become obligated to make any severance, termination or similar
payment to any current or former employee or director, or otherwise modifies the at-will
relationship with an employee, or (C)&nbsp;pursuant to which any of the Acquired Companies is or may
become obligated to make any bonus or similar payment (whether in the form of cash, stock or other
securities, excluding payments constituting base salary and sales commissions) in excess of
$100,000 to any current or former employee or director;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi)&nbsp;each Contract that provides for the indemnification of any Person;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii)&nbsp;all Contracts with any Governmental Authority to which an Acquired Company is a party;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii)&nbsp;all Contracts imposing any restriction on the right or ability of the Company (A)&nbsp;to
compete with, or solicit any customer of, any other Person, (B)&nbsp;to acquire any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->57<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">product or other
asset or any services from any other Person, (C)&nbsp;to solicit, hire or retain any Person as an
employee, consultant or independent contractor, (D)&nbsp;to develop, sell, supply, distribute, offer,
support or service any product or any technology or other asset to or for any other Person, (E)&nbsp;to
perform services for any other Person, or (F)&nbsp;to transact business or deal in any other manner with
any other Person;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv)&nbsp;all Contracts that contain a clause that would trigger adverse consequences for Parent
or Merger Sub or any Acquired Company by virtue of the change in control resulting from the
completion of the Transactions;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xv)&nbsp;all Contracts that result in any Person holding a power of attorney from any Acquired
Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvi)&nbsp;all Contracts related to professional services rendered to any Acquired Company in
connection with this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvii)&nbsp;all Contracts relating to the design, development, testing, manufacture, or clinical
trials relating to the Products;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xviii)&nbsp;all Contracts between an Acquired Company and another Acquired Company; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xix)&nbsp;all other Contracts, whether or not made in the Ordinary Course of Business, which are
material to any Acquired Company, or the absence of which would have a Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each Material Contract is valid, existing, and is enforceable against the parties
thereto, in accordance with its terms, subject to laws of general application relating to
bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting
creditors generally and by general equity principles.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Except as set forth in Section&nbsp;4.19(b)(i) of the Company Disclosure Schedule, none of the
Acquired Companies has materially violated or breached, or committed any material default under,
any Material Contract, and, to the Knowledge of the Company, no other party to a Material Contract
has materially violated or breached, or committed any material default under, any Material
Contract.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;No event has occurred, and no circumstance or condition exists, that (with or without
notice or lapse of time) will, or would reasonably be expected to, (A)&nbsp;result in a violation or
breach of any of the provisions of any Material Contract, (B)&nbsp;give any party to a Material Contract
the right to accelerate the maturity or performance of any Material Contract, or (C)&nbsp;give any party
to a Material Contract the right to cancel, terminate or materially modify any Material Contract.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;None of the Acquired Companies has received any written notice regarding any unresolved
issue that would constitute a violation or breach of, or default under, any Material Contract.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->58<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;To the Knowledge of the Acquired Companies, no Acquired Company has waived any of its
rights under any Material Contract. The Company has delivered to Parent true and complete copies
of all Material Contracts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.20</U> <U>Insurance</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Section&nbsp;4.20(a) of the Company Disclosure Schedule sets forth a true and complete list of
each insurance policy under which any Acquired Company has been an insured, the named insured or
otherwise the principal beneficiary of coverage at any time within the past three (3)&nbsp;years (i)
the names of the insurer, the principal insured and each named insured, (ii)&nbsp;the policy number,
(iii)&nbsp;the period, scope and amount of coverage, (iv)&nbsp;the premium charged and (v)&nbsp;a current,
complete and accurate list of all insurance claims notified during the three (3)&nbsp;years preceding
the date of this Agreement. Pursuant to such insurance policies:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;all assets of the Acquired Companies which are of an insurable nature are fully insured to
their full replacement value against all risks normally insured against;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;the Acquired Companies are and have at all times been adequately covered against all
legal Liability and risks normally insured against (including Liability to employees or third
parties for personal injury or loss or damage to property, product liability and loss of profit);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;the insurance is sufficient for compliance with Law and for compliance with any
obligation under any Contract to which any Acquired Company is a party; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;the insurance is provided by established, reputable and nationally recognized insurers.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) All material insurable risks of the Acquired Companies in respect of the businesses of
each are covered by such insurance policies and the types and amounts of coverage provided therein
are usual and customary in the context of the businesses and operations in which each Acquired
Company is engaged.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) With respect to such insurance policies: (i)&nbsp;each policy is legal, valid, binding and
enforceable in accordance with its terms and, except for policies that have expired under their
terms in the ordinary course, and is in full force and effect; and (ii)&nbsp;none of the Acquired
Companies is in material breach or default (including any such breach or default with respect to
the payment of premiums or the giving of notice), and no event has occurred which, with notice or
the lapse of time, would constitute such a breach or default, or permit termination or
modification, under the policy.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) There has been no circumstance or breach of any terms, conditions, representations or
warranties under any of the insurance policies or under Law that would entitle insurers to decline
to pay all or any part of any claim made under the policies. The Acquired Companies have paid all
premiums when due and have otherwise performed all of their respective obligations under all
insurance policies. No insurer has threatened to terminate
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->59<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">any of the insurance policies, to
reduce the scope of the insurance or to materially increase the premiums owed. The Acquired
Companies have given notice to the insurers of all claims that may be insured under the insurance
policies. The insurance policies will continue to be in full force and effect following the
closing of the Transaction and will not terminate or lapse by reason of the Transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.21</U> <U>Certain Business Practices</U>. No Acquired Company or any of their
respective directors, officers, or employees (in their capacity as directors, officers, or
employees) has: (a)&nbsp;used any funds for unlawful contributions, gifts, entertainment or other
unlawful expenses relating to political activity in respect of the Acquired Company&#146;s business; (b)
directly or indirectly, paid or delivered any fee, commission or other sum of money or item of
property, however characterized, to any finder, agent, or other party acting on behalf of or under
the auspices of a governmental official or Governmental Authority which is in any manner illegal
under any Laws of the United States or any other country having jurisdiction; or (c)&nbsp;made any
payment to any customer or supplier of the Acquired Company, or given any other consideration to
any such customer or supplier in respect of the Acquired Company&#146;s business that violates
applicable Law in any material respect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.22</U> <U>Interested-Party Transactions</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) No Related Party has or has had, any direct or indirect interest in any material asset
used in or otherwise relating to the business of any of the Acquired Companies (other than as a
result of its ownership of Company Stock).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) No Related Party is or has been, indebted to any of the Acquired Companies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) No Related Party is competing, or has at any time competed, with any of the Acquired
Companies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) No Related Party has any claim or right against any of the Acquired Companies (other than
as a result of its ownership interest in Company Stock (including by way of ownership of Company
Options) or Subordinated Notes or except for (1)&nbsp;compensation and benefits identified pursuant to
Section&nbsp;4.13(a) of the Company Disclosure Schedule not yet paid (including any amounts payable in
connection with the consummation of the Transactions), (2)&nbsp;reimbursement for expenses incurred by
any such Related Party in the ordinary course of his or her employment by an Acquired Company,
which are reimbursable under the Company&#146;s expense reimbursement policies, (3)&nbsp;accrued vacation,
subject to the Company&#146;s policies on accrual and carryforward and (4)&nbsp;rights to indemnification
under the Acquired Companies&#146; certificates of incorporation and bylaws or the indemnification
agreements listed on Section&nbsp;6.01 of the Company Disclosure Schedule).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) No Related Party has entered into, or has had any direct or indirect financial interest
in, any Contract, transaction or business dealing involving any of the Acquired Companies (other
than as a result of its ownership interest in Company Stock), including an economic interest in
any Person that has furnished or sold, or furnishes or sells, services or products that any
Acquired Company furnishes or sells, or proposes to furnish or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->60<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">sell or
an economic interest in any
Person that purchases from or sells or furnishes to, any Acquired Company, any goods or services.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.23</U> <U>Products Liability</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) No claim has been made or threatened in connection with the product liability of the
Products and no Governmental Authority has commenced or threatened to initiate any Action or
request the recall of any Product, or commenced or threatened to initiate any Action to enjoin the
production of any Product.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The goods and services supplied by each Acquired Company have complied with all Laws and
with all government, trade association and other mandatory and voluntary requirements,
specifications and other forms of guidance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) No customer of any Acquired Company has complained of any quality, design, engineering or
safety issue with respect to the Products that could adversely impact the sales, the business, the
operations or the reputation of any Acquired Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) No Products manufactured or sold by the Acquired Companies prior to the Closing contained
or will contain any quality, design, engineering, manufacturing or safety defect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.24</U> <U>Brokers</U>. Other than Merrill Lynch &#038; Co. and Cowen &#038; Co. LLC, no broker, finder or investment banker
is entitled to any brokerage, finder&#146;s or other fee or commission in connection with the
Transactions based upon arrangements made by or on behalf of an Acquired Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.25</U> <U>Information Statement</U>. The information supplied by the Company
for inclusion in the Information Statement sent or to be sent to the Company Stockholders in
connection with the solicitation of their consent to, and adoption of, this Agreement and the
Merger shall not, on the date the Information Statement is first mailed to the Company
Stockholders, at the time of the Stockholder Written Consent and at the Effective Time, contain any
statement which, at such time, is false or misleading with respect to any material fact, or omit to
state any material fact necessary in order to make the statements made therein, in light of the
circumstances under which they are made, not false or misleading; or omit to state any material
fact necessary to correct any statement in any earlier communication with respect to the
solicitation of proxies or written consents for the Stockholder Written Consent which has become
false or misleading.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 4.26</U> <U>Disclosure</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Information Statement or any other document mailed, delivered or otherwise furnished
to the Company Stockholders in connection with the solicitation of their consent to, and adoption
of, this Agreement and the Merger will not contain as of its date, any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements made
therein, in light of the circumstances under which made not misleading.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->61<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) This Agreement (including the Company Disclosure Schedule) does not, and none of the
certificates or the other Contracts delivered to Parent or Merger Sub in connection with the
Transactions will, (a)&nbsp;contain any representation or warranty of the Company or a Company
Securityholder or information regarding an Acquired Company or the Products or regarding a Company
Securityholder that is false or misleading with respect to any material fact, or (b)&nbsp;omit to state
any material fact regarding an Acquired Company or the Products or regarding a Company
Securityholder necessary in order to make the representations, warranties and information
contained and to be contained herein and therein (in the light of the circumstances under which
such representations, warranties and information were or will be made or provided) not false or
misleading.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE V<BR>
REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As an inducement to the Company to enter into this Agreement, Parent and Merger Sub hereby,
jointly and severally, represent and warrant to the Company that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 5.01</U> <U>Corporate Organization</U>. Each of Parent and Merger Sub is a
corporation duly organized, validly existing and in good standing under the laws of its
jurisdiction of incorporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 5.02</U> <U>Authority Relative to This Agreement</U>. Each of Parent and Merger
Sub has the requisite power and authority to execute and deliver this Agreement and the Ancillary
Documents to which it is a party, to perform its obligations hereunder and thereunder and to
consummate the Transactions. This Agreement and the Ancillary Documents to which Parent or Merger
Sub is a party and the performance by Parent or Merger Sub, as the case may be, of its obligations
hereunder and thereunder have been duly authorized by all requisite action on the part of Parent
and Merger Sub. This Agreement and the Ancillary Documents to which Parent or Merger Sub is a
party have been duly executed and delivered by Parent or Merger Sub, as the case may be, and,
assuming this Agreement and such Ancillary Documents constitute the valid and binding obligation of
the other parties hereto and thereto, constitute the legal, valid and binding obligations of Parent
and Merger Sub (to the extent they are a party thereto), enforceable against them in accordance
with their terms, except as such enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium and similar Laws relating to or affecting creditors generally and by
general equity principles.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 5.03</U> <U>No Conflict; Required Filings and Consents</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Neither the execution and delivery of this Agreement nor the other Ancillary Documents to
which Parent or Merger Sub is a party by Parent or Merger Sub (as the case may be), nor the
consummation by Parent or Merger Sub of the Transactions will (i)&nbsp;conflict with, or result in any
violation or breach of, any provision of the certificate of incorporation or bylaws of Parent or
Merger Sub, (ii)&nbsp;result in any violation or breach of, or constitute (with or without notice or
lapse of time, or both) a default (or give rise to a right of termination, cancellation or
acceleration of any obligation or loss of any benefit) under, result in a Lien under, or require a
consent or waiver under, any of the terms, conditions or provisions of any Contract of Parent or
Merger Sub or (iii)&nbsp;conflict with or violate any Permit, concession,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->62<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">franchise, license or Law
applicable to Parent or Merger Sub or any of their properties or assets, except, with respect to
subclauses &#147;(ii)&#148; and &#147;(iii)&#148;, for any such conflicts, violations, breaches, defaults or other
occurrences which would not, individually or in the aggregate, prevent or materially delay
consummation of any of the Transactions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except as may be required by the HSR Act, no Order or authorization of, or registration,
declaration or filing with, any Governmental Authority is required by Parent or Merger Sub in
connection with the execution and delivery of this Agreement or the Ancillary Documents to which
Parent or Merger Sub is a party or the consummation by Parent or Merger Sub of the Transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 5.04</U> <U>Brokers</U>. No broker, finder or investment banker is entitled to
any brokerage, finder&#146;s or other fee or commission in connection with the Transactions based upon
arrangements made by or on behalf of Parent or Merger Sub.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 5.05</U> <U>Financing</U>. At the Closing, either Parent or Merger Sub will have available the funds necessary to
deliver the Closing Date Total Cash Consideration and to pay all fees and expenses of Parent and
Merger Sub in connection with the Transactions.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VI<BR>
ADDITIONAL AGREEMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.01</U> <U>Indemnification of Officers and Directors</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Parent and Merger Sub agree that all rights to indemnification for acts or omissions
occurring prior to the Effective Time existing as of the date of this Agreement in favor of the
current directors and officers of the Company (the &#147;<U>Company Indemnified Persons</U>&#148;) as
provided in the Company&#146;s certificate of incorporation and bylaws or the indemnification
agreements identified in Section&nbsp;6.01 of the Company Disclosure Schedule shall survive the Merger
and shall continue in full force and effect in accordance with their terms for at least six years
following the Effective Time, and Parent shall cause the Surviving Corporation to fulfill and
honor such obligations to the maximum extent permitted by applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Parent shall purchase a prepaid directors&#146; and officers&#146; liability insurance policy for
events that shall have occurred prior to the Effective Time, that shall provide the maximum amount
of coverage for a cost not to exceed two hundred fifty percent (250%) of the Company&#146;s current
one-year directors&#146; and officers&#146; liability insurance policy premium and that shall remain in
effect for a period of six (6)&nbsp;years after the Effective Time, covering those persons that have
served as directors and officers of the Company prior to the Effective Time who are currently
covered by the Company&#146;s existing directors&#146; and officers&#146; liability insurance policy.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The provisions of this <U>Section&nbsp;6.01</U> shall survive the Closing and are intended to
be for the benefit of, and enforceable by, each director and officer of the Company and his or her
heirs and personal representatives.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->63<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.02</U> <U>Conduct of Business by the Company</U>. During the period from the
date of this Agreement to the Closing, except as set forth in Section&nbsp;6.02 of the Company
Disclosure Schedule, as consented to in writing in advance by Parent (which consent may be granted
or withheld in Parent&#146;s sole discretion), or as otherwise permitted by this <U>Section&nbsp;6.02</U>,
each Acquired Company shall carry on its business in the Ordinary Course of Business and as
currently proposed by such Acquired Company to be conducted prior to the Closing (including in
respect of product sales, research, development and clinical trial activities and programs) and
shall use commercially reasonable efforts to carry on such business in compliance with all
applicable Laws and, to the extent consistent therewith, use all commercially reasonable efforts to
(x)&nbsp;preserve intact its current business organizations, (y)&nbsp;keep available the services of its
current officers, employees and consultants and, except as required by the Company Divestiture, or
(z)&nbsp;preserve its relationships with customers, suppliers,
licensors, licensees, distributors and others having business dealings with it with the
intention that its goodwill and ongoing business shall not be impaired at the Closing in any
material respect. In addition to, and without limiting the generality of, the foregoing, during
the period from the date of this Agreement to the Closing, except as otherwise set forth in Section
6.02 of the Company Disclosure Schedule or as consented to in writing in advance by Parent, or as
permitted by this Section&nbsp;6.02, no Acquired Company shall or shall permit any of its Subsidiaries
to:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) (i)&nbsp;declare, set aside or pay any dividends on, or make any other distributions (whether
in cash, stock or property) in respect of, any of its capital stock, (ii)&nbsp;split, combine or
reclassify any of its capital stock or issue or authorize the issuance of any other securities in
respect of, in lieu of or in substitution for shares of its capital stock or (iii)&nbsp;purchase,
redeem or otherwise acquire any shares of its capital stock or any other securities thereof or any
rights, warrants or options to acquire any such shares or other securities;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) (i)&nbsp;issue, deliver, sell, grant, pledge or otherwise encumber or subject to any Lien any
Equity Participations any other voting securities or any securities convertible into, or any
rights, warrants or options to acquire, any such securities, including pursuant to Contracts as in
effect on the date hereof (other than the issuance of Common Stock upon the exercise of Company
Options outstanding on the date hereof or upon the exercise of the Warrant, in each case, in
accordance with their terms on the date hereof) or (ii)&nbsp;amend the terms or change the period of
exercisability of any Company Securities, or purchase, repurchase, redeem or otherwise acquire any
Company Securities;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) amend its Organizational Documents, except for the Charter Amendment or as may be
required by Law (and in such event, only after providing five days prior notice of such amendment,
including a copy of the proposed amendment, to Parent);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) directly or indirectly acquire (i)&nbsp;by merging or consolidating with, or by purchasing
assets of, or by any other manner, any Person or division, business or equity interest of any
Person or (ii)&nbsp;any asset or assets except for new capital expenditures, which shall be subject to
the limitations of <U>Section&nbsp;6.02(g)</U> below, and except for purchases of Product, finished
goods or supplies in the Ordinary Course of Business;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) (i)&nbsp;except for the Company Divestiture or sales of Products in the Ordinary Course of
Business, sell, lease, license, sell and leaseback or otherwise subject to any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->64<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">Lien or otherwise
dispose of any of its properties or other assets or any interests therein (including
securitizations), or (ii)&nbsp;enter into, modify or amend any lease of real property;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) except for the borrowing by the Company of up to an additional Ten Million Dollars
($10,000,000) of unsecured debt from existing Company Stockholders that (A)&nbsp;is subordinate to any
amounts outstanding pursuant to the Loan Agreement and (B)&nbsp;is required to be repaid immediately
upon the Closing, (i)&nbsp;incur any Indebtedness, issue or sell any debt securities or calls, options,
warrants or other rights to acquire any debt securities of the Company or any of its Subsidiaries,
guarantee any debt securities of another Person, enter into any &#147;keep well&#148; or other Contract to
maintain any financial statement condition of another Person or enter into any arrangement having
the economic effect of any of the foregoing, (ii)
fail to satisfy its obligations and Liabilities when they come due in the Ordinary Course of
Business or (iii)&nbsp;make any loans, advances or capital contributions to, or investments in, any
other Person;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) make any new capital expenditure or expenditures, other than those which, in the
aggregate, are less than or equal to $50,000;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) except as required by any Law or for those capital expenditures permitted under
<U>Section&nbsp;6.02(g)</U>, (i)&nbsp;pay, discharge, settle or satisfy any Action, (ii)&nbsp;cancel any
Indebtedness owed to an Acquired Company, (iii)&nbsp;waive or assign any claims or rights or (iv)&nbsp;waive
any benefits of, or agree to modify in any respect, or, subject to the terms hereof, fail to
enforce, or consent to any matter with respect to which consent is required under, any standstill
or similar Contract to which the Company or any of its Subsidiaries is a party or (v)&nbsp;waive any
material benefits of, or agree to modify in any material respect, or, subject to the terms hereof,
fail to enforce in any material respect, or consent to any matter with respect to which consent is
required under, any material confidentiality or similar Contract to which the Acquired Company is
a party;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) (i)&nbsp;except as required by the Company Divestiture, enter into any Contracts relating to
research, clinical trial, development, distribution, sale, supply, license, marketing,
co-promotion or manufacturing by third parties of the Products, or the Acquired Company IP or (ii)
initiate, launch or commence any sale, marketing, distribution, co-promotion or any similar
activity with respect to any new product (including products under development) in or outside the
United States;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) enter into any Contract that would constitute a Material Contract or amend, modify or,
except as required by the Company Divestiture, consent to the termination of any Material Contract
or the Acquired Company&#146;s rights thereunder, or waive, release or assign any rights or claims
thereunder, including taking any action pursuant to the Indevus License Agreement that would
constitute an amendment to the Indevus License Agreement or would be binding on the Company
thereunder (including by committee action thereunder), except upon prior written consent of
Parent, not to be unreasonably withheld or delayed;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) enter into any Contract with any Related Parties (i)&nbsp;except for the borrowing by the
Company of up to an additional Ten Million Dollars ($10,000,000) of unsecured debt from existing
Company Stockholders that (A)&nbsp;is subordinate to any amounts
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->65<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">outstanding pursuant to the Loan
Agreement and (B)&nbsp;is required to be repaid immediately upon the Closing and (ii)&nbsp;except as
permitted by <U>Section&nbsp;6.02(o)</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) except as required by the Company Divestiture, enter into, modify, amend or terminate any
Contract or waive, release, assign or fail to exercise or pursue any material rights or claims
thereunder, which if so entered into, modified, amended, terminated, waived, released, assigned,
or not exercised or pursued would reasonably be expected to (i)&nbsp;adversely affect in any material
respect the Company, (ii)&nbsp;impair in any material respect the ability of the Company to perform its
obligations under this Agreement or (iii)&nbsp;prevent or materially delay the consummation of the
Transactions;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) enter into any Contract to the extent consummation of the Transactions or compliance by
the Company with the provisions of this Agreement would reasonably be expected to conflict with,
or result in a violation or breach of, or default (with or without notice or lapse of time, or
both) under, or give rise to a right of, or result in, termination, cancellation or acceleration
of any obligation or to the loss of a benefit under, or result in the creation of any Lien in or
upon any of the properties or other assets of the Acquired Company under, or require Parent to
license or transfer any Acquired Company IP or other material assets under, or give rise to any
increased, additional, accelerated, or guaranteed right or entitlements of any third party under,
or result in any material alteration of, any provision of such Contract;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) except as required by the Company Divestiture, sell, transfer or license to any Person or
adversely amend or modify any rights to any Acquired Company IP;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) except as otherwise expressly permitted or contemplated by this Agreement or as required
to ensure that any Benefit Plan is not then out of compliance with applicable Laws or to comply
with any Contract or Benefit Plan entered into prior to the date hereof, (i)&nbsp;adopt, enter into,
terminate or amend (A)&nbsp;any collective bargaining agreement or Benefit Plan or (B)&nbsp;any employment
or benefit Contract involving any Acquired Company and any director or officer of an Acquired
Company or, other than in the Ordinary Course of Business, any employee or consultant of any
Acquired Company, (ii)&nbsp;increase in any manner the compensation, bonus or fringe or other benefits
of, or pay any bonus of any kind or amount whatsoever to any director or officer of an Acquired
Company or, other than in the Ordinary Course of Business, any of the employees or consultants of
any Acquired Company, (iii)&nbsp;pay to any director or officer of any Acquired Company or, other than
in the Ordinary Course of Business, any employee or consultant of any Acquired Company, any
benefit or amount not required under any Benefit Plan, (iv)&nbsp;grant or pay (other than as required
pursuant to the terms of the Contracts listed in Section&nbsp;4.13(a) of the Company Disclosure
Schedule and taken into account in the determining the amount of Change in Control Payments) any
change in control, severance or termination compensation or benefits to, or increase in any manner
the change in control, severance or termination compensation or benefits of, any current or former
director, officer, employee or consultant of the Acquired Company, (v)&nbsp;grant any awards under the
Stock Plan or any other Benefit Plan (including the grant of Company Options, &#147;phantom&#148; stock,
stock appreciation rights, &#147;phantom&#148; stock rights, stock based or stock related awards,
performance units or restricted stock or the removal of existing restrictions in any employment or
benefit agreements, Benefit Plan or agreements with respect to awards made thereunder), (vi)&nbsp;amend
or modify any Company Option, (vii)&nbsp;take any action to fund or in any other way
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->66<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">secure the payment
of compensation or benefits under any employment or benefit Contract or Benefit Plan, except as
required by Law, or the terms of such Contract or Benefit Plan in effect on the date of this
Agreement, or (viii)&nbsp;except as required by this Agreement with respect to the Company Options or
in Section&nbsp;3.10 with respect to restricted shares of Common Stock, take any action to accelerate
the vesting or payment of any compensation or benefit under any Contract or Benefit Plan, or (ix)
materially change any actuarial or other assumption used to calculate funding obligations with
respect to any pension plan of any Acquired Company or change the manner in which contributions
to any such pension plan are made or the basis on which such contributions are determined;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) fail to pay obligations or satisfy Liabilities as the same become due and payable or
request an extension for the payment of obligations or satisfaction of Liabilities that would have
otherwise become due and payable;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) commence an Action other than (i)&nbsp;for the routine collection of bills, or (ii)&nbsp;in such
cases where it in good faith determines that failure to commence an Action would result in the
material impairment of a valuable aspect of its business, <I>provided </I>that it consults with Parent
prior to the filing of such Action;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) except as required by GAAP or accounting methods, principles or practices required under
applicable accounting rules or any Law, revalue any material assets of any Acquired Company or
make any change in any material respect in accounting methods, principles or practices (including
for tax purposes);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) change any election in respect of Taxes, adopt or change any accounting method in respect
of Taxes, agree or settle any claim or assessment in respect of Taxes, file any amended Tax
Return, enter into any tax allocation agreement, tax sharing agreement, tax indemnity agreement or
closing agreement relating to any Tax, surrender any right to claim a material Tax refund, or
extend or waive the limitation period applicable to any claim or assessment in respect of Taxes;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) take any action that would reasonably be expected to result in a material breach of the
representations or warranties in <U>Article&nbsp;IV</U> hereof; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) authorize any of, or commit or agree to take any of the foregoing actions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.03</U> <U>Written Consents; Information Statement</U>. Immediately following
the execution of this Agreement, the Company shall ensure that the Key Stockholders (together with
any other Company Stockholders) provide the Requisite Stockholder Approval by executing and
delivering the Stockholders&#146; Written Consent. As promptly as practicable following the date of
this Agreement, the Company shall prepare an information statement accurately describing this
Agreement, the Merger, the other Transactions and the provisions of Section&nbsp;262 of the DGCL (the
&#147;<U>Information Statement</U>&#148;), and shall deliver the Information Statement to those of the
Company Stockholders who did not execute the Stockholders&#146; Written Consent for the purpose of
informing them of the approval of the Merger, the adoption of this Agreement and the approval of
the Charter Amendment. The Information Statement shall
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->67<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">include, subject to the fiduciary duties of
the board of directors of the Company, a statement to the effect that the board of directors of the
Company unanimously recommends that the Company Stockholders execute the Stockholders&#146; Written
Consent approving the Merger, adopting this Agreement and approving the Charter Amendment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.04</U> <U>Access to Information</U>. Subject to the provisions of <U>Section
6.05(b)</U>, during the period from the date of this Agreement until the Closing, upon reasonable
notice, the Company shall cause the Acquired Companies&#146; managers, officers, directors, employees,
agents, representatives, accountants and
counsel to: (a)&nbsp;afford the officers, employees, agents, accountants, counsel, financing
sources and representatives of Parent and Merger Sub reasonable access, during normal business
hours, to the offices, properties, plants, other facilities, books and records of the Acquired
Companies and to those managers, officers, directors, employees, agents, accountants and counsel of
the Acquired Companies who have any Knowledge relating to the Acquired Companies or their business
and (b)&nbsp;furnish to the officers, employees, agents, accountants, counsel, financing sources and
representatives of Parent and Merger Sub such additional financial and operating data and other
information regarding the assets, liabilities and goodwill of the Acquired Companies (or legible
copies thereof) as Parent or Merger Sub may from time to time reasonably request, including
financial statements prepared in accordance with GAAP for the Acquired Companies covering the
period from the date of its most recent audited financial statement to the date of the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.05</U> <U>Confidentiality</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company agrees to, and shall cause the agents, representatives, Affiliates,
employees, officers, directors and managers of each of the Acquired Companies to use commercially
reasonable efforts to: (a)&nbsp;treat and hold as confidential (and not disclose or provide access to
any Person) all information relating to trade secrets, processes, patent applications, product
development, price, customer and supplier lists, pricing and marketing plans, policies and
strategies, details of client and consultant Contracts, operations methods, product development
techniques, business acquisition plans, new personnel acquisition plans and all other confidential
or proprietary information with respect to the Acquired Companies, (b)&nbsp;in the event that an
Acquired Company or any such agent, representative, affiliate, employee, officer, director or
manager becomes legally compelled to disclose any such information, provide Parent and Merger Sub
with prompt written notice of such requirement so that Parent or Merger Sub may seek a protective
Order or other remedy or waive compliance with this <U>Section&nbsp;6.05</U>, and (c)&nbsp;in the event
that such protective Order or other remedy is not obtained, or Parent or Merger Sub waives
compliance with this <U>Section&nbsp;6.05</U>, furnish only that portion of such confidential
information that is legally required to be provided and exercise its commercially reasonable
efforts to obtain assurances that confidential treatment will be accorded such information;
<I>provided, however</I>, that this sentence shall not apply to any information that, at the time of
disclosure, is available publicly and was not disclosed in breach of this Agreement by the
Acquired Companies, and the agents, representatives, Affiliates, employees, officers directors or
managers of the Acquired Companies; and <I>provided further </I>that, with respect to Acquired Company
IP, specific information shall not be deemed to be within the foregoing exception merely because
it is embraced in general disclosures in the public domain. In addition, with respect to Acquired
Company IP, any combination of features shall not be deemed to be within the foregoing exception
merely because the individual
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->68<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">features are in the public domain unless the combination itself and
its principle of operation are in the public domain.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The parties acknowledge that the Company and Parent have previously executed the
Non-Disclosure Agreement dated January&nbsp;29, 2007 (the &#147;<U>Confidentiality Agreement</U>&#148;), which
Confidentiality Agreement will continue in full force and effect in
accordance with its terms. Each of Parent and the Company will hold, and will cause its
respective directors, officers, employees, agents, advisors and representatives (including
attorneys, accountants, consultants, bankers and financial advisors) to hold any Confidential
Information (as defined in the Confidentiality Agreement) confidential in accordance with the
terms of the Confidentiality Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Unless otherwise required by Law, the Escrow Participants&#146; Representative agrees that it
(and its legal, financial, accounting and other representatives) shall hold in confidence all
Confidential Information (as defined in the Confidentiality Agreement) as if the Escrow
Participants&#146; Representative were a party thereto. The parties acknowledge and agree that any and
all Damages suffered or incurred by any of the Parent Indemnified Parties that arise from or as a
result of, or are directly or indirectly connected to, a breach of this <U>Section&nbsp;6.05(c)</U> by
the Escrow Participants&#146; Representative or its legal, financial, accounting and other
representatives shall be recoverable <U>only</U> from the Indemnification Escrow Fund as set
forth in <U>Article&nbsp;IX</U>. Notwithstanding the foregoing, the parties agree and acknowledge
that Damages would not be a sufficient remedy for the breach (or threatened breach) of this
<U>Section&nbsp;6.05(c)</U> by the Escrow Participants&#146; Representative or its legal, financial,
accounting and other representatives and Parent or the Surviving Corporation shall be entitled to
equitable relief, including the obtaining of an injunction and the seeking of specific
performance, as a remedy for any such breach (or threatened breach).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.06</U> <U>Regulatory and Other Authorizations; Notices and Consents</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each of Parent, Merger Sub and the Company shall use its commercially reasonable efforts
to provide all notices and obtain all authorizations, consents, orders and approvals of all
Governmental Authorities and officials that may be or become necessary for the execution and
delivery of, and the performance of its obligations pursuant to, this Agreement and the Ancillary
Documents, and the Company will cause the other Acquired Companies to cooperate fully with Parent
and Merger Sub in promptly seeking to obtain all such authorizations, consents, orders and
approvals.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) In addition to and not in limitation of the covenants contained in <U>Section
6.06(a)</U>, each of Parent and the Company will (a)&nbsp;take promptly all actions necessary to make
the filings required of Parent and the Company under the HSR Act, (b)&nbsp;comply at the earliest
practicable date with any request for additional information received by the parties from the FTC
or the Antitrust Division of the DOJ pursuant to the HSR Act and (c)&nbsp;cooperate with each other in
connection with the other party&#146;s filing under the HSR Act and in connection with resolving any
investigation or other inquiry concerning the transactions contemplated by this Agreement
commenced by either the FTC or the Antitrust Division of the DOJ or state attorneys general.
Nothing contained herein shall require Parent to agree to divest,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->69<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">sell, dispose of, hold separate
or otherwise take or commit to take any action relating to its business, product lines or assets.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Each Acquired Company shall give promptly such notices to third parties and use its
commercially reasonable efforts to obtain such third party consents and estoppel certificates as
Parent or Merger Sub may reasonably deem necessary or desirable in connection with the
Transactions, including obtaining such third party consents necessary for the assignment of
certain Contracts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.07</U> <U>Notice of Developments</U>. From the date hereof and continuing
until the earlier of the termination of this Agreement or the Effective Time, Parent and the
Company shall promptly advise the other party in writing of (a)&nbsp;any event or circumstance that
would reasonably be expected to result in any representation or warranty made by it in this
Agreement becoming untrue or inaccurate in any respect so as to cause the Closing condition set
forth in <U>Section&nbsp;8.01</U> or <U>Section&nbsp;8.02</U>, respectively, to fail to be satisfied, (b)
the failure by it to comply in any material respect with or satisfy in any material respect any
covenant, condition or agreement to be complied with or satisfied by it under this Agreement prior
to the Effective Time, (c)&nbsp;with respect to the Company, any change or event having, or which is
reasonably likely to have, a Material Adverse Effect or (d)&nbsp;with respect to the Company, any notice
or other communication from any Person alleging that the consent of such Person is or may be
required in connection with the transactions contemplated by this Agreement; <I>provided</I>, <I>however</I>,
that no such notification will be deemed to prevent or cure any breach of, or inaccuracy in, amend
or supplement any Section of the Company Disclosure Schedule, or otherwise disclose an exception
to, or affect in any manner, the representations, warranties, covenants or agreements of the
parties (or remedies with respect thereto) or the conditions to the obligations of the parties or
the Company Securityholders under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.08</U> <U>No Solicitation or Negotiation</U>. The Company agrees that between
the date of this Agreement and the earlier of (a)&nbsp;the Closing and (b)&nbsp;the termination of this
Agreement, none of the Company Securityholders, any Acquired Company or any of their respective
Affiliates, managers, officers, directors, representatives or agents will (i)&nbsp;solicit, initiate,
consider, knowingly encourage or accept any other proposals or offers from any Person (A)&nbsp;relating
to any acquisition or purchase of all or any portion of Company Stock, any Equity Participations in
an Acquired Company or the assets of an Acquired Company (other than the sale of products in the
Ordinary Course of Business and other than the issuance of Common Stock upon the exercise of
Company Options or the Warrant outstanding as of the date of this Agreement) or (B)&nbsp;to enter into
any merger, consolidation, business combination, recapitalization, reorganization or other
extraordinary business transaction involving or otherwise relating to an Acquired Company or (ii)
participate in any discussions, conversations, negotiations and other communications regarding, or
furnish to any other Person any information with respect to, or otherwise cooperate in any way,
assist or participate in, facilitate or encourage any effort or attempt by any other Person to seek
to do any of the foregoing. The Company immediately shall and shall cause each Acquired Company
and each of their respective Affiliates, managers, officers, directors, representatives or agents
to cease, and cause to be terminated all existing discussions, conversations, negotiations and
other communications with any Persons conducted heretofore with respect to any of the foregoing.
The Company shall notify Parent promptly if any such proposal or offer, or any inquiry or other
contact with any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->70<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Person with respect thereto, is made and shall, in any such notice to Parent,
indicate in reasonable detail the identity of the Person making such proposal, offer, inquiry or
contact and the terms and conditions of such proposal, offer, inquiry or other contact. The
Company agrees not to, and to cause the Acquired Companies not to, without the prior written
consent of Parent, release any Person from, or waive any provision of, any standstill agreement to
which any Acquired Company is a party that relates to any aspect of the assets or business of the
Acquired Companies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.09</U> <U>Use of Intellectual Property</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company Securityholders acknowledge that from and after the Closing, the name
&#147;Esprit&#148; and &#147;Sanctura&#148;, and all similar or related Proprietary Names and logos shall be owned by
the Acquired Companies, that neither the Company Securityholders nor any of their Affiliates shall
have any rights in such Proprietary Names or logos and that neither the Company Securityholders
nor any of their Affiliates will contest the ownership or validity of any rights of Parent, Merger
Sub, the Company or any Subsidiary of the Company in or to such Proprietary Names.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) From and after the Closing, neither the Company Secuirtyholders nor any of their
Affiliates shall use any of the Acquired Company IP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.10</U> <U>Company Divestiture</U>. The Company will use commercially
reasonable efforts to consummate the Company Divestiture prior to the Closing. Parent shall have
the right to approve, in its sole discretion, any term or condition of the Company Divestiture to
the extent that such term or condition could reasonably be expected to result in Liability to any
Acquired Company following the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.11</U> <U>Transaction Expenses; Change of Control Payments; Closing Cash
Balance</U>. At least two (2)&nbsp;Business Days prior to the Closing Date, the Company shall prepare
and deliver to Parent the updated Transaction Schedule pursuant to <U>Section&nbsp;4.05(a)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.12</U> <U>Termination of the Stock Plan</U>. Unless otherwise requested by
Parent prior to the Closing, the Company shall take all actions reasonably necessary to terminate
the Stock Plan prior to the Closing, subject to the satisfaction of all obligations thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.13</U> <U>Termination of 401(k) Plan</U>. The Company shall, upon the request
of Parent (in its sole and absolute discretion), take all actions necessary to terminate the
Company&#146;s 401(k) plan and provide to Parent (i)&nbsp;executed resolutions of the Board of Directors of
the Company authorizing the termination of any 401(k) plan, effective no later than the day prior
to the Closing Date, and (ii)&nbsp;an executed amendment to
any 401(k) plan sufficient to assure compliance with all applicable requirements of the Code
and regulations thereunder so that the Tax-qualified status of any such 401(k) plan will be
maintained at the time of termination if such plan has been adopted or is in existence.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->71<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.14</U> <U>Employee Benefits.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) As of the Closing Date, all the former employees of the Acquired Companies who become
employees of Parent or any of its Affiliates, as determined by Parent in Parent&#146;s sole discretion,
will either continue to participate in the Benefit Plans or participate in the employee pension,
health and welfare plans sponsored by Parent or its Affiliates to the same extent as similarly
situated employees of Parent or its Affiliates participate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Parent will maintain or cause to be maintained in effect the severance policy of the
Acquired Companies at the same benefit levels for a period of at least one year from the Closing
Date with respect to employees of the Acquired Companies who become employees of Parent and its
Affiliates as of the Closing Date, <I>provided </I>that, Parent will have no obligation to honor such
severance policy to the extent that the employee is terminated by Parent for cause. As of the
Closing Date, Parent will honor or cause its Affiliates to honor all severance agreements and
employment-related Contracts with the officers and employees of the Acquired Companies as
disclosed in <U>Section&nbsp;4.19</U> of this Agreement and as in effect immediately prior to the
Closing Date; <I>provided </I>that, Parent will have no obligation to honor such agreements and such
Contracts to the extent that the applicable officer or employee is terminated by Parent for cause.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) As of the Closing Date, Parent will, and it will cause its Affiliates to (a)&nbsp;waive all
limitations as to preexisting conditions, exclusions and waiting periods with respect to
participation and coverage requirements applicable to the individuals who at the Closing Date were
employed by the Acquired Companies and who continue to be employed by Parent or any of its
Affiliates after the Closing, under any health or welfare plan of Parent of any of its Affiliates
in which such employees are eligible to participate after the Closing to the extent such
preexisting conditions, exclusions and waiting periods did not apply to such individuals under the
Benefit Plans of the Acquired Companies immediately prior to the Closing Date, (b)&nbsp;provide each
such employee with credit for any co-payments and deductibles paid prior to the Closing in
satisfying any applicable deductible or out of pocket requirements under any health or welfare
plans of Parent or any of its Affiliates in which such employee is eligible to participate after
the Closing to the extent such deductible or out of pocket requirements were incurred in the
calendar year or plan year in which such employee becomes eligible to participate in the health or
welfare plans maintained by Parent or any of its Affiliates and (c)&nbsp;provide each such employee
with credit for all service with the Acquired Companies under each pension, health or welfare plan
of Acquired Companies in which such employee is eligible to participate after the Closing for
vesting, eligibility and benefit accrual and contribution calculation purposes; <I>provided, however,</I>
that in no event will such employees be entitled to any credit to the extent that it would result
in a duplication of benefits with respect to the same period of service; <I>provided further,</I>
notwithstanding the foregoing, such employee will not receive credit for service with the Acquired
Companies for purposes of eligibility to receive allocations of &#147;Retirement Contributions&#148; under
the Allergan, Inc. Savings and Investment Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Notwithstanding the foregoing, nothing in the preceding or any other provision of the
Agreement shall be interpreted to interfere with the right of Parent or its Affiliates to amend or
terminate any of the employee benefit plans, programs, policies and arrangements maintained by
Parent or its Affiliates, or interpreted as an amendment or other modification of any Benefit
Plan.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->72<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) All provisions contained in this Agreement with respect to employee benefit plans or
employee compensation are included for the sole benefit of the respective parties hereto and shall
not create any right in any other Person, including any employee or former employee of the
Acquired Companies, Parent or its Affiliates, or any participant or beneficiary in any Benefit
Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.15</U> <U>Amendment of Severance Policy</U>. Prior to the Closing, the Company
shall take all actions necessary to amend its severance policy as set forth on <U>Schedule&nbsp;E</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.16</U> <U>General Release</U>. At or prior to the Closing, the Company shall
cause each Key Stockholder and each officer and director of an Acquired Company to execute and
deliver to Parent and the Company a General Release.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.17</U> <U>Resignation of Officers and Directors</U>. The Company shall use
commercially reasonable efforts to obtain and deliver to Parent at or prior to the Closing the
resignation of each officer and director of each of the Acquired Companies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.18</U> <U>Delivery of Financial Statements; Cooperation in Preparing Pro Forma
Financial Statements</U>. From the date hereof until the Closing, the Company will deliver to
Parent, not later than ten (10)&nbsp;days after the end of each calendar month, an unaudited,
consolidated balance sheet as of the end of such month and an unaudited, consolidated statement of
income and stockholders&#146; equity for such month. The Company covenants and agrees that such
financial statements and the notes thereto, if any, shall be complete and accurate in all material
respects and fairly present the financial condition of the Company on a consolidated basis at the
respective dates thereof and the consolidated results of its operations for the respective months
then ended, and shall be prepared in accordance with the books and records of the Company in
conformity with GAAP, consistently applied with the financial statements referred to in <U>Section
4.09</U>, except for the omission of footnotes and normal, immaterial year-end adjustments. The
Company agrees to cooperate, and use its commercially reasonable efforts to cause its accountants
to cooperate, in providing (a)&nbsp;historical financial information to Parent in a manner for Parent to
satisfy its filing obligations with the Securities and Exchange Commission and (b)&nbsp;any other
information reasonably requested by Parent in order to comply with the requirements of Rule&nbsp;3-05 of
Regulation&nbsp;S-X of the Securities Act of 1933, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.19</U> <U>280G Payments</U><B>. </B>As promptly as practicable after the execution of
this Agreement, the Company shall submit to the Company Stockholders (in a manner satisfactory to
Parent) for approval by such Company Stockholders as is required by the terms of Section
280G(b)(5)(B) of the Code a written consent in favor of a single proposal to render the parachute
payment provisions of Section&nbsp;280G of the Code and the Treasury Regulations thereunder
(collectively, &#147;<U>Section&nbsp;280G</U>&#148;) inapplicable to any and all payments and/or benefits
provided pursuant to any Benefit Plan (including any severance policy), employment agreements or
other Contracts (including payments pursuant to any employee bonus plan adopted in connection with
the Transactions) that might result, separately or in the aggregate, in the payment of any amount
and/or the provision of any benefit that would not be deductible by reason of Section&nbsp;280G or that
would be subject to an excise tax under Section
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->73<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4999 of the Code (together, the &#147;<U>Section&nbsp;280G
Payments</U>&#148;). Any such Company Stockholder approval shall be obtained in a manner which
satisfies all applicable requirements of Section&nbsp;280G(b)(5)(B) of the Code and the Treasury
Regulations thereunder, including Q-7 of Section&nbsp;1.280G-1 of such Treasury Regulations. The
Company agrees that: (i)&nbsp;in the absence of such Company Stockholder approval, no Section&nbsp;280G
Payments shall be made; and (ii)&nbsp;promptly after execution of this Agreement, the Company shall
deliver to Parent waivers duly executed by each Person who might receive any Section&nbsp;280G Payment.
The form and substance of all stockholder approval documents contemplated by this <U>Section
6.19</U>, including the waivers, shall be subject to the review and approval of Parent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 6.20</U> <U>Further Action</U>. Each of the parties hereto shall, whether prior
to or after the Closing, use all reasonable efforts to take, or cause to be taken, all appropriate
action, do or cause to be done all things necessary, proper or advisable under applicable Law, and
to execute and deliver such documents and other papers, as may be required to carry out the
provisions of this Agreement and the Ancillary Documents to which it is a party and consummate and
make effective the Transactions.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VII<BR>
TAX MATTERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 7.01</U> <U>Tax Periods Ending on or before the Closing Date</U>. Parent shall
prepare or cause to be prepared and file or cause to be filed all Tax Returns for the Acquired
Companies for all periods ending on or prior to the Closing Date which are filed after the Closing
Date. Parent shall deliver to the Escrow Participants&#146; Representative a draft of each Tax Return
referred to in the preceding sentence at least fifteen (15)&nbsp;Business Days prior to the date such
Tax Return is to be filed and shall permit the Escrow Participants&#146; Representative to review and
comment on each such Tax Return described in the preceding sentence prior to filing and shall make
such revisions to such Tax Returns as are reasonably requested by the Escrow Participants&#146;
Representative. Failure of the Parent to provide Escrow Participants&#146; Representative with a draft
of any such Tax Return at least fifteen (15)&nbsp;Business Days prior to the date it is to be filed
shall be treated as a waiver of the right to receive indemnification with respect to Taxes covered
by such Tax Return.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 7.02</U> <U>Tax Periods Beginning Before and Ending After the Closing Date</U>.
Parent shall prepare or cause to be prepared and file or cause to be filed any Tax Returns of
the Acquired Companies for Tax periods which begin before the Closing Date and end after the
Closing Date. Parent shall deliver a draft of each Tax Return referred to in the preceding
sentence, other than Tax Returns that are filed on a combined, consolidated or unitary basis
with any Person that is not an Acquired Company, to the Escrow Participants&#146; Representative for
review at least fifteen (15)&nbsp;Business Days prior to the date such Tax Return is to be filed and
shall permit the Escrow Participants&#146; Representative to comment on any such Tax Return prior to
filing and shall make such revisions to such Tax Returns as are reasonably requested by the
Escrow Participants&#146; Representative. Failure of Parent to provide the Escrow Participants&#146;
Representative with a draft of any such Tax Return at least fifteen (15)&nbsp;Business Days prior to
the date it is to be filed shall be treated as a waiver of the right to receive indemnification
with respect to Taxes covered by such Tax Return.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->74<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 7.03</U> <U>Tax Cooperation</U>. Parent, the Company, the Escrow Participants&#146;
Representative and the Company Securityholders shall cooperate fully, as and to the extent
reasonably requested by the other party, in connection with the filing of Tax Returns pursuant to
this Agreement and any audit, litigation or other proceeding with respect to Taxes. Such
cooperation shall include the retention and (upon the other party&#146;s request) the provision of
records and information which are reasonably relevant to any such audit, litigation or other
proceeding and making employees available on a mutually convenient basis to provide additional
information and explanation of any material provided hereunder. Parent, the Company, the Escrow
Participants&#146; Representative and the Company Securityholders agree (A)&nbsp;to retain all books and
records with respect to Tax matters pertinent to each of the Acquired Companies relating to any
taxable period beginning before the Closing Date until the expiration of the statute of limitations
(and, to the extent notified by Parent, any extensions thereof) of the respective Taxable periods,
and to abide by all record retention agreements entered into with any Governmental Authority, (B)
to deliver or make available to Parent, within sixty (60)&nbsp;days after the Closing Date, copies of
all such books and records, and (C)&nbsp;to give the other party reasonable written notice prior to
transferring, destroying or discarding any such books and records and, if the other party so
requests, Parent, the Company, the Escrow Participants&#146; Representative and the Company
Securityholders, as the case may be, shall allow the other party to take possession of such books
and records at such other party&#146;s expense. Parent and the Escrow Participants&#146; Representative
further agree, upon request, to use their best efforts to obtain any certificate or other document
from any Governmental Authority or any other Person as may be necessary to mitigate, reduce or
eliminate any Tax that could be imposed (including, with respect to the transactions contemplated
hereby).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 7.04</U> <U>Contest Provisions</U>. If, subsequent to the Closing, Parent or any
Acquired Company receives notice of a Tax Contest with respect to any Tax Return for a Tax period
or portion thereof ending on or before the Closing Date (a &#147;Pre-Closing Return&#148;), then within
fifteen (15)&nbsp;Business Days after receipt of such notice, the Parent shall notify the Escrow
Participants&#146; Representative of such notice.
The Escrow Participants&#146; Representative shall have the right to control the conduct and
resolution of such Tax Contest, <I>provided, however</I>, that if any of the issues raised in such Tax
Contest could adversely impact Taxes of the Company for a Tax period or portion thereof beginning
on or after the Closing Date (a &#147;<U>Post-Closing Tax Period</U>&#148;), then the Escrow Participants&#146;
Representative shall afford Parent the opportunity to control jointly the conduct and resolution of
the portion of such Tax Contest which could have an impact on Taxes of the Company in any
Post-Closing Tax Period. If the Escrow Participants&#146; Representative shall have the right to
control the conduct and resolution of such Tax Contest but elects in writing not to do so, then
Parent shall have the right to control the conduct and resolution of such Tax Contest, <I>provided</I>
that Parent shall keep the Escrow Participants&#146; Representative informed of all developments on a
timely basis and Parent shall not resolve such Tax Contest in a manner that could reasonably be
expected to have an adverse impact on the Escrow Participants&#146; indemnification obligations under
this Agreement without Escrow Participants&#146; Representative written consent, which shall not be
unreasonably withheld. Each party shall bear its own costs for participating in such Tax Contest.
&#147;<U>Tax Contest</U>&#148; means any audit, other administrative proceeding or inquiry or judicial
proceeding involving Taxes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 7.05</U> <U>Certain Taxes</U>. All transfer, documentary, sales, use, stamp,
registration and other substantially similar Taxes and fees (including any penalties and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->75<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">interest)
incurred in connection with this Agreement (collectively, &#147;<U>Transfer Taxes</U>&#148;) shall be paid
by the Company Securityholders when due, and the party responsible for filing any necessary Tax
Returns and other documentation with respect to all such Transfer Taxes will, at their own expense,
file such Tax Returns and, if required by applicable Law, the other party or parties will, and will
cause their affiliates to, join in the execution of any such Tax Returns and other documentation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 7.06</U> <U>Carrybacks</U>. The parties agree and acknowledge that any net
operating losses or similar Tax attribute of the Acquired Companies is an asset of the Company that
(subject to any applicable limitations imposed by Law) is being acquired by Parent pursuant to the
Merger, and that the Acquired Companies shall not elect to carryback any such Tax attributes to
prior years of the Acquired Companies or otherwise act so as to limit the ability of Parent to use
such attributes subsequent to the Merger.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VIII<BR>
CONDITIONS TO CLOSING</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 8.01</U> <U>Conditions to Obligations of the Company</U>. The obligations of the
Company to consummate the Transactions shall be subject to the fulfillment or written waiver, at or
prior to the Closing, of each of the following conditions:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each of the representations and warranties made by Parent and Merger Sub in <U>Article
V</U> of this Agreement and in each of the other Contracts delivered to the Company in connection
with the Transactions shall have been accurate in all material respects
as of the date of this Agreement, and shall be accurate in all material respects as of the
Closing as if made at the Closing; <I>provided, however</I>, that the condition set forth in this
<U>Section&nbsp;8.01(a)</U> shall be deemed to have been satisfied notwithstanding the existence of
inaccuracies in such representations and warranties if the circumstances rendering such
representations and warranties inaccurate have not had and would not reasonably be expected to
have or result in an adverse effect on Parent&#146;s or Merger Sub&#146;s ability to consummate the
Transactions;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) All of the covenants and obligations that Parent and Merger Sub are required to comply
with or to perform at or prior to the Closing shall have been complied with and performed in all
material respects;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) All necessary approvals of Governmental Authorities as may be required for the completion
of the Transactions, including the possible requirement of filings, notifications or requests with
relevant competition or merger control authorities, including under the HSR Act, shall have been
received, and, if any filing, notification or request for approval of a Governmental Authority is
required under any applicable Law, any applicable waiting period shall have expired or any
required approval thereunder shall have been received, in form and substance reasonably
satisfactory to the Escrow Participants&#146; Representative;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) No temporary restraining Order, preliminary or permanent injunction or other Order
preventing the consummation of the Transactions shall have been issued against an Acquired Company
by any court of competent jurisdiction and remain in effect, and there shall
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->76<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">not be any Law
enacted or deemed applicable to an Acquired Company, the Company Securityholders or the
Transactions that makes consummation of the Transactions by the Company Securityholders illegal;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Requisite Stockholder Approval shall have been obtained;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Parent and Merger Sub shall have delivered or caused to be delivered all closing
deliveries set forth in <U>Section&nbsp;3.09</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 8.02</U> <U>Conditions to Obligations of Parent and Merger Sub</U>. The
obligations of Parent and Merger Sub to consummate the Transactions shall be subject to the
fulfillment or written waiver, at or prior to the Closing, of each of the following conditions:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each of the representations and warranties of the Company set forth in <U>Article&nbsp;IV</U>
and in each of the other Contracts delivered to Parent or Merger Sub in connection with the
Transactions: (i)&nbsp;shall have been accurate in all material respects as of the date of this
Agreement; and (ii)&nbsp;shall be accurate in all material respects as of the Closing as if made at the
Closing (except that any representation and warranty that is made exclusively as of, and that
refers specifically to, a specified date need only have been accurate in all material respects as
of such specified date), except in the case of both clauses (i)&nbsp;and (ii) (individually and
together), for inaccuracies that would not, individually or in the aggregate, reasonably be
expected to result in or otherwise involve Damages in excess of Twenty Seven Million Seven
Hundred Fifty Thousand Dollars ($27,750,000); <I>provided, however</I>, that in determining the
accuracy of such representations and warranties for purposes of this <U>Section&nbsp;8.02(a)</U>, all
&#147;Material Adverse Effect&#148; and other materiality qualifications limiting the scope of such
representations and warranties shall be disregarded; <I>provided, further </I>that nothing contained in
this <U>Section&nbsp;8.02(a)</U> shall affect a Parent Indemnified Party&#146;s right to indemnification
pursuant to <U>Article&nbsp;IX</U> if the Closing occurs;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each of the covenants and obligations that an Acquired Company is required to comply with
or to perform at or prior to the Closing shall have been complied with and performed in all
material respects;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Neither any Change in Control Payments made, nor any Company Options granted, nor any
other payments made to any Person in connection with or in contemplation of the Transactions shall
constitute a &#147;parachute payment&#148; under Sections&nbsp;280G and 4999 of the Code;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) All necessary approvals of Governmental Authorities as may be required for the completion
of the Transactions, including the possible requirement of filings, notifications or requests with
relevant competition or merger control authorities, including the HSR Act, shall have been
received, and, if any filing, notification or request for approval of a Governmental Authority is
required under any applicable Law, any applicable waiting period shall have expired or any
required approval thereunder shall have been received, in form and substance reasonably
satisfactory to Parent and Merger Sub;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) No temporary restraining Order, preliminary or permanent injunction or other Order
preventing the consummation of the Transactions shall have been issued by any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->77<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">court of competent
jurisdiction and remain in effect, and there shall not be any Law enacted or deemed applicable to
the Transactions that makes consummation of the Transactions illegal;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) All approvals, waivers, ratifications or similar consents of a third party listed on
<U>Schedule&nbsp;F</U> shall have been obtained and shall be in full force and effect;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Since the date of this Agreement, there shall not have occurred any Material Adverse
Effect, and no event shall have occurred or circumstance shall exist that, in combination with any
other events or circumstances, would reasonably be expected to have or result in a Material
Adverse Effect;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) There shall be no Action pending against Parent, Merger Sub or any of the Acquired
Companies or any of their respective Affiliates by any Governmental Authority or any Law enacted
or deemed applicable (i)&nbsp;seeking to enjoin or make illegal, delay or otherwise restrain or
prohibit the consummation of the Transactions, (ii)&nbsp;that would result in the Transactions being
rescinded following consummation, (iii)&nbsp;seeking material damages in connection with the
Transactions; (iv)&nbsp;seeking to prohibit or limit the exercise by Parent or Merger Sub of any
material right pertaining to its ownership of Company Stock; (v)&nbsp;seeking to compel an Acquired
Company, Parent, Merger Sub or any Subsidiary of Parent to dispose of or hold separate any
material assets as a result of the Transactions; or (vi)&nbsp;seeking to impose any
criminal sanctions or Liability on Parent, Merger Sub or the Acquired Companies in connection
with the Transactions;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Company Securityholders and the Company shall have delivered or caused to be
delivered all closing deliveries set forth in <U>Section&nbsp;3.12</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) Within one (1)&nbsp;Business Day after the execution and delivery of this Agreement, the
Merger shall have been duly approved by the Requisite Stockholder Approval pursuant to the
execution and delivery to Parent of the Stockholders&#146; Written Consent;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) The Company shall have amended its existing severance policy as set forth in <U>Section
6.15</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) The Indevus Agreement shall be, or upon the Closing shall become, in full force and
effect in accordance with its terms;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) The Company shall have delivered the Statement of Closing Net Working Capital;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) Each of the Acquired Companies shall have filed their federal, state and local income Tax
Returns for the year ended December&nbsp;31, 2006.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) No more than five percent (5%) of the aggregate number of shares of Company Stock
outstanding as of the Closing Date shall be Dissenting Shares or shall have the right under the
DGCL to become Dissenting Shares;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) The Company shall have provided to Parent (i)&nbsp;executed resolutions of the board of
directors of the Company authorizing the termination, effective no later than one
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->78<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">day prior to the
Closing Date, of any 401(k) plan adopted or in existence and (ii)&nbsp;an executed amendment to any
401(k) Plan sufficient to assure compliance with all applicable requirements of the Code and
regulations thereunder so that the tax qualified status of any 401(k) Plan will be maintained at
the time of termination; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) The Company shall have completed the Company Divestiture in a manner that will not result
in any Liability of the Surviving Corporation and is otherwise reasonably acceptable to Parent.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IX<BR>
INDEMNIFICATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 9.01</U> <U>Survival of Representations and Warranties</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The representations and warranties of the Company and the Escrow Participants&#146;
Representative contained in this Agreement or in any document, certificate or other instrument
required to be delivered hereunder in connection with the Transactions shall survive the Closing
until the date that is eighteen (18)&nbsp;months after the Closing Date; <I>provided,
however</I>, that (i)&nbsp;the representations and warranties made pursuant to <U>Section&nbsp;4.03</U>
(<I>Capitalization</I>), <U>Section&nbsp;4.05</U> (<I>Transaction Schedule</I>) and <U>Section&nbsp;4.13</U> (<I>Benefit
Plans</I>) shall survive the Closing until the date that is four (4)&nbsp;years after the Closing Date and
(ii)&nbsp;the representations and warranties contained in <U>Section&nbsp;4.17</U> (<I>Taxes</I>) shall survive
the Closing until the date that is seven (7)&nbsp;years <U>and</U> six (6)&nbsp;months after the Closing
Date with respect to the Tax liabilities in question.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) All representations and warranties of Parent and Merger Sub contained herein or in any
document, certificate or other instrument required to be delivered hereunder in connection with
the transactions contemplated hereby shall terminate at the Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) All covenants and agreements of the Company, the Company Securityholders, the Escrow
Participants&#146; Representative, Parent and Merger Sub contained herein shall survive the Closing
(except as provided in <U>Section&nbsp;9.01(a)</U>).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) If written notice of a claim has been given prior to the expiration of the applicable
representations and warranties by Parent to the Escrow Participants&#146; Representative, then the
relevant representations and warranties shall survive as to such claim, until such claim has been
finally resolved.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Notwithstanding anything to the contrary contained in <U>Section&nbsp;9.01(a)</U>, the
limitations set forth in <U>Section&nbsp;9.01(a)</U> shall not apply in the case of claims based upon
fraud.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 9.02</U> <U>Indemnification of Parent Indemnified Parties</U>. Each Escrow
Participant shall be deemed to have agreed, and hereby agrees, to indemnify, defend and hold
harmless the Parent Indemnified Parties from, against and in respect of, and to pay the Parent
Indemnified Parties the amount of, any and all Damages suffered or incurred by any of the Parent
Indemnified Parties or to which any of the Parent Indemnified Parties may otherwise become directly
or indirectly subject (regardless of whether or not such Damages relate to any
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->79<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Third Party Claim),
and that arise from or as a result of, or are directly or indirectly connected with any of the
following (each a &#147;<U>Parent Claim</U>&#148;):
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) any misrepresentation or breach or failure to be true and correct of any representation
or warranty made by the Company or the Escrow Participants&#146; Representative in this Agreement or in
any document, certificate or other instrument required to be delivered by the Company or the
Escrow Participants&#146; Representative under this Agreement (in each case, as such representation or
warranty would read if all qualifications as to materiality, including, each reference to the
defined term Material Adverse Effect, were deleted therefrom) (for purposes of this Agreement,
each statement or other item of information set forth in the Company Disclosure Schedule shall be
deemed to be a representation and warranty made by the Company in this Agreement);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any breach or non-fulfillment of any covenant or agreement made or to be performed by the
Company Securityholders, the Company or the Escrow Participants&#146;
Representative in this Agreement or in any agreement or instrument entered into in connection
with this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) all Transaction Expenses, except to the extent that such Transaction Expenses have been
included in Closing Transaction Expenses;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) all Company Debt, except to the extent that such Company Debt has been included in
Closing Company Debt;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) all Excess Change in Control Payments;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) any fraud or intentional misrepresentation or breach of this Agreement by a Company
Securityholder, the Company or the Escrow Participants&#146; Representative in connection with the
Transactions;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) any amounts that a Company Securityholder is entitled to receive in connection with the
Merger pursuant to the Company Organizational Documents, a written or oral agreement with the
Company or any other Law that is in excess of the amount indicated on the updated Transaction
Schedule delivered to Parent prior to the Closing as the amount such Company Securityholder is
entitled to receive in connection with the Merger;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) any other inaccuracy in the Transaction Schedule;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) (i)&nbsp;any Taxes of the Acquired Companies with respect to any Tax year ending on or before
the Closing Date and for any Tax year beginning before and ending after the Closing Date, any
Taxes allocable (as determined in the following sentence) to the portion of such period beginning
before and ending on the Closing Date and (ii)&nbsp;the unpaid Taxes of any Person (other than the
Company) under Treasury Regulations Section&nbsp;1.1502-6 (or any similar provision of state, local or
foreign Law) to the extent any Acquired Company is liable therefore as a result of events
occurring on or prior to the Closing Date, as a transferee or successor, by Contract, or
otherwise. For purposes of the preceding sentence, in the case of any Taxes that are imposed on a
periodic basis and are payable for a Tax period that includes (but does not end on) the Closing
Date, the portion of such Tax that relates to the portion of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->80<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">such Tax period ending on the Closing
Date shall (i)&nbsp;in the case of any Taxes other than Taxes based upon or related to income or
receipts, be deemed to be the amount of such Tax for the entire Tax period multiplied by a
fraction the numerator of which is the number of days in the Tax period ending on the Closing Date
and the denominator of which is the number of days in the entire Tax period, and (ii)&nbsp;in the case
of any Tax based upon or related to income or receipts, be deemed equal to the amount which would
by payable if the relevant Tax period ended on the Closing Date;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) any Contract between Depomed, Inc. and the Company, including the ProQuinXR Agreements
and the Termination and Assignment Agreement dated July&nbsp;5, 2007;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) that certain letter agreement by and between the Company and John T. Spitznagel, Sr.
dated July&nbsp;5, 2007 entered into in connection with the termination of the ProQuinXR Agreements;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) any Liabilities that arise from or are a result of, or are directly or indirectly
connected with the assets related to Prosed (including the disposition thereof) or the assets
acquired by Pharma pursuant to the Stock Purchase Agreement by and among Pharma and the
stockholders of Metagen Pharmaceuticals, Inc., dated September&nbsp;18, 2005;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) any breach of <U>Section&nbsp;6.05(c)</U> by the Escrow Participants&#146; Representative or its
legal, financial, accounting and other representatives;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) any legal proceeding relating to any inaccuracy, breach, or other matter of the type
referred to in <U>Section&nbsp;9.02(a) &#150; (m)</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) the amount, if any, by which the Closing Net Working Capital Deficit Amount (if any) is
greater than the Net Working Capital Escrow Fund; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) any amount paid by Parent, the Company or the Surviving Corporation to any Company
Stockholder with respect to Dissenting Shares pursuant to the DGCL in excess of the value such
Person would have received in the Merger for such Dissenting Shares had such shares been converted
pursuant to <U>Article&nbsp;II</U>, and all interest, costs, expenses and fees (including attorneys&#146;
fees) incurred by the Company, Parent or the Surviving Corporation in connection with the exercise
of all appraisal rights under the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 9.03</U> <U>Damages of Company</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The parties acknowledge and agree that, if the Company suffers, incurs or otherwise becomes
subject to any Damages as a result of or in connection with any inaccuracy in or breach of any
representation, warranty, covenant or obligation of the Company Securityholders, the Company or the
Escrow Participants&#146; Representative, then (without limiting any of the rights of the Company as a
Parent Indemnified Party), Parent and Merger Sub shall also be deemed, by virtue of their ownership
of the stock of the Company following the Closing, to have incurred Damages as a result of and in
connection with such inaccuracy or breach (it being understood that any Damages suffered or
incurred by the Company shall be recoverable under this <U>Article&nbsp;IX</U> by either Parent, Merger
Sub or the Company).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->81<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 9.04</U> <U>Limits on Indemnification</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Except for indemnification for any Damages that are suffered or incurred by any of the
Parent Indemnified Parties or to which any of the Parent Indemnified Parties may otherwise become
subject (regardless of whether or not such Damages relate to any Third Party Claim or Action), and
that arise from or as a result of, or are connected with (i)&nbsp;fraud or intentional
misrepresentation or breach of this Agreement or any Ancillary Agreement by the Company, the
Escrow Participants&#146; Representative or any Company Securityholder or (ii)&nbsp;a breach or failure of
any representation and warranty in <U>Section&nbsp;4.03</U> (<I>Capitalization</I>), <U>Section&nbsp;4.05</U>
(<I>Transaction Schedule</I>) and <U>Section&nbsp;4.13</U> (<I>Benefit Plans</I>), the sole and exclusive remedy of
the Parent Indemnified Parties in respect of a Parent Claim shall be limited to
recourse against the Indemnification Escrow Fund. In the event of a breach or failure of any
representation or warranty referenced in subclause &#147;(ii)&#148; of the foregoing sentence the Parent
Indemnified Parties shall not be entitled to make a Parent Claim to the extent all Damages
previously recovered by the Parent Indemnified Parties under <U>Section&nbsp;9.02</U>, together with
any Damages resulting from any such breach or failure of any representation or warranty referenced
in subclause &#147;(ii)&#148; of the foregoing sentence (but for the avoidance of doubt, all Damages shall
be counted only once), exceed Twenty Seven Million Seven Hundred Fifty Thousand Dollars
($27,750,000). Except in the event of fraud or willful misconduct of the Company prior to the
Effective Time, the aggregate amount of indemnification available to the Parent Indemnified
Parties hereunder shall be limited to the Indemnification Escrow Amount. Nothing contained in
this Agreement shall limit the rights of any Parent Indemnified Party to seek or obtain injunctive
relief or any other equitable remedy to which such Parent Indemnified Party is otherwise entitled.
The Liability of the Escrow Participants for indemnification that is not satisfied by the
Indemnification Escrow Fund shall be several and not joint. Except as set forth in the
immediately preceding sentence and <U>Sections&nbsp;9.05</U> and <U>9.09</U>, the procedure for
satisfaction of Parent Claims is set forth in the Escrow Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except in the event of fraud or willful misconduct of the Company prior to the Effective
Time, no Parent Indemnified Party shall be entitled to recover any Damages pursuant to <U>Section
9.02(a)</U> and <U>Section&nbsp;9.02(b)</U> (but solely with respect to <U>Section&nbsp;9.02(a)</U> and
<U>Section&nbsp;9.02(b)</U>) (i)&nbsp;in respect of any claim for Damages that are less than Twenty
Thousand Dollars ($20,000) (<I>provided </I>that claims relating to the same subject matter shall be
aggregated for purposes of determining the amount of Damages under this clause (i)), and all such
Damages shall be taken into account in determining whether or the extent to which the thresholds
set forth in clause (ii)&nbsp;of this paragraph has been met or exceeded, and (ii)&nbsp;unless and until
such time as the total amount of all Damages otherwise indemnifiable pursuant to such Sections
that have been directly or indirectly suffered or incurred by any one or more of the Parent
Indemnified Parties, or to which any one or more of the Parent Indemnified Parties has or have
otherwise become subject, exceeds On Million Five Hundred Thousand Dollars ($1,500,000), in which
event the Parent Indemnified Parties shall be entitled to recover all of such Damages in excess of
Seven Hundred Fifty Thousand Dollars ($750,000).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->82<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 9.05</U> <U>Notification of Certain Claims; Third Party Claims</U>. Except as
otherwise provided in <U>Section&nbsp;7.04</U>:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) If a Parent Indemnified Party is of the opinion that any Parent Claim has occurred or
will occur, an authorized officer or representative of such Parent Indemnified Party, as
applicable, may so notify the Escrow Participants&#146; Representative. Each such notice shall be in
writing and shall describe with reasonable specificity, and to the extent known by the applicable
Parent Indemnified Party, the nature of such Parent Claim and the amount of Damages related
thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If a Parent Indemnified Party shall receive notice of any Action audit, demand or
assessment (each, a &#147;<U>Third Party Claim</U>&#148;) which may give rise to a claim for Damages under
this <U>Article&nbsp;IX</U>, Parent will, promptly after receipt of notice of any such Third Party
Claim, notify the Escrow Participants&#146; Representative (or, in the event indemnification is
being sought hereunder directly from a Escrow Participant, such Escrow Participant) of the
commencement thereof. The failure to so notify the Escrow Participants&#146; Representative (or, in
the event indemnification is being sought hereunder directly from a Escrow Participant, such
Escrow Participant) of the commencement of any such Third Party Claim will not relieve any Escrow
Participant from Liability in connection therewith, except to the extent that such failure
materially and adversely affects the ability of such Escrow Participant to defend its interests in
such Third Party Claim. If such Third Party Claim does not involve any claims for any injunction,
specific performance or any other non-monetary remedy or relief, the Escrow Participants&#146;
Representative shall have the right, at its election, at any time prior to the end of the 90-day
period commencing with the commencement of discovery proceedings related to such Third Party
Claim, by delivering a written notice to Parent of such election, to proceed with the defense of
such Third Party Claim on its own with counsel reasonably acceptable to Parent. If the Escrow
Participants&#146; Representative so proceeds with the defense of any such Third Party Claim: (i)&nbsp;the
Escrow Participants&#146; Representative shall be deemed to have conclusively agreed that all Damages
suffered by a Parent Indemnified Party as a result of or in connection with the Third Party Claim
are recoverable from the Escrow Participants under this <U>Article&nbsp;IX</U>, subject to the
provisions of <U>Section&nbsp;9.04</U>; (ii)&nbsp;all reasonable out-of-pocket expenses relating to the
defense of such Third Party Claim shall be borne and paid exclusively by the Escrow Participants;
(iii)&nbsp;Parent shall use commercially reasonable efforts to make available to the Escrow
Participants&#146; Representative reasonable access to properties, documents, materials and employees
(subject to the execution of reasonable confidentiality agreements that permit such confidential
information to be used in the legal proceedings) to the extent that the Escrow Participants&#146;
Representative determines in good faith that such access is necessary to the defense of such Third
Party Claim; (iv)&nbsp;Parent may, at its own cost and expense, participate in the investigation, trial
and defense of such Third Party Claim; and (v)&nbsp;the Escrow Participants&#146; Representative shall have
the right to settle, adjust or compromise such Third Party Claim only with the prior written
consent of Parent (which consent shall not be unreasonably withheld, conditioned or delayed). In
addition, the Escrow Participants&#146; Representative shall not have the right to assume the control
of the defense of any such Third Party Claim and shall be required, at Parent&#146;s election, to
relinquish control of any such defense previously assumed if (i)&nbsp;the amount claimed in such Third
Party Claim, in the aggregate with the amount claimed in other Third Party Claims and direct
claims against the Escrow Participants asserted as of such time against the Escrow Participants
under this <U>Article&nbsp;IX</U>, would exceed the limitation of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->83<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">Escrow Participants&#146; liability
set forth in <U>Section&nbsp;9.04</U>, or (ii)&nbsp;there are or may be legal defenses available to Parent
that are different from or additional to those available to the Escrow Participants and that could
not be adequately advanced by counsel to the Escrow Participants&#146; Representative, or if a conflict
or potential conflict exists between Parent and the Escrow Participants&#146; Representative that would
make having separate representation advisable for Parent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If, with respect to any Third Party Claim described in <U>Section&nbsp;9.05(b)</U>, the
Escrow Participants&#146; Representative is not permitted to proceed with the defense of such Third
Party Claim or is required to cease its control of such Third Party Claim, or does not elect (or
has not yet informed Parent in writing that it is electing) to proceed with the defense of any
such Third Party Claim, Parent may proceed with the defense of such Third Party Claim with counsel
reasonably acceptable to the Escrow Participants&#146; Representative. If Parent so proceeds with the
defense of any such Third Party Claim: (i)&nbsp;if it is ultimately agreed or
otherwise determined that Parent is entitled to indemnification for Damages resulting from
such Third Party Claim pursuant to this <U>Article&nbsp;IX</U>, all reasonable out-of-pocket expenses
relating to the defense of such Third Party Claim shall, subject to <U>Section&nbsp;9.04</U>, be borne
and paid exclusively by the Escrow Participants; (ii)&nbsp;the Escrow Participants&#146; Representative
shall use commercially reasonable efforts to make available to Parent any documents and materials
that Parent determines in good faith may be necessary to the defense of such Third Party Claim;
(iii)&nbsp;the Escrow Participants&#146; Representative may, at its own cost and expense, participate in the
investigation, trial and defense of such Third Party Claim; and (iv)&nbsp;Parent shall have the right
to settle, adjust or compromise such Third Party Claim; <I>provided, however</I>, that if Parent settles,
adjusts or compromises any such Third Party Claim without the consent of the Escrow Participants&#146;
Representative, Parent shall bear the burden of proof to establish the Damages arising as result
of such Third Party Claim for which the Parent Indemnified Parties are entitled to be held
harmless, indemnified, compensated or reimbursed pursuant to this <U>Article&nbsp;IX</U>.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->84<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 9.06</U> <U>Treatment of Adjustments</U>. The Escrow Participants, on the one
hand, and Parent and Merger Sub, on the other hand, agree that all payments made by or on behalf of
either of them to or for the benefit of the other (including any payments to the Company) under
this <U>Article&nbsp;IX</U> shall be treated as adjustments to the consideration payable pursuant to
this Agreement for Tax and other purposes and that such treatment shall govern for purposes hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 9.07</U> <U>No Right of Contribution from Parent, Merger Sub or the Company</U>.
Each Escrow Participant waives, and acknowledges and agrees that such Escrow Participant shall not
have and shall not exercise or assert (or attempt to exercise or assert), any right of
contribution, right of indemnity or other right or remedy against Parent, Merger Sub or the
Company, or any of their respective directors, officers, employees, Affiliates, agents, attorneys,
representatives, assigns or successors, for any indemnification claims asserted by any Parent
Indemnified Parties in connection with any indemnification obligation or any other Liability to
which such Escrow Participant may become subject under or in connection with this Agreement, it
being acknowledged and agreed that the representations, warranties, covenants and agreements of the
Escrow Participants are solely for the benefit of the Parent Indemnified Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 9.08</U> <U>Investigation; No Company Recourse</U>. The right to indemnification
or any other remedy based on representations, warranties, covenants and agreements of the Company
Securityholders, the Company or the Escrow Participants&#146; Representative in this Agreement, or any
document, certificate or other instrument required to be delivered by the Company Securityholders,
the Company or the Escrow Participants&#146; Representative under this Agreement shall not be affected
by any investigation conducted by any Parent Indemnified Party or any other Person at any time, or
any knowledge acquired (or capable of being acquired) by any Parent Indemnified Party or any other
Person at any time, whether before or after the execution and delivery of this Agreement or the
Closing, with respect to the accuracy or inaccuracy of, or compliance with, any such representation,
warranty, covenant or agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 9.09</U> <U>Exclusivity</U>. Except as a result of Damages that are suffered or
incurred by any of the Parent Indemnified Parties or to which any of the Parent Indemnified Parties
may otherwise become subject (regardless of whether or not such Damages relate to any Third Party
Claim or Action), and that arise from or as a result of, or are connected with fraud or intentional
misrepresentation or breach of this Agreement or any Ancillary Agreement by the Company, after the
Effective Time, the rights to indemnification for Damages set forth in this <U>Article&nbsp;IX</U>
shall be the sole and exclusive remedies of Parent and its Affiliates for any breach of
representation or warranty or nonfulfillment or failure to be performed of any covenant or
agreement made in or pursuant to this Agreement by the Company, and of the Company Securityholders
or the Escrow Participants&#146; Representative and Parent and its Affiliates shall not be entitled to a
rescission of this Agreement or to any further indemnification rights or claims of any nature
whatsoever in respect thereof, all of which Parent hereby waives; provided that nothing contained
in this Agreement shall limit the rights of any Parent Indemnified Party to seek or obtain
injunctive relief or any other equitable remedy to which such Parent Indemnified Party is otherwise
entitled.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->85<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE X<BR>
REPRESENTATIVE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 10.01</U> <U>Appointment of the Escrow Participants&#146; Representative</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) If this Agreement, the Ancillary Agreements and the Transactions are approved by the
Company Stockholders, effective upon such vote, and without any further act of any Company
Stockholder, Andrew J. Einhorn is appointed as the true and lawful representative, agent, proxy,
and attorney-in-fact for each Escrow Participant (and for the other Company Securityholders with
respect to matters relating to the Post-Closing Cash Consideration, if any) with respect , with
the obligations, duties, rights, powers and authority as set forth in this <U>Article&nbsp;X</U> (the
&#147;<U>Escrow Participants&#146; Representative</U>&#148;). The power of attorney granted in this <U>Section
10.01</U>: (i)&nbsp;is coupled with an interest and is irrevocable; (ii)&nbsp;may be delegated by the
Escrow Participants&#146; Representative; and (iii)&nbsp;shall survive the dissolution, death or incapacity
of each Escrow Participant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Escrow Participants&#146; Representative agrees to act as, and to undertake the duties and
responsibilities of, such representative, agent, proxy and attorney-in-fact for and on behalf of
each Escrow Participant. The Escrow Participants&#146; Representative hereby agrees to do such acts,
and execute further documents, as shall be necessary to carry out the provisions of this Agreement
and the Ancillary Documents and otherwise necessary for the consummation of the Transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 10.02</U> <U>Powers of the Escrow Participants&#146; Representative</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Escrow Participants&#146; Representative shall have and may exercise all of the powers
conferred upon him, her or it pursuant to this Agreement and the Escrow Agreement, including:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;The power to execute as Escrow Participants&#146; Representative the this Agreement, the
Ancillary Documents and any other agreement, document or instrument entered into or executed in
connection with the Transactions;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;The power to give or receive any notice or instruction permitted or required under this
Agreement or the Ancillary Documents, or any other agreement, document or instrument entered into
or executed in connection herewith or therewith, to be given or received by any Escrow Participant,
and each of them (other than notice for service of process relating to any Action before a court or
other tribunal of competent jurisdiction, which notice must be given to each Escrow Participant
individually, as applicable), and to take any and all actions for and on behalf of the Escrow
Participants, and each of them, under this Agreement, the Ancillary Documents or any other such
agreement, document or instrument, including to amend, modify, cancel, extend, or waive the terms
of this Agreement, any Ancillary Document or any other agreement, document or instrument entered
into or executed in connection herewith or therewith;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;The power to (A)&nbsp;contest, negotiate, defend, compromise or settle any Actions for which
a Parent Indemnified Party may be entitled to indemnification hereunder, (B)&nbsp;authorize payment to
any Parent Indemnified Party of any of the Indemnification Escrow Amount, or any portion thereof,
in satisfaction of any Parent Claims, (C)&nbsp;agree to, negotiate,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->86<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">enter into settlements and
compromises of, and demand arbitration and comply with Orders and awards of arbitrators with
respect to such Parent Claims, (D)&nbsp;take any actions necessary to resolve any Parent Claims, (E)
take any actions in connection with the resolution of any dispute relating hereto or to the
Transactions by arbitration, settlement or otherwise, and (F)&nbsp;take or forego any or all actions
permitted or required of any Escrow Participant or necessary in the judgment of the Escrow
Participants&#146; Representative for the accomplishment of the foregoing and all of the other terms,
conditions and limitations of this Agreement and the Escrow Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;The power to select, retain, hire and consult with legal counsel, independent public
accountants and other experts selected by the Escrow Participants&#146; Representative, solely at the
cost and expense of the Escrow Participants;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;The power to review, negotiate, agree to and authorize any payments from the
Indemnification Escrow Fund in satisfaction of any payment obligation, in each case, on behalf of
the Escrow Participants, as contemplated hereunder;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;The power to waive any terms and conditions of this Agreement or the Escrow Agreement
providing rights or benefits to the Escrow Participants (other than the payment of the
consideration payable to such Escrow Participants pursuant to <U>Articles II</U> and <U>III</U>
of this Agreement in accordance with the terms hereof and in the manner provided herein); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;The power to take any actions in regard to such other matters as are reasonably
necessary for the consummation of the Transactions or as the Escrow Participants&#146; Representative
reasonably believes are in the best interests of Escrow Participants.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Escrow Participants&#146; Representative represents and warrants to Parent and Merger Sub
that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;The Escrow Participants&#146; Representative has all necessary power and authority to execute
and deliver this Agreement, the Escrow Agreement and any Ancillary Document to which Escrow
Participants&#146; Representative is a party, and to carry out his, her or its obligations hereunder and
thereunder;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;This Agreement has been duly executed and delivered by the Escrow Participants&#146;
Representative and, assuming the due authorization, execution and delivery of this Agreement by the
other parties hereto, constitutes the valid and legally binding obligation of the Escrow
Participants&#146; Representative, enforceable against the Escrow Participants&#146; Representative in
accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium and similar laws relating to or affecting creditors generally and by
general equity principles; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;The Escrow Agreement will be duly executed and delivered by the Escrow Participants&#146;
Representative and, assuming the due authorization, execution and delivery of the Escrow Agreement
by the other parties hereto, will constitute a legal, valid and binding obligation of the Escrow
Participants&#146; Representative, enforceable against the Escrow Participants&#146; Representative in
accordance with its terms, except as such enforceability may be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->87<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">limited by bankruptcy, insolvency,
reorganization, moratorium and similar laws relating to or affecting creditors generally and by
general equity principles.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 10.03</U> <U>Escrow Participants&#146; Representative Discretion</U>. The Escrow
Participants&#146; Representative shall have the discretion to take such action as he, she or it shall
determine to be in the best interest of all of the Escrow Participants; <I>provided</I>, <I>however</I>, that, in
any event, all Escrow Participants are treated in substantially the same manner.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 10.04</U> <U>Notices to Escrow Participants&#146; Representative</U>. Any notice
given to the Escrow Participants&#146; Representative will constitute notice to each and all of the
Escrow Participants at the time notice is given to the Escrow Participants&#146; Representative (other
than notice to a Escrow Participant for service of process relating to any Action before a court or
other tribunal of competent jurisdiction, which notice must be given to such Escrow Participant
individually, as applicable). Any action taken by, or notice or instruction received from, the
Escrow Participants&#146; Representative will be deemed to be action by, or notice or instruction from,
each and all of the Escrow Participants. Parent, Merger Sub and the Company may, and the Escrow
Agent will, disregard any notice or instruction received from any one or more individual Escrow
Participants, other than the Escrow Participants&#146; Representative.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 10.05</U> <U>Payment of Costs and Liability of Escrow Participants&#146;
Representative</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Escrow Participants&#146; Representative shall not be personally liable as the Escrow
Participants&#146; Representative to any Escrow Participant for any act done or omitted hereunder as
Escrow Participants&#146; Representative or error in judgment, in each case while acting in good faith,
except for any act done or omitted which represents gross negligence or willful misconduct. The
Escrow Participants&#146; Representative shall be entitled to rely on the advice of counsel, public
accountants or other independent experts experienced in the matter at issue, and any error in
judgment or other act or failure to act on the part of the Escrow Participants&#146; Representative
pursuant to such advice shall not subject the Escrow Participants&#146; Representative to liability to
any Escrow Participant. The Escrow Participants&#146; Representative undertakes to perform such duties
and only such duties as are specifically set forth in this Agreement and no implied covenants or
obligations shall be read into this Agreement against the Escrow Participants&#146; Representative.
Each of the Escrow Participants hereby severally, and not jointly, agrees to indemnify, defend and
hold harmless the Escrow Participants&#146; Representative and any of its representatives and agents
from and against any Damages or expenses incurred or paid by the Escrow Participants&#146;
Representative arising out of or in connection with the acceptance or administration of the Escrow
Participants&#146; Representative&#146;s duties (except as caused by the Escrow Participants&#146;
Representative&#146;s fraud, bad faith gross negligence or willful misconduct), including legal costs
and expenses of defending the Escrow Participants&#146; Representative against any claim or liability
in connection with the performance of the Escrow Participants&#146; Representative&#146;s duties under this
Agreement and the Escrow Agreement (&#147;<U>Escrow Participants&#146; Representative Costs</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Following the Closing, the Escrow Participants&#146; Representative shall be entitled to, at
any time and from time to time, to pay in cash any Escrow Participants&#146; Representative Costs out
of the Expense Amount. For the avoidance of doubt, all unpaid
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->88<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">Escrow Participants&#146; Representative
Costs that shall be paid out of the Expense Amount prior to any payment or disbursement of the
Expense Amount to the Escrow Participants and, notwithstanding anything herein to the contrary:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;if any Escrow Participants&#146; Representative Costs are paid from the Expense Amount, amounts
available for disbursement from the Expense Amount to the Escrow Participants shall be reduced by
the amount of such Escrow Participants&#146; Representative Costs;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;the Expense Amount shall not be available for payment of any indemnification obligation
under <U>Article&nbsp;IX</U> but only for payment of Escrow Participants&#146; Representative Costs, with
any remaining amounts to be paid to the Escrow Participants at such time as the Indemnification
Escrow Fund is released to the Escrow Participants pursuant to the terms of the Escrow Agreement;
and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;any payment of the Expense Amount to the Escrow Participants&#146; Representative shall be
allocated to each Escrow Participant in accordance with each Escrow Participant&#146;s Aggregate
Proceeds Contribution Fraction set forth on the Transaction Schedule.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) All of the indemnities, immunities and powers granted to the Escrow Participants&#146;
Representative under this Agreement shall survive the termination of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 10.06</U> <U>Reliance on Escrow Participants&#146; Representative</U>. Parent, Merger
Sub, their respective Affiliates and the Escrow Agent shall be entitled to rely on the appointment
the Escrow Participants&#146; Representative and treat such Escrow Participants&#146; Representative as the
duly appointed attorney-in-fact of each Escrow Participant and as having the duties, powers and
authority provided for in this Agreement and the Escrow Agreement. Neither Parent, Merger Sub,
their respective Affiliates (including after the Closing, the Company) nor the Escrow Agent shall
be liable to any Escrow Participant for any actions taken or omitted by them in reliance upon any
instructions, notice, documents or other instruments delivered by the Escrow Participants&#146;
Representative. No resignation of the Escrow Participants&#146; Representative shall become effective
unless at least thirty (30)&nbsp;days prior written notice of the replacement or resignation of such
Escrow Participants&#146; Representative shall be provided to Parent, Merger Sub and the Escrow Agent.
Parent, Merger Sub, their respective Affiliates (including after the Closing, the Company) and the
Escrow Agent shall be entitled to rely at any time after receipt of any such notice on the most
recent notice so received. The Escrow Participants&#146; Representative may not be removed unless
holders of at least a two-thirds (2/3) interest of the Indemnification Escrow Fund agree to such
removal. Any vacancy of the Escrow Participants&#146; Representative hereunder may be filled by a
written instrument signed by Escrow Participants holding a majority interest in the Indemnification
Escrow Fund held in escrow at such time.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->89<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE XI<BR>
TERMINATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 11.01</U> <U>Termination Events</U>. This Agreement may be terminated prior to
Closing:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) By the mutual written consent of Parent and the Company;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) By either Parent or the Company if the Closing has not taken place on or before December
31, 2007; <I>provided </I>that the right to terminate this Agreement under this <U>Section&nbsp;11.01(b)</U>
shall not be available to any party whose action or failure to act has been a principal cause of,
or resulted in the failure of, the Merger to occur on or before such date and such action or
failure to act constitutes a breach of this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) By Parent if (i)&nbsp;any representation or warranty of the Company or the Escrow
Participants&#146; Representative contained in this Agreement shall be inaccurate or shall have been
breached as of the date of this Agreement, or shall have become inaccurate or shall be breached as
of a date subsequent to the date of this Agreement (as if made on such subsequent date), such that
the condition set forth in <U>Section&nbsp;8.02(a)</U> would not be satisfied; or (ii)&nbsp;any of the
covenants or obligations of the Acquired Companies or the Company Securityholders contained in
this Agreement shall have been breached in any material respect;
<I>provided, however</I>, that if an inaccuracy in or breach of any representation or warranty of
the Company or the Escrow Participants&#146; Representative as of a date subsequent to the date of this
Agreement or a breach of a covenant by an Acquired Company or the Escrow Participants&#146;
Representative is curable by the same through the use of commercially reasonable efforts during
the 30-day period after Parent notifies the Company in writing of the existence of such inaccuracy
or breach (the &#147;<U>Company Cure Period</U>&#148;), then Parent may not terminate this Agreement under
this <U>Section&nbsp;11.01(c)</U> as a result of such inaccuracy or breach prior to the expiration of
the Company Cure Period, <I>provided </I>the Company, during the Company Cure Period, continues to
exercise commercially reasonable efforts to cure such inaccuracy or breach (it being understood
that Parent may not terminate this Agreement pursuant to this <U>Section&nbsp;11.01(c)</U> if Parent
is in material breach of this Agreement or if such breach by an Acquired Company or the Escrow
Participants&#146; Representative is cured such that such conditions would then be satisfied);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) by the Company if: (i)&nbsp;any representation or warranty of either Parent or Merger Sub
contained in this Agreement shall be inaccurate or shall have been breached as of the date of this
Agreement, or shall have become inaccurate or shall be breached as of a date subsequent to the
date of this Agreement (as if made on such subsequent date), such that the condition set forth in
<U>Section&nbsp;8.01(a)</U> would not be satisfied; or (ii)&nbsp;if any of Parent&#146;s or Merger Sub&#146;s
covenants contained in this Agreement shall have been breached in any material respect; <I>provided,
however</I>, that if an inaccuracy in or breach of any representation or warranty of Parent or Merger
Sub as of a date subsequent to the date of this Agreement or a breach of a covenant by Parent or
Merger Sub is curable by the same through the use of commercially reasonable efforts during the
30-day period after the Company notifies Parent in writing of the existence of such inaccuracy or
breach (the &#147;<U>Parent Cure Period</U>&#148;), then the Company may not terminate this Agreement under
this <U>Section&nbsp;11.01(d)</U> as a result of such inaccuracy or breach prior to the expiration of
the Parent Cure Period, <I>provided </I>Parent or Merger Sub, during the Parent Cure Period, continues to
exercise commercially reasonable efforts to cure such inaccuracy or breach (it being understood
that the Company may not terminate this Agreement pursuant to this <U>Section&nbsp;11.01(d)</U> if the
Company is in material breach of this Agreement or if such breach by the Parent or Merger Sub is
cured such that such conditions would then be satisfied);
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->90<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) by Parent if: (i)&nbsp;there shall have occurred any Material Adverse Effect; or (ii)&nbsp;any
event shall have occurred or circumstance shall exist that, in combination with any other events
or circumstances, could reasonably be expected to have or result in a Material Adverse Effect;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) by Parent, if any condition contained in <U>Section&nbsp;8.02</U> shall become incapable of
fulfillment by the Outside Date;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) by the Company, if any condition contained in <U>Section&nbsp;8.01</U> shall become incapable
of fulfillment by the Outside Date; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) by Parent if the Requisite Stockholder Approval is not obtained within one Business Day
after the date of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 11.02</U> <U>Effect of Termination</U>. If a party wishes to terminate this
Agreement pursuant to <U>Section&nbsp;11.01</U>, then such party shall deliver to the other parties to
this Agreement a written notice stating that such party is terminating this Agreement and setting
forth a brief description of the basis on which such party is terminating this Agreement. In the
event of the termination of this Agreement, this Agreement shall be of no further force or effect,
except (i)&nbsp;as set forth in <U>Section&nbsp;6.04</U>, this <U>Section&nbsp;11.02</U> and <U>Article
XII</U>, each of which shall survive the termination of this Agreement and (ii)&nbsp;the parties hereto
shall remain liable for any willful or intentional breaches of representations and warranties
contained in this Agreement, any breaches of covenants contained in this Agreement and any willful
failure to fulfill any condition set forth in this Agreement prior to such termination.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE XII<BR>
GENERAL PROVISIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.01</U> <U>Expenses</U>. Except as otherwise specified in this Agreement, all
costs and expenses, including Transaction Expenses, incurred in connection with this Agreement and
the Transactions shall be paid by the party incurring such costs and expenses, whether or not the
Closing shall have occurred. Notwithstanding the foregoing, without limitation, Parent and Merger
Sub shall be responsible for the payment of all fees of legal counsel to Parent and Merger Sub
related to the Transactions, and the Company shall be responsible for the payment of all
Transaction Expenses incurred by the Company, including the fees of legal counsel and financial
advisors to the Company or the Company Securityholders directly related to the Transactions
<I>provided, however, </I>that Parent and the Company shall each be responsible for one-half of all filing
fees required to be paid in connection with the Merger pursuant to the HSR Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.02</U> <U>Notices</U>. All notices, requests, demands, claims and other
communications which are required or may be given under this Agreement shall be in writing and
shall be deemed to have been duly given when received if personally delivered; when transmitted if
transmitted by confirmed facsimile with a copy sent by another means specified herein; the Business
Day after it is sent, if sent for next day delivery to a domestic address by recognized overnight
delivery service (e.g., Federal Express); and five Business Days after the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->91<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">date mailed by certified
or registered mail, postage prepaid, if sent by certified or registered mail, return receipt
requested. In each case notice shall be sent to:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If to Parent or the Merger Sub, addressed to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 2%; margin-top: 6pt">Allergan, Inc.<BR>
2525 Dupont Drive<BR>
Irvine, California 92612<BR>
Attn: General Counsel<BR>
Telephone: 714-246-4500<BR>
Fax: 714-246-4774
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 2%; margin-top: 6pt">with a copy to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 2%; margin-top: 6pt">Latham &#038; Watkins LLP<BR>
650 Town Center Drive<BR>
20<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor<BR>
Costa Mesa, California 92626<BR>
Attn: Jonn R. Beeson and Cary K. Hyden<BR>
Telephone: (714)&nbsp;540-1235<BR>
Fax: (714)&nbsp;755-8290
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 2%; margin-top: 6pt">If to the Escrow Participants, addressed to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 2%; margin-top: 6pt">Andrew J. Einhorn, as Escrow Participants&#146; Representative<BR>
c/o Milbank, Tweed, Hadley &#038; McCloy LLP<BR>
One Chase Manhattan Plaza<BR>
New York, NY 10005<BR>
Facsimile No.: 212-822-5680<BR>
Attn: Robert S. Reder, Esq.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 2%; margin-top: 6pt">If to the Company, to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 2%; margin-top: 6pt">Esprit Pharma Holding Company, Inc.<BR>
Two Tower Center Blvd.<BR>
East Brunswick, NJ 08816<BR>
Facsimile No.:<BR>
E-mail: steve.bosacki@espritpharma.com<BR>
Attn: General Counsel
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 2%; margin-top: 6pt">with a copy to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 2%; margin-top: 6pt">Milbank, Tweed, Hadley &#038; McCloy LLP<BR>
One Chase Manhattan Plaza<BR>
New York, NY 10005<BR>
Facsimile No.: 212-822-5680<BR>
Attn: Robert S. Reder, Esq.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->92<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or to such other place and with such other copies as each of Parent, Merger Sub, the Company and
the Escrow Participants&#146; Representative may designate as to itself by written notice to the other
(in accordance with this <U>Section&nbsp;12.02</U>).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.03</U> <U>Release</U> . Effective as of the Effective Time, each Company Securityholder shall be deemed to have,
and hereby does, unconditionally release and forever discharge the Company, Parent, Merger Sub,
their Affiliates and their respective agents, representatives, officers and directors, from (a)&nbsp;any
and all obligations or duties the Company might have to such Person and (b)&nbsp;any and all claims of
Liability, whether legal or equitable, of every kind and nature, which such Person ever had, now
has or may claim against the Company in each case arising out of facts or circumstances occurring
at any time on or prior to the date hereof; <I>provided, however</I>, that such release shall exclude
those claims, liabilities, obligations and duties of the Company, Parent and Merger Sub under this
Agreement and the Escrow Agreement and shall exclude, to the extent applicable with respect to any
Person who is a director, officer or employee of the Company, (i)&nbsp;compensation and benefits not yet
paid (including any amounts payable in connection with the consummation of the Transactions), (ii)
reimbursement for expenses incurred by any such Person in the ordinary course of his or her
employment which are reimbursable under the Company&#146;s expense reimbursement policies, (iii)&nbsp;accrued
vacation, subject to the Company&#146;s policies on accrual and carryforward, and (iv)&nbsp;rights to
indemnification under the Acquired Companies&#146; certificates of incorporation and bylaws or the
indemnification agreements listed on Section&nbsp;6.01 of the Company Disclosure Schedule). For the
purposes of this <U>Section&nbsp;12.03</U>, each such Person hereby expressly waives the benefits of
Section&nbsp;1542 of the California Civil Code (or any Law of similar effect) which reads as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 10%">A general release does not extend to claims which the creditor does
not know or suspect to exist in his or her favor at the time of
executing the release which if known to him or her must have
materially affected his settlement with the debtor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms and provisions of this <U>Section&nbsp;12.03</U> are specific terms of the Transactions,
and the approval and adoption of this Agreement and approval of the Merger by the Company
Stockholders pursuant to the Stockholders&#146; Written Consent shall constitute approval by such
Company Stockholders, as specific terms of the Merger, and the irrevocable agreement of such
Company Stockholders to be bound by such terms and provisions. Parent and Merger Sub would not
have entered into this Agreement but for the terms and provisions of this <U>Section&nbsp;12.03</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.04</U> <U>Public Announcements</U>. Parent and the Company will consult with
each other before issuing, and provide each other the opportunity to review and make reasonable
comment upon, any press release or any public statement with respect to this Agreement and the
transactions contemplated hereby and, except as may be required by applicable Law or any listing
agreement with the New York Stock Exchange, will not issue any such press release or make any such
public statement prior to such consultation and the consent of the other party, not to be
unreasonably withheld or delayed; <I>provided, however</I>, that Parent may make any public statement in
response to specific questions by the press, analysts, investors or those attending industry
conferences or financial analyst conference calls, so long as any such statements are not
inconsistent with previous press releases, public disclosures or public statements made jointly by
Parent and the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->93<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.05</U> <U>Severability</U>. If any term or other provision of this Agreement is invalid, illegal or incapable of being
enforced as a result of any rule of Law or public policy, all other terms and other provisions of
this Agreement shall nevertheless remain in full force and effect so long as the economic or legal
substance of the Transactions is not affected in any manner materially adverse to any party. Upon
such determination that any term or other provision is invalid, illegal or incapable of being
enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect
the original intent of the parties as closely as possible in an acceptable manner to the end that
the Transactions are fulfilled to the greatest extent possible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.06</U> <U>Entire Agreement</U>. This Agreement, including the Company
Disclosure Schedule, Schedules and Exhibits and the other agreements referred to herein (including
the Ancillary Documents), is complete, and all promises, representations, understandings,
warranties and agreements with reference to the subject matter hereof, and all inducements to the
making of this Agreement relied upon by all the parties hereto, have been expressed herein or in
such Company Disclosure Schedule, Schedules, Exhibits or such other agreements and this Agreement,
including such Company Disclosure Schedule, Schedules, Exhibits and such other agreements,
supersede any prior understandings, negotiations, agreements or representations by or among the
parties, written or oral, to the extent they related in any way to the subject matter hereof or
thereof, including that certain Exclusivity Agreement by and between Parent and the Company dated
August&nbsp;10, 2007. Neither this Agreement nor any of the terms or provisions hereof are binding upon
or enforceable against any party hereto unless and until the same is executed and delivered by all
of the parties hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.07</U> <U>Successors and Assigns</U>. All covenants and agreements and other
provisions set forth in this Agreement and made by or on behalf of any of the parties hereto shall
bind and inure to the benefit of the successors, heirs and permitted assigns of such party, whether
or not so expressed. Neither this Agreement nor any of the rights or obligations hereunder may be
assigned by and Company Securityholder or the Company without the prior written consent of Parent,
or assigned by Parent or Merger Sub without the prior written consent of the Company (prior to the
Closing) or the Escrow Participants&#146; Representative (after the Closing), <I>provided</I>, that Parent and
Merger Sub (including the Surviving Corporation) may, without obtaining the prior written consent
of the Company or the Escrow Participants&#146; Representative, assign any of its rights, or delegate
any of its obligations under this Agreement to any Affiliate of Parent so long as Parent also
remains obligated for the performance of its obligations under this Agreement. The Escrow
Participants&#146; Representative shall execute such acknowledgments of such assignments in such forms
as Parent or Merger Sub (including the Surviving Corporation) may from time to time reasonably
request. Any purported assignment or delegation of rights or obligations in violation of this
<U>Section&nbsp;12.07</U> is void and of no force or effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.08</U> <U>Amendment</U>. This Agreement may not be amended except in an
instrument in writing signed on behalf of each of the parties hereto or by a waiver in accordance
with <U>Section&nbsp;12.09</U>. Subject to
the foregoing and applicable Law, any provision of this Agreement may be amended or waived
prior to the Effective Time; <I>provided </I>that, after approval and adoption of this Agreement and the
Merger by the Company Stockholders and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->94<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">without their further approval, no amendment or waiver shall
be made that by Law requires further approval by the Company Stockholders without such further
approval.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.09</U> <U>Waiver</U>. Subject to the last sentence of <U>Section&nbsp;12.08</U>,
each party to this Agreement may (a)&nbsp;extend the time for the performance of any of the obligations
or other acts of the other parties, (b)&nbsp;waive any inaccuracies in the representations and
warranties of the other parties contained herein or in any document delivered by the other party
pursuant hereto or (c)&nbsp;waive compliance with any of the agreements of the other parties or
conditions to such parties&#146; obligations contained herein. Any such extension or waiver shall be
valid only if set forth in an instrument in writing signed by the party to be bound thereby.
Except where a specific period for action or inaction is provided herein, neither the failure nor
any delay on the part of any party in exercising any right, power or privilege under this Agreement
or the documents referred to in this Agreement shall operate as a waiver thereof, nor shall any
waiver on the part of any party of any such right, power or privilege, nor any single or partial
exercise of any such right, power or privilege, preclude any other or further exercise thereof or
the exercise of any other such right, power or privilege. The failure of a party to exercise any
right conferred herein within the time required shall cause such right to terminate with respect to
the transaction or circumstances giving rise to such right, but not to any such right arising as a
result of any other transactions or circumstances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.10</U> <U>No Third Party Beneficiaries</U>. This Agreement shall be binding
upon and shall inure to the benefit of, the parties hereto and their respective successors and
permitted assigns. This Agreement and all of its conditions and provisions are for the sole and
exclusive benefit of the parties hereto and their respective successors and permitted assigns, and
nothing in this Agreement (except as provided in this <U>Section&nbsp;12.10</U>), express or implied,
is intended to confer upon any Person, including any union or any employee or former employee of
the Company, other than the parties hereto any rights or remedies of any nature whatsoever,
including any rights of employment for any specified period, under or by reason of this Agreement
or any provision hereof; <I>provided, however </I>that the Company Indemnified Persons are entitled to the
rights and remedies of third party beneficiaries with respect to <U>Section&nbsp;6.01</U> and the
Parent Indemnified Parties not party hereto are entitled to the rights and remedies of third party
beneficiaries with respect to <U>Article&nbsp;IX</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.11</U> <U>Specific Performance</U>. Each of the parties hereto acknowledges
and agrees that the other parties would be damaged irreparably, and in a manner for which monetary
damages would not be an adequate remedy, in the event any of the provisions of this Agreement are
not performed in accordance with its specific terms or otherwise are breached. Accordingly, each
of the parties hereto agrees that the other parties shall be entitled to an injunction or
injunctions to prevent breaches of the
provisions of this Agreement and to enforce specifically this Agreement and the terms and
provisions hereof in any Action instituted in any court of the United States or any state thereof
having jurisdiction over the parties and the matter, in addition to any other remedy to which they
may be entitled, at law or in equity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.12</U> <U>Governing Law</U>. This Agreement (and any claim or controversy
arising out of or relating to this Agreement) shall be governed by the laws of the State of New
York applicable to contracts made and to be performed entirely in such State
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->95<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">without regard to
conflict of laws principles that would result in the application of any Law other than the Law of
the State of New York; <I>provided</I>, <I>however</I>, that the Merger shall be governed by the DGCL.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.13</U> <U>Arbitration</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All disputes, controversies or claims arising out of or in relation to this Agreement or
the Transactions shall be finally resolved by arbitration before one (1)&nbsp;arbitrator selected by
Parent and the Escrow Participants&#146; Representative; <I>provided, however</I>, that if an arbitrator is
not selected within thirty (30)&nbsp;days (or such other period of time as the parties agree in
writing) following the date of receipt of the written arbitration demand delivered by the party
seeking arbitration to the other party, then Judicial Arbitration and Mediation Services (&#147;JAMS&#148;)
shall select an arbitrator from the New York metropolitan area. The arbitration shall be in New
York County, New York and shall be administered by JAMS in accordance with its Comprehensive
Arbitration Rules and Procedures. Each of the parties hereto agrees that a judgment in such
action may be enforced in other jurisdictions by suit on the judgment or in any other manner
provided by any applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each of the parties hereto hereby irrevocably consents to process being served by any
party to this Agreement in any dispute, controversy or claim arising out of or in relation to this
Agreement or the Transactions by delivery of a copy thereof in accordance with the provisions of
<U>Section&nbsp;12.02</U>. Nothing in this Agreement will affect the right of any party to this
Agreement to serve process in any other manner permitted by Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) EACH PARTY TO THIS AGREEMENT ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE
UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT
HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT
OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT AND ANY OF
THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS. EACH PARTY CERTIFIES AND
ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED,
EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO
ENFORCE EITHER OF SUCH WAIVERS, (B)&nbsp;IT UNDERSTANDS AND HAS
CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (C)&nbsp;IT MAKES SUCH WAIVERS VOLUNTARILY, AND (D)
IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS <U>SECTION 12.13</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.14</U> <U>Cumulative Remedies</U>. All rights and remedies of either party
hereto are cumulative of each other and of every other right or remedy such party may otherwise
have at law or in equity, and the exercise of one or more rights or remedies shall not prejudice or
impair the concurrent or subsequent exercise of other rights or remedies.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->96<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.15</U> <U>Representation by Counsel</U>. Each party hereto represents and
agrees with each other that it has been represented by or had the opportunity to be represented by,
independent counsel of its own choosing, and that it has had the full right and opportunity to
consult with its respective attorney(s), that to the extent, if any, that it desired, it availed
itself of this right and opportunity, that it or its authorized officers (as the case may be) have
carefully read and fully understand this Agreement and the Ancillary Documents in their entirety
and have had it fully explained to them by such party&#146;s respective counsel, that each is fully
aware of the contents thereof and its meaning, intent and legal effect, and that it or its
authorized officer (as the case may be) is competent to execute this Agreement and has executed
this Agreement free from coercion, duress or undue influence. The parties hereto have participated
jointly in the negotiation and drafting of this Agreement in connection with the Transactions, with
the opportunity to seek advice as to their legal rights from such counsel. In the event an
ambiguity or question of intent or interpretation arises, this Agreement is to be construed as
jointly drafted by the parties hereto and no presumption or burden of proof is to arise favoring or
disfavoring any party by virtue of the authorship of any provision of this Agreement or by reason
of the extent to which any such provision is inconsistent with any prior draft hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECTION 12.16</U> <U>Execution and Counterparts</U>. This Agreement may be executed in
two or more counterparts, each of which when executed shall be deemed an original and all of which
together shall constitute one and the same instrument. The parties agree that this Agreement shall
be legally binding upon the electronic transmission, including by facsimile or email, by each party
of a signed signature page to this Agreement to the other party.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signature Page Follows&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->97<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Parent, Merger Sub, the Company and the Escrow Participants&#146;
Representative have caused this Agreement to be executed as of the date first written above by
their respective officers thereunto duly authorized.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">ALLERGAN, INC.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Douglas S. Ingram</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Douglas S. Ingram</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Executive Vice President, Chief</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Administrative Officer, General Counsel and
Secretary</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">ESMERALDE ACQUISITION, INC.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Douglas S. Ingram</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Douglas S. Ingram</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Secretary</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">ESPRIT PHARMA HOLDING COMPANY, INC.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ John T. Spitznagel</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">John T. Spitznagel</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">ESCROW PARTICIPANTS&#146; REPRESENTATIVE</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Andrew J. Einhorn</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Andrew J. Einhorn, solely in his capacity</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">as Escrow Participants&#146; Representative</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">(Agreement
and Plan of Merger)</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ACTION BY WRITTEN CONSENT OF<BR>
STOCKHOLDERS OF<BR>
ESPRIT PHARMA HOLDING COMPANY, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>September </B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U><B>, 2007</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the provisions of Section&nbsp;228, Section&nbsp;242 and Section&nbsp;251 of the Delaware General
Corporation Law (the &#147;<U>DGCL</U>&#148;), the undersigned (each a &#147;<U>Stockholder</U>&#148; and
collectively, the &#147;<U>Stockholders</U>&#148;), do hereby consent to, approve and adopt pursuant to
action by written consent in lieu of a vote at a meeting of stockholders, effective as of the date
first set forth above, the following resolutions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, each Stockholder owns beneficially and of record the number of shares of Series&nbsp;A
Convertible Preferred Stock, par value $0.0001 per share (&#147;<U>Series&nbsp;A Stock</U>&#148;), Series&nbsp;B
Convertible Preferred Stock, par value $0.0001 per share (&#147;<U>Series&nbsp;B Stock</U>&#148; and, together
with the Series&nbsp;A Stock, the &#147;<U>Preferred Stock</U>&#148;), and/or Common Stock, par value $0.0001 per
share (&#147;<U>Common Stock</U>&#148;), of Esprit Pharma Holding Company, Inc., a Delaware corporation (the
&#147;<U>Company</U>&#148;), set forth on Schedule&nbsp;I hereto;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Stockholders collectively own beneficially and of record at least (i)&nbsp;60% of the
outstanding shares of Preferred Stock, (ii)&nbsp;a majority of the outstanding shares of Common Stock
and (iii)&nbsp;a majority of the outstanding shares of Common Stock and Preferred Stock (on an
as-converted basis) voting together as a single class;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Board of Directors of the Company (the &#147;<U>Board</U>&#148;) has adopted resolutions
(i)&nbsp;approving that certain Agreement and Plan of Merger substantially in the form of Schedule&nbsp;II
hereto (the &#147;<U>Merger Agreement</U>&#148;) by and among the Company, Allergan, Inc., a Delaware
corporation (&#147;<U>Parent</U>&#148;), a newly-formed Delaware corporation which is a wholly owned
subsidiary of Parent (&#147;<U>Merger Sub</U>&#148;), and the Escrow Participants&#146; Representative (as such
term is defined in the Merger Agreement), and declaring its advisability, (ii)&nbsp;approving the
transactions contemplated by the Merger Agreement, including, but not limited to, the consummation
of the merger of Merger Sub with and into the Company, with the Company as the surviving
corporation (the &#147;<U>Merger</U>&#148;) and (iii)&nbsp;determining that the Merger Agreement and the
transactions contemplated thereby are fair to and in the best interests of the Company and its
stockholders;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Board has resolved to submit the Merger Agreement to the stockholders of the
Company for the purpose of acting on the Merger Agreement in accordance with the provisions of
Section&nbsp;251 of the DGCL and the Amended and Restated Certificate of Incorporation of the Company,
and has recommended that the stockholders of the Company adopt the Merger Agreement and approve the
transactions contemplated thereby, including the consummation of the Merger;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Merger Agreement also contemplates that prior to or concurrently with the
execution of the Merger Agreement, the Company will adopt an
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">amendment to the Company&#146;s Amended and Restated Certificate of Incorporation substantially in
the form attached hereto as <U>Schedule&nbsp;III</U> (the &#147;<U>Charter Amendment</U>&#148;), which will
become effective, if approved by the requisite vote of the Stockholders, when filed with the
Delaware Secretary of State immediately prior to the Effective Time (as defined in the Merger
Agreement) of the Merger; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Board has adopted resolutions approving the Charter Amendment and has resolved to
submit the Charter Amendment to the Stockholders for the purpose of adopting the Charter Amendment
in accordance with the provisions of Section&nbsp;242 of the DGCL and the Amended and Restated
Certificate of Incorporation of the Company, and has recommended that the Stockholders adopt the
Charter Amendment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, BE IT:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESOLVED, that the Stockholders hereby consent to, approve, authorize and vote their shares of
Common Stock and Preferred Stock in favor of the adoption of the Merger Agreement in substantially
the form attached hereto and the approval of the transactions contemplated thereby;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESOLVED, that the escrow and indemnification obligations set forth in the Merger Agreement
and the deposit of cash in the amount of Indemnification Escrow Fund (as defined in the Merger
Agreement) and the Net Working Capital Escrow Fund (as defined in the Merger Agreement) are hereby
approved, authorized and adopted in all respects;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESOLVED, that each of the Stockholders hereby approves the appointment of Anthony A. Rascio
as the Escrow Participants&#146; Representative pursuant to the terms of the Merger Agreement and
designates the Escrow Participants&#146; Representative to act as the attorney-in-fact and agent for and
on behalf of the Company&#146;s stockholders and to give and receive notices and communications, to
authorize delivery to Parent of cash from the Indemnification Escrow Fund and/or the Net Working
Capital Escrow Fund in satisfaction of claims by Parent, to object to claims, to agree to,
negotiate and enter into settlements and compromises of claims, to demand, prosecute and defend
arbitration or other actions with respect to claims and to take any and all actions, to make any
decisions required or permitted to be taken by the Escrow Participants&#146; Representative under the
Merger Agreement and to take all actions necessary or appropriate in the judgment of the Escrow
Participants&#146; Representative for the accomplishment of the foregoing;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESOLVED, that the undersigned hereby affirms that (a)&nbsp;upon the consummation of the Merger,
the rights of such Stockholder with respect to his, her or its Common Stock and/or Preferred Stock
shall be governed by the Merger Agreement and such Stockholder&#146;s ownership interest in the Company
shall be converted solely into the right to receive cash pursuant to the Merger Agreement, and (b)
the allocation of the consideration of the Merger among the holders of the capital stock of the
Company in accordance with the terms and conditions of the Merger Agreement is hereby approved;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESOLVED, that in consideration of the payments to be made to the Stockholders pursuant to the
Merger Agreement, each Stockholder waives, and releases and forever discharges the Company and its
subsidiary and their respective officers, directors, employees, agents and affiliates from, to the
fullest extent permitted by law, any and all rights, claims or actions whatsoever arising out of or
relating to any alleged breach, default or failure to perform by the Company or its subsidiary of
any duty or obligation, contractual, fiduciary or other, that the Stockholders shall or may have,
at any time prior to the effectiveness of the Merger, by reason of or in connection with the
Stockholders&#146; capacity as a stockholder of the Company, other than in respect of any rights to
which the Stockholders are entitled pursuant to the express terms of the Merger Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESOLVED, that the Stockholders agree and recognize that, by consenting to the Merger
Agreement and the transactions contemplated thereby, the Stockholders waive any right that the
Stockholders might have to an appraisal of their shares of Common Stock and Preferred Stock under
the DGCL; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESOLVED, that the Stockholders hereby consent to and vote their shares of Common Stock and
Preferred Stock in favor of the adoption of the Charter Amendment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delivery of any copy, facsimile or other reliable reproduction of an executed copy of this
Written Consent shall be as effective as delivery of a manually signed copy of this Written
Consent, <U>provided</U> that such copy, facsimile or other reproduction is a complete
reproduction of the entire original writing.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signature page follows&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN WITNESS WHEREOF</B>, this written consent may be executed in separate counterparts and, when
executed by each of the Stockholders listed below, the foregoing resolutions will be duly adopted
as of the date first written above.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>APAX EXCELSIOR VI, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Apax Excelsior VI Partners, L.P.<BR>
its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Apax Managers, Inc.<BR>
its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">153 East 53<SUP style="font-size: 85%; vertical-align: text-top">rd</SUP> Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">New York, NY 10022</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>APAX EXCELSIOR VI-A, C.V.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Apax Excelsior VI Partners, L.P.<BR>
its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Apax Managers, Inc.<BR>
its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

 <TR>
  <TD>&nbsp;</TD>
 </TR>

<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">153 East 53<SUP style="font-size: 85%; vertical-align: text-top">rd</SUP> Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">New York, NY 10022</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>APAX EXCELSIOR VI-B, C.V.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Apax Excelsior VI Partners, L.P.<BR>
its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Apax Managers, Inc.<BR>
its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">153 East 53<SUP style="font-size: 85%; vertical-align: text-top">rd</SUP> Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">New York, NY 10022</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>PATRICOF PRIVATE INVESTMENT
CLUB III, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Apax Excelsior VI Partners L.P.<BR>
its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Apax Managers, Inc.<BR>
its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">153 East 53rd Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">New York, NY 10022</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>DOMAIN PARTNERS VI, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">One Palmer Square Associates VI, L.L.C., its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">One Palmer Square</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Suite&nbsp;515</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Princeton, NJ 08542</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>DP VI ASSOCIATES, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">One Palmer Square Associates VI, L.L.C., its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">One Palmer Square</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Suite&nbsp;515</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Princeton, NJ 08542</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>NEW ENTERPRISE ASSOCIATES 11, LIMITED PARTNERSHIP</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NEA Partners 11, Limited<BR>
Partnership, its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NEA 11 GP, LLC, its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Manager</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">1119 St. Paul Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Baltimore, MD 21202</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>NEW ENTERPRISE ASSOCIATES 10, LIMITED
PARTNERSHIP</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NEA Partners 10, Limited<BR>Partnership,
its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">1119 St. Paul Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Baltimore, MD 21202</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>NEW ENTERPRISE ASSOCIATES 9, LIMITED PARTNERSHIP</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NEA Partners 9, Limited<BR>
Partnership, its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">1119 St. Paul Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Baltimore, MD 21202</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>MONTAGU NEWHALL GLOBAL PARTNERS II, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montagu Newhall General Partner II, L.P., its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montagu Newhall Associates, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ashton Newhall</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">100 Painters Mill Road</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Owings Mills, MD 21117</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>MONTAGU NEWHALL GLOBAL PARTNERS II-A, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montagu Newhall General Partner II, L.P., its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montagu Newhall Associates, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ashton Newhall</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">100 Painters Mill Road</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Owings Mills, MD 21117</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>MONTAGU NEWHALL GLOBAL PARTNERS II-B, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montagu Newhall General Partner II, L.P., its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montagu Newhall Associates, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ashton Newhall</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">100 Painters Mill Road</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Owings Mills, MD 21117</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>MONTAGU NEWHALL GLOBAL PARTNERS III, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montagu Newhall General Partner III, L.P., its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montagu Newhall General Partner III, L.L.C.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Kevin Campbell, Managing Member</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">100 Painters Mill Road</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Owings Mills, MD 21117</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>MONTAGU NEWHALL GLOBAL PARTNERS III-A, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montagu Newhall General Partner III, L.P., its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montagu Newhall General Partner III, L.L.C.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Kevin Campbell, Managing Member</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">100 Painters Mill Road</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Owings Mills, MD 21117</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>MONTAGU NEWHALL GLOBAL PARTNERS III-B, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montagu Newhall General Partner III, L.P., its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montagu Newhall General Partner III, L.L.C.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Kevin Campbell, Managing Member</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">100 Painters Mill Road</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Owings Mills, MD 21117</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>OAK INVESTMENT PARTNERS XII, LIMITED PARTNERSHIP</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">One Gorham Island</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Westport, CT 06880</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>FIRST PLAZA GROUP TRUST, SOLELY FOR THE BENEFIT OF POOL PMI-127</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">JPMorgan Chase Bank, N.A., as trustee of the First Plaza Group
Trust</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Performance Equity Management, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">2 Pickwick Plaza Suite&nbsp;310</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Greenwich, CT 06830-5424</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>FIRST PLAZA GROUP TRUST, SOLELY FOR THE BENEFIT OF POOL PMI-128</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">JPMorgan Chase Bank, N.A., as trustee of the First Plaza Group
Trust</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Performance Equity Management, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">2 Pickwick Plaza Suite&nbsp;310</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Greenwich, CT 06830-5424</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>FIRST PLAZA GROUP TRUST, SOLELY FOR THE BENEFIT OF POOL PMI-129</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">JPMorgan Chase Bank, N.A., as trustee of the First Plaza Group
Trust</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Performance Equity Management, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">2 Pickwick Plaza Suite&nbsp;310</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Greenwich, CT 06830-5424</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>FIRST PLAZA GROUP TRUST, SOLELY FOR THE BENEFIT OF POOL PMI-130</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">JPMorgan Chase Bank, N.A., as trustee of the First Plaza Group
Trust</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Performance Equity Management, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">2 Pickwick Plaza Suite&nbsp;310</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Greenwich, CT 06830-5424</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>JOHN T. SPITZNAGEL, JR.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">c/o Esprit Pharma Holding Company, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Two Tower Center Boulevard</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">East Brunswick, NJ 08816</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>ROSEANNE BRANCIFORTE</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">240 Gravel Hill Road</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Monroe, NJ 08831</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>ROBERT BROWN</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">2110 North Ocean Boulevard, Apt 14B</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Fort Lauderdale, FL 33305</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>NEA VENTURES 2005, LIMITED PARTNERSHIP</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>RICHARD J. LANE</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>SUNDANCE AP, LLC</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>LOUIS P. BERARDI</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>ANDREW J. EINHORN</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>ERNEST BICZAK</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>GREGORY STOKES</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>ROGER HERRIGAL</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>RONALD NORDMANN</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>JON RUBINTON</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>JOHN W. HADDEN II</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>CLAREMONT DELAWARE TRUST</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>ERIC KAUFMAN</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>MARVIN AMSTER</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>JIM PETRY</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>DAVID ROBINSON</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>JOSEPH SMITH</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>PATRICK J. LEPORE</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>BOB BALDINI</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>EILEEN MOORE</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>ROBERT PREVIDI</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>MARY ANN CARBONARO</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>STUART LEVINE</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>G&#038;H PARTNERS</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>ROBERT BROWN</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>LEW MYERS</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>ALAN WRIGHT</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>BONNIE WRIGHT</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>EDWARD BOGART</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>SCOTT DAVIDSON</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>JOHN CULLEN</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>MELISA POOLE</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>LIZBETH LEON</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>LORETTA WOTOMSKI</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>STEVEN BOSACKI</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>NANSKE WOOD</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>MARK JANOFSKY</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>ANTHONY RASCIO</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>GRAHAM MAY</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>STAN OSBORN</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>LISA FANELLI</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>ROBERT NILES</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>BLANE ADAMS</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>GARY DEAN</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>ALISON BALL</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>DON CROUSE</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>LYN ADANICH</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>JAMENQ AYOUB</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>KATIE BROWN</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>JEFFREY CABBS</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>CRAIG COPAS</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>DENISE DELELLIS</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>DEBORAH FABAC</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>JENNIFER FAUCETT</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>EVA FOWLER</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>JAMES FRANKLIN</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>JESSE FULLER</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>ROBERT GILL</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>ROBERT GUKIEN</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>JOHN HATCHETT</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>PAMELA KIGGEN</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>CHRISTINA KOMETER</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>LARRY LABRADOR</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>MARK LENNON</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>JOHN MAGEE</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>MATTHEW MCLEOD</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>MEREDITH MILAM</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>JAIME NEUENSCHWANTER</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>KRISTEN NIEDZWIECKI</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>JAMIE NORTON</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>ANDREA PLUBELL</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>VERNON SMITH II</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>LISA STRICKLIN</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>DANIEL TELL</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>SCHEDULE I </B></U><BR>
<U><B>STOCKHOLDERS</B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Stockholder</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Shares Owned</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Percentage</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Apax Excelsior VI, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Apax Excelsior VI-A, C.V.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Apax Excelsior VI-B, C.V.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Patricof Private Investment Club III, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Domain Partners VI, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">DP VI Associates, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">New Enterprise Associates 11, Limited  Partnership</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">New Enterprise Associates 10, Limited  Partnership</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">New Enterprise Associates 9, Limited  Partnership</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Montagu Newhall Global Partners II, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Montagu Newhall Global Partners II-A, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Montagu Newhall Global Partners II-B, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Montagu Newhall Global Partners III, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Montagu Newhall Global Partners III-A, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Montagu Newhall Global Partners III-B, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Oak Investment Partners XII, Limited Partnership</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">First Plaza Group Trust, Solely for the
Benefit of Pool PMI-127</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">First Plaza Group Trust, Solely for the
Benefit of Pool PMI-128</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">First Plaza Group Trust, Solely for the
Benefit of Pool PMI-129</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">First Plaza Group Trust, Solely for the
Benefit of Pool PMI-130</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">John T. Spitznagel, Jr.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Roseanne Branciforte</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert Brown</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">NEA Ventures 2005, Limited Partnership</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Richard J. Lane</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sundance AP, LLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Louis P. Berardi</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Andrew J. Einhorn</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Ernest Biczak</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Gregory Stokes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Stockholder</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Shares Owned</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Percentage</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Roger Herrigal</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Ronald Nordmann</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Jon Rubinton</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">John W. Hadden II</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Claremont Delaware Trust</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Eric Kaufman</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Marvin Amster</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Jim Petry</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">David Robinson</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Joseph Smith</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Patrick J. LePore</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Bob Baldini</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Eileen Moore</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert Previdi</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Mary Ann Carbonaro</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Stuart Levine</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">G&#038;H Partners</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert Brown</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Lew Myers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Alan Wright</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Bonnie Wright</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Edward Bogart</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Scott Davidson</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">John Cullen</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Melisa Poole</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Lizbeth Leon</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Loretta Wotomski</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Steven Bosacki</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Nanske Wood</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Mark Janofsky</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Anthony Rascio</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Graham May</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Stan Osborn</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Lisa Fanelli</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert Niles</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Blane Adams</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Gary Dean</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Alison Ball</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Don Crouse</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Lyn Adanich</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Jamenq Ayoub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Katie Brown</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Jeffrey Cabbs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Craig Copas</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Denise Delellis</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Stockholder</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Shares Owned</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Percentage</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Deborah Fabac</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Jennifer Faucett</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Eva Fowler</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">James Franklin</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Jesse Fuller</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert Gill</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert Gukien</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">John Hatchett</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Pamela Kiggen</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Christina Kometer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Larry Labrador</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Mark Lennon</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">John Magee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Matthew McLeod</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Meredith Milam</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Jaime Neuenschwanter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Kristen Niedzwiecki</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Jamie Norton</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Andrea Plubell</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Vernon Smith II</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Lisa Stricklin</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Daniel Tell</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT B</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Certificate of Amendment to </B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Amended and Restated </B></FONT>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Certificate of Incorporation of </B></FONT>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Esprit Pharma holding Company, Inc.</B></FONT>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Esprit Pharma Holding Company, Inc. (the &#147;Corporation&#148;), a corporation organized and
existing under and by virtue of the provisions of the General Corporation Law of the State of
Delaware (the &#147;General Corporation Law&#148;), does hereby certify:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>FIRST: </B>That pursuant to Section&nbsp;141 and 242 of the General Corporation Law, the Board of
Directors of the Corporation duly adopted resolutions proposing to amend the Amended and Restated
Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and in
the best interests of this Corporation and its stockholders, as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>A.&nbsp;</B>A new subsection B.7. shall be added to Article&nbsp;IV as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>7. </B><U><B>Allergan Merger</B></U>. Notwithstanding anything to the contrary
contained in this Amended and Restated Certificate of Incorporation of the
Corporation, the holders of shares of Preferred Stock shall not be entitled to
receive or be required to take any amounts or consideration on account of such
shares in connection with the merger (the &#147;Allergan Merger&#148;) of the Corporation with
Esmeralde Acquisition, Inc., a wholly-owned subsidiary of Allergan, Inc., pursuant
to the terms of that certain Agreement and Plan of Merger, dated September&nbsp;18, 2007
by and among Allergan, Inc., Esmeralde Acquisition, Inc., the Corporation and the
Escrow Participants&#146; Representative named therein (the &#147;Allergan Merger Agreement&#148;),
other than the amounts set forth in Section&nbsp;2.02(c) of the Allergan Merger
Agreement.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>B.&nbsp;</B>A new subsection C.5. shall be added to Article&nbsp;IV as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#147;<B>5. </B><U><B>Allergan Merger</B></U>. Notwithstanding anything to the contrary
contained in this Amended and Restated Certificate of Incorporation of the
Corporation, the holders of shares of Common Stock shall not be entitled to receive
or be required to take any amounts or consideration on account of such shares in
connection with the Allergan Merger, other than the amounts set forth in Section
2.02(d) of the Allergan Merger Agreement.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>THIRD: </B>Thereafter, pursuant to a resolution of the Board of Directors, this Certificate of
Amendment was submitted to the stockholders of the Corporation for their approval, and was duly
adopted in accordance with the provisions of Sections&nbsp;228 and 242 of the General Corporation Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>FOURTH: </B>This amendment shall become effective immediately upon filing with the Secretary of
State of Delaware. All other provisions of the Amended and Restated Certificate of Incorporation
of the Corporation, as currently on file with the Secretary of State of the State of Delaware,
shall remain in full force and effect.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>In Witness Whereof</B></FONT>, the undersigned has executed this Certificate of Amendment this
&#95;&#95;&#95;day of October&nbsp;2007.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Esprit Pharma Holding Company, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Steven M. Bosacki
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President and General Counsel</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->2&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT&nbsp;C</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDED AND RESTATED LICENSE,</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>COMMERCIALIZATION AND SUPPLY AGREEMENT</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>by and between</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INDEVUS PHARMACEUTICALS, INC.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>and</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ESPRIT PHARMA, INC.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>dated</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>September&nbsp;18, 2007</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Page</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">1.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Definitions</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">2.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Grant of Rights</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Grants by Indevus
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sublicenses of Third Party Rights
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Retained Rights; No Implied Licenses; Limitations
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2.4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Competition
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2.5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Sublicense by Esprit
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2.6</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Regulatory Filings
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2.7</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Access to Information
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2.8</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Grant by Esprit
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2.9</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Further Development by Indevus
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">3.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Governance</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Development Committee
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Marketing Committee
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">21</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Supply Committee
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3.4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Meetings
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">25</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3.5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Minutes of Committee Meetings
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">25</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3.6</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Disbanding of Committees
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">26</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3.7</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Project Coordinators
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">26</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">4.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Development and Regulatory Matters</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">26</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Development
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">26</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Regulatory Matters
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">26</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">5.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Promotion of Products</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">30</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">30</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Promotion Plan
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Target Prescribers; Product Advisors
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Esprit Promotional Activities
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Indevus Promotional Activities
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">33</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.6</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Promotional Materials and Activities
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">34</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.7</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Samples
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">36</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.8</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Training Program
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">37</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.9</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Additional Services and Assistance by Esprit
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">39</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.10</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Additional Personnel and Support
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">40</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.11</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Covenants of the Parties
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">40</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Page</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">6.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Payments and Statements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">41</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Upfront and Milestone Payments
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">41</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sublicensing Royalties, Minimum Royalties and Third Party Royalties
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">41</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sales Force Reimbursement
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">46</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6.4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Reports and Payments
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">47</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6.5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Audits
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">49</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6.6</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">License to Dominating Patent
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">50</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">7.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Representations and Warranties</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">51</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General Representations
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">51</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Additional Representations and Warranties of Indevus
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">52</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Additional Representations and Warranties of Esprit
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">53</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7.4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Disclaimer of Additional Warranties
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">54</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7.5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Limitation of Liability
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">54</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">8.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Patent Matters</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">54</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ownership
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">54</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Maintenance and Prosecution
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">54</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Third Party Infringement
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">55</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8.4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Third Party Intellectual Property
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">56</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8.5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Patent Term Extensions
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">57</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8.6</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conflict with Certain Existing Agreements
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">57</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">9.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Trademark Matters</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">57</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">57</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Maintenance
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">58</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Use of Trademark
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">58</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9.4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Enforcement
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">58</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9.5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Avoidance of Confusion
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">58</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9.6</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trademark Security Interest
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">58</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">10.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Adverse Experiences</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">59</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">11.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Confidentiality and Publicity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">60</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Disclosure and Non-Use Obligations
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">60</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Permitted Disclosure of Proprietary Information
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">60</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Disclosure of Agreement to Governmental Authority
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">61</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11.4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Publications
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">61</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11.5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Other Public Statements
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">62</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">12.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Term and Termination</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">62</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Page</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Term and Expiration
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">62</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Early Termination
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">63</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rights Not Affected
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">64</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12.4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Effect of Expiration or Termination
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">65</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">13.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Indemnification and Insurance</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">66</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Indemnity
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">66</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Esprit Indemnification
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">66</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Indevus Indemnification
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">66</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13.4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Indemnification Procedure
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">67</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13.5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Defense of Claims
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">67</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13.6</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Settlement of Indemnified Claims
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">68</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13.7</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Product Liability Claims
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">68</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13.8</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Insurance
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">70</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">14.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Orders and Supply</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">70</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Orders and Terms of Sale
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">70</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Misdirected Orders
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">70</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Product Returns
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">70</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Supply Obligations
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">71</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Forecasts for Products
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">71</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.6</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Purchase Orders
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">73</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.7</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Delivery
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">73</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.8</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Supply Price and Payments
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">74</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.9</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conformity; Specifications; Quality Control
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">76</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.10</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Inspection; Non-conformance
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">76</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.11</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Inventory Management
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">77</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.12</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Shortages; Failure to Supply
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">77</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.13</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assumption of Processing Activities
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">78</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14.14</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ex-US Supply Agreement
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">80</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">15.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS">Miscellaneous</FONT></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">80</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Force Majeure
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">80</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assignment
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">80</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Severability
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">82</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15.4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notices
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">82</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15.5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Specific Performance
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">83</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15.6</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Applicable Law and Venue
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">83</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15.7</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Entire Agreement
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">83</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15.8</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Independent Contractors
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">84</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15.9</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Waiver
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">84</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15.10</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Headings; References; Interpretation
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">84</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15.11</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Release
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">84</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15.12</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Counterparts
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">84</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>THIS AMENDED AND RESTATED LICENSE, COMMERCIALIZATION AND SUPPLY AGREEMENT</B></FONT> (the
&#147;<B>Agreement</B>&#148;) is made as of September&nbsp;18, 2007 (the &#147;<B>Execution Date</B>&#148;), and, except as otherwise
specified herein, is to become effective on the Effective Date (as defined below), by and between
<B>INDEVUS PHARMACEUTICALS, INC.</B>, a corporation organized and existing under the laws of the State of
Delaware and having its principal office at 99 Hayden Avenue, Suite&nbsp;200, Lexington, MA 02421,
United States (&#147;<B>Indevus</B>&#148;), and <B>ESPRIT PHARMA, INC.</B>, a corporation organized and existing under the
laws of the State of Delaware and having its principal office at 2 Tower Center Boulevard, East
Brunswick, NJ 08816, United States (&#147;<B>Esprit</B>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RECITALS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>WHEREAS</B></FONT>, Odyssey Pharmaceuticals, Inc. and Indevus entered into a certain License,
Commercialization and Supply Agreement, effective as of April&nbsp;6, 2004, as amended by Amendment No.
1 thereto, dated as of April&nbsp;30, 2005, as further amended by the Amendment and Consent Agreement,
dated as of May&nbsp;14, 2005 by and among Indevus, Odyssey Pharmaceuticals, Inc. and Esprit (f/k/a
Saturn Pharmaceuticals, Inc.) (collectively, the &#147;<B>Original Agreement</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>WHEREAS</B></FONT>, pursuant to a certain Asset Purchase Agreement, effective as of May&nbsp;14,
2005, Odyssey Pharmaceuticals, Inc. assigned to Esprit (formerly known as &#147;Esprit Pharma Holding
Company, Inc.&#148; and prior to that &#147;Saturn Pharmaceuticals, Inc.&#148;) the rights of Odyssey
Pharmaceuticals, Inc., and Esprit assumed the obligations of Odyssey Pharmaceuticals, Inc., in and
under the Original Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>WHEREAS</B></FONT>, simultaneously with the execution of this Agreement, Esprit Pharma Holding
Company, Inc. (&#147;<B>Esprit Holding</B>&#148;), the current parent company of Esprit is entering into an
Agreement and Plan of Merger by and among Allergan, Inc., a Delaware corporation (&#147;<B>Allergan</B>&#148;),
Andrew Einhorn, solely in his capacity as the Escrow Participants&#146; Representative, Esmerelde
Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of Allergan, and Esprit
Holding (the &#147;<B>Merger Agreement</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>WHEREAS</B></FONT>, pursuant to the Merger Agreement, Esmerelde Acquisition, Inc. will merge
with and into Esprit Holding, and Esprit Holding will survive the merger as a wholly-owned
subsidiary of Allergan; and<FONT style="font-variant: SMALL-CAPS"> </FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>WHEREAS</B></FONT>, Indevus and Esprit desire to amend and restate the Original Agreement to
reflect the agreements of the Parties to be effective as of the Effective Date or, as specifically
set forth in Article&nbsp;14, on the Execution Date, all on the terms and conditions set forth below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>NOW, THEREFORE</B></FONT>, in consideration of the foregoing statements and the mutual
agreements and covenants herein contained, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, Indevus and Esprit hereby agree as
follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Definitions</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless specifically set forth to the contrary herein, the following terms, where used in the
singular or plural, shall have the respective meanings set forth below:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.1 </B>&#147;<B>Act</B>&#148; means the United States Food, Drug, and Cosmetic Act of 1938, as amended, and the
rules and regulations promulgated thereunder, or any successor act, as the same shall be in effect
from time to time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.2 </B>&#147;<B>Adverse Experience</B>&#148; or &#147;AE(s)&#148; means adverse drug experiences, as defined by 21 CFR
Section&nbsp;314.80.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.3 </B>&#147;<B>Affiliate</B>&#148; of a Party means (i)&nbsp;any corporation or business entity of which at least
fifty percent (50%) of the securities or other ownership interests representing the equity, the
voting stock or general partnership interest are owned, controlled or held, directly or indirectly,
by a Party; (ii)&nbsp;any corporation or business entity which, directly or indirectly, owns, controls
or holds at least fifty percent (50%) (or the maximum ownership interest permitted by law) of the
securities or other ownership interests representing the equity, voting stock or general
partnership interest of a Party; (iii)&nbsp;any corporation or business entity of which, directly or
indirectly, an entity described in the immediately preceding subsection (ii)&nbsp;controls or holds at
least fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or
other ownership interests representing the equity, voting stock or general partnership interest of
such corporation or entity; or (iv)&nbsp;any corporation or business entity of which a Party has the
right to acquire, directly or indirectly, at least fifty percent (50%) of the securities or other
ownership interests representing the equity, voting stock or general partnership interest thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.4 </B>&#147;<B>Agreement Term</B>&#148; has the meaning set forth in Section&nbsp;12.1.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.5 </B>&#147;<B>Allergan</B>&#148; has the meaning set forth in the Recitals.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.6 </B>&#147;<B>Annual Purchased Amount</B>&#148; means, with respect to Finished Product and/or Samples of
Trospium Twice-Daily the sum of (a)&nbsp;the amount of such Finished Product and/or Samples that is
delivered to Esprit during any one (1)&nbsp;year period commencing on September&nbsp;1, 2007 or an
anniversary thereof plus (b)&nbsp;the amount of such Finished Product and/or Samples subject to accepted
and open (non-cancelled) firm Purchase Orders submitted by Esprit and requesting delivery during
the applicable annual period, in accordance with the terms and conditions of Article&nbsp;14, if such
Finished Product and/or Samples have not been delivered on a timely basis through no fault of
Esprit.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.7 </B>&#147;<B>Batch</B>&#148; means a specific quantity of Product or Compound that is produced in a process or
series of processes according to a single manufacturing order during the same cycle of manufacture
so that it is homogeneous within specified limits. The batch quantities are approximately
&#091;...***...&#093; tablets for Trospium Twice-Daily and are estimated to be approximately
&#091;...***...&#093; capsules for Trospium Once-Daily.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.8 </B>&#147;<B>Business Day</B>&#148; means any day that is not a Saturday or a Sunday or a day on which the New
York Stock Exchange is closed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.9 </B>&#147;<B>Calendar Quarter</B>&#148; means for each Calendar Year, each of the three (3)&nbsp;month periods
ending March&nbsp;31, June&nbsp;30, September&nbsp;30 and December&nbsp;31; <U>provided</U>, <U>however</U>, that (a)
the first Calendar Quarter of any particular period shall extend from the commencement of such
period to the end of the first complete Calendar Quarter thereafter; and (b)&nbsp;the last Calendar
Quarter shall end upon the expiration or termination of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.10 </B>&#147;<B>Calendar Year</B>&#148; means (a)&nbsp;for the first Calendar Year of the Agreement Term, the period
beginning on the Effective Date and ending on (i)&nbsp;December&nbsp;31, 2007 if the Effective Date occurs
prior to December&nbsp;31, 2007 or (ii)&nbsp;December&nbsp;31, 2008 if the Effective Date occurs after December
31, 2007 and prior to December&nbsp;31, 2008, (b)&nbsp;for each Calendar Year of the Agreement Term
thereafter, each successive period beginning on January 1 and ending twelve (12)&nbsp;consecutive
calendar months later on December&nbsp;31, and (c)&nbsp;for the last Calendar Year of the Agreement Term, the
period beginning on January 1 of the Calendar Year in which the Agreement terminates or expires and
ending on the effective date of expiration or termination of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.11 </B>&#147;<B>Catalent Agreements</B>&#148; means the (a)&nbsp;Manufacturing and Supply Agreement by and between
Catalent Pharma Solutions LLC (&#147;<B>Catalent</B>&#148;) and Indevus, entered into as of September&nbsp;17, 2007 and
(b)&nbsp;Quality Agreement by and between Catalent and Indevus, entered into as of September&nbsp;13, 2007;
in each case, as in effect as of the Execution Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.12 </B>&#147;<B>CFR</B>&#148; means the United States Code of Federal Regulations.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.13 </B>&#147;<B>cGMP</B>&#148; means current Good Manufacturing Practice as defined in Parts 210 and 211 of Title
21 of the CFR, as may be amended from time to time, or any successor thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.14 </B>&#147;<B>Claims</B>&#148; has the meaning set forth in Section&nbsp;13.2.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.15 </B>&#147;<B>Collateral</B>&#148; has the meaning set forth in Section&nbsp;2.6(b)(i).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.16 </B>&#147;<B>Commercially Reasonable Efforts</B>&#148; means that degree of skill, effort, expertise, and
resources normally used (including the promptness in which such efforts and resources would be
applied) consistent with standards generally accepted in the pharmaceutical industry, with respect
to the diligent development, manufacture and commercialization of pharmaceutical products of
similar market and profit potential at a similar stage in development or product life as a Product
in the Field.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.17 </B>&#147;<B>Competing Product</B>&#148; means any product in the Field that contains Compound as one of its
active ingredients &#091;...***...&#093;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.18 </B>&#147;<B>Compound</B>&#148; means the chemical compound known as Trospium Chloride whose specific chemical
name is 3-alpha-benziloyloxynortropane-8-spiro-1&#146;-
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">pyrrolidinium chloride, also known as
spiro&#091;8-azoniabicyclo&#091;3,2,1&#093;octane-8,1&#146;-pyrrolidinium&#093;-3-&#091;(hydroxydiphenyl-acetyl)-oxy&#093;chloride((1&#225;,
3&#226;, 5&#225;))-(9Cl) and any related analogues, homologues, derivative and other pharmaceutically active
salts.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.19 </B>&#147;<B>Control</B>&#148; means possession of the ability to grant a license or sublicense as provided
for herein without violating the terms of any agreement with any Third Party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.20 </B>&#147;<B>Copromotion Period</B>&#148; means the period commencing on the Effective Date and expiring on
(a)&nbsp;September&nbsp;30, 2008, or (b)&nbsp;if extended by Indevus in accordance with Section&nbsp;5.5(b)(ii), on
December&nbsp;31, 2008 or March&nbsp;31, 2009, as applicable, or (c)&nbsp;the last day of any applicable Cure
Period in which Indevus completes its Detail Obligations in accordance with Section&nbsp;5.5(b)(ii)
after the dates set forth in subsections (a)&nbsp;and (b)&nbsp;above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.21 </B>&#147;<B>Cure Period</B>&#148; means any two (2)&nbsp;consecutive Calendar Quarters immediately following a
Deficient Quarter.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.22 </B>&#147;<B>Data</B>&#148; means any and all research data, pharmacology data, preclinical data, clinical
data and/or all other documentation submitted, or required to be submitted, to the FDA in
association with an IND or NDA for a Product (excluding any Drug Master Files (DMFs), Chemistry,
Manufacturing and Control (CMC)&nbsp;data, or similar documentation).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.23 </B>&#147;<B>Deficient Quarter</B>&#148; means any Calendar Quarter in which the Indevus Sales Force fails to
deliver &#091;...***...&#093; of the Quarterly Indevus Details applicable to such Calendar Quarter.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.24 </B>&#147;<B>Deploy</B>&#148; means the act of designating a particular employee of Esprit or Indevus as a
member of the Esprit Sales Force or Indevus Sales Force, as applicable, and the inception by such
member of services to Detail the Products; <U>provided</U>, <U>however</U>, that no such member
shall be Deployed without first satisfying the requirements set forth in Section&nbsp;5.8.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.25 </B>&#147;<B>Detail</B>&#148; means a face-to-face contact by a Representative with a Target Prescriber in an
individual or group practice setting (not including dinner meetings, medical conventions, medical
education meetings, Sample drops or incidental contacts that do not otherwise constitute a Detail
as defined herein), and during which the FDA-approved indicated uses, safety, effectiveness,
contraindications, side effects, warnings, and other relevant characteristics of a Product are
described by the Representative in a fair and balanced manner consistent with the requirements of
the Act and with FDA-approved Product information sheets, and using, as necessary or desirable, the
Product Labeling and/or the Promotional Materials. When used as a verb, &#147;<B>Detail</B>&#148; shall mean to
engage in a Detail.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.26 </B>&#147;<B>Development Committee</B>&#148; has the meaning set forth in Section&nbsp;3.1(a).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.27 </B>&#147;<B>Effective Date</B>&#148; means the Effective Time (as such term is defined in the Merger
Agreement).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.28 </B>&#147;<B>Esprit Sales Force</B>&#148; has the meaning set forth in Section&nbsp;5.4(a).
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.29 </B>&#147;<B>Ex-US Supply Agreement</B>&#148; means, if Indevus exercises the Ex-US Supply Option, the
agreement to be effective as of the Processing Assumption Date between Indevus and Esprit pursuant
to which Esprit shall supply Indevus or its designees with bulk capsules of Trospium Once-Daily
prior to being in their finished, labeled and packaged form solely for use outside the Territory.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.30 </B>&#147;<B>Ex-US Supply Option</B>&#148; has the meaning set forth in Section&nbsp;14.14.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.31 </B>&#147;<B>FDA</B>&#148; means the United States Food and Drug Administration and any successor agency
having substantially the same functions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.32 </B>&#147;<B>FDA Approval</B>&#148; means with respect to a Product in the Field, all authorizations by the
FDA that are required for the marketing of such Product in the United States.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.33 </B>&#147;<B>Field</B>&#148; means &#091;...***...&#093;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.34 </B>&#147;<B>Finished Product</B>&#148; means Trospium Twice-Daily or Trospium Once-Daily, as applicable,
in its finished, labeled and packaged form, ready for distribution in the Field in the Territory.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.35 </B>&#147;<B>Firm Commitment</B>&#148; has the meaning set forth in Section&nbsp;14.5(b)(ii).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.36 </B>&#147;<B>Force Majeure</B>&#148; means, with respect to a Party, any fire, flood, earthquake, explosion,
storm, blockage, embargo, war, acts of war (whether war be declared or not), terrorism,
insurrection, riot, civil commotion, strike, lockout or other labor disturbance, failure of public
utilities or common carriers, act of God or act, omission or delay in acting by any governmental
authority or the other Party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.37 </B>&#147;<B>Forecasted Supply Price</B>&#148; has the meaning set forth in Section&nbsp;14.8(b)(ii).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.38 </B>&#147;<B>GAAP</B>&#148; means generally accepted accounting principles in the United States, consistently
applied.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.39 </B>&#147;<B>Generic Competition</B>&#148; shall be deemed to exist as of any date if Generic Products have a
market share in the United States of &#091;...***...&#093; or greater of the total unit volume of
Trospium Once-Daily in the United States (as so shown by the average of the monthly IMS (or
IMS-equivalent) data) for the most recent Calendar Quarter ended prior to such date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.40 </B>&#147;<B>Generic Product</B>&#148; means any product containing Compound that is an AB rated equivalent to
Trospium Once-Daily as defined in the 23rd edition of Approved Drug Products with Therapeutic
Equivalence Evaluations issued by the United States Department of Health and Human Services, for
which FDA Approval in the United States has been obtained &#091;...***...&#093;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.41 </B>&#147;<B>Helsinn Agreements</B>&#148; means the (a)&nbsp;API Supply Agreement dated as of November&nbsp;22,
2006 by and between Indevus and Helsinn Chemicals SA and Helsinn Advanced Synthesis SA
(collectively, &#147;<B>Helsinn</B>&#148;) and (b)&nbsp;Quality Technical Agreement dated as of August&nbsp;21, 2007 by and
between Helsinn and Indevus; in case, as in effect as of the Execution Date and as amended from
time to time during the Agreement Term.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.42 </B>&#147;<B>Improvements</B>&#148; means all inventions and know-how, patentable or otherwise, made, created,
developed, conceived or reduced to practice by or on behalf of a Party and/or any of its Affiliates
during the Agreement Term, that have application or relate to Compound or Products for use in the
Field, including developments in the manufacture, formulation, ingredients, preparation,
presentation, means of delivery or administration, dosage, indication, methods of use or packaging
and/or sale of Products in the Field, including a process for manufacturing a Product, an
intermediate used in such process, a formulation of a Product in the Field, or a use or indication
of a Product in the Field.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.43 </B>&#147;<B>IND</B>&#148; means an Investigational New Drug application, as described in 21 CFR Section
312.23, obtained for purposes of conducting clinical trials in accordance with the requirements of
the Act and the regulations promulgated thereunder, including all supplements and amendments
thereto, relating to the use of Compound or a Product in the Field.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.44 </B>&#147;<B>Indevus Intellectual Property</B>&#148; means Indevus Patent Rights and Indevus Know-How.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.45 </B>&#147;<B>Indevus Invention</B>&#148; has the meaning set forth in Section&nbsp;8.1.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.46 </B>&#147;<B>Indevus Know-How</B>&#148; means all unpatented information and Data that are as of the Effective
Date or become during the Agreement Term owned or otherwise Controlled by Indevus, including
discoveries, Improvements, processes, formulas, inventions, know-how and trade secrets, to the
extent necessary or useful for the development, manufacture, and/or commercialization of a Compound
or Product in the Field. Indevus Know-How does not include any Patent Rights. Indevus Know-How
also includes, other than marketing rights and marketing approvals transferred to Esprit on the NDA
Transfer Date, all marketing authorizations and marketing approvals granted by the FDA (e.g.,
approved NDAs, INDs, and related applications and other forms of marketing authorization) to
Indevus for the marketing of Products in the Field in the Territory. Such marketing authorizations
and marketing approvals shall be deemed embodiments of Data and Indevus Know-How.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.47 </B>&#147;<B>Indevus Logo</B>&#148; has the meaning set forth on Schedule&nbsp;1.47.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.48 </B>&#147;<B>Indevus Patent Rights</B>&#148; means all Patent Rights in the Territory that are as of the
Effective Date or become during the Agreement Term owned or otherwise Controlled by Indevus and
that generically or specifically claim, or are otherwise related to, the making, having made, use,
offer for sale, sale or importation of Products in the Field or claim any Improvements in the Field
made by Indevus, including Indevus&#146; interest in any Patent Rights in Joint Inventions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.49 </B>&#147;<B>Indevus Sales Force</B>&#148; means those Representatives Deployed by Indevus on a full-time
basis and the field sales management supervising such Representatives.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.50 </B>&#147;<B>Indevus Target Prescribers</B>&#148; means those Target Prescribers with whom, pursuant to the
terms of this Agreement, the Indevus Sales Force conducts Primary Position Details and/or Secondary
Position Details; <U>provided</U> that such Target Prescribers shall be determined from a list of
Target Prescribers agreed to in writing between the Parties prior to the Effective Date, as such
list may be amended from time to time with the prior written approval of both Parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.51 </B>&#147;<B>Initial Indication</B>&#148; means the use of a Product in the treatment of overactive bladder
and/or urinary incontinence.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.52 </B>&#147;<B>Initial Purchase Order</B>&#148; has the meaning set forth in Section&nbsp;14.6.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.53 </B>&#147;<B>Joint Invention</B>&#148; has the meaning set forth in Section&nbsp;8.1.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.54 </B>&#147;<B>Launch Period</B>&#148; means the period commencing on the date of launch of Trospium Once-Daily
in the United States and expiring on the last day of the (a)&nbsp;fourth (4th) complete Calendar Quarter
commencing after such launch date if such launch date is on or after the forty-fifth (45th) day of
a Calendar Quarter or (b)&nbsp;third (3rd) complete Calendar Quarter commencing after such launch date
if such launch date is prior to the forty-fifth (45th) day of a Calendar Quarter.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.55 </B>&#147;<B>Law(s)</B>&#148; means all laws, statutes, rules, regulations, ordinances and other
pronouncements having the binding effect of law of any governmental authority.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.56 </B>&#147;<B>Losses</B>&#148; means any and all damages (including all incidental, consequential, statutory
and treble damages), awards, deficiencies, settlement amounts, defaults, assessments, fines, dues,
penalties (including penalties imposed by any governmental authority), costs, fees, liabilities,
obligations, taxes, liens, losses, lost profits and expenses (including court costs, interest and
reasonable fees of attorneys, accountants and other experts) awarded or otherwise paid or payable
to Third Parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.57 </B>&#147;<B>Madaus</B>&#148; means Madaus GmbH, a successor to Madaus AG, a company with limited liability
organized under the laws of Germany and having its principal office at Colonia-Allee 15, 51067
Cologne, Germany, and any successor thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.58 </B>&#147;<B>Madaus Agreements</B>&#148; means the Madaus Amendment, Madaus Compound Supply Agreement, Madaus
License, Madaus License and Supply Agreement, and the Madaus Supply Agreement, as any of such
agreements may be amended from time to time during the Agreement Term.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.59 </B>&#147;<B>Madaus Amendment</B>&#148; means the Amendment and Agreement by and between Indevus and Madaus,
made as of November&nbsp;3, 2006, as in effect as of the Execution Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.60 </B>&#147;<B>Madaus Compound Supply Agreement</B>&#148; means the Compound Supply Agreement by and between
Indevus and Madaus, made as of November&nbsp;3, 2006, as in effect as of the Execution Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.61 </B>&#147;<B>Madaus License</B>&#148; means the License Agreement by and between Madaus and Indevus effective
as of November&nbsp;26, 1999, as in effect as of the Execution Date and as amended by the Madaus
Amendment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.62 </B>&#147;<B>Madaus License and Supply Agreement</B>&#148; means the License and Supply Agreement by and
between Indevus and Madaus, made as of November&nbsp;3, 2006, as in effect as of the Execution Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.63 </B>&#147;<B>Madaus Supply Agreement</B>&#148; means the Supply Agreement by and between Indevus and Madaus,
made as of December&nbsp;16, 2002, as in effect as of the Execution Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.64 </B>&#147;<B>Marketing Committee</B>&#148; has the meaning set forth in Section&nbsp;3.2(a).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.65 </B>&#147;<B>Merger Agreement</B>&#148; has the meaning set forth in the Recitals.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.66 </B>&#147;<B>Minimum Requirement</B>&#148; has the meaning set forth in Section&nbsp;14.5(b)(iii).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.67 </B>&#147;<B>Minimum Royalties</B>&#148; means the minimum royalties payable to Indevus by Esprit in the
applicable Calendar Year determined in accordance with the table set forth in Section&nbsp;6.2(b)(i).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.68 </B>&#147;<B>Minimum Royalty Shortfall</B>&#148; has the meaning set forth in Section&nbsp;6.2(b)(i).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.69 </B>&#147;<B>NDA</B>&#148; means a New Drug Application as defined in the Act that is submitted under Section
505 (b)&nbsp;of the Act to apply for FDA Approval.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.70 </B>&#147;<B>NDA Transfer Date</B>&#148; means the earlier of (a)&nbsp;September&nbsp;30, 2012 and (b)&nbsp;at Esprit&#146;s sole
election, the date, if any, that Indevus assigns its rights or obligations under this Agreement to
another person or entity in connection with the transfer or sale of Indevus&#146; business or all or
substantially all of its assets or in the event of a merger, consolidation, change in control or
similar corporate transaction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.71 </B>&#147;<B>Net Sales</B>&#148; means the gross amount invoiced for all commercial sales of Finished Products
to Third Parties in the Field in the Territory by Esprit and its Affiliates, less the following
deductions actually allowed or taken in accordance with GAAP:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>credits or allowances actually granted for damaged or spoiled Finished Product, returns,
recalls or rejections of such Finished Product, and retroactive price adjustments;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>normal and customary trade, cash and quantity discounts, allowances and credits actually
allowed for such Finished Product;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>sales, value added, excise or similar taxes paid or allowed, or other governmental charges
imposed upon the importation, use or sale of such Finished Product in the Territory;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>fees paid to Third Party distributors and legally allowed chargebacks, rebates or similar
payments actually granted to customers with respect to such Finished Product, including managed
health care organizations, wholesalers, distributors, buying groups, retailers, health care
insurance carriers, pharmacy benefit management companies, health maintenance organizations or
other institutions or health care organizations or to federal, state/provincial, local and other
governments, their agencies and purchasers and reimbursers;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>freight, postage, shipping and insurance charges related to delivery of such Finished
Product; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>any other items that reduce gross sales amounts as required by GAAP.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Sales or other transfers between Esprit and its Affiliates shall be excluded from the computation
of Net Sales and no payments will be payable on such sales or transfers except where such
Affiliates are end users, but Net Sales shall include the subsequent sales to Third Parties by such
Affiliates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.72 </B>&#147;<B>Original Agreement</B>&#148; has the meaning set forth in the Recitals.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.73 </B>&#147;<B>Party</B>&#148; means Indevus or Esprit.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.74 </B>&#147;<B>Patent Rights</B>&#148; means any patents, patent applications, certificates of invention, or
applications for certificates of invention and any supplemental protection certificates, together
with any extensions, registrations, confirmations, reissues, substitutions, divisions,
continuations or continuations-in-part, reexaminations or renewals thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.75 </B>&#147;<B>PDMA</B>&#148; means the United States Prescription Drug Marketing Act of 1987, as amended, or
any successor act thereto, and the regulations promulgated thereunder from time to time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.76 </B>&#147;<B>Phase IV Clinical Trials</B>&#148; means a human clinical trial for a Product in the Field
commenced after receipt of FDA Approval in the United States and that is conducted within the
parameters of the FDA Approval for such Product. Phase IV Clinical Trials may include
epidemiological studies, modeling and pharmacoeconomic studies, investigator sponsored clinical
trials of such Product and post-marketing surveillance studies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.77 </B>&#147;<B>Primary Position Detail</B>&#148; means a Detail of a Product in the Field in which (a)&nbsp;such
Product is the first product Detailed during a Detail to a Target Prescriber, (b)&nbsp;at
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">least &#091;...***...&#093; of the total time of the Detail is spent on the presentation of
such Product, and (c)&nbsp;the Representative delivers a message to the Target Prescriber in which key
attributes of such Product are verbally promoted.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.78 </B>&#147;<B>Primary Training</B>&#148; has the meaning set forth in Section&nbsp;5.8(a).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.79 </B>&#147;<B>Prime Rate</B>&#148; has the meaning set forth in Section&nbsp;6.4(d).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.80 </B>&#147;<B>Processing Activities</B>&#148; means the activities required to be undertaken by (a)&nbsp;Indevus or
its Third Party Manufacturers in order to manufacture and supply Esprit with Trospium Once-Daily
Finished Product and/or Samples prior to the Processing Assumption Date, and (b)&nbsp;in the event the
Ex-US Supply Agreement is executed between the Parties, Esprit or its Third Party Manufacturers in
order to manufacture and supply Indevus and/or its designees after the Processing Assumption Date
with Trospium Once-Daily solely for use outside the Territory either in (i)&nbsp;bulk capsule form prior
to being in its finished, labeled and packaged form or (ii)&nbsp;finished, labeled and packaged form.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.81 </B>&#147;<B>Processing Assumption Date</B>&#148; means the effective date of Esprit&#146;s assumption of the
Processing Activities of Indevus in accordance with the terms of Section&nbsp;14.13, which date shall be
agreed to by the Parties in writing, but in any event shall not be earlier than the Effective Date
nor later than June&nbsp;30, 2008.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.82 </B>&#147;<B>Product</B>&#148; means any pharmaceutical preparation in final form (or, where the context so
indicates, the form under development) containing Compound as a primary active therapeutic
ingredient that, except for Samples thereof, requires a prescription from a physician or other
health care professional, for use in the Territory.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.83 </B>&#147;<B>Product Adverse Event</B>&#148; means the occurrence of any of the following: (a)&nbsp;Generic
Competition; (b)&nbsp;any materially adverse change to a Trospium Once-Daily Product label such as an
FDA-mandated addition of a &#147;Black Box&#148; warning on the Product Labeling of Trospium Once-Daily that
is unique to such product among the class of anti-cholinergic drugs for the treatment of overactive
bladder; (c)&nbsp;any recall or withdrawal of Trospium Once-Daily mandated by the FDA or reasonably
initiated by a Party (other than actions arising out of or resulting from the manufacturing of
Trospium Once-Daily on or after the Processing Assumption Date); (d)&nbsp;a determination by a court of
competent jurisdiction that a patent owned by a Third Party is infringed by the manufacture, use,
sale, offer for sale or importation of Trospium Once-Daily in the Territory; or (e)&nbsp;failure to
deliver at least (i) &#091;...***...&#093; of Trospium Once-Daily Finished Product and Samples for
receipt by Esprit or its designee by &#091;...***...&#093; (<U>provided</U> that Esprit provides
any modifications requested by Esprit to the trade dress for such Finished Product and Samples on
or before &#091;...***...&#093;, and the FDA does not reject any such modifications to the trade
dress, <U>provided</U> that, if Esprit does not provide such modifications or if the FDA rejects
any such modifications to the trade dress, such delivery date shall be extended by a period of time
equal to the period between &#091;...***...&#093; and the date upon which Esprit provides such
modifications or the FDA approves such trade dress, as applicable), (ii) &#091;...***...&#093; (not
including the &#091;...***...&#093; to be delivered by &#091;...***...&#093;, as described in
subsection (i)&nbsp;above) of Trospium Once-
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Daily Finished Product and Samples by &#091;...***...&#093;, and/or (iii)
&#091;...***...&#093; (not including the &#091;...***...&#093; to be delivered by
&#091;...***...&#093;, as applicable, as described in subsections (i)&nbsp;and (ii)&nbsp;above) of Trospium
Once-Daily Finished Product and Samples by &#091;...***...&#093;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.84 </B>&#147;<B>Product Label(ing)</B>&#148; has the same meaning as defined in the Act and as interpreted by the
FDA.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.85 </B>&#147;<B>Product Liability Claims</B>&#148; means any and all claims by purchasers or users of Products in
the Field, or their family members, insurers, health care providers, subrogees or assignees,
seeking damages for personal injury, death, expense, economic loss (including loss of value of such
Products), or any other relief or remedy, arising out of or related to any alleged defect in the
design, labeling, packaging or marketing of such Products, including a failure to warn.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.86 </B>&#147;<B>Product NDAs</B>&#148; means the NDAs owned by Indevus as of the Effective Date relating to
Trospium Twice-Daily (No.&nbsp;21-595) and Trospium Once-Daily (No.&nbsp;22-103), together with all
amendments, supplements and updates thereto, as well as the corresponding INDs (with respect to
Trospium Twice-Daily, IND 61,381, and with respect to Trospium Once-Daily, IND 71,305).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.87 </B>&#147;<B>Product Procurement Costs</B>&#148; means the costs associated with the manufacturing,
purchasing, procurement and warehousing of Trospium Twice-Daily, Trospium Once-Daily and Compound,
as applicable, and with any other Processing Activities, that are actually incurred by Indevus
(<U>provided </U>that in all cases such amounts are not included in, and do not form the basis of,
any payments payable by Esprit to Indevus pursuant to Section&nbsp;6.2(c)), including (a)&nbsp;costs
associated with procuring active pharmaceutical ingredients and other materials used to manufacture
Finished Products and/or Samples, (b)&nbsp;the cost of transportation, testing, inspections, shrinkage
and scrap, related taxes (but in all cases excluding taxes based upon income or receipts), (c)&nbsp;the
cost of storage, insurance and any subcontracted costs, and amounts payable to Third Party
Manufacturers in connection with the manufacture and supply of Finished Products and/or Samples,
including any fees related to minimum purchase requirements, (d)&nbsp;direct labor and, to the extent
not in excess of (i) &#091;...***...&#093; for Trospium Once-Daily and Trospium Twice-Daily through
the Processing Assumption Date, provided the aggregate production Batches do not exceed
&#091;...***...&#093; through the Processing Assumption Date, and (ii) &#091;...***...&#093;
annually thereafter for Trospium Twice-Daily provided aggregate annual production Batches do not
exceed &#091;...***...&#093; (plus, solely with respect to this Section&nbsp;1.87(d)(ii), the increase
on &#091;...***...&#093; and each anniversary of such date in the Producer Price Index,
Pharmaceutical Preparations (Series&nbsp;ID 325412325412) (as published by the U.S. Bureau of Labor and
Statistics (http://www.bls.gov/ppi)) multiplied by such price<B>)</B>, overhead costs, including an
allocation for Indevus&#146; internal costs and expenses for supply chain management, including supply
chain production planning, the formulation and placement of orders with Third Party Manufacturers,
the management of inventories throughout the supply chain process, quality control/quality
assurance, regulatory and Third Party Manufacturer oversight and cost accounting and including,
with respect to Trospium Once-Daily Finished Product, and (e)&nbsp;an amount equal to the amounts
payable by Indevus to Madaus pursuant to Section&nbsp;3.7(b)(2) of the
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Madaus License (<U>provided </U>that such amounts are not included in any payments payable by
Esprit to Indevus pursuant to Section&nbsp;6.2(c)).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.88 </B>&#147;<B>Promotion</B>&#148; means those activities normally undertaken by a pharmaceutical company to
implement promotion plans and strategies aimed at encouraging the appropriate use of a particular
prescription pharmaceutical product under a common trademark, up to the point of offering a product
for sale. When used as a verb, &#147;<B>Promote</B>&#148; shall mean to engage in such activities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.89 </B>&#147;<B>Promotional Materials</B>&#148; means all written, printed or graphic material, other than
Product Labeling, packaging, or trade dress, intended for use by Representatives during Details of
Trospium Twice-Daily or Trospium Once-Daily under this Agreement, including visual aids, file
cards, premium items, clinical studies, reprints, business cards, identification tags and any other
promotional support items or advertisements provided in accordance with the terms of the relevant
Promotion Plan and Section&nbsp;5.6.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.90 </B>&#147;<B>Promotion Plan</B>&#148; means the then-current plan relating to the Promotion of a Product, as
contemplated by and in accordance with the requirements of Section&nbsp;5.2.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.91 </B>&#147;<B>Proprietary Information</B>&#148; means any and all scientific, clinical, regulatory, marketing,
financial and commercial information or data, whether communicated in writing, orally or by any
other means, that is owned and under the protection of one Party and is provided by that Party to
the other Party in connection with this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.92 </B>&#147;<B>Pro Rated Minimum Royalty</B>&#148; has the meaning set forth in Section&nbsp;6.2(b)(i).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.93 </B>&#147;<B>Purchase Order</B>&#148; has the meaning set forth in Section&nbsp;14.6.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.94 </B>&#147;<B>Quarterly Indevus Details</B>&#148; means the aggregate number of Details to be performed by the
Indevus Sales Force to the Indevus Target Prescribers during each Calendar Quarter period of the
Copromotion Period, as set forth in Section&nbsp;5.5(b).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.95 </B>&#147;<B>Regulatory Documents</B>&#148; means filings, applications, modifications, amendments,
supplements, revisions, reports, submissions, authorizations and approvals, including any IND or
NDA, and any reports or amendments necessary to maintain FDA Approvals.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.96 </B>&#147;<B>Representative</B>&#148; means a sales representative employed (or in the case of Esprit,
otherwise engaged) on a full-time basis by a Party to conduct Details pursuant to this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.97 </B>&#147;<B>Rolling Forecast</B>&#148; has the meaning set forth in Section&nbsp;14.5(b)(i).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.98 </B>&#147;<B>Sales Force(s)</B>&#148; means the Esprit Sales Force and/or the Indevus Sales Force, as
applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.99 </B>&#147;<B>Sales Force Reimbursement</B>&#148; has the meaning set forth in Section&nbsp;6.3.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.100 </B>&#147;<B>Samples</B>&#148; means units of the Product described in the Specifications distributed or
provided to health care professionals in the Territory for dispensing, in turn, to patients for
&#147;trial use&#148; at no cost to the patient pursuant to Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.101 </B>&#147;<B>Secondary Position Detail</B>&#148; means a promotional message involving a Product delivered by
a Representative during a face-to face contact with a Target Prescriber in which key product
attributes are verbally presented after presenting a detail for another product, consistent with
the terms of this Agreement, and where such Product is given an important but not primary emphasis,
and shall be at least &#091;...***...&#093; of the total time of such face-to face contact. A
Secondary Position Detail shall meet all of the requirements for a Detail, except as specified in
this Section&nbsp;1.101 and Section&nbsp;5.5(b)(ii).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.102 </B>&#147;<B>Sublicensing Royalties</B>&#148; has the meaning set forth in Section&nbsp;6.2(a)(i).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.103 </B>&#147;<B>Specifications</B>&#148; means the respective specifications for Trospium Twice-Daily and
Trospium Once-Daily Finished Product as set forth in the applicable Product NDAs, as such may be
modified from time to time in such Product NDAs and pursuant to Section&nbsp;4.2(x).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.104 </B>&#147;<B>Supernus</B>&#148; means Supernus Pharmaceuticals, Inc. (f/k/a Shire Laboratories, Inc.), a
Delaware corporation with a principal place of business at 1550 East Gude Drive, Rockville,
Maryland 20850.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.105 </B>&#147;<B>Supernus Agreement</B>&#148; means the Development and License Agreement by and between Supernus
and Indevus, effective as of March&nbsp;11, 2003, as in effect as of the Execution Date, and as such
agreement may be amended from time to time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.106 </B>&#147;<B>Supply Committee</B>&#148; has the meaning set forth in Section&nbsp;3.3(a).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.107 </B>&#147;<B>Supply Price</B>&#148; has the meaning set forth in Section&nbsp;14.8(b).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.108 </B>&#147;<B>Supply Term</B>&#148; has the meaning set forth in Section&nbsp;14.4.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.109 </B>&#147;<B>Target Prescribers</B>&#148; means those physicians determined to be high potential prescribers
of urologic products to treat overactive bladder and set forth in a list specified in the Promotion
Plan by the Marketing Committee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.110 </B>&#147;<B>Technology Transfer</B>&#148; means the transfer of technology to Esprit in connection with
Esprit&#146;s assumption of Processing Activities, as set forth in Section&nbsp;14.13 and as may be further
agreed to by the Parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.111 </B>&#147;<B>Territory</B>&#148; means the United States of America, including the District of Columbia, and
its territories and possessions, such as Puerto Rico.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.112 </B>&#147;<B>Third Party(ies)</B>&#148; means a person or entity who or which is neither a Party nor an
Affiliate of a Party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.113 </B>&#147;<B>Third Party Manufacturer(s)</B>&#148; means Third Parties that have been, or may during the
Agreement Term be, engaged by a Party to perform services or supply facilities or goods (including
Finished Product and/or Samples) in connection with any part of the manufacture, testing and/or
packaging of Finished Product and/or Samples.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.114 </B>&#147;<B>Third Party Royalties</B>&#148; means the amount payable by Indevus (a)&nbsp;to Madaus pursuant to
Section&nbsp;5.2.1(d)(ii) of the Madaus License as a result of payments made by Esprit to Indevus
pursuant to Section&nbsp;6.2(a) and (b); <U>provided</U> that the amounts payable by Esprit to Indevus
pursuant to Section&nbsp;6.2(c) shall not give effect to the credit due to Indevus from Madaus as
provided for in Section&nbsp;5.1(a) of the Madaus License; and/or (b)&nbsp;to Supernus pursuant to Section
5.6.1 of the Supernus Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.115 </B>&#147;<B>Trademark(s)</B>&#148; means the SANCTURA trademarks, owned by Esprit, and all related domain
names and other trademark related rights, and/or any other trademark that either Party may apply to
register in the Territory if such alternate trademark is selected for use in the Promotion of a
Product in the Field by the Parties under this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.116 </B>&#147;<B>Training Program(s)</B>&#148; means the training program(s) described in Section&nbsp;5.8.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.117 </B>&#147;<B>Trospium Once-Daily</B>&#148; means a controlled or extended-release oral formulation of Product
that is indicated for administration once per day for the Initial Indication.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.118 </B>&#147;<B>Trospium Twice-Daily</B>&#148; means a twenty milligram (20 mg) dosage oral formulation of
Product that is indicated for administration twice per day for the Initial Indication and that is
marketed by Esprit in the Territory as of the Execution Date as SANCTURA<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Grant of Rights</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.1 Grants by Indevus. </B>In consideration of the commitments and undertakings of Esprit under
this Agreement, and subject to the terms and conditions of this Agreement, Indevus hereby grants to
Esprit during the Agreement Term:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>an exclusive (even as to Indevus, subject to Section&nbsp;2.8) right and license in the Field
(with the right to grant sublicenses, subject to the provisions of Section&nbsp;2.5), under the Indevus
Intellectual Property, to use, import, offer for sale, and Promote Products in the Territory;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>an exclusive (even as to Indevus) right and license in the Field (with the right to grant
sublicenses, subject to the provisions of Section&nbsp;2.5), under the Indevus Intellectual Property, to
sell and distribute Products in the Territory;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>effective on the Processing Assumption Date, an exclusive right and license under the
Indevus Intellectual Property, to make and have made Trospium Once-Daily for use in the Field in
the Territory; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>during the Copromotion Period and any period of time thereafter that Esprit has
Promotional Materials that were printed prior to the end of the Copromotion Period and that contain
the Indevus Logo, an exclusive (even as to Indevus, subject to Section&nbsp;2.8) right and license in
the Field in the Territory (with the right to grant sublicenses, subject to the provisions of
Section&nbsp;2.5) to use the Indevus Logo on the Promotional Materials solely in accordance with this
subsection (d). All representations of the Indevus Logo that Esprit intends to use, if not
previously approved by Indevus, will first be submitted to Indevus for approval, such approval not
to be unreasonably withheld. Indevus will have thirty (30)&nbsp;days to review the representation of
the Indevus Logo. If Indevus does not provide written notice of its approval or disapproval
(together with its reasons for such disapproval) within such thirty (30)&nbsp;day period, Indevus will
be deemed to have approved such representation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Notwithstanding the rights and licenses granted under Sections&nbsp;2.1(a), (b)&nbsp;and (c), Esprit does not
expect or anticipate receiving any further Indevus Intellectual Property subsequent to the NDA
Transfer Date, and through the Agreement Term, as Indevus has represented to Esprit that it
believes that it is remote that after the NDA Transfer Date that Indevus will be performing any
research or development activities which would generate any future Indevus Intellectual Property
related to the licenses granted hereunder with respect to Product in the Field. Indevus shall not
refund any consideration received from Esprit or pay any penalties if Indevus terminates any or all
development activities which may result in additional Indevus Intellectual Property on or prior to
NDA Transfer Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.2 Sublicenses of Third Party Rights.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The licenses granted to Esprit under Section&nbsp;2.1 include exclusive sublicenses by Indevus
in the Field of Indevus&#146; rights under the Madaus License and the Supernus Agreement to use, import,
offer for sale, and sell Products in and, effective as of the Processing Assumption Date, make
Trospium Once-Daily for use in, the Territory. Esprit acknowledges that it is a sublicensee under
the Madaus License and the Supernus Agreement to the extent stated in the foregoing sentence and
agrees not to act inconsistently with the terms of such agreements to the extent applicable to the
sublicenses granted to Esprit hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Provided that Esprit is in compliance with its obligations to pay the applicable Third
Party Royalties in accordance with this Agreement, the payments required by Section&nbsp;14.13(e)(iv)
and the portion of Product Procurement Costs described in Section&nbsp;1.87(e), and is otherwise in
material compliance with its obligations hereunder, Indevus shall pay all amounts that Indevus
shall owe to Madaus or Supernus under the Madaus Agreements or the Supernus Agreement,
respectively, by virtue of this Agreement and shall perform in all material respects its
obligations under the Madaus Agreements or the Supernus Agreement, as applicable,
that are required to enable Esprit to perform its obligations or exercise the rights granted
to Esprit under this Agreement. In the event that Indevus fails to make any such payment when due,
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Esprit, in its sole discretion, may elect to directly pay Madaus or Supernus, as applicable, any
such payment and to offset against any payments due from Esprit to Indevus under this Agreement an
amount equal to such payments made by Esprit to Madaus or Supernus. Indevus shall use good faith
efforts to obtain the right, including by amendment of the Madaus Agreements and the Supernus
Agreement, for Esprit to make such payments to Madaus and Supernus, as applicable, as described in
and in accordance with this Section&nbsp;2.2(b). Without limiting the generality of the foregoing, (i)
as between the Parties, Indevus shall be responsible for any required milestone payments to Madaus
pursuant to the Madaus Agreements and to Supernus pursuant to the Supernus Agreement, and (ii)
Esprit shall, to the extent required by and in accordance with the terms of Section&nbsp;6.2(c),
reimburse Indevus for any Third Party Royalties payable pursuant to such agreements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>In the event that Indevus receives notice from Madaus or Supernus that Indevus has
breached the Madaus Agreements (other than the Madaus License and Supply Agreement) or the Supernus
Agreement, respectively, which breach gives rise to a right (whether upon further notice, or with
or without the passage of time) by Madaus or Supernus, as applicable, to terminate the respective
agreement in a way that would terminate or materially adversely affect Esprit&#146;s ability to perform
its obligations or exercise the rights granted to Esprit under this Agreement, Indevus shall notify
Esprit of such situation as soon as practicable, and in any event within sixty (60)&nbsp;hours after
receipt of such notice, and use commercially reasonable efforts to promptly cure such breach.
Provided that Esprit is in compliance with its obligations to pay the applicable Third Party
Royalties in accordance with this Agreement, the payments required by Section&nbsp;14.13(e)(iv) and the
portion of Product Procurement Costs described in Section&nbsp;1.87(e), and is otherwise in material
compliance with its obligations hereunder, if Indevus is unable to cure such breach, and Esprit has
not materially breached its obligations under this Agreement, Indevus shall, to the extent
possible, permit Esprit to cure such breach (and any costs or expenses of Esprit incurred in curing
such breach shall, at Esprit&#146;s election, either be reimbursed by Indevus to Esprit or offset by
Esprit against any amounts owed to Indevus under this Agreement). As soon as reasonably
practicable after the Effective Date, Indevus shall also use commercially reasonable efforts to
obtain the agreements of each of Madaus and Supernus, as applicable, to grant, in the event that
the Madaus Agreements (other than the Madaus License and Supply Agreement) or Supernus Agreement,
as applicable, are terminated for any reason and Esprit is in compliance with its obligations to
pay the applicable Third Party Royalties in accordance with this Agreement, the payments required
by Section&nbsp;14.13(e)(iv) and the portion of Product Procurement Costs described in Section&nbsp;1.87(e),
and is otherwise in material compliance with its obligations hereunder, substantially equivalent
rights on substantially equivalent terms as those granted to Indevus pursuant to the Madaus
Agreements (other than the Madaus License and Supply Agreement) or Supernus Agreement, as
applicable, as are necessary for Esprit to exercise its rights and perform its obligations under
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Notwithstanding anything to the contrary in this Agreement, except with respect to the
payment obligation in Section&nbsp;6.2(c)(i), Section&nbsp;14.13(e)(iv), and the portion of Product
Procurement Costs described in Section&nbsp;1.87(e), in no event shall Esprit be
responsible for or liable with respect to, or have any obligation to reimburse Indevus in
respect of, any payments, claims, demands, actions, causes of action, damages, costs, expenses,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">attorneys&#146; fees, obligations and liabilities of whatever kind or nature, in law or equity, arising
under the Madaus Agreements or the Supernus Agreement, and, as between the Parties, Indevus shall
be solely responsible and liable with respect to any such payments, claims, demands, actions,
causes of action, damages, costs, expenses, attorneys&#146; fees, obligations and liabilities, and shall
bear all costs associated therewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.3 Retained Rights; No Implied Licenses; Limitations. </B>All rights not specifically granted by
a Party in this Agreement are reserved and retained by such Party. Nothing in this Agreement shall
be deemed to constitute the grant of any license or other right to either Party, to or in respect
of any product, patent, trademark, Proprietary Information, trade secret or other data or any other
intellectual property of the other Party, except as expressly set forth herein. Except as
otherwise set forth in this Agreement, neither Party shall grant any license to, or permit or
authorize, any Third Party to Promote Products in the Field in the Territory without the prior
written consent of the other Party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.4 Non-Competition. </B>During the Agreement Term, neither Party will Promote, or permit its
Affiliates to Promote, market or sell any Competing Product in the Territory, or acquire, or permit
its Affiliates to acquire, directly or indirectly any rights or interest in or to a Competing
Product that is being detailed, Promoted, marketed or sold in the Territory; <U>provided</U>,
<U>however</U>, that, in the event that &#091;...***...&#093;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.5 Proposed Sublicense by Esprit. </B>Esprit shall have the right to grant sublicenses to an
Affiliate under any of the rights or licenses granted to it by Indevus under this Agreement as set
forth in this Section&nbsp;2.5. Esprit shall advise Indevus in advance of any proposed sublicense and
give due consideration to Indevus&#146; comments with respect thereto. Any sublicense shall be subject
to the terms and conditions of this Agreement, including the provisions relating to payments set
forth in Article&nbsp;6, and Esprit shall be responsible to Indevus for any non-performance by any
sublicensee of Esprit&#146;s obligations under this Agreement that are assumed by the sublicensee. In
the event Esprit grants a sublicense to an Affiliate, any payment due to Indevus under this
Agreement must be received in its full amount by Indevus in the United States without any tax
withholding or tax deduction therefrom.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.6 Regulatory Filings.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Transfer of Product NDAs. </B>Indevus hereby assigns to Esprit all right, title and interest
in the Product NDAs, effective as of the NDA Transfer Date. On the NDA Transfer Date, Indevus
shall submit to the FDA a letter authorizing the transfer of
ownership from Indevus to Esprit of the Product NDAs. As soon as practicable after the
submission of such letter and the receipt by Esprit of the FDA&#146;s acknowledgment letter, Esprit
shall execute and submit to the FDA a letter, accompanied by the Product NDA transfer letter
referred to in the preceding sentence, acknowledging Esprit&#146;s commitment to assume ownership of the
Product NDAs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Security Interest.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;Grant of Security Interest. </B>The Parties acknowledge and agree that pursuant to the
Original Agreement, as security for Indevus&#146; performance of its material covenants and obligations
thereunder, Indevus granted to Esprit a security interest in Indevus&#146; right, title and interest in
and to Indevus&#146; FDA marketing authorizations or marketing approvals related to a Product in the
Field in the Territory (including the Product NDAs), subject to the Madaus Agreements (other than
the Madaus License and Supply Agreement) and the Supernus Agreement and to Laws. Indevus hereby
reaffirms the grant of such security interest, and hereby grants Esprit, as security for Indevus&#146;
performance of its material covenants and obligations hereunder, a security interest in Indevus&#146;
right, title and interest in and to any Indevus&#146; FDA marketing authorizations or marketing
approvals related to a Product in the Field in the Territory that were not in existence as of the
date of the Original Agreement (together with the subject matter described in the first sentence of
this Section&nbsp;2.6(a), the &#147;<B>Collateral</B>&#148;). The security interest is granted as security only and,
except for the security interest granted, shall not transfer or in any way otherwise affect or
modify any rights of Indevus with respect to the Collateral. The security interest shall be
released on the earlier of (A)&nbsp;the NDA Transfer Date or (B)&nbsp;termination of this Agreement by
Indevus pursuant to Section&nbsp;12.2(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;Further Assurances and Attorney in Fact.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;Indevus agrees that from time to time, at Esprit&#146;s expense, Indevus shall promptly execute
and deliver all further instruments and documents, and take all further action, that Esprit may
reasonably request in order to perfect, protect or more fully evidence any security interest
granted or purported to be granted hereby or to enable Esprit to exercise or enforce its rights and
remedies hereunder with respect to the Collateral.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;To the extent permitted by Law, Indevus hereby authorizes Esprit, to file at Esprit&#146;s
expense, one or more financing or continuation statements, and amendments thereto and assignments
thereof, relating to all or any part of the Collateral now existing or hereafter arising without
the signature of Indevus, and Esprit shall promptly upon the filing thereof by it deliver to
Indevus a copy of each such financing or continuation statement or amendment or assignment. To the
extent permitted by Law, a carbon, photographic or other reproduction of this Agreement or any
financing statement covering the Collateral or any part thereof shall be sufficient as a financing
statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)&nbsp;Indevus hereby irrevocably appoints Esprit as Indevus&#146; attorney in fact, with full
authority in the place and stead of Indevus and in the name of Indevus or otherwise, from time to
time in Esprit&#146;s reasonable discretion upon the occurrence
and during the continuance of a material default by Indevus of its covenants and obligations
hereunder, to take any action and to execute any instrument that Indevus may reasonably deem
necessary or advisable to accomplish the purposes of the security interests in the Collateral
granted by Indevus hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.7 Access to Information. </B>Subject to the terms and conditions of this Agreement, Indevus
shall promptly provide to Esprit all Data obtained by Indevus or any of its licensees related to
the Products and data and information with respect to pharmacovigilance
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">related to the Products, and Indevus shall cooperate in good faith to provide Esprit access to and reasonable assistance
with all Indevus Intellectual Property and other Proprietary Information as may be required for
Esprit to exercise the rights and licenses explicitly granted and to perform its obligations
hereunder. After the disbanding of any committee pursuant to Section&nbsp;3.6, Esprit shall have the
right to continue to receive the information it would otherwise be entitled to receive under this
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.8 Grant by Esprit. </B>In consideration of the commitments and undertakings of Indevus
under this Agreement, and subject to the terms and conditions of this Agreement, Esprit hereby
grants to Indevus, during the Copromotion Period:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>an exclusive (except as to Esprit), nontransferable right and license in the Field in the
Territory to Promote Products solely for the purpose of co-Promoting Products with Esprit in
accordance with and subject to the terms of Article&nbsp;5; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>an exclusive (except as to Esprit), nontransferable right and license in the Field in the
Territory to use the trademarks owned or otherwise controlled by Esprit that are included in
Promotional Materials provided by Esprit pursuant to this Agreement in connection with the use of
such Promotional Materials in connection with the Promotion of Products; <U>provided</U> that
Indevus shall not have the right to use any representations of such trademark except as set forth
in Section&nbsp;5.6(e).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.9 No Further Development by Indevus. </B>The Parties acknowledge and agree that Indevus has no
obligation under this Agreement to develop or continue to develop any Indevus Intellectual Property
and that after the NDA Transfer Date Indevus shall not be permitted to develop or continue to
develop any inventions or intellectual property in the Field in the Territory relating to Products.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Governance</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.1 Development Committee.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Members. </B>Pursuant to the Original Agreement, the Parties established a joint development
committee with certain obligations and powers. Effective as of the Effective Date, the Parties
shall establish a new joint development committee (the &#147;<B>Development Committee</B>&#148;) composed of four
(4)&nbsp;individuals, two (2)&nbsp;of whom shall be appointed by Indevus and two (2)&nbsp;of whom shall be
appointed by Esprit and all of whom shall be qualified to appropriately represent their respective
Party at the Development Committee level. The members of the Development Committee as of the
Effective Date shall be as set forth on Schedule&nbsp;3.1. Membership shall include representation from
each Party&#146;s scientific, clinical development, and regulatory affairs and/or such other departments
as the Development Committee may deem appropriate. Either Party may replace any or all of its
representatives on the Development Committee at any time upon written notice to the other Party. A
Party may designate a substitute to temporarily attend and perform the functions of such Party&#146;s
designated representative at any meeting of the Development Committee. The Development Committee
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shall be chaired by a representative of Esprit. The chairperson shall appoint a secretary of the
Development Committee, who shall be a representative of Indevus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Role and Responsibilities. </B>The Development Committee shall have as its overall purpose,
subject to Section&nbsp;4.2 and Section&nbsp;5.6, the oversight of development, including review of clinical
protocols and timetables for development, oversight of development and selection of entities or
individuals, including Indevus or Esprit, to perform tasks required in connection with development
of Products in the Field in the Territory. In particular, the Development Committee shall perform
the following functions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>Review development activities conducted under this Agreement with respect to Compound and
Products in the Field in the Territory, including any Phase IV Clinical Trials;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>Monitor regulatory strategy and communications with FDA;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>In concert with the Marketing Committee, assist in the coordination and monitoring of
regulatory strategy and activities for Phase IV Clinical Trials in the Field in the Territory;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>Review and approve in advance any Promotional Materials or educational materials and
literature related to Trospium Twice-Daily or Trospium Once-Daily, including Product advertising;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(v)&nbsp;</B>Oversee any changes to the Specifications proposed by the Parties and propose whether any
such changes require any supplements to a Product NDA, as further described in Section&nbsp;4.2(a)(x);
and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vi)&nbsp;</B>Have such other responsibilities as may be assigned to the Development Committee pursuant
to this Agreement or as may be mutually agreed upon by the Parties from time to time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Primary Contact. </B>Indevus and Esprit each shall appoint a person (a &#147;<B>Development Primary
Contact</B>&#148;) to be the primary contact between the Parties with respect to development and to
coordinate related correspondence between the Parties. The Development Primary Contact of each
Party as of the Effective Date is set forth on Schedule&nbsp;3.1. Each Party shall notify the other in
writing as soon as practicable upon changing its Development Primary Contact. The Development
Primary Contact of each Party will be one of its representatives on the Development Committee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Oversight. </B>The Development Committee may make decisions with respect to any subject
matter that is subject to the Development Committee&#146;s decision-making authority and
responsibilities as set forth in Section&nbsp;3.1(b). The Development Committee shall use its good
faith efforts to resolve by consensus any issue relevant to development of Products. The
Development Committee shall give consideration to the views,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the
document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">position and recommendations of each
Party on any issue that has been brought before the Development Committee. If the Development
Committee shall arrive at a consensus on any issue relating to the development of a Product, such
consensus shall be binding upon the Parties. All decisions of the Development Committee shall be
made by unanimous vote or written consent, as indicated by all members signing the written minutes
thereof, with Esprit representatives collectively having one (1)&nbsp;vote and Indevus representatives
collectively having one (1)&nbsp;vote in all decisions. If the Development Committee cannot reach
consensus on a matter brought to its attention, Esprit shall be entitled to make the final decision
with respect to such matter, subject to Section&nbsp;3.1(e) and Section&nbsp;5.6(a).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>The Development Committee shall have only the powers assigned to it in this Section&nbsp;3.1.
All activities conducted by the Development Committee shall be consistent with and subject to the
provisions of this Agreement, and the Development Committee shall not have any power to take any
action that conflicts with the terms of this Agreement or to amend, modify or waive compliance with
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.2 Marketing Committee.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Members. </B>Pursuant to the Original Agreement, the Parties established a joint marketing
committee with certain obligations and powers. Effective as of the Effective Date, the Parties
shall establish a new joint marketing committee (the &#147;<B>Marketing Committee</B>&#148;) composed of four (4)
individuals, two (2)&nbsp;of whom shall be appointed by Indevus and two (2)&nbsp;of whom shall be appointed
by Esprit and all of whom shall be qualified to appropriately represent such Party at the Marketing
Committee level. The members of the Marketing Committee as of the Effective Date shall be as set
forth on Schedule&nbsp;3.2. Either Party may replace any or all of its respective representatives on
the Marketing Committee at any time upon written notice to the other Party. Either Party may
designate a substitute to temporarily attend and perform the functions of such Party&#146;s designated
representative at any meeting of the Marketing Committee. The Marketing Committee shall be chaired
by a representative of Esprit.

The chairperson shall appoint a secretary of the Marketing Committee, who shall be a
representative of Indevus.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Role and Responsibilities. </B>The Marketing Committee will be used as the forum for the
Parties to discuss the Promotion strategy for Products and, subject to the terms and conditions of
this Agreement, will review the pre-launch, launch, post-launch and ongoing Promotional activities
for Products in the Territory. In particular, the Marketing Committee shall perform the following
functions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>Review and provide recommendations regarding the Promotion Plan and any material
amendments or modifications to the Promotion Plan;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>Discuss the actual results of the Promotion of Trospium Twice-Daily and Trospium
Once-Daily in the Territory as compared to the Promotion Plan;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>In concert with the Development Committee, assist in the coordination and monitoring of
regulatory strategy and activities for Phase IV Clinical Trials in the Field in the Territory;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>Propose the launch date for Trospium Once-Daily in the Territory, subject to the
provisions of Section&nbsp;5.1;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(v)&nbsp;</B>Discuss the state of the markets for Trospium Twice-Daily and Trospium Once-Daily in the
Territory and opportunities and issues concerning the Promotion of such Products in the Territory,
including consideration of marketing and promotional strategy, marketing research plans, labeling,
Product positioning and Product profile issues, to determine the kind of marketing and selling
efforts that are appropriate, in accordance with the Promotion Plan and Law;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vi)&nbsp;</B>Review Training Program(s) and promotional activities to be performed by the Parties in
the Promotion of Trospium Twice-Daily and Trospium Once-Daily in the Territory;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vii)&nbsp;</B>Review the overall performance and effectiveness of the Sales Forces;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(viii)&nbsp;</B>Review and propose physicians to be high potential prescribers of urologic products to
treat overactive bladder and propose a list of such physicians for inclusion in the Promotion Plan;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ix)&nbsp;</B>Review in advance any Promotional Materials or educational materials and literature
related to Trospium Twice-Daily or Trospium Once-Daily, including Product advertising; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(x)&nbsp;</B>Have such other responsibilities and address any other matters delegated to the Marketing
Committee under this Agreement or as may be mutually
agreed upon in writing by the Parties from time to time, as well as any other matters
pertaining to each Party&#146;s performance of its Promotion obligations under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Primary Contact. </B>Indevus and Esprit each shall appoint a person (a &#147;<B>Marketing Primary
Contact</B>&#148;) to be the primary contact between the Parties with respect to the Promotion Plan and to
coordinate related correspondence between the Parties. The Marketing Primary Contact is set forth
on Schedule&nbsp;3.2. Each Party shall notify the other in writing as soon as practicable upon changing
its Marketing Primary Contact appointment. The Marketing Primary Contact of each Party will be one
of its two representatives on the Marketing Committee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Oversight. </B>The Marketing Committee may make decisions with respect to any subject matter
that is subject to the Marketing Committee&#146;s decision-making authority and responsibilities as set
forth in Section&nbsp;3.2(b). The Marketing Committee shall use its good faith efforts to resolve by
consensus any issue relevant to the commercialization of
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Products. Each Party shall provide input
with respect to the Promotion Plan, and the Marketing Committee shall give substantial
consideration to the views, position and recommendations of each Party on any issue that has been
brought before the Marketing Committee. If the Marketing Committee shall arrive at a consensus on
any issue relating to the commercialization of Products, such consensus shall be binding upon the
Parties. All decisions of the Marketing Committee shall be made by unanimous vote or written
consent, as indicated by all members signing the written minutes thereof, with Esprit
representatives collectively having one (1)&nbsp;vote and Indevus representatives collectively having
one (1)&nbsp;vote in all decisions. If the Marketing Committee cannot reach consensus on a matter
brought to its attention, Esprit shall be entitled to make the final decision with respect to such
matter, subject to Section&nbsp;3.2(e).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>The Marketing Committee shall have only the powers assigned to it in this Section&nbsp;3.2.
All activities conducted by the Marketing Committee shall be consistent with and subject to the
provisions of this Agreement, and the Marketing Committee shall not have any power to take any
action that conflicts with the terms of this Agreement or to amend, modify or waive compliance with
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.3 Supply Committee.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Members. </B>Effective as of the Effective Date, the Parties shall establish a joint supply
committee (the &#147;<B>Supply Committee</B>&#148;) composed of four (4)&nbsp;individuals, two (2)&nbsp;of whom shall be
appointed by Indevus and two (2)&nbsp;of whom shall be appointed by Esprit and all of whom shall be
qualified to appropriately represent their respective Party at the Supply Committee level. The
members of the Supply Committee as of the Effective Date are set forth on Schedule&nbsp;3.3. Membership
shall include representation from each Party&#146;s manufacturing department and/or such other
departments as the Supply Committee may deem appropriate. Either Party may replace any or all of
its respective representatives on the Supply Committee at any time upon written notice to the other
Party. A Party may designate a substitute
to temporarily attend and perform the functions of such Party&#146;s designated representative at
any meeting of the Supply Committee. The Supply Committee shall be chaired by a representative of
Esprit. The chairperson shall appoint a secretary of the Supply Committee, who shall be a
representative of Indevus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Role and Responsibilities. </B>The Supply Committee shall oversee all aspects of supply of
Trospium Twice-Daily and Trospium Once-Daily under this Agreement and shall have as its overall
purpose the management of the supply to Esprit of Finished Products and/or Samples prior to the
Processing Assumption Date, the transition of Processing Activities from Indevus to Esprit pursuant
to the terms of this Agreement and, if Indevus exercises the Ex-US Supply Option, the management of
the supply of Trospium Once-Daily solely for use outside the Territory either in (i)&nbsp;bulk capsule
form prior to being in its finished, labeled and packaged form or (ii)&nbsp;finished, labeled and
packaged form. In particular, the Supply Committee shall perform the following functions:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>Oversee all aspects of the supply of Trospium Twice-Daily prior to the NDA Transfer Date
and Trospium Once-Daily prior to the Processing Assumption Date;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>Prepare a supply plan coordinating the entire supply chain to support all needs for
Products in the Field within and outside the Territory;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>Oversee all Processing Activities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>Identify and propose actions to prevent potential interruptions of supply;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(v)&nbsp;</B>Oversee audits of Third Party Manufacturers;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vi)&nbsp;</B>Propose new Third Party Manufacturers, subject to the terms and conditions of Indevus&#146;
agreements with Third Party Manufacturers;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vii)&nbsp;</B>Oversee quality control and assurance, implementation process improvements, cost
reduction initiatives, and logistics initiatives;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(viii)&nbsp;</B>Coordinate the supply of Compound in sufficient quantities for Indevus to satisfy its
obligations under Section&nbsp;14.6(b);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ix)&nbsp;</B>Coordinate assumption by Esprit of Processing Activities, including the Technology
Transfer, and recommend a timeline and procedures for the Technology Transfer in its first meeting;
and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(x)&nbsp;</B>Have such other responsibilities and address any other matters delegated to the Supply
Committee under this Agreement or as may be mutually agreed upon in writing by the Parties from
time to time, as well as any other matters pertaining to each Party&#146;s performance of its supply
obligations under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Oversight. </B>The Supply Committee may make decisions with respect to any subject matter
that is subject to the Supply Committee&#146;s decision-making authority and responsibilities as set
forth in Section&nbsp;3.3(b). The Supply Committee shall use its good faith efforts to resolve by
consensus any issue relevant to the supply of Finished Products and/or Samples. Each Party shall
provide input with respect to the supply of Finished Products and/or Samples, and the Supply
Committee shall give substantial consideration to the views, position and recommendations of each
Party on any issue that has been brought before the Supply Committee. If the Supply Committee
shall arrive at a consensus on any issue relating to the supply of Finished Products and/or
Samples, such consensus shall be binding upon the Parties. All decisions of the Supply Committee
shall be made by unanimous vote or written consent, as indicated by all members signing the written
minutes thereof, with Esprit representatives collectively having one (1)&nbsp;vote and Indevus
representatives collectively having one (1)&nbsp;vote in all decisions. If the Supply Committee cannot
reach consensus on a matter brought to its
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">attention, Esprit shall be entitled to make the final
decision with respect to such matter, subject to Section&nbsp;3.3(d).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>The Supply Committee shall have only the powers assigned to it in this Section&nbsp;3.3. All
activities conducted by the Supply Committee shall be consistent with and subject to the provisions
of this Agreement and, if applicable, the Ex-US Supply Agreement, and the Supply Committee shall
not have any power to take any action that conflicts with the terms of this Agreement or to amend,
modify or waive compliance with this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.4 Meetings. </B>The chairpersons of the Development Committee, Marketing Committee, and Supply
Committee shall call meetings as reasonably requested by one of the Parties; <U>provided</U>,
<U>however</U>, that:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>the Marketing Committee shall meet at least three (3)&nbsp;times per year (with a meeting to be
held not later than thirty (30)&nbsp;days after the Effective Date at Esprit&#146;s offices) through the end
of the Copromotion Period, unless the Parties agree otherwise;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>the Development Committee shall meet at least three (3)&nbsp;times per year (with a meeting to
be held not later than thirty (30)&nbsp;days after the Effective Date at Indevus&#146; offices) through the
NDA Transfer Date, unless the Parties agree otherwise; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>the Supply Committee shall meet on at least a Calendar Quarterly basis (with a meeting to
be held not later than thirty (30)&nbsp;days after the Effective Date at Indevus&#146; offices) through the
Processing Assumption Date, unless the Parties agree otherwise, and, after the Processing
Assumption Date through the NDA Transfer Date, the Supply Committee shall meet at least three (3)
times per year.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Meetings may be held in person, by telephone, or by video conference call, and, except as set forth
above, the location of each meeting shall alternate between the Parties&#146; headquarters or such other
location as may be mutually agreed upon by the Parties. On advance written notice to
the other Party, additional participants may be invited by any representative to attend meetings
where appropriate. Each Party shall be responsible for all travel and related costs and expenses
of its members and other representatives to participate or attend committee meetings. The Parties
shall cause their respective representatives on the committees to use good faith efforts to resolve
all matters presented to them. Any Proprietary Information disclosed in any meeting of the
Development Committee, Marketing Committee, or Supply Committee by a Party shall remain Proprietary
Information of the disclosing Party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.5 Minutes of Committee Meetings. </B>Minutes of the each committee meeting shall be transcribed
and issued by the secretary within thirty (30)&nbsp;days after each meeting (or, if shorter, at least
ten (10)&nbsp;Business Days prior to the date of the next scheduled meeting of such committee) and shall
be approved as the first order of business at the immediately succeeding meeting of such committee.
Such minutes shall include only key discussion points and decisions made and provide a list of any
identified issues yet to be resolved, either within such committee or through the relevant
resolution process, if any.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.6 Disbanding of Committees.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The Parties shall have the right to disband any or all of the Development Committee,
Marketing Committee, and Supply Committee, upon mutual agreement. Additionally, to the extent the
applicable committee is not disbanded pursuant to the preceding sentence, the Development Committee
shall be automatically disbanded effective on the NDA Transfer Date, the Marketing Committee shall
be automatically disbanded effective on the expiration of the Copromotion Period, and the Supply
Committee shall be automatically disbanded effective on the NDA Transfer Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>After the disbanding of a committee, Esprit shall be entitled to make the final decision
with respect to any and all matters or actions for which it had the right to make such decisions
prior to the disbanding of any such committee subject to any provisions applicable to such
decision.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.7 Project Coordinators. </B>Promptly following the Effective Date, each Party shall designate
an appropriate expert to facilitate communication and coordination of the Parties&#146; activities under
this Agreement relating to Products and to provide support and guidance to the Development
Committee, Marketing Committee, and Supply Committee (each, a &#147;<B>Project Coordinator</B>&#148;). Each Project
Coordinator shall be experienced in project management and may also serve as one of the
representatives of its respective Party on any of the Development Committee, Marketing Committee,
and Supply Committee. From time to time each Party may replace its Project Coordinator by written
notice to the other Party specifying such replacement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Development and Regulatory Matters</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.1 Development.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;General. </B>After the Effective Date, Development of Products in the Field in the Territory
shall be conducted, administered and funded solely by Esprit or its designees, and Indevus shall
not conduct any development activities with respect to Products in the Field in the Territory.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Phase IV Clinical Trials. </B>After the Effective Date, all Phase IV Clinical Trials or other
pre-clinical or clinical trials that are required by the FDA as a condition to or in connection
with an FDA Approval in the United States shall be conducted, administered and funded solely by
Esprit or its designees. Indevus shall have the right, but not the obligation, to provide
appropriate personnel to support and assist in the conduct of such Phase IV Clinical Trials, as
mutually agreed to between the Parties, subject to reimbursement of Indevus&#146; costs and expenses
associated therewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.2 Regulatory Matters.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Prior to the NDA Transfer Date. </B>The Parties acknowledge that Indevus has obtained FDA
Approval for Trospium Twice-Daily and Trospium Once-Daily and is
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the owner of the Product NDAs as
of the Execution Date and is expected to be the owner of the Product NDAs as of the Effective Date.
Prior to the NDA Transfer Date:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>Indevus shall own and control all Regulatory Documents relating to a Product in the Field
in the Territory.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>Indevus shall have sole authority and responsibility for the timely preparation, filing,
prosecution, and maintenance of all Regulatory Documents relating to a Product in the Field in the
Territory, including Product NDAs and any reports or amendments necessary to maintain FDA
Approvals, and for seeking any revisions of the conditions of each FDA Approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>Indevus shall have sole authority and responsibility to seek and/or obtain any necessary
FDA approvals of any Product Label(ing), packaging, advertising or other promotional or
informational materials used in connection with Product and Promotional Materials and for
determining whether the same requires FDA approval, and Indevus shall submit Promotional Materials
to the FDA after approval of both Parties, in accordance with the procedures set forth in Section
5.6.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>Indevus shall remain the primary contact with the FDA and shall be solely responsible for
all communications with the FDA that relate to any IND or NDA relating to a Product in the Field in
the Territory prior to and after any FDA Approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(v)&nbsp;</B>Esprit shall have the right, but not the obligation, to assist and consult with Indevus
with respect to all regulatory submissions, including applications for FDA Approvals, prior to
making any such submissions. At least thirty (30)&nbsp;days prior to the filing of any documents with
the FDA relating to Products in the Field, Indevus shall provide Esprit with copies of all such
filings, submissions, authorizations and FDA Approvals, including any correspondence related to
manufacturing of Products in the Field; <U>provided</U> that, if Indevus believes it is required
by Law to make such submission sooner, Indevus shall provide Esprit with final copies of such
submissions for Esprit&#146;s review at least two (2)&nbsp;Business Days prior to filing them with the FDA.
Indevus shall consider in good faith any comments of Esprit with respect to the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vi)&nbsp;</B>Indevus shall provide Esprit with a copy of all safety data received by Indevus regarding
Products in the Field worldwide.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vii)&nbsp;</B>Indevus shall provide advance notice to Esprit of any planned meetings, discussions, or
other communications with the FDA relating to Products in the Field. Esprit shall have the right,
but not the obligation, to participate with respect to such meetings, discussions, or other
communications; <U>provided</U> that, in providing any such assistance, Esprit shall not contact
the FDA without the prior approval of Indevus and, if contacted by the FDA with respect to Product,
shall refer such contact to Indevus.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(viii)&nbsp;</B>If contacted by the FDA with respect to a Product in the Field, Indevus shall notify
Esprit within two (2)&nbsp;Business Days of such contact, and provide Esprit with any related official
correspondence received from the FDA, including as applicable minutes of any meetings or telephone
conferences and/or discussions between Indevus and the FDA. Esprit shall have a right to
participate in and provide comments with respect to any subsequent meetings, discussions, or other
communications with respect to such contact.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ix)&nbsp;</B>To the extent Esprit reasonably believes that a filing or submission relating to Products
in the Territory is required by Law, Esprit shall notify Indevus. If Indevus decides not to
prepare such filing or submission, Indevus shall promptly notify Esprit, but in no event later than
thirty (30)&nbsp;days, unless notified by Esprit that a shorter period of review is mandated by FDA or
Law, after such notice by Esprit of such decision, and Esprit shall be entitled to prepare such
filing or submission, to be filed or submitted by Indevus; <U>provided</U> that Esprit shall use
good faith efforts to include any comments of Indevus in such filing or submission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(x)&nbsp;</B>Prior to the Processing Assumption Date, changes to the Specifications shall be made only
by mutual prior agreement of the Parties, except as required by Law. The Parties shall determine
whether any such changes require any supplements to a Product NDA, and each Party shall provide the
other Party with notice of any such changes as
soon as practicable. After the Processing Assumption Date, but prior to the NDA Transfer Date,
changes to the Specifications shall be made only after prior notification to Indevus of any such
changes as soon as practicable, and the Parties shall determine whether any such changes require
any supplements to a Product NDA, except as required by Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xi)&nbsp;</B>Notwithstanding anything herein to the contrary, Indevus shall not file with the FDA any
regulatory submissions that are intended to change or modify the Product label or FDA-approved
prescribing information for, or the indications of, Trospium Twice-Daily or Trospium Once-Daily in
the Territory without providing to Esprit a draft of such submission at least ten (10)&nbsp;days prior
to planned submission to the FDA and giving prompt and reasonable consideration to any comments
Esprit may have; <U>provided</U> that, if and to the extent required by Law Indevus is required to
file any such submission in less than ten (10)&nbsp;days after notice from the FDA, Indevus will notify
Esprit of any such requirement promptly and in no event later than two (2)&nbsp;Business Days after such
notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(xii)&nbsp;</B>Notwithstanding Section&nbsp;14.13(f), during the period beginning on the Processing
Assumption Date and ending on the NDA Transfer Date, in connection with Indevus&#146; responsibilities
as holder of the Product NDAs, Indevus and Esprit shall cooperate in good faith, in coordination
with the Supply Committee, for Indevus to subcontract or assign the performance and management of
quality assurance responsibilities to Esprit, while retaining the authority for Indevus to monitor
Esprit&#146;s performance, as subcontractor to Indevus with respect to such activities, consistent with
Indevus&#146; quality obligations under the Product NDA for Trospium Once-Daily.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;After the NDA Transfer Date. </B>After the NDA Transfer Date:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>Esprit shall own and control all Regulatory Documents relating to a Product in the Field
in the Territory. Indevus hereby assigns to Esprit all right, title and interest in such
Regulatory Documents, effective as of the NDA Transfer Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>Esprit will be solely responsible for the timely preparation, filing, prosecution, and
maintenance of all Regulatory Documents relating to a Product in the Field in the Territory,
including Product INDs and NDAs and any reports or amendments necessary to maintain FDA Approvals,
and for seeking any revisions of the conditions of each FDA Approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>Esprit shall have sole authority and responsibility to develop, modify, seek and/or
obtain any necessary FDA approvals of any Product Label(ing), packaging, advertising or other
promotional or informational materials used in connection with Product in the Field in the
Territory, and Promotional Materials and for determining whether the same requires FDA approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>Esprit will be the primary contact with the FDA and shall be solely responsible for all
communications with the FDA that relate to any IND or NDA relating to a Product in the Field in the
Territory prior to and after any FDA Approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(v)&nbsp;</B>Esprit may, in its sole discretion, file any submissions that are intended to change or
modify the Product label or FDA-approved prescribing information for, or the indications of,
Trospium Twice-Daily or Trospium Once-Daily in the Territory <U>provided</U> that, except as
required by Laws, it provides to Indevus a draft of such submission at least ten (10)&nbsp;days prior to
planned submission to the FDA and gives prompt and reasonable consideration to any comments Indevus
may have.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vi)&nbsp;</B>To the extent Indevus reasonably believes that a filing or submission relating to
Products in the Field in the Territory is required by Law, Indevus shall notify Esprit. If Esprit
decides not to prepare such filing or submission, it shall promptly notify Indevus, but in no event
later than thirty (30)&nbsp;days, unless notified by Indevus that a shorter period of review is mandated
by FDA or Law, after such notice by Indevus of such decision, and Indevus shall be entitled to
prepare such filing or submission, to be filed or submitted by Esprit; <U>provided</U> that
Indevus shall use good faith efforts to include any comments of Esprit in such filing or
submission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(vii)&nbsp;</B>Indevus may, but is not required to, assist Esprit, at Esprit&#146;s election, in Esprit&#146;s
efforts to seek and obtain FDA Approvals, subject to reimbursement of Indevus&#146; related costs and
expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Regulatory Cooperation. </B>Each Party shall inform the Development Committee or, if the
Development Committee has been disbanded, the other Party, within twenty four (24)&nbsp;hours, of its
receipt of any information that: (i)&nbsp;raises any concern regarding the safety of Compound or
Product; (ii)&nbsp;concerns suspected or actual tampering, counterfeiting (excluding diversion, which is
subject to Section&nbsp;5.7(c)) or contamination or other
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">similar problems with respect to Compound or
Product; (iii)&nbsp;is reasonably likely to lead to a recall or market withdrawal of a Product; or (iv)
concerns any ongoing or potential FDA investigation, inspection, detention, seizure or injunction
involving a Compound or Product.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Adverse Experiences. </B>The reporting of Adverse Experiences shall be governed by Article
10.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;Recalls and Other Corrective Action. </B>The Development Committee shall make all final
decisions with respect to any recall, market withdrawal or any other corrective action related to a
Product in the Field in the Territory, and neither Party shall initiate any such action without the
approval of the Development Committee; <U>provided</U>, <U>however</U>, that nothing herein shall
prohibit Indevus, prior to the NDA Transfer Date, from initiating or conducting any recall or other
corrective action mandated by the FDA or Law. At a Party&#146;s request, the other Party shall provide
reasonable assistance in conducting such recall, market withdrawal or other corrective action,
including providing all pertinent records that such Party may reasonably request to assist in
effecting such action, subject to reimbursement of such other Party&#146;s reasonable costs and expenses
associated with providing such cooperation. Any documented, direct, out-of-pocket costs incurred
(paid or accrued) with respect to such recall, market withdrawal or other corrective action prior
to the Processing Assumption Date shall be borne by Indevus; <U>provided</U>, <U>however</U>,
that, in the event that the recall or other corrective action
is attributable solely to Promotional activities under Article&nbsp;5, Esprit shall bear such
expenses. Any documented, direct, out-of-pocket costs incurred (paid or accrued) with respect to a
recall, market withdrawal or other corrective action with respect to Products in the Field in the
Territory after the Processing Assumption Date shall be borne by Esprit. Neither Party shall have
any obligation to reimburse or otherwise compensate the other Party or its Affiliates for any
consequential damages, lost profits or income that may arise in connection with any recall, market
withdrawal or corrective action with respect to Products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Promotion of Products</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.1 General.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Subject to the terms and conditions of this Agreement, Esprit shall during the Agreement
Term, and Indevus shall during the Copromotion Period, use Commercially Reasonable Efforts to
Promote Products in the Field in the Territory and to perform their respective obligations under
this Agreement. All activity conducted by a Party under this Agreement shall occur at such Party&#146;s
sole expense except as otherwise expressly provided in this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Without limiting the generality of the foregoing, Esprit shall use Commercially Reasonable
Efforts to launch Trospium Once-Daily in the United States by &#091;...***...&#093;, subject to the
following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>If Indevus has complied in all material respects with its obligations under this Agreement
and there has not been an event of Force Majeure, Esprit shall
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">launch Trospium Once-Daily in the
United States by the later of (a) &#091;...***...&#093; or (b) &#091;...***...&#093; in the event
that Esprit pays Indevus, on or before &#091;...***...&#093;, if necessary, &#091;...***...&#093;
or such other amount, if any, agreed to by &#091;...***...&#093;, or (c)&nbsp;such other date to which
the Parties may mutually agree.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>If, because of a Force Majeure event, Esprit is unable to launch Trospium Once-Daily in
the United States on or before &#091;...***...&#093;, Esprit shall launch Trospium Once-Daily in
the United States on the date that is the number of days beyond &#091;...***...&#093; equal to the
number of days of Force Majeure, and Indevus, on or before &#091;...***...&#093;, shall be required
to obtain an extension of the launch requirement &#091;...***...&#093; if required to prevent a breach of &#091;...***...&#093;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>If, because Indevus has not complied with its obligations under this Agreement, Esprit
is unable to launch Trospium Once-Daily in the United States on or before &#091;...***...&#093;,
Indevus, on or before &#091;...***...&#093;, shall be required to obtain an extension of the launch
date requirement, which extended launch date requirement shall not be before &#091;...***...&#093;,
including &#091;...***...&#093;, if necessary, &#091;...***...&#093; (in which case the extended
launch date requirement shall be &#091;...***...&#093; ) or such other lesser amount, if any, agreed
to &#091;...***...&#093;; and Indevus shall not have the right to terminate this Agreement for
Esprit&#146;s failure to launch Trospium Once-Daily on
or before &#091;...***...&#093; provided that Esprit launches Trospium Once-Daily by such
extended launch date requirement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Notwithstanding anything herein to the contrary, if Esprit determines, in consultation
with the Development Committee prior to the NDA Transfer Date, in its sole discretion, that market
acceptance of Trospium Once-Daily relative to Trospium Twice-Daily justifies the discontinuation of
Trospium Twice-Daily, it shall have the right to discontinue Promotion of Trospium Twice-Daily and
to require Indevus to provide notice of discontinuation of Trospium Twice-Daily to the FDA by
providing written notice to Indevus and citing this Section&nbsp;5.1(c). For the avoidance of doubt,
the exercise of the rights provided in this Section&nbsp;5.1(c) by Esprit and the related obligation by
Indevus shall not be deemed a Product Adverse Event.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.2 Promotion Plan. </B>Esprit will prepare a Promotion Plan and budget, which will be provided
to the Marketing Committee by not later than &#091;...***...&#093; before the commencement of the
Launch Period, covering the Copromotion Period; <U>provided</U> that any and all Promotion Plans
shall terminate and shall have no effect upon termination of the Copromotion Period. Subject to
the other terms and conditions of this Agreement, the Promotion Plan shall focus on the Promotion
of Products in the Field in the Territory, and shall include matters such as:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The determination and review of the content, quantity, method of distribution of, and
guidelines for the use of Promotional Materials related to, Trospium Twice-Daily and Trospium
Once-Daily, including any claims made about such Products, including any seminars, conferences or
medical education materials, which shall be consistent with the provisions of Section&nbsp;5.6.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>The quantity and timing of distribution of Samples of Trospium Twice-Daily and Trospium
Once-Daily.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>The level of marketing and other support for Trospium Twice-Daily and Trospium Once-Daily
to be provided by either Party; <U>provided</U>, <U>however</U>, that no additional obligations
or costs may be imposed upon either Party without the prior written consent of such Party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.3 Target Prescribers; Product Advisors.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>For each Calendar Year, Esprit shall review with the Marketing Committee by October 1 of
the immediately preceding Calendar Year (or, for the Calendar Year ending December&nbsp;31, 2008, thirty
(30)&nbsp;days after the Effective Date) the specific Target Prescribers for Trospium Twice-Daily and
Trospium Once-Daily and the planned copromotion coverage by Esprit and Indevus; <U>provided</U>,
<U>however</U>, that (a)&nbsp;the Target Prescribers for the
Indevus Sales Force shall be the Indevus Target Prescribers; and (b)&nbsp;Esprit may also conduct
Details to the Indevus Target Prescribers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Notwithstanding and in addition to any rights or requirements set forth in any other
provision of this Agreement, during the Copromotion Period, Indevus shall, with the prior consent
of Esprit, and at Indevus&#146; cost, have the right to (i)&nbsp;have reasonable access to all medical
advisors and consultants and with medical education, advertising and public relations agencies
engaged by any Party with respect to Trospium Twice-Daily and Trospium Once-Daily (collectively,
&#147;<B>Product Advisors</B>&#148;) and (ii)&nbsp;participate in meetings or discussions relating to marketing, medical
education programs, advertising or any other promotional activities relating principally to
Trospium Twice-Daily and Trospium Once-Daily between any Party or any Affiliate of any Party and
any Product Advisor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.4 Esprit Promotional Activities.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Esprit intends to provide a professional fully trained sales force to support Esprit&#146;s
obligations under this Agreement (the &#147;<B>Esprit Sales Force</B>&#148;). The Esprit Sales Force shall include
Representatives Promoting Products to Target Prescribers and sales managers and sales directors who
shall observe and supervise each Esprit Representative in the field, conduct and provide meaningful
field evaluations, time supervision, territory management and field reports and other miscellaneous
paperwork on behalf of the Esprit Sales Force. Esprit will provide the Marketing Committee at each
meeting (but not more often than each meeting) with a report with respect to the monthly number and
composition of the Esprit Sales Force.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>The Esprit Sales Force may conduct Details of products other than Products, as may be
determined by Esprit from time to time. Esprit acknowledges and agrees that the absence of a
requirement in this Agreement that Esprit provide a specified minimum number of Representatives or
annual or quarterly Details shall not in any way minimize Esprit&#146;s commitment to Promote Products
hereunder.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.5 Indevus Promotional Activities.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The Indevus Sales Force shall include Representatives Promoting Products to the Indevus
Target Prescribers and sales managers and sales directors who shall observe and supervise each such
Indevus Representative in the field, conduct and provide meaningful field evaluations, time
supervision, territory management and field reports and other miscellaneous paperwork on behalf of
the Indevus Sales Force. Indevus will provide the Marketing Committee at each meeting (but not
more often than each meeting) with a report with respect to the monthly number and composition of
the Indevus Sales Force.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Detail Requirements.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>For the portion of the Copromotion Period ending September&nbsp;30, 2008, the number of
Quarterly Indevus Details, all of which shall be Primary Position Details, to be delivered to the
Indevus Target Prescribers shall &#091;...***...&#093;, during each Calendar Quarter;
<U>provided</U>, <U>however</U>, that, if the period from the Effective Date to the end of the
first Calendar Quarter ending after the Effective Date is less a full Calendar Quarter, the number
of such Details shall be subject to pro rata adjustment to the give effect to the reduced number of
days in such period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>Indevus may extend the Copromotion Period until December&nbsp;31, 2008 by providing written
notice of such extension to Esprit by not later than July&nbsp;31, 2008. Indevus may further extend the
Copromotion Period until March&nbsp;31, 2009 by providing written notice of such extension to Esprit by
not later than October&nbsp;31, 2008. In the event Indevus elects to extend the Copromotion Period, the
determination as to the number of Quarterly Indevus Details during each extended Calendar Quarter
shall be mutually agreed to by the Parties by not later than June&nbsp;30, 2008 and September&nbsp;30, 2008
for the Calendar Quarter ending December&nbsp;31, 2008 and March&nbsp;31, 2009, respectively;
<U>provided</U>, <U>however</U>, that the number of Quarterly Indevus Details during each such
extended Calendar Quarter shall be not less than &#091;...***...&#093;. The foregoing Details in
each such extended Calendar Quarter may be Primary Position Details or Secondary Position Details
in such proportion as is specified by Indevus on or prior to June&nbsp;30, 2008 or September&nbsp;30, 2008,
as applicable; <U>provided </U>that, for the purpose of determining the number of Details
completed pursuant to this Section&nbsp;5.5(b)(ii), each Primary Position Detail conducted by Indevus
during such extended Calendar Quarter shall equal one (1)&nbsp;Detail, and each Secondary Position
Detail conducted by Indevus during such extended Calendar Quarter shall equal &#091;...***...&#093;
Detail.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Detail Adjustments. </B>The Quarterly Indevus Details may be adjusted from time to time based
on the Marketing Committee&#146;s determination that the Product is promotionally sensitive as measured
by immediate sales increases through promotional efforts and such other measurements of
then-current market conditions (qualitative or/and quantitative) as may be commercially reasonable;
<U>provided</U>, <U>however</U>, that any such adjustments shall be subject to the prior written
approval of Indevus. The Indevus Sales Force may also conduct details of products other than
Product, as may be determined by Indevus from time to time.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Failure to Meet Detail Requirements. </B>If, for any Calendar Quarter during the Copromotion
Period, the Indevus Sales Force delivers less than one hundred percent (100%) of the Quarterly
Indevus Details set forth in Section&nbsp;5.5(b) for such Calendar Quarter, such Calendar Quarter shall
be deemed a Deficient Quarter, and the following shall be applicable:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>If the Indevus Sales Force delivers less than one hundred percent (100%) but greater than
&#091;...***...&#093; of the Quarterly Indevus Details set forth in Section
5.5(b) for such Deficient Quarter, the Indevus Sales Force shall cure the deficiency by
delivering the deficient number of Details during the Cure Period in addition to its required
Quarterly Indevus Details for the Cure Period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>If the Indevus Sales Force delivers less than or equal to &#091;...***...&#093; but
greater than &#091;...***...&#093; of the Quarterly Indevus Details set forth in Section&nbsp;5.5(b) for
such Deficient Quarter, (A)&nbsp;the Indevus Sales Force shall, at Esprit&#146;s election, cure the
deficiency by delivering the deficient number of Details during the Cure Period in addition to its
required Quarterly Indevus Details for the Cure Period and (B)&nbsp;Esprit&#146;s Sales Force Reimbursement
payment obligations for such Deficient Quarter pursuant to Section&nbsp;6.3 shall be reduced to
&#091;...***...&#093; of the amount that would otherwise have been due for such Calendar Quarter
pursuant to Section&nbsp;6.3.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>If the Indevus Sales Force delivers less than or equal to &#091;...***...&#093; but
greater than &#091;...***...&#093; of the Quarterly Indevus Details set forth in Section&nbsp;5.5(b) for
such Deficient Quarter, (A)&nbsp;the Indevus Sales Force shall, at Esprit&#146;s election, cure the
deficiency by delivering the deficient number of Details during the Cure Period in addition to its
required Quarterly Indevus Details for the Cure Period and (B)&nbsp;Esprit&#146;s Sales Force Reimbursement
payment obligations for such Deficient Quarter pursuant to Section&nbsp;6.3 shall be reduced to
&#091;...***...&#093; of the amount that would otherwise have been due for such Calendar Quarter
pursuant to Section&nbsp;6.3.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>If the Indevus Sales Force delivers less than or equal to &#091;...***...&#093; of the
Quarterly Indevus Details set forth in Section&nbsp;5.5(b) for such Deficient Quarter, at Esprit&#146;s
election, (A)&nbsp;the Copromotion Period shall terminate and the Indevus Sales Force shall, at Esprit&#146;s
election, cease all Details and (B) &#091;...***...&#093; pursuant to Section&nbsp;6.3 for such
Deficient Quarter or thereafter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>The actual number of Details made by the Indevus Sales Force to Target Prescribers during
each Calendar Quarter shall be determined and reported in accordance with a call reporting system
provided by Esprit to Indevus under this Agreement during the Copromotion Period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.6 Promotional Materials and Activities. </B>During the Copromotion Period, and in compliance
with Law, Esprit shall have the sole right to create and develop the Promotional Materials with,
during the Copromotion Period, input and participation from the Marketing Committee, subject to
Section&nbsp;5.6(a). During the Copromotion Period, prior to
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">finalizing such Promotional Materials and
promotional activities, each Party shall include the other Party in its internal circulation of
information regarding such promotional materials and activities during the development of such
Promotional Materials and any event related materials and upon the finalization of such materials.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Neither Party shall produce (other than as concepts for consideration by the other Party),
distribute or otherwise use any Promotional Materials that have
not been approved in advance by the Development Committee for purposes of determining
compliance with Law and agreed upon standard operating procedures of each Party. Prior to the NDA
Transfer Date, Promotional Materials shall be submitted to Indevus&#146; internal regulatory compliance
personnel for timely review pursuant to applicable internal standard operating procedures, for an
assessment of compliance with Law and shall be subject to Indevus&#146; approval solely with respect to
compliance with Law. Such assessment shall be provided to both Parties. Each Party shall limit
its statements, discussions and claims regarding Products, including those as to safety and
efficacy, to those that are consistent with the Product Labeling and the Promotional Materials.
Neither Party shall add, delete, modify or distort claims of safety or efficacy in the Detailing of
Products, nor shall it make any changes (including underlining or otherwise highlighting any
language or adding any notes thereto) or alter the presentation order or format in the Promotional
Materials.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Esprit shall own all right, title and interest in and to the copyrights in all marketing,
sales, advertising or Promotional Materials relating to the Products in the Field in the Territory
(&#147;<B>Territory Copyrighted Works</B>&#148;). Indevus shall execute all documents and take all actions as are
reasonably requested by Esprit to vest title to such Territory Copyrighted Works in Esprit. Esprit
shall be responsible, at its expense, for searching, clearing and filing applications for
registration of all such Territory Copyrighted Works. To the extent such materials include or
incorporate original works of authorship created by Indevus prior to the Effective Date, Indevus
shall not use, or make any proprietary claim with regard to, those pre-existing materials separate
and apart from their use and inclusion in Territory Copyrighted Works relating to Products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Subject to Section&nbsp;5.6(b), Esprit and Indevus shall retain all rights, including all
copyrights and trademarks, to all of their respective programs and materials existing as of the
Effective Date in all formats (including print, video, audio, digital, and computer formats)
regarding sales training, patient education and disease management programs owned or licensed by
each at the time such materials are shared with the other Party, as well as any modifications of
such programs each may develop in the future that are not specific to Products in the Field.
Esprit and Indevus shall, from time to time, each notify the other as to the identity of such
proprietary programs. In addition, all new programs that are not specific to Products in the Field
that are jointly developed by Esprit and Indevus pursuant to this Agreement shall be jointly owned
by Esprit and Indevus, and each Party shall have the right to use such jointly developed programs
free of charge after the expiration of the Agreement Term.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Esprit shall be the primary Party responsible for preparing all submissions with the FDA
regarding approval of all Promotional Materials that require FDA
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">approval; <U>provided</U> that
prior to the NDA Transfer Date Indevus shall be responsible for filing all such submissions and
participating with Esprit in any interactions with the FDA regarding such matters. After the NDA
Transfer Date, Esprit shall be responsible for all submissions and interactions with the FDA
regarding approval of all Promotional Materials that require FDA approval.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>Except as otherwise prohibited by Law, during the Copromotion Period, all Promotional
Materials used by Indevus in connection with the Promotion of Products under this Agreement shall
be only those supplied by Esprit. Indevus may display on such Promotional Materials the Indevus
Logo; <U>provided</U> that the trademark of and specified by Esprit (or any person or entity to
which Esprit assigns or sublicenses rights hereunder) shall appear to the left of and/or above the
Indevus Logo. Indevus shall not use any representations of any mark of Esprit other than those
supplied by Esprit in Promotional Materials. Solely to the extent required by Law, all Promotional
Materials used by Esprit will indicate that a Product is sold under license from Indevus and
promoted by Esprit or any such Affiliate, as directed by Esprit. All promotional materials used by
Indevus in connection with the Promotion of Products under this Agreement shall indicate that the
Trademarks (except for the Indevus Logo) are owned by Esprit or any such Affiliate, as directed by
Esprit. Notwithstanding anything to the contrary in this Section&nbsp;5.6(e), except to the extent
required by Law, in no event shall any packaging, trade dress, journal advertising and sales aids,
or FDA approved Product Labeling display any mark of Indevus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>Within ninety (90)&nbsp;days after the expiration or termination of this Agreement, each Party
shall return (unless prohibited by Law), or otherwise dispose of in accordance with instructions
from the other Party, all remaining Promotional Materials provided by the other Party and will
provide the other Party with a certified statement that all remaining Promotional Materials have
been returned or otherwise properly disposed of and that the Party is no longer in possession or
control of any such Promotional Materials in any form or fashion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.7 Samples. </B>The following terms shall apply to any Samples in the Territory:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Esprit shall distribute to each Party Samples to be used by the Sales Forces. All supply
and costs of Samples shall be subject to the provisions of Article&nbsp;14.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Each Party shall receive and use such Samples in accordance with the Promotion Plan and
Laws. The quantity of Samples to be provided to each Party and the method of distribution shall be
determined by Esprit; <U>provided</U>, that the number of Samples provided to a Party shall be
consistent with the number of Samples provided to the other Party based on the respective number of
Details expected to be made by each Party&#146;s Representatives under the Promotion Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Each Party shall maintain and adhere to its established internal standard operating
procedures to assure that such Party and such Party&#146;s Sales Force comply with all requirements of
the PDMA with respect to the Promotion of Products and other activities
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">under this Agreement, as
well as material compliance with other Laws. Indevus shall notify Esprit promptly, but no less
than in sufficient time after Indevus learns that any Samples shipped by Esprit to Indevus have
been lost or have not been received as scheduled, such that Esprit will have a reasonable period of
time to enable it to comply with all legal requirements and file any reports with respect to such
Samples. Furthermore, such procedures shall include a requirement
that each Party shall be responsible for reporting directly to the FDA any known thefts or
significant losses of Samples, as the same is required by the then applicable FDA regulations, and
Esprit shall promptly provide Indevus with a complete copy of any such report submitted by Esprit.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Within &#091;...***...&#093; after the expiration or termination of the Copromotion
Period, Indevus shall return, or otherwise dispose of in accordance with instructions from Esprit
and Law, all remaining Samples controlled by Indevus and will provide Esprit with a certified
statement that all remaining Samples have been returned or otherwise properly disposed of and that
Indevus is no longer in possession or control of any such Samples in any form or fashion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>Upon not less than &#091;...***...&#093; advance written notice to the other Party, during
the Copromotion Period each Party shall be entitled, at its sole expense, to conduct an inspection
and audit of the other Party&#146;s compliance with Section&nbsp;5.7(b) and (c).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.8 Training Program.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Primary Training. </B>No person shall be Deployed as a Sales Force member unless and until
such person has received and successfully completed the training, certification and testing set
forth in this Section&nbsp;5.8 (the &#147;<B>Primary Training</B>&#148;). The Parties acknowledge and agree that as of
the Effective Date, pursuant to the Original Agreement, the Indevus Sales Force has completed the
Primary Training with respect to Trospium Twice-Daily. The Primary Training shall initially consist
of home study training and an initial training program, which shall include such medical and
technical information about Trospium Once-Daily and, as applicable, Trospium Twice-Daily, and such
sales training as the Marketing Committee deems necessary and appropriate, including training on
the proper handling of Adverse Experiences encountered with respect to Trospium Twice-Daily and
Trospium Once-Daily and on timely reporting to Esprit of inquiries relating to Trospium Twice-Daily
and Trospium Once-Daily and other requests for information related to Trospium Twice-Daily and
Trospium Once-Daily and the reporting thereof to Esprit. Esprit, with consultation from the
Marketing Committee shall plan, formulate and conduct the Primary Training with respect to Trospium
Once-Daily to the extent not completed as of the Effective Date, and Esprit shall be responsible
for all expenses (e.g., airfare, hotel, and expense of instructors) except for salaries and
compensation of members of the Indevus Sales Force incurred in connection with attending such
Primary Training; <U>provided</U> that Indevus may participate in planning and conducting any such
Primary Training relating to the Indevus Sales Force. The Product training of each Party&#146;s Sales
Force shall be consistent with the direction of Esprit, the Promotion Plan, and the Product
training materials. Promptly after the Effective Date, Esprit and Indevus shall agree on a mutually
convenient schedule which will enable the Parties to complete the Primary Training of
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Sales
Force with respect to Trospium Once-Daily in sufficient time to enable the Sales Forces to meet the
launch date for Trospium Once-Daily in the United States.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Each Party may conduct the Training Program for its employees at sites to be determined by
such Party. Each Party shall bear all costs associated with any Training Programs for its
employees; <U>provided</U> that Esprit shall provide the training materials for each Training
Program, including an up-to-date learning unit for Trospium Twice-Daily and Trospium Once-Daily for
&#147;at home&#148; study prior to the commencement of the Training Program. Esprit shall also provide for
distribution to the Sales Force, Product promotional training and training materials regarding the
Detailing of Trospium Twice-Daily and Trospium Once-Daily to the Target Prescribers in accordance
with the Promotion Plan for the Products. Such materials shall be provided to Indevus free of
charge for distribution to the Indevus Sales Force.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Additional Training. </B>In addition to the Primary Training, during the Agreement Term, each
Party shall conduct, at its sole expense, separate training programs for its respective Sales Force
with respect to the &#147;Medicare and Medicaid Anti-Kickback Statute,&#148; set forth at 42 U.S.C.
&#167;1320(a)-7b(b) and the prohibited acts set forth thereunder, PDMA regulations, and other applicable
guidelines relating to promotion of Products in the Field, such as the Pharmaceutical Research and
Manufacturers of America Code on Interactions with Healthcare Professionals, with the content of
said training programs to be pre-approved by both Parties. Upon completion of such additional
training, each Sales Force member shall be required to sign a certificate acknowledging their
receipt of such training and certifying and acknowledging their understanding of such statutes and
the specified actions prohibited thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Testing/Certification of Product Knowledge. </B>No person shall be Deployed as a Sales Force
member unless and until such person has demonstrated a thorough knowledge of Trospium Twice-Daily
and Trospium Once-Daily by passing the Product certifications. Such Product certifications shall
be administered to each trainee near the completion of the Primary Training (or of any subsequent
Product training), and the scores of such certification shall be verified to the satisfaction of
both Parties. Each Party reserves, and shall at all times have, the right to review any and all
Product certifications taken by any member of the other Party&#146;s Sales Force during the Copromotion
Period. The Parties shall review and determine minimum score standards prior to the administering
of the certifications. Any Representative failing to meet such minimum standards is not eligible
for assignment to Detail Products under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;Ongoing Training. </B>Each Party shall be responsible for, and shall plan, coordinate and
conduct and pay for such ongoing training as is otherwise required to Deploy new or replacement
members of its Sales Force and account for any changes in the Promotion Plan, the Products or Laws,
which training shall be substantially equivalent to the Primary Training.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;Assistance of the Parties. </B>Each Party shall cooperate with the other Party to coordinate
the Training Programs.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.9 Additional Services and Assistance by Esprit.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>During the Agreement Term, in addition to the other services to be provided by Esprit
under this Agreement, Esprit shall provide to Indevus the services or assistance set forth in this
Section&nbsp;5.9.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Esprit or its Third Party contractor shall provide all order entry, customer service
(including forwarding to Indevus product complaints), reimbursement management, medical affairs
(including reports for all Adverse Experiences in accordance with Article&nbsp;10), medical information,
warehousing, physical distribution, invoicing, credit and collections, production forecasting and
other related facilities and services necessary or desirable for the distribution, marketing,
Promotion and sales of Products under this Agreement. Such services shall include contract
administration, including handling wholesaler chargebacks, managed care contracts, federal and
state government contracts, rebate contracts, long-term care contracts, performance-based contracts
and hospital purchasing contracts, and Esprit shall be responsible for managing and performing
visits to national accounts, including managed care, trade and government accounts. Esprit shall
be exclusively responsible for accepting and filling purchase orders for Products pursuant to this
Agreement and for processing billing and returns with respect to such Products, in accordance with
Article&nbsp;14. Prior to the Processing Assumption Date, <U>provided</U> that Esprit&#146;s storage and
handling of Finished Products and Samples after receipt from Indevus conforms to Specifications,
Esprit shall have no obligation or responsibility for Finished Products and Samples meeting
Specifications under this Agreement, which shall be solely the obligation and responsibility of
Indevus until the Processing Assumption Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>During the Copromotion Period, Esprit shall make available to Indevus the right to use
Esprit&#146;s call reporting system which system shall be reasonably satisfactory to Indevus and shall
be in compliance with all PDMA regulations and Esprit shall provide Indevus with up to
&#091;...***...&#093; during the Copromotion Period of its call reporting system, to use for such
purposes. Each Party shall provide all necessary and appropriate support to such Party&#146;s Sales
Force for sample and call reporting and tracking, in each case in compliance with all PDMA
regulations and reasonably satisfactory to the other Party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>At Indevus&#146; reasonable request, Esprit shall make available to Indevus reasonable
regulatory support with respect to Products, as agreed by the Parties; <U>provided</U> that such
support does not require Esprit to incur significant expenses, as determined by Esprit at its sole
discretion, and does not require Esprit to defer or delay regulatory support of any other products
or product candidates in its portfolio.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>Esprit shall make available to Indevus reasonable support regarding Esprit&#146;s indigent
patient program and other patient assistance programs, as agreed to between the Parties and PDMA
compliance, in accordance with Esprit&#146;s internal standard operating procedures.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>Esprit shall provide Indevus on a &#091;...***...&#093; basis for the immediately
preceding &#091;...***...&#093; (i)&nbsp;sales reports of Net Sales (including any deductions from the
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">gross amount invoiced) in the Territory, in a format to be approved by the Marketing Committee and
(ii)&nbsp;monthly data that measures prescriptions written for a Finished Product by each Target
Prescriber in the Territory from a source mutually agreed in writing by the Parties, as such data
becomes available, as agreed by the Parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g)&nbsp;</B>Esprit and its Third Party contractors shall be responsible for responding to medical
questions or inquiries from members of the medical and paramedical professions and consumers
regarding Products in the Field, including the distribution of standard medical information letters
(<U>provided</U> a form of such letter has been approved by Esprit regulatory personnel) resulting
from the marketing activities of the Sales Forces. Indevus shall refer all such medical inquiries
that it receives to Esprit; <U>provided</U> that Esprit shall provide copies of the responses
given, all in accordance with Laws, including regulations and policies of the FDA, to Indevus. The
Parties shall work together to formulate, and shall mutually agree upon, responses to such
inquiries, including the content of any Frequently Asked Questions. If appropriate, the Parties
shall establish a centralized database to document and track medical inquiries. Indevus shall
provide information and access to data, records and reports reasonably requested or needed by
Esprit to fulfill its obligations under this Section&nbsp;5.9(g).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.10 Additional Personnel and Support. </B>Each Party shall provide as necessary for the diligent
performance of this Agreement additional personnel needed to coordinate, support and enhance the
quality and effectiveness of the activities of each Representative Detailing Products under this
Agreement; <U>provided</U>, <U>however</U>, that none of such non&#150;Sales Force personnel shall
directly or indirectly engage in Detailing the Products, nor shall any such non&#150;Sales Force member
be given access to or control over any Samples.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.11 Covenants of the Parties.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Esprit covenants that the Esprit Sales Force during the Agreement Term shall (i)&nbsp;limit its
claims of efficacy and safety for Products in the Field in the Territory to those that are
consistent with approved promotional claims in the Promotion Plan and are consistent with the
FDA-approved prescribing information for Products in the Field in the Territory; (ii)&nbsp;not add,
delete or modify claims of efficacy and safety in the Promotion of Products under this Agreement
from those claims of efficacy and safety that are contained in the Promotion Plan and that are
consistent with the FDA-approved prescribing information and with Law; (iii)&nbsp;use the Promotional
Materials in accordance with Section&nbsp;5.6; (iv)&nbsp;Promote Products under this Agreement in accordance
with the Promotion Plan and Laws, and in compliance with the then current Pharmaceutical Research
and Manufacturers of America Code on Interactions with Healthcare Professionals; and (v)&nbsp;except as
required by Law, not intentionally do anything
that could reasonably be expected to materially jeopardize or harm the NDA for, or materially
harm the commercial value, commercial reputation or Net Sales of, Products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Indevus covenants that, during the Copromotion Period, the Indevus Sales Force shall (i)
limit its claims of efficacy and safety for Products in the Field in the Territory to those that
are consistent with approved promotional claims in the Promotion Plan and are consistent with the
FDA-approved prescribing information for Products in the Field in
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Territory; (ii)&nbsp;not add,
delete or modify claims of efficacy and safety in the Promotion of Products under this Agreement
from those claims of efficacy and safety contained in the Promotion Plan and that are consistent
with the FDA-approved prescribing information and Law; (iii)&nbsp;use the Promotional Materials in
accordance with Section&nbsp;5.6; (iv)&nbsp;Promote Products under this Agreement in accordance with the
Promotion Plan and Laws, and in compliance with the then current Pharmaceutical Research and
Manufacturers of America Code on Interactions with Healthcare Professionals; and (v)&nbsp;except as
required by Law, not intentionally do anything that could reasonably be expected to materially
jeopardize or harm the NDA for, or materially harm the commercial value, commercial reputation or
Net Sales of, Products. After expiration of the Copromotion Period, Indevus shall not conduct any
Promotion activities with respect to Products in the Field in the Territory.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>During the Agreement Term, neither Party shall solicit any employee of the other Party or
any of its Affiliates, with whom it has come in contact or interacted for the purposes of the
performance of this Agreement, including any member of such other Party&#146;s Sales Force, to leave the
employment of such other Party and accept employment or work as a consultant with such Party or any
of its Affiliates; <U>provided</U> that, for purposes of the foregoing, &#147;solicit&#148; shall not be
deemed to mean (i)&nbsp;circumstances where an employee of one Party initiates contact with the other
Party or any of its Affiliates with regard to possible employment or (ii)&nbsp;general solicitations of
employment not specifically targeted at employees of a Party or any of its Affiliates, including
responses to general advertisements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Payments and Statements</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.1 Upfront and Milestone Payments. </B>In consideration of the rights granted by Indevus
hereunder:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Esprit shall pay Indevus on the Effective Date by wire transfer of immediately available
funds to an account designated by Indevus an up-front license fee of US$25,000,000 (twenty-five
million dollars), a portion of which shall be creditable in accordance with Section&nbsp;6.2(a)(ii).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Esprit shall pay Indevus on December&nbsp;31, 2013 by wire transfer of immediately available
funds to an account designated by Indevus a milestone payment of US$20,000,000 (twenty million
dollars); &#091;...***...&#093;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.2 Sublicensing Royalties, Minimum Royalties and Third Party Royalties.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Sublicensing Royalties.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>In consideration of the rights granted by Indevus hereunder, during the Agreement Term,
Esprit shall pay Indevus sublicensing royalties equal to twelve and one-half percent (12.5%) of
aggregate Net Sales in the Field in the Territory in each Calendar Year (&#147;<B>Sublicensing Royalties</B>&#148;),
subject to Section&nbsp;6.2(a)(ii).
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>Commencing on the earlier of (A)&nbsp;January&nbsp;1, 2010 or (B)&nbsp;the occurrence of a Product
Adverse Event that is due to Generic Competition or that results in termination by Esprit of all
commercialization activities of Esprit with respect to Trospium Once-Daily in the Field in the
Territory: Esprit shall be entitled to credit against Sublicensing Royalties otherwise payable by
Esprit pursuant to Section&nbsp;6.2(a)(i) the amounts set forth in this Section&nbsp;6.2(a)(ii) below to the
extent the aggregate amount so credited does not during the Agreement Term exceed US$20,000,000
(twenty million dollars); <U>provided</U> that the amount that may be credited against
Sublicensing Royalties in any Calendar Year shall not exceed the lesser of (W)
&#091;...***...&#093; or (X)&nbsp;the greater of (1) &#091;...***...&#093; of such Sublicensing
Royalties otherwise payable for such Calendar Year prior to the occurrence of a Product Adverse
Event and (2) &#091;...***...&#093; of such Sublicensing Royalties otherwise payable for such
Calendar Year after a Product Adverse Event has occurred. Notwithstanding the foregoing, Esprit
shall not be entitled to credit, for each Calendar Quarter, more than the lesser of (Y)
&#091;...***...&#093; or (Z)&nbsp;the greater of (1) &#091;...***...&#093; of such Sublicensing
Royalties otherwise payable for such Calendar Quarter prior to the occurrence of a Product Adverse
Event and (2) &#091;...***...&#093; of such Sublicensing Royalties otherwise payable for such
Calendar Quarter after a Product Adverse Event has occurred; <U>provided</U> that, to give effect
to the maximum credit available for each Calendar Year, for the fourth Calendar Quarter of a
Calendar Year, or portion thereof, if applicable, Esprit will calculate the maximum amount
creditable by Esprit pursuant to the first sentence of this Section&nbsp;6.2(a)(ii) for such Calendar
Year, and, if the maximum amount creditable pursuant to the first sentence of this Section
6.2(a)(ii) for such Calendar Year is greater than the actual amount credited during the first three
Calendar Quarters of such Calendar Year, Esprit may credit an amount equal to such difference
against any payments payable to Indevus for the fourth Calendar Quarter of such Calendar Year, or
thereafter if Esprit is not able to fully credit such amount because such creditable amount is
greater than Sublicensing Royalties otherwise payable to Indevus for such Calendar Quarter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>Esprit shall be entitled to credit amounts in accordance with Section&nbsp;6.2(a)(ii) until
Esprit has fully credited US$20,000,000 (twenty million dollars) against payments due from Esprit
to Indevus. For clarity, if any such amount is not credited during a Calendar Quarter, such amount
shall be creditable in subsequent Calendar Quarters, in accordance with Section&nbsp;6.2(a)(ii).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Minimum Royalties. </B>In consideration of the rights granted by Indevus hereunder, to the
extent that Sublicensing Royalties payable to Indevus under Section&nbsp;6.2(a) for a Calendar Year
(without taking account of any credit applied pursuant to Section&nbsp;6.2(a)(ii) during such Calendar
Year) specified in the table in Section&nbsp;6.2(b)(i) do not equal or exceed the Minimum Royalties set
forth adjacent to such Calendar Year in the table in Section&nbsp;6.2(b)(i), Esprit shall pay to Indevus
an amount equal to the difference, as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>Subject to Sections&nbsp;6.2(b)(ii) and (iii), to the extent that Sublicensing Royalties
payable to Indevus under Section&nbsp;6.2(a) for each Calendar Quarter (excluding the fourth Calendar
Quarter, for which Sublicensing Royalties and Minimum Royalties, to the extent applicable, shall be
paid in accordance with Section&nbsp;6.2(b)(iv)) of a Calendar Year specified in the table in this
Section&nbsp;6.2(b)(i) below (without taking account of
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">any credit applied pursuant to Section
6.2(a)(ii)) (the &#147;<B>Actual Sublicensing Royalties</B>&#148;), do not equal or exceed &#091;...***...&#093; of
the Minimum Royalties set forth adjacent to such Calendar Year in the table in this Section&nbsp;6.2(b)
below (as may be adjusted pursuant to Sections&nbsp;6.2(b)(ii) and (iii)) (the &#147;<B>Pro Rated Minimum
Royalty</B>&#148;), Esprit shall pay to Indevus, in accordance with Section&nbsp;6.4(b), an amount equal to the
difference between (A)&nbsp;the Pro Rated Minimum Royalty applicable for such Calendar Quarter and (B)
the Actual Sublicensing Royalties for such Calendar Quarter (such difference for any Calendar
Quarter, the &#147;<B>Minimum Royalty Shortfall</B>&#148;).
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Calendar Year ending December 31,</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Minimum Royalties</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">

<TD align="left"><DIV style="margin-left:15px; text-indent:-15px;margin-left:12%">2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">US$</TD>
    <TD align="right">8,125,000 </TD>
    <TD nowrap>*</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="left"><DIV style="margin-left:15px; text-indent:-15px;margin-left:12%">2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">US$</TD>
    <TD align="right">8,125,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">

<TD align="left"><DIV style="margin-left:15px; text-indent:-15px;margin-left:12%">2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">US$</TD>
    <TD align="right">10,625,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="left"><DIV style="margin-left:15px; text-indent:-15px;margin-left:12%">2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">US$</TD>
    <TD align="right">15,625,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">

<TD align="left"><DIV style="margin-left:15px; text-indent:-15px;margin-left:12%">2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">US$</TD>
    <TD align="right">18,125,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="left"><DIV style="margin-left:15px; text-indent:-15px;margin-left:12%">2012</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">US$</TD>
    <TD align="right">20,625,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">

<TD align="left"><DIV style="margin-left:15px; text-indent:-15px;margin-left:12%">2013</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">US$</TD>
    <TD align="right">23,500,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="left"><DIV style="margin-left:15px; text-indent:-15px;margin-left:12%">2014</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">US$</TD>
    <TD align="right">26,250,000</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>For the avoidance of doubt, the 2007 Minimum Royalty shall apply only for the period, if any,
after the Effective Date and prior to December&nbsp;31, 2007. Prior to the Effective Date, the minimum
royalties provided for in the Original Agreement shall continue to apply.</TD>
</TR>

</TABLE>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>Notwithstanding Section&nbsp;6.2(b)(i), the Pro Rated Minimum Royalty for any Calendar Quarter
that is less than a complete Calendar Quarter (such as for the
Calendar Quarter in which the Effective Date occurs or a Calendar Quarter that is less than a
complete Calendar Quarter due to the termination of this Agreement), shall be subject to pro rata
adjustment, based on the applicable number of days in such Calendar Quarter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>Notwithstanding Section&nbsp;6.2(b)(i), in the event of a Product Adverse Event, the
following shall be applicable:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;Esprit&#146;s obligation to pay the Minimum Royalty Shortfall for a particular Calendar Quarter
or a Calendar Year shall be suspended effective as of the date on which the Product Adverse Event
occurs and shall either terminate for such Calendar Quarter and all Calendar Quarters thereafter or
be reinstated in accordance with the following subsections (B)&nbsp;through (D).
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;Upon the occurrence of a Product Adverse Event that (1)&nbsp;is due to Generic Competition or
(2)&nbsp;results in termination by Esprit of all commercialization activities of Esprit with respect to
Trospium Once-Daily in the Field in the Territory, Esprit&#146;s obligation to pay the Minimum Royalties
shall terminate for such Calendar Quarter and all Calendar Quarters thereafter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)&nbsp;Upon the occurrence of a Product Adverse Event (1)&nbsp;that is not due to Generic Competition,
(2)&nbsp;that does not result in termination by Esprit of all commercialization activities of Esprit
with respect to Trospium Once-Daily in the Field in the Territory, and (3)&nbsp;following which, the
average Net Sales for the two (2)&nbsp;complete Calendar Quarters commencing immediately after
termination of such Product Adverse Event (the &#147;<B>Post Adverse Event Net Sales</B>&#148;), does not equal or
exceed the product of (x)&nbsp;the average Net Sales for the two (2)&nbsp;complete Calendar Quarters
immediately preceding the commencement of such Product Adverse Event and (y)&nbsp;the sum of the Pro
Rated Minimum Royalties for each of the two (2)&nbsp;complete Calendar Quarters immediately after the
termination of such Product Adverse Event divided by the sum of the Pro Rated Minimum Royalties for
each of the two (2)&nbsp;complete Calendar Quarters immediately preceding the occurrence of such Product
Adverse Event, each as calculated from the table set forth in Section&nbsp;6.2(b)(i) (such product, the
&#147;<B>Pre Adverse Event Sales Base</B>&#148;), then the Minimum Royalties set forth in the table in Section
6.2(b)(i) for the Calendar Year in which the Product Adverse Event occurs and for each Calendar
Year thereafter shall be reduced as follows: the applicable Minimum Royalties set forth in the
table in Section&nbsp;6.2(b)(i) shall be multiplied by the Post Adverse Event Net Sales and divided by
the Pre Adverse Event Sales Base. The Product of such calculation shall be &#147;<B>New Minimum
Royalties</B>&#148;. Effective as of the termination of such Product Adverse Event, Esprit&#146;s obligation to
satisfy the Minimum Royalties shall be reinstated but such Minimum Royalties shall, for all
purposes under this Agreement, be the New Minimum Royalties. In such event, all references herein
to the Minimum Royalties shall be deemed to be such New Minimum Royalties and all references herein
to the Pro Rated Minimum Royalty or the Minimum Royalty Shortfall shall be calculated based on such
New Minimum Royalties. Notwithstanding the foregoing, such New Minimum Royalties shall be subject
to pro rata adjustment, as set forth in Section&nbsp;6.2(b)(ii), to give effect to any portion of a
Calendar Quarter in which the obligation to pay the Minimum Royalty Shortfall is suspended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)&nbsp;If the Product Adverse Event (1)&nbsp;is not due to Generic Competition, (2)&nbsp;does not result in
termination by Esprit of all commercialization activities of Esprit with respect to Trospium
Once-Daily in the Field in the Territory, and (3)&nbsp;the Post Adverse Event Net Sales equals or
exceeds the Pre Adverse Event Sales Base, then upon termination of such Product Adverse Event, the
Minimum Royalties set forth in the table in Section&nbsp;6.2(b)(i) shall be reinstated;
<U>provided</U>, <U>however</U>, that such Minimum Royalties shall be subject to pro rata
adjustment, as set forth in Section&nbsp;6.2(b)(ii), to give effect to any portion of a Calendar Quarter
in which the obligation to pay the Minimum Royalty Shortfall is suspended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>For each Calendar Year, as part of the report for the fourth Calendar Quarter of such
Calendar Year, Esprit will calculate the maximum Sublicensing Royalties payable to Indevus pursuant
to Section&nbsp;6.2(a) for such Calendar Year (without taking
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">account of any credit applied pursuant to
Section&nbsp;6.2(a)(ii)) (for purposes of this Section&nbsp;6.2(b)(iv) and for each Calendar Year, the
&#147;<B>Annual Sublicensing Royalties</B>) and, if applicable, the Minimum Royalties payable to Indevus
pursuant to Section&nbsp;6.2(b)(i)&#150;(iii) for such Calendar Year (for purposes of this Section&nbsp;6.2(b)(iv)
and for each Calendar Year, the &#147;<B>Annual Minimum Royalties</B>&#148;). The amount payable by Esprit to
Indevus for the fourth Calendar Quarter of each Calendar Year pursuant to Section&nbsp;6.2(a) and (b),
or creditable by Esprit as described below, shall be calculated as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;If the Annual Sublicensing Royalties payable for any Calendar Year are (1)&nbsp;greater than
the Annual Minimum Royalties payable for such Calendar Year and (2)&nbsp;greater than the sum of all
Sublicensing Royalty payments and Minimum Royalty Shortfall payments paid by Esprit to Indevus
during the first three (3)&nbsp;Calendar Quarters of such Calendar Year, Esprit shall pay to Indevus, in
accordance with Section&nbsp;6.4(b), an amount equal to the difference between (1)&nbsp;such Annual
Sublicensing Royalties and (2)&nbsp;the sum of all Sublicensing Royalty payments and Minimum Royalty
Shortfall payments paid by Esprit to Indevus during the first three (3)&nbsp;Calendar Quarters of such
Calendar Year;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;If the Annual Sublicensing Royalties payable for any Calendar Year are (1)&nbsp;greater than
the Annual Minimum Royalties payable for such Calendar Year and (2)&nbsp;less than the sum of all
Sublicensing Royalty payments and Minimum Royalty Shortfall payments paid by Esprit to Indevus
during the first three (3)&nbsp;Calendar Quarters of such Calendar Year, Esprit may credit, in
accordance with Section&nbsp;6.4(b), an amount equal to the difference between (1)&nbsp;such Annual
Sublicensing Royalties and (2)&nbsp;the sum of all Sublicensing Royalty payments and Minimum Royalty
Shortfall payments paid by Esprit to Indevus during the first three (3)&nbsp;Calendar Quarters of such
Calendar Year, against any amounts payable to Indevus under this Agreement for such fourth Calendar
Quarter, or for any Calendar Quarter thereafter if Esprit is not able to fully credit such amount
because such creditable amount is greater than payments otherwise payable to Indevus for such
fourth Calendar Quarter;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)&nbsp;If the Annual Minimum Royalties payable for any Calendar Year are (1)&nbsp;greater than the
Annual Sublicensing Royalties payable for such Calendar Year and (2)&nbsp;greater than the sum of all
Sublicensing Royalty payments and Minimum Royalty Shortfall payments paid by Esprit to Indevus
during the first three (3)&nbsp;Calendar Quarters of such
Calendar Year, Esprit shall pay, in accordance with Section&nbsp;6.4(b), to Indevus an amount equal
to the difference between (1)&nbsp;such Annual Minimum Royalties and (2)&nbsp;the sum of all Sublicensing
Royalty payments and Minimum Royalty Shortfall payments paid by Esprit to Indevus during the first
three (3)&nbsp;Calendar Quarters of such Calendar Year; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)&nbsp;If the Annual Minimum Royalties payable for any Calendar Year are (1)&nbsp;greater than the
Annual Sublicensing Royalties payable for such Calendar Year and (2)&nbsp;less than the sum of all
Sublicensing Royalty payments and Minimum Royalty Shortfall payments paid by Esprit to Indevus
during the first three (3)&nbsp;Calendar Quarters of such Calendar Year, Esprit may credit, in
accordance with Section&nbsp;6.4(b), an amount equal to the difference between (1)&nbsp;such Annual Minimum
Royalties and (2)&nbsp;the sum of all Sublicensing Royalty payments and Minimum Royalty Shortfall
payments paid by Esprit to Indevus during
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the first three (3)&nbsp;Calendar Quarters of such Calendar
Year, against any amounts payable to Indevus under this Agreement for such fourth Calendar Quarter,
or for any Calendar Quarter thereafter if Esprit is not able to fully credit such amount because
such creditable amount is greater than payments otherwise payable to Indevus for such fourth
Calendar Quarter.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Third Party Royalties.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>In further consideration of the rights granted by Indevus hereunder, during the Agreement
Term (or such shorter period or periods in which any such amounts are payable to Madaus or
Supernus, as applicable, under the Madaus License and the Supernus Agreement, respectively) Esprit
shall also reimburse Indevus an amount equal to the aggregate Third Party Royalties payable for any
Calendar Quarter by Indevus in accordance with the report described in Section&nbsp;6.4(b)(iii);
<U>provided</U>, <U>however</U>, that in no event shall Esprit have any obligation to pay any
such Third Party Royalties in excess of &#091;...***...&#093; of Net Sales in any Calendar Quarter.
Each such payment shall be non-refundable to and non-creditable by Esprit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>The upfront payment, milestone payment, Sublicensing Royalties and Minimum Royalties
payable to Indevus pursuant to Section&nbsp;6.2(a) and/or Section&nbsp;6.2(b) are exclusive of the Third
Party Royalties payable to Indevus under this Section&nbsp;6.2(c).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.3 Sales Force Reimbursement. </B>Subject to Section&nbsp;5.5:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Esprit shall pay to Indevus, as a sales force reimbursement for the Indevus Sales Force,
an amount equal to (i)&nbsp;US$2,318,461 (two million three hundred eighteen thousand four hundred
sixty-one dollars) for each Calendar Quarter from October&nbsp;1, 2007 through June&nbsp;30, 2008 and (ii)
US$2,318,461 (two million three hundred eighteen thousand four hundred sixty-one dollars) (plus an
industry standard cost-of-living increase (not to exceed the percentage change since January&nbsp;1,
2008 in the National Compensation Survey, Private Industry Compensation as reported by the
Department of Labor, Bureau of Labor Statistics, or successor agency)) for the Calendar Quarter
ending September&nbsp;30, 2008; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>If Indevus elects to extend the Copromotion Period, Esprit shall pay Indevus as sales
force reimbursement for the Indevus Sales Force, an amount equal to US$2,318,461 (two million three
hundred eighteen thousand four hundred sixty-one dollars) (plus an industry standard cost-of-living
increase (not to exceed the percentage change since January&nbsp;1, 2008 in the National Compensation
Survey, Private Industry Compensation as reported by the Department of Labor, Bureau of Labor
Statistics, or successor agency)) for each extended Calendar Quarter from October&nbsp;1, 2008 through
December&nbsp;31, 2008 or, if Indevus elects to extend the Copromotion Period through March&nbsp;31, 2009,
through March&nbsp;31, 2009, as applicable.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The sales force reimbursement amounts set forth in (a)&nbsp;and (b), above (the &#147;<B>Sales Force
Reimbursement</B>&#148;) shall be payable in accordance with Section&nbsp;6.4(a).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Esprit shall pay on the Effective Date the amounts, if any, that are stated in any
statements for Sales Force Reimbursement, as such term is defined in the Original
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Agreement,
submitted by Indevus for September&nbsp;2007 and any subsequent month ending after the Execution Date to
the extent the same are unpaid as of the Effective Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.4 Reports and Payments.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Within fifteen (15)&nbsp;days following the end of each Calendar Quarter that begins or ends
during the Copromotion Period, Indevus shall submit to Esprit a statement for the Sales Force
Reimbursement and a report containing an accounting of all Details performed by the Indevus Sales
Force to the Target Prescribers during such Calendar Quarter. Such accounting shall include, to
the extent available from the call reporting system provided to Indevus by Esprit, a summary of
actual physician data, the number of Primary Position Details made, the number of Secondary
Position Details made, the date on which such Details were made and the location made.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Within twenty (20)&nbsp;days after the end of each Calendar Quarter that begins or ends during
the Agreement Term, Esprit shall furnish to Indevus a written report showing:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>all Net Sales during (A)&nbsp;such Calendar Quarter, including a reconciliation to Net Sales
and a breakdown of all deductions from the gross amount invoiced to arrive at Net Sales, and (B)
the Calendar Year to date through the end of such Calendar Quarter;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>the total number of units of each Finished Product sold during that Calendar Quarter
(which, with respect to Trospium Once-Daily, is the total number of capsules sold during such
Calendar Quarter) and not returned; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>a calculation of (A)&nbsp;Third Party Royalties payable for such Calendar Quarter, (B)
Sublicensing Royalties, (C)&nbsp;Minimum Royalties, Pro Rated Minimum Royalties and/or Minimum Royalty
Shortfall, as applicable, for such Calendar Quarter and, (D)
any amounts creditable under this Agreement, including pursuant to Section&nbsp;6.2(a)(ii),
6.2(b)(iv), and 14.8(b)(iii), and (E)&nbsp;any amounts payable pursuant to Section&nbsp;14.13(e)(iv).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>if a report has not previously been provided under Section&nbsp;6.5(e) of the Original
Agreement for the Calendar Quarter ending September&nbsp;30, 2007, or any other Calendar Quarter than
commences after the Execution Date but prior to the Effective Date, the first report provided under
this Section&nbsp;6.4(b) after the Effective Date shall also include, for the applicable periods
referenced in this Section&nbsp;6.4(b)(vi) and ending on the day immediately prior to the Effective
Date, the information required by Section&nbsp;6.5(e) and (f)&nbsp;of the Original Agreement with respect to
Sublicensing Royalties, Third Party Royalties and Minimum Royalties as such terms are defined in
the Original Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(v)&nbsp;</B>Each such report shall be accompanied by (A)&nbsp;with respect to the period commencing on the
Effective Date, payment of the Third Party Royalties under Section&nbsp;6.2(c), Sublicensing Royalties
under Section&nbsp;6.2(a), the amount required under Section&nbsp;6.2(b) and the Minimum Royalty Shortfall
required under Section&nbsp;6.2(b) in respect of such
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Calendar Quarter, if any, and the Sales Force
Reimbursement under Section&nbsp;6.3, subject to any offsets due to creditable amounts, (B)&nbsp;with respect
to the Calendar Quarter in which the true-up of the Supply Price occurs pursuant to Section
14.8(b)(iii), the amounts payable pursuant to Section&nbsp;14.8(b) and (C)&nbsp;with respect to any Calendar
Quarter that begins prior to the Processing Assumption Date, the amount payable under Section
14.13(e)(iv). In addition, the first report provided after the Effective Date shall also be
accompanied by payment of applicable Third Party Royalties, Sublicensing Royalties and the
difference between the pro rated portion of the Minimum Royalties and the cumulative Sublicensing
Royalties (as each of such terms are defined in the Original Agreement) paid by Esprit to Indevus
(if any), for the period commencing on July&nbsp;1, 2007 and ending on the day immediately prior to the
Effective Date, as contemplated by Section&nbsp;6.4(b)(iv), except to the extent such payments are made
on or prior to the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Esprit acknowledges and agrees that it has been provided with copies of the Madaus License,
including the Madaus Amendment, and agrees to comply with, and to enable Indevus to comply with,
the provisions of Section&nbsp;5.3 of the Madaus License with respect to the audit and other rights of
Madaus to verify the information required to be provided by Indevus to Madaus under such Section
5.3.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Any change in the amount that would have been payable from one Party to the other Party
under this Agreement that results from any restatements to a prior period&#146;s financial results due
to errors, omissions, or any other misstatements, shall be added to or deducted from, as
applicable, the amount of the next payment due under this Agreement. Esprit shall keep and shall
require its Affiliates to keep complete and accurate records in connection with the purchase, use
and/or sale by or for it of the Products hereunder in sufficient detail to permit accurate
determination of all amounts necessary for calculation and verification of all payment obligations
set forth in this Article&nbsp;6.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Without limiting any Party&#146;s remedies hereunder, in the event payments required to be made
under this Section&nbsp;6.4 are not made on or prior to the required payment date, the amount of the
late payment shall bear interest at the Prime Rate commencing on the date such payment is due until
such date as the payment is made. &#147;<B>Prime Rate</B>&#148; shall mean the prime rate of Citibank, N.A. in New
York, New York as published in the Wall Street Journal computed on a daily basis and shall change
when and as the Prime Rate changes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>A Party required to make a payment to the other Party under this Agreement shall be
entitled to deduct and withhold from the amount otherwise payable such amounts to the extent it is
required to deduct and withhold with respect to such payment under any provision of federal, state,
local or foreign tax Law. Such withheld amounts shall be treated for all purposes of this
Agreement as having been paid to the Party on whose behalf it was withheld. No deduction shall be
made to the extent the paying Party is timely furnished with necessary documents certifying that
the payment is exempt from tax or subject to a reduced tax rate.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>Except as otherwise defined herein, all financial calculations by either Party under this
Agreement shall be calculated in accordance with GAAP. All payments due by one Party to the other
Party under this Agreement shall be payable in United States dollars. In addition, all calculations
herein shall give pro-rata effect to and shall proportionally adjust (by giving effect to the
number of applicable days in such Calendar Quarter) for any Calendar Quarter that is shorter than a
standard Calendar Quarter or any Calendar Year (or twelve month period) that is shorter than four
consecutive full Calendar Quarters or twelve consecutive months, as applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.5 Audits.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Independent Audit</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>Upon the written request of Indevus, but in no event more than once in any twelve (12)
month period, Esprit shall permit an independent certified public accounting firm of recognized
standing, selected by Indevus and reasonably acceptable to Esprit, to have access during normal
business hours to such of the records of Esprit as may be reasonably necessary to verify the
accuracy of the reports under Section&nbsp;6.4 for any year ending not more than &#091;...***...&#093;
months prior to the date of such request. The accounting firm shall disclose to Indevus whether
the reports are correct or incorrect, the specific details concerning any discrepancies (including
the accuracy of the calculation of Net Sales, and the resulting effect of such calculations on the
amounts payable by Esprit under this Agreement) and such other information that should properly be
contained in a report required under this Agreement. Esprit shall have reciprocal audit rights for
reports to be provided by Indevus under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;Dispute. </B>If there is a dispute between the Parties following any audit performed
pursuant to Section&nbsp;6.5(a)(i), either Party may refer the issue (an &#147;<B>Audit
Disagreement</B>&#148;) to a second independent certified public accounting firm of recognized standing
for resolution. In the event an Audit Disagreement is submitted for resolution by either Party,
the Parties shall comply with the following procedures:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;The Party submitting the Audit Disagreement for resolution shall provide written notice to
the other Party that it is invoking the procedures of this Section&nbsp;6.5(a)(ii).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;Within five (5)&nbsp;Business Days of the giving of such notice, the Parties shall jointly
select a recognized national accounting firm to act as an independent expert to resolve such Audit
Disagreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)&nbsp;The Audit Disagreement submitted for resolution shall be described by the Parties to such
independent expert, which description may be in written form, within ten (10)&nbsp;Business Days of the
selection of such independent expert.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)&nbsp;Such independent expert shall render a decision on the matter as soon as practicable.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(E)&nbsp;The decision of such independent expert shall be final and binding and shall not be
subject to Section&nbsp;15.6 unless such Audit Disagreement involves alleged fraud, breach of this
Agreement, or construction or interpretation of any of the terms and conditions hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>If, pursuant to Section&nbsp;6.5(a)(i) or 6.5(a)(ii), as applicable, an accounting firm
concludes that additional amounts were owed during a year, the audited Party shall pay the
additional payments, together with interest at the Prime Rate on the amount of such additional
payments, within ten (10)&nbsp;days of the date the auditing Party delivers to the audited Party such
accounting firm&#146;s written report so concluding. In the event such accounting firm concludes that
amounts were overpaid by the audited Party during such period, the auditing Party shall repay the
audited Party the amount of such overpayment, together with interest at the Prime Rate on the
amount of such overpayment, within ten (10)&nbsp;days after the date the auditing Party delivers to the
audited Party such accounting firm&#146;s written report so concluding. The fees charged by such
accounting firm shall be paid by the auditing Party; <U>provided</U>, <U>however</U>, that, if an
error in favor of the auditing Party of more than five percent (5%) of the payments due hereunder
for the period being reviewed is discovered, then the fees and expenses of the accounting firm
shall be paid by the audited Party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Upon the expiration of &#091;...***...&#093; months following the end of any year for
which Esprit has made payment in full of amounts payable with respect to such year, and in the
absence of negligence or willful misconduct of Esprit or a contrary finding by an accounting firm
pursuant to Section&nbsp;6.5(a)(i) or 6.5(a)(ii), as applicable, such calculation shall be binding and
conclusive upon Esprit, and Esprit shall be released from any liability or accountability with
respect to royalties or other payments for such year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Each Party shall treat all financial information subject to review under this Section&nbsp;6.5
in accordance with the confidentiality provisions of Article&nbsp;11, subject to its existing agreements
with Third Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.6 License to Dominating Patent.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>If Esprit would be prevented from making, using, selling, offering for sale or importing
Products in the Field in the Territory on the grounds that by doing so Esprit would infringe a
Dominating Patent, Indevus shall use commercially reasonable efforts to procure a license to such
Dominating Patent for the benefit of Esprit. If Indevus does not procure such a license for the
benefit of Esprit, Esprit may attempt to procure a license. If Esprit procures such a license,
then Indevus shall promptly reimburse Esprit for the cost, if any, of procuring such Dominating
Patent. To the extent that Indevus has failed to so reimburse Esprit, Esprit shall have the right
to offset the amount of such costs against payments payable by Esprit to Indevus under this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>For purposes of this Section&nbsp;6.6, a &#147;<B>Dominating Patent</B>&#148; means an unexpired United States
patent that (i)&nbsp;is owned by a Third Party, (ii)&nbsp;has not been invalidated by a court or other
governmental agency of competent jurisdiction and (iii) (A)&nbsp;the CEOs of the
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document.
This copy of the document filed as an Exhibit omits the confidential information subject to
the confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this
document has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Parties reasonably
determine is required to be licensed in order for Esprit to make, use, import, offer for sale or
sell Products in the Field in the Territory without infringing such patent or (B)&nbsp;has been
determined by a court of competent jurisdiction to be infringed by the manufacture, use, sale,
offer for sale or importation of Trospium Once-Daily in the Territory.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Representations and Warranties</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.1 General Representations. </B>Each Party hereby represents and warrants to the other Party, as of the Execution Date and
the Effective Date, as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Such Party is a corporation duly organized, validly existing and is in good standing under
the laws of the jurisdiction of its incorporation, is qualified to do business and is in good
standing as a foreign corporation in each jurisdiction in which the conduct of its business or the
ownership of its properties requires such qualification and failure to have such would prevent it
from performing its obligations under this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>The execution, delivery and performance by such Party of this Agreement have been duly
authorized by all necessary corporate action and do not and will not (i)&nbsp;violate any provision of
any law, rule, regulation, order, writ, judgment, injunction, decree, determination or award
presently in effect having applicability to it or any provision of its charter or bylaws; or (ii)
conflict with or constitute a default under any other agreement to which such Party is a party;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>This Agreement has been duly executed and is a legal, valid and binding obligation of such
Party, enforceable against it in accordance with the terms and conditions hereof, except as
enforceability may be limited by (i)&nbsp;any applicable bankruptcy, insolvency, reorganization,
moratorium or similar law affecting creditor&#146;s rights generally, or (ii)&nbsp;general principles of
equity, whether considered in a proceeding in equity or at law;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Such Party is not under any obligation to any person or entity, contractual or otherwise,
that is in conflict with the terms of this Agreement, nor will such Party undertake any such
obligation during the Agreement Term;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>Such Party has obtained all authorizations, consents and approvals, governmental or
otherwise, necessary for the execution and delivery of this Agreement, and to otherwise perform
such Party&#146;s obligations under this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>Except (i)&nbsp;with respect to Indevus, for any rights of Madaus under the Madaus License (ii)
with respect to Indevus, for any rights of Supernus under the Supernus Agreement, (iii)&nbsp;with
respect to Esprit, for any rights of Allergan, Inc., neither Party, nor any of its Affiliates, are
a party to, or are otherwise bound by, any oral or written contract that will result in any Third
Party obtaining any interest in, or that would give to any Third Party any right to assert any
claim in or with respect to, any of such Party&#146;s or the other Party&#146;s rights under this Agreement;
and
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g)&nbsp;</B>Such Party shall perform its obligations hereunder in accordance with all Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.2 Additional Representations and Warranties of Indevus. </B>Indevus represents and warrants to Esprit that as of the Execution Date and the Effective
Date:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Indevus has no reason to believe that any of the Indevus Patent Rights are, or are likely
to be held, invalid; the Indevus Patent Rights are in full force and not subject to any pending or
threatened re-examination, opposition, interference or litigation proceedings;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Except for any rights of Madaus under the Madaus License and Supernus under the Supernus
Agreement, in the Territory, (i)&nbsp;Indevus is the sole and exclusive owner of or exclusively Controls
the Indevus Intellectual Property in the Field in the Territory; and (ii)&nbsp;the Indevus Intellectual
Property is not subject to any encumbrance, lien or claim of ownership by any Third Party in the
Field in the Territory;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>At no time during the Agreement Term shall Indevus assign, transfer, encumber or grant
rights in or with respect to the Indevus Intellectual Property inconsistent with the rights or
security interest granted to Esprit under this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>At no time after the Execution Date and/or during the Agreement Term shall Indevus enter
into any agreement, or any amendment of an agreement to which Indevus is a party as of the
Execution Date (including any agreement with Madaus, Supernus, Catalent or Helsinn) with a Third
Party relating to the Product in the Field in the Territory if such agreement or amendment could
reasonably be expected to adversely affect Esprit&#146;s rights hereunder, without the prior written
consent of Esprit;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>The Data provided in writing to Esprit or its Affiliates relating to Trospium Once-Daily
and Trospium Twice-Daily has been accurate in all material respects and Indevus has made no
material misrepresentation or material omission in connection with such Data. Indevus has also
provided Esprit or its Affiliates with access to summaries of all material adverse events known to
it relating to the Compound;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>To Indevus&#146; knowledge, the manufacture, use importation and/or sale of Trospium Once-Daily
or Trospium Twice-Daily in the Territory as contemplated under this Agreement does not infringe or
misappropriate any patents or other intellectual property right of any Third Party that are not
Controlled by Indevus;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g)&nbsp;</B>All Products manufactured by Indevus, or manufactured by a Third Party on behalf of
Indevus, and delivered to Esprit under this Agreement shall be manufactured in compliance with cGMP
and all other Laws;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(h)&nbsp;</B>Indevus, or its Third Party designee, shall supply adequate commercial quantities of
Finished Product and/or Samples pursuant to and subject to the terms and conditions of this
Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>Each of the Madaus Agreements and the Supernus Agreement is in full force and effect in
accordance with its terms. Indevus is not in default or breach in any material respect of the
Madaus Agreements or the Supernus Agreement, nor has it received any notice of any defaults,
breaches or violation thereunder. To Indevus&#146; knowledge, no other party to the Madaus Agreements
or the Supernus Agreement is in default or breach of such agreement. Indevus has provided Esprit
with copies of the Madaus Agreements and the Supernus Agreement that are true, correct and complete
as of the Execution Date;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(j)&nbsp;</B>Indevus is the owner of record of the Product NDAs and has the exclusive right to grant
licenses with respect to, and transfer ownership of, the Product NDAs in the Territory subject to
acceptance by Esprit, and Indevus shall not transfer ownership of or rights in or to any Product
NDA owned by Indevus as of the Execution Date to any Third Party;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(k)&nbsp;</B>No claim or demand has been asserted in writing against Indevus alleging trademark
infringement resulting from the use and/or registration of the SANCTURA Trademark;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(l)&nbsp;</B>To Indevus&#146; knowledge, (i)&nbsp;under 21 CFR 314.108(b)(2), Indevus, as the holder of the NDA
for Trospium Twice-Daily, is entitled to marketing exclusivity until
May&nbsp;28, 2009, during which time the FDA may not accept any Third Party&#146;s application to market
a drug containing the same active chemical moiety as Trospium Twice -Daily for review, except as
set forth in 21 CFR 314.108(b)(2); and (ii)&nbsp;under 21 CFR 314.108(b)(4), Indevus, as the holder of
the NDA for Trospium-Once Daily, is entitled to marketing exclusivity until August&nbsp;3, 2010 during
which time the FDA may not make effective a Third Party&#146;s application under Section&nbsp;505(b)(2) of
the Act or abbreviated new drug application under Section&nbsp;505 (j)&nbsp;of the Act as set forth in 21 CFR
314.108(b)(4); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(m)&nbsp;</B>No effective financing statement naming Indevus as &#147;debtor&#148; or other instrument similar in
effect covering all or any part of the Collateral is on file or recorded in any filing or recording
office in the United States in favor of any Person other than Esprit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.3 Additional Representations and Warranties of Esprit. </B>Esprit represents and warrants to Indevus that as of the Execution Date and the Effective
Date:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>To the knowledge of Esprit, the Trademarks are not subject to any encumbrance, lien or
claim of ownership by any Third Party, and no claim or demand has been asserted in writing against
Esprit or any of its Affiliates alleging trademark infringement resulting from the use and/or
registration of the SANCTURA Trademark; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Esprit has utilized its own scientific, marketing and distribution expertise and
experience to analyze and evaluate both the scientific and commercial value of the Products in the
Field in the Territory and has solely relied on such analysis and evaluation in deciding to enter
into this Agreement.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.4 Disclaimer of Additional Warranties. </B>EACH PARTY HEREBY EXPRESSLY DISCLAIMS ANY OTHER WARRANTIES OR CONDITIONS, EXPRESS, IMPLIED,
STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING ANY IMPLIED
WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE, EVEN IF EITHER
PARTY HAS BEEN ADVISED OF SUCH PURPOSE.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.5 Limitation of Liability. </B>EXCEPT FOR A BREACH OF ARTICLE 11 OR FOR CLAIMS OF A THIRD PARTY WHICH ARE SUBJECT TO
INDEMNIFICATION UNDER ARTICLE 13, NEITHER PARTY SHALL BE LIABLE TO THE OTHER WITH RESPECT TO ANY
SUBJECT MATTER OF THIS AGREEMENT, WHETHER UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER
LEGAL OR EQUITABLE THEORY, FOR ANY INCIDENTAL, INDIRECT, SPECIAL, EXEMPLARY, PUNITIVE, MULTIPLE, OR
CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS, LOSS OF USE, DAMAGE TO GOODWILL, OR LOSS OF
BUSINESS).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Patent Matters</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.1 Ownership. </B>The provisions of this Section&nbsp;8.1 are qualified by and subject to the provisions of
Section&nbsp;5.6. As between the Parties, Indevus shall have and retain all right, title and interest
in or Control over, as applicable, all Indevus Patent Rights, inventions, discoveries, and Indevus
Know-How concerning Products in the Field, including formulations thereof, or methods of making or
using same which have been made, conceived, reduced to practice or generated by its employees,
agents, or other persons acting under its authority prior to the Effective Date. As between the
Parties, during the Agreement Term, except as otherwise provided in and subject to the terms of
this Agreement, (a)&nbsp;Indevus shall have and retain all rights, title and interest in all inventions,
discoveries and know-how relating to Products, including formulations thereof, or methods of making
or using same, or Improvements thereof, that are made, conceived, reduced to practice or generated,
solely by Indevus&#146; employees, agents, or other persons acting under its authority (&#147;<B>Indevus
Inventions</B>&#148;); (b)&nbsp;Esprit shall have and retain all rights, title and interest in all inventions,
discoveries and know-how relating to Products, including formulations thereof, or methods of making
or using same, or Improvements thereof, that are made, conceived, reduced to practice or generated,
singly by Esprit&#146;s employees, agents, or other persons acting under its authority (&#147;<B>Esprit
Inventions</B>&#148;); and (c)&nbsp;the Parties shall jointly own all right, title and interest in its interest
in all inventions, discoveries and know-how relating to Products, including formulations thereof,
or methods of making or using same, or Improvements thereof, that are made, conceived, reduced to
practice or generated jointly by Indevus&#146; employees, agents, or other persons acting under Indevus&#146;
authority and Esprit&#146;s employees, agents, or other persons acting under Esprit&#146;s authority (&#147;<B>Joint
Inventions</B>&#148;), subject to the license granted to Esprit in the Field under this Agreement. Indevus
shall notify Esprit promptly of any Indevus Inventions, and Esprit shall notify Indevus promptly of
any Esprit Inventions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.2 Maintenance and Prosecution. </B>Indevus shall have the first right to file, prosecute and maintain the Indevus Patent
Rights and any patent application(s) or patent(s)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->54<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">arising from Joint Inventions in Indevus&#146; name,
using patent counsel selected by Indevus and shall be responsible for the payment of all patent
prosecution and maintenance costs. Indevus agrees to keep Esprit informed of the course of patent
prosecution or other proceedings, including by providing Esprit with copies of office actions and
communications received by Indevus from, and communications sent by Indevus to, the United States
Patent and Trademark Office and foreign patent offices concerning such Patent Rights. Indevus
shall solicit Esprit&#146;s review of the nature and text of such patent applications and important
prosecution matters related thereto in reasonably sufficient time prior to filing thereof, and
Indevus shall take into account Esprit&#146;s reasonable comments related thereto. Upon Indevus&#146;
request, Esprit shall reasonably cooperate in the filing, prosecution or maintenance of any such
patent application or patent. If Indevus elects not to file, prosecute or maintain a patent
application or patent included in such Patent Rights in the Territory, it shall provide Esprit with
no less than forty-five (45)&nbsp;days&#146; written advance notice sufficient to avoid any loss or
forfeiture, and Esprit shall have the right, but not the obligation, at its sole expense, to file,
prosecute or
maintain such patent application or patent as owner thereof. Esprit shall have the sole right
to file, prosecute and maintain any patent application(s) or patent(s) arising from the Esprit
Inventions, at its sole expense.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.3 Third Party Infringement.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Each Party shall promptly give the other Party notice of any actual or suspected
infringement in the Territory of any patent included in the Indevus Patent Rights and the Parties&#146;
interests in Joint Inventions (collectively, the &#147;<B>Parties&#146; Patent Rights</B>&#148;), which comes to such
Party&#146;s attention. The Parties will thereafter consult and cooperate to determine a course of
action, including the commencement of legal action by any Party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Esprit shall have the first right to initiate and prosecute such legal action at its own
expense and in the name of Indevus and/or Esprit, or to control the defense of any declaratory
judgment action relating to the Parties&#146; Patent Rights in the Territory. Indevus shall render, at
its expense, all assistance reasonably requested in connection with any action taken by Esprit or
to prevent such infringement. However, the control of such action, including whether to initiate
any legal proceeding and/or the settlement thereof, shall solely be under the control of Esprit;
<U>provided</U> that Esprit shall not, settle any such claim or proceeding in a manner that
materially adversely affects Indevus&#146; rights under this Agreement or which results in any material
monetary payment by or financial loss to Indevus, without Indevus&#146; written consent, which consent
shall not be unreasonably withheld.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>If Esprit elects not to initiate and prosecute an infringement or defend a declaratory
judgment action in any country in the Territory as provided in Section&nbsp;8.3(b) and Indevus elects to
do so, the cost of any agreed-upon course of action, including the costs of any legal action
commenced or any declaratory judgment action defended, shall be borne solely by Indevus and any
award of any damages shall be solely retained by Indevus, <U>provided</U>, <U>however</U>, that
Indevus shall not enter into any settlement or compromise of any claim relating to the Parties&#146;
Patent Rights licensed hereunder without the prior written consent of Esprit, which consent shall
not be unreasonably withheld.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->55<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>For any such legal action or defense, in the event that any Party is unable to initiate,
prosecute, or defend such action solely in its own name, the other Party will join such action
voluntarily and will execute all documents necessary for the Party to prosecute, defend and
maintain such action. In connection with any such action, the Parties will cooperate fully and
will provide each other with any information or assistance that either reasonably may request. Any
recovery or award obtained by either Party as a result of any such action or settlement shall be
shared as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>the Party that initiated and prosecuted, or maintained the defense of, the action shall
recoup all of its costs and expenses (including reasonable attorneys&#146; fees) incurred in connection
with the action, whether the recovery is by settlement or otherwise;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>the other Party then shall, to the extent possible, recover its reasonably documented
costs and expenses (including reasonable outside attorneys&#146; fees) incurred in connection with the
action;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>if Indevus initiated and prosecuted, or maintained the defense of, the action, the
amount of any recovery remaining then shall be retained by Indevus; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>if Esprit initiated and prosecuted, or maintained the defense of, the action, the amount
of any recovery remaining shall be retained by Esprit, except that Indevus shall receive a portion
equivalent to the amount it would have received in accordance with the terms of this Agreement if
such amount were deemed Net Sales of Esprit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.4 Third Party Intellectual Property.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>In the event that a Party becomes aware of any claim that the manufacture, import, use,
offer for sale, or sale of a Product hereunder infringes the intellectual property rights of any
Third Party in the Territory, such Party shall promptly notify the other Party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Esprit shall have the first right, but not the obligation, to defend any action in the
Territory related to the intellectual property rights of any Third Party or to initiate and
prosecute legal action related to the intellectual property rights of any Third Party at its own
expense and in the name of Indevus and/or Esprit. Indevus shall render, at its expense, all
assistance reasonably requested in connection with any action taken by Esprit. However, the
control of such action, including whether to initiate any legal proceeding and/or the settlement
thereof, shall solely be under the control of Esprit; <U>provided</U> that Esprit shall not settle
any such claim or proceeding in a manner that materially adversely affects Indevus&#146; rights under
this Agreement or that results in any material monetary payment by or financial loss to Indevus,
without Indevus&#146; written consent, which consent shall not be unreasonably withheld.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>If Esprit elects not to defend an infringement action in any country in the Territory as
provided in Section&nbsp;8.4(b), and Indevus elects to do so, the cost of any agreed-
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->56<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">upon course of
action, including the costs of any legal action commenced or any infringement action defended,
shall be borne solely by Indevus; <U>provided</U> that Indevus shall not enter into any settlement
or compromise of any claim without the prior written consent of Esprit, which consent shall not be
unreasonably withheld.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>For any such legal action or defense, in the event that any Party is unable to initiate,
prosecute, or defend such action solely in its own name, the other Party will join such action
voluntarily and will execute all documents necessary for the Party to prosecute, defend and
maintain such action. In connection with any such action, the Parties will cooperate
fully and will provide each other with any information or assistance that either reasonably
may request.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.5 Patent Term Extensions. </B>The Parties shall cooperate with each other in obtaining patent term extensions or
restorations or supplemental protection certificates or their equivalents in any country in the
Territory where applicable and where desired by either Party. Any expenses incurred by the Parties
in connection with the foregoing shall be (a)&nbsp;shared equally if both Parties agree to pursue such
patent term extension or restoration or supplemental protection certificates or their equivalents
or (b)&nbsp;borne by Esprit if Indevus does not agree that the Parties should pursue such patent term
extension or restoration or supplemental protection certificates or their equivalents. If
elections with respect to obtaining such extension or supplemental protection certificates are to
be made, Indevus shall have the right but not the obligation to make the election. If Indevus
chooses in its sole discretion not to pursue such patent term extension, then at Esprit&#146;s request
Indevus, shall authorize Esprit to act as Indevus&#146; agent for the purpose of making any application
for any extensions of the term of any such Indevus Patent Rights in the Territory and Indevus shall
provide all reasonable assistance therefore to Esprit at Esprit&#146;s expense.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.6 Conflict with Certain Existing Agreements. </B>To the extent that Indevus is not authorized under either the Madaus License or the
Supernus Agreement, to grant Esprit any of the rights set forth in this Article&nbsp;8 with respect to
the filing, prosecution, maintenance and/or enforcement of any of the Indevus Patent Rights,
Esprit&#146;s rights under this Article&nbsp;8 shall be limited to those which are permitted under such
agreements in a manner to effectuate, to the greatest extent, the intent and purposes of this
Article&nbsp;8.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Trademark Matters</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.1 General. </B>It is the intent of the Parties to use the Trademarks on and in connection with the
marketing, sale, advertising and/or Promotion of Products in the Field in the Territory. The
Parties acknowledge and agree that pursuant to the Original Agreement, Indevus assigned to Esprit
its right, title and interest in the Territory to the Trademarks. Accordingly, as of the Effective
Date, Esprit holds all right, title and interest in and to such Trademarks in the Territory,
subject to the rights retained by or granted to Indevus herein. Esprit or its Affiliates consent
to the use by Indevus or its Affiliates of the Trademarks in connection with the performance of
Indevus&#146; or its Affiliate&#146;s obligations and in connection with the programs and materials developed
by Indevus pursuant to this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->57<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.2 Maintenance. </B>Esprit, at is sole discretion, shall use commercially reasonable efforts to maintain all
registrations of the Trademarks in the Territory. If necessary to permit Indevus to use the
Trademarks as contemplated hereunder, Esprit shall make application to register Indevus as a
permitted user or registered user of the Trademarks.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.3 Use of Trademark. </B>All packaging materials, package inserts, labels, labeling, and marketing, sales,
advertising and Promotional Materials relating to Products in the Field and distributed in the
Territory shall properly display the Trademark notice in the form and style and with a placement
determined by Esprit. Indevus shall not use any trademark that has not been approved by Esprit in
connection with Promotional activities conducted under this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.4 Enforcement. </B>Esprit and Indevus shall cooperate with each other and use commercially reasonable efforts
to protect the Trademarks from infringement by Third Parties. Without limiting the foregoing, each
Party shall promptly notify the other Party of any known, threatened or suspected infringement,
imitation or unauthorized use of or unfair competition relating to the Trademarks. Esprit shall
have the first right to determine in its discretion whether to and to what extent to institute,
prosecute and/or defend any action or proceedings involving or affecting any rights relating to the
Trademarks in the Territory. Upon Esprit&#146;s reasonable request, Indevus shall cooperate with and
assist Esprit in any of Esprit&#146;s enforcement efforts with respect to the Trademarks in the
Territory. If Esprit determines not to take action against any actual or suspected infringement of
the Trademark in the Territory within sixty (60)&nbsp;days after having become aware of such
infringement, then Indevus shall have the right, but not the obligation, to bring or assume control
of any action against the allegedly infringing Third Party as Indevus determines may be necessary
in its sole discretion. In the event that Indevus brings or assumes control of any such action,
then Esprit agrees to reasonably assist Indevus in connection therewith. The Parties shall share
equally in all costs and expenses reasonably incurred by either of them in connection with any such
action, and, following each Party&#146;s recovery of its respective costs and expenses, the Parties will
share equally in all money damages, if any, recovered in connection with such action.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.5 Avoidance of Confusion. </B>Neither Indevus nor Esprit, nor any of their Affiliates, shall market, promote, sell and/or
distribute in the Territory, or authorize or permit another to market, promote, sell and/or
distribute in the Territory, any product other than a Product in the Field under the Trademarks or
any confusingly similar trademark. Indevus and its Affiliates shall not, directly or indirectly,
contest the validity of or Esprit&#146;s rights in the Trademarks in the Territory or assist any Third
Party in doing so. In the event that actual confusion should arise, or either Party reasonably
believes that a likelihood of confusion may arise, in connection with the Parties&#146; respective uses
of the Trademarks in the Territory, the Parties will fully cooperate in an effort to eliminate such
confusion and to avoid the possibility of such a likelihood of confusion.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.6 Trademark Security Interest. </B>In the event at any time during the Agreement Term, Esprit intends to grant to any Third
Party any security interest in, or create any other lien or encumbrance on any of the Trademarks,
Esprit shall, prior to taking any such action,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->58<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">in order to secure the payment and performance of
Esprit&#146;s obligations hereunder and under the Agreement, grant to Indevus a security interest in and
to all of Esprit&#146;s right, title and interest in the Trademarks (the &#147;<B>Trademark Security Interest</B>&#148;).
Esprit will execute, deliver, file and record any statement, instrument, agreement or other
document and take any other action (including, without limitation, any filings with the United
States Patent and Trademark Office and any filings of financing or continuation statements under
the Uniform Commercial Code) in order to create, preserve, upgrade in rank, perfect, confirm or
validate the Trademark Security Interest or enable Indevus to obtain the full benefits of the
Trademark Security Interest.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Adverse Experiences </B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.1 </B>The Development Committee shall establish operating procedures to report Adverse
Experiences to the FDA in accordance with Laws; <U>provided</U> that, subject to Section&nbsp;4.2(a),
prior to the NDA Transfer Date, Indevus shall be responsible for the timely filing with the FDA of
all Adverse Experience reports in the United States and after the NDA Transfer Date, Esprit shall
be responsible for the timely filing with the FDA of all Adverse Experience reports in the United
States. Such operating procedures shall provide for the exchange of safety information between the
Parties sufficient to enable each Party to comply with its legal obligations to report to the FDA,
include any measures necessary for each Party to comply with Laws applicable to such Party. Each
Party shall promptly provide the other Party with copies of all such reports, analyses, summaries
and all submissions to the FDA or any other governmental agency. The Adverse Experience procedures
utilized in the preparation and filing of such reports will incorporate the provisions set forth in
Section&nbsp;10.2. The Parties agree to implement, or update any pharmacovigilance agreement in effect
as of the Effective Date between the Parties, as applicable, concerning responsibilities and case
exchange. The agreed procedures will be reviewed jointly on a regular basis or when there is a
change in regulations governing Adverse Experience reporting.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.2 </B>Esprit&#146;s central safety department has established and shall continue to maintain a
toll-free phone number for patients, physicians and others to report Adverse Experiences. The
costs of such reporting and of all services provided by any Third Party contractor in connection
with Adverse Experiences hereunder shall be borne by Esprit. As of the Effective Date, the Parties
anticipate that Esprit or a Third Party contractor will timely collect reasonable information about
the Adverse Experiences, initiate and conduct reasonably required investigations, interact with
Indevus if physical or other testing of a Product appears to be reasonably required, determine the
nature of the Adverse Experience based on data and reports it has obtained, and issue any reports,
analyses or summaries of its activities as may be required by Law, including, prior to the NDA
Transfer Date, providing to Indevus on a timely basis such reports, which, in form and substance,
are necessary and appropriate for Indevus to file such periodic reports on a timely basis with the
FDA. Copies of all such reports, including reports filed by Indevus with the FDA, will be promptly
provided to Esprit.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.3 </B>All safety related reports and correspondence shall be addressed to, for Esprit, Sharon
Tonetta; or to such other safety representative as may be designated by Esprit., and for Indevus:
Senior Vice President, Clinical Development and Medical Affairs, Indevus
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->59<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pharmaceuticals, Inc., 33
Hayden Avenue, Lexington, MA 02421 (facsimile number 781-863-2564; telephone number 781-402-3444),
or such other safety representative as may be designated by Esprit for Esprit or by Indevus for
Indevus.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.4 </B>Notwithstanding anything in this Article&nbsp;10 to the contrary, prior to the NDA Transfer
Date, Indevus shall have the right, at its own cost and expense, to conduct any investigations
required under Law(s), and, subject to Section&nbsp;4.2, to communicate with the FDA regarding the
results of those investigations, regarding Products and Product quality; <U>provided</U>,
<U>however</U>, that upon Indevus&#146; request, Esprit shall provide reasonable assistance and
cooperation in connection with any such investigations at Indevus&#146; cost and expense.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Confidentiality and Publicity</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.1 Non-Disclosure and Non-Use Obligations. </B>All Proprietary Information disclosed by one Party to the other Party hereunder shall be
maintained in confidence and shall not be disclosed to any Third Party or used for any purpose
except as expressly permitted herein without the prior written consent of the Party that disclosed
the Proprietary Information to the other Party during the Agreement Term and for a period of seven
(7)&nbsp;years thereafter. The foregoing non-disclosure and non-use obligations shall not apply to the
extent that such Proprietary Information:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>is known by the receiving Party at the time of its receipt, and not through a prior
disclosure by the disclosing Party, as documented by business records;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>is or becomes properly in the public domain or knowledge without breach by either Party;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>is subsequently disclosed to a receiving Party by a Third Party who, to the knowledge of
the receiving Party, is lawfully able do so and, to the knowledge of the receiving Party, is not
under an obligation of confidentiality to the disclosing Party; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>is developed by the receiving Party independently of Proprietary Information received from
the other Party, as documented by research and development records.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.2 Permitted Disclosure of Proprietary Information. </B>Notwithstanding Section&nbsp;11.1, a Party receiving Proprietary Information of another Party
may disclose such Proprietary Information:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>to governmental or other regulatory agencies in order to obtain Patent Rights pursuant to
this Agreement, or to gain approval to conduct clinical trials or to market Products, but such
disclosure may be made only to the extent reasonably necessary to
obtain such Patent Rights or authorizations and in accordance with the terms of this Agreement
or as otherwise requested by the FDA;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>in connection with the performance of this Agreement and solely on a need-to-know basis,
to Affiliates; potential or actual collaborators (including potential
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->60<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">sublicensees); potential or
actual investment bankers, accountants, investors, lenders, or acquirers; or employees, independent
contractors (including consultants and clinical investigators) or agents, each of whom prior to
disclosure must be bound by written obligations of confidentiality and non-use no less restrictive
than the obligations set forth in this Article&nbsp;11 or to counsel for such Party; <U>provided</U>,
<U>however</U>, that the receiving Party shall (i)&nbsp;undertake reasonable precautions to safeguard
and protect the confidentiality of the Proprietary Information; (ii)&nbsp;remain responsible for any
failure by any Person who receives Proprietary Information pursuant to this Article&nbsp;11 to treat
such Proprietary Information as required under this Article&nbsp;11; and (iii)&nbsp;take all reasonable
measures to restrain the receiving Party and any such Persons from prohibited or unauthorized
disclosure or use in violation of this Article&nbsp;11; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>if required to be disclosed by Law or court order, provided that notice is promptly
delivered to the non-disclosing Party in order to provide an opportunity to challenge or limit the
disclosure obligations.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If and whenever any Proprietary Information is disclosed in accordance with this Section&nbsp;11.2, such
disclosure shall not cause any such information to cease to be Proprietary Information except to
the extent that such disclosure results in a public disclosure of such information (other than in
breach of this Agreement). Where reasonably possible and subject to Section&nbsp;11.3, the receiving
Party shall notify the disclosing Party of the receiving Party&#146;s intent to make such disclosure
pursuant to Sections&nbsp;11.2(a)&#150;(c) sufficiently prior to making such disclosure so as to allow the
disclosing Party adequate time to take whatever action it may deem appropriate to protect the
confidentiality of the information, and the receiving Party shall cooperate with the disclosing
Party in such efforts.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.3 Disclosure of Agreement to Governmental Authority. </B>Without limiting any of the foregoing, it is understood that the Parties or their
Affiliates may make disclosure of this Agreement and the terms hereof in any filings required by
the United States Securities and Exchange Commission and any successor agency having substantially
the same functions (the &#147;<B>SEC</B>&#148;), other governmental authority or securities exchange, may file this
Agreement as an exhibit to any filing with the SEC, other governmental authority or securities
exchange, and may distribute any such filing in the ordinary course of its business;
<U>provided</U>, that, to the maximum extent allowable by the rules and regulations of the SEC,
other governmental authority, or securities exchange, and except as required by Laws, Indevus and
Esprit shall seek to redact any confidential information set forth in such filings, and each Party
shall provide a draft of the redacted version of this Agreement to the other Party no less than
five (5)&nbsp;Business Days prior to filing with the SEC, other governmental authority, or securities
exchange, and give reasonable consideration to the other Party&#146;s comments regarding any proposed
redaction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.4 Publications. </B>Indevus and Esprit each acknowledge the other Party&#146;s interest in publishing its results
related to Products in the Field to obtain recognition within the scientific community and to
advance the state of scientific knowledge. Each Party also recognizes the mutual interest in
obtaining valid patent protection and in protecting business interests and trade secret
information. Accordingly, prior to the NDA Transfer Date, neither Party shall submit for written
or oral publication any manuscript, abstract or the like relating to
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->61<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Products in the Field without
the prior review by the other Party. Any Party proposing to submit such publication shall deliver
the proposed publication or an outline of the oral disclosure at least ten (10)&nbsp;Business Days prior
to planned submission or presentation (twenty-four (24)&nbsp;hours for a meeting abstract). At the
reasonable request of the other Party, the submission of such publication may be delayed such that
any issues of patent protection may be addressed. In the absence of any such request, upon
expiration of the applicable period referred to in this Section&nbsp;11.4 the publishing Party shall be
free to proceed with the publication or presentation. If the other Party requests modifications to
the publication to prevent disclosure of trade secret or proprietary business information prior to
submission of the publication or presentation, the publishing Party shall so edit such publication.
The contribution of each Party, if any, shall be noted in all publications or presentations by
acknowledgment or co-authorship, whichever is appropriate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.5 Other Public Statements.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Esprit and Indevus shall each ensure that no claims or representations in respect of
Products in the Field or the characteristics thereof are made by or on behalf of itself (by members
of its respective Sales Force or otherwise) that have not been approved by the Development
Committee or the Marketing Committee, or that are not consistent with the Promotion Plan and with
Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Except as set forth in this Agreement or as required by Law, neither Party shall make any
press release or other public announcement or other disclosure to a Third Party concerning the
existence of or terms of this Agreement or relating to Products in the Field without the prior
written consent of the other Party, which consent shall include agreement upon the nature and text
of such announcement or disclosure and shall not be unreasonably withheld. Each Party agrees to
provide to the other Party a copy of any public announcement as soon as reasonably practicable
under the circumstances prior to its scheduled release. Each Party shall have the right to
expeditiously (but in any event within forty-eight (48)&nbsp;hours of receipt) review and recommend
changes to any press release or announcement regarding this Agreement or the subject matter of this
Agreement; <U>provided</U>, <U>however</U> that such right of review and recommendation shall
only apply for the first time that specific information is to be disclosed, and shall not apply to
the subsequent disclosure of substantially similar information that has previously been disclosed
unless there have been material developments relating to Products since the date of the previous
disclosure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>12.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Term and Termination</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>12.1 Term and Expiration. </B>Except for provisions expressly provided in Article&nbsp;14 to be effective as of the Execution
Date, this Agreement shall be effective as of the Effective Date and, unless terminated earlier
pursuant to Section&nbsp;12.2, shall extend for a period that shall expire on the later of (a)&nbsp;the
twelfth (12th) anniversary of the launch date of Trospium Once-Daily in the Territory or (b)&nbsp;the
expiration of the last to expire patent included in the Indevus Patent Rights covering Trospium
Once-Daily in the Territory (the &#147;<B>Agreement Term</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->62<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>12.2 Early Termination.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Either Party may, without prejudice to any other remedies available to it under this
Agreement or at law or in equity, terminate this Agreement prior to expiration of the Agreement
Term in the event that the other Party (as used in this Section&nbsp;12.2(a), the &#147;<B>Breaching Party</B>&#148;) has
materially breached or defaulted in the performance of any of its material obligations hereunder,
and has not cured such breach within (i)&nbsp;thirty (30)&nbsp;days after notice of such breach is provided
by the non-breaching Party to the Breaching Party, in case such breach is a non-payment of any
amount due under this Agreement (which shall be deemed a material breach of a material obligation)
and (ii)&nbsp;sixty (60)&nbsp;days (or, if such breach cannot be cured within such sixty (60)&nbsp;day period, if
the Breaching Party does not commence and diligently continue actions to cure such breach during
such sixty (60)&nbsp;day period) after notice of such breach is provided by the non-breaching Party to
the Breaching Party for other cases of breach. The termination shall become effective at the end
of the (x)&nbsp;thirty (30)&nbsp;day period in case the breach is a non-payment of any amount due under this
Agreement if the Breaching Party has not cured such breach during such thirty (30)&nbsp;day period, or
(y)&nbsp;sixty (60)&nbsp;day period for other cases of breach unless (A)&nbsp;the Breaching Party cures such
breach during such sixty (60)&nbsp;day period, or (B)&nbsp;if such breach is not susceptible to cure within
such sixty (60)&nbsp;day period, the Breaching Party has commenced and is diligently pursuing a cure
(unless such breach, by its nature, is incurable, in which case the Agreement may not be terminated
unless the Breaching Party fails use its best commercially reasonable efforts to prevent a similar
subsequent breach). The right of either Indevus or Esprit to terminate this Agreement as provided
in this Section&nbsp;12.2 shall not be affected in any way by such Party&#146;s waiver or failure to take
action with respect to any previous breach or default.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Either Party may, without prejudice to any other remedies available to it under this
Agreement or at law or in equity, terminate this Agreement upon the filing or institution of
bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a
substantial portion of the assets for the benefit of creditors by the other Party;
<U>provided</U>, <U>however</U>, in the case of any involuntary bankruptcy, reorganization,
liquidation, receivership or assignment proceeding such right to terminate shall only become
effective if such
other Party consents to the involuntary proceeding or such proceeding is not dismissed within
ninety (90)&nbsp;days after the filing thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Notwithstanding Sections&nbsp;12.2(a) and (b), if, at any time prior to the Effective Date,
Indevus seeks to terminate the Original Agreement or this Agreement pursuant to Section&nbsp;12.2(a) or
(b), or any prior agreement between Indevus and Esprit, Indevus shall notify Allergan, in
accordance with Section&nbsp;15.4, of such situation as soon as practicable, and in any event at least
thirty (30)&nbsp;days prior to such termination, and provide Allergan or its designated Affiliate an
opportunity to (i)&nbsp;assume all rights and obligations of Esprit under this Agreement by assignment
from Esprit and/or (ii)&nbsp;enter into an agreement with Indevus that provides Allergan and Indevus
with substantially equivalent rights on substantially equivalent terms as those granted to Esprit
or Indevus, respectively, under the agreement to be so terminated.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->63<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Without prejudice to any other remedies available to it under this Agreement or at law or
in equity, <U>provided</U> that Indevus has complied in all material respects with its obligations
under this Agreement and Catalent has complied with its obligations under the Catalent Agreements,
Indevus may terminate this Agreement on thirty (30)&nbsp;days written notice to Esprit, if Esprit (i)
after having launched Trospium Once-Daily, discontinues commercial sale of Trospium Once-Daily for
a period of &#091;...***...&#093; or more for reasons unrelated to Force Majeure, regulatory or
safety issues or manufacturing or Product quality issues and subsequently fails to resume sales of
Trospium Once-Daily within thirty (30)&nbsp;days of having been notified in writing of such failure by
Indevus; and (ii)&nbsp;does not launch Trospium Once-Daily in the United States by the applicable date
set forth in Section&nbsp;5.1(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>This Agreement, except for Article&nbsp;14 which shall remain in full force and effect to
amend and restate Article&nbsp;14 of the Original Agreement with respect to provisions therein that are
effective as of the Execution Date, shall terminate effective upon the effective date of
termination of the Merger Agreement in accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>12.3 Rights Not Affected. </B>All rights and licenses granted pursuant to this Agreement are, and shall otherwise be
deemed to be, for purposes of Section 365(n) of the Bankruptcy Code licenses of rights to
&#147;intellectual property&#148; as defined under Section&nbsp;101(35A) of the Bankruptcy Code. The Parties
agree that Esprit and Indevus shall retain and may fully exercise all of their respective rights,
remedies and elections under the Bankruptcy Code. The Parties further agree that, in the event of
the commencement of a bankruptcy or reorganization case by or against a Party under the Bankruptcy
Code, the other Party shall be entitled to all applicable rights under Section&nbsp;365 (including
365(n)) of the Bankruptcy Code. Upon rejection of this Agreement by a Party or a trustee in
bankruptcy for such Party, pursuant to Section&nbsp;365(n), the other Party may elect (a)&nbsp;to treat this
Agreement as terminated by such rejection or (b)&nbsp;to retain its rights (including any right to
enforce any exclusivity provision of this Agreement) to intellectual property (including any
embodiment of such intellectual property) under this Agreement and under any agreement
supplementary to this Agreement for the duration of this Agreement and any period for which
this Agreement could have been extended by such other Party, subject, however, to the
continued payment of all amounts owing under this Agreement, all of which amounts shall be deemed
to be royalties for purposes of Section 365(n) of the Bankruptcy Code. Upon written request to the
trustee in bankruptcy or bankrupt Party, the trustee or Party, as applicable, shall (i)&nbsp;provide to
the other Party any intellectual property, including all Indevus Intellectual Property (including
any embodiment of such intellectual property) held by the trustee or the bankrupt Party and shall
provide to the other Party a complete duplicate of (or complete access to, as appropriate) any such
intellectual property including all Indevus Intellectual Property and all embodiments of such
intellectual property and (ii)&nbsp;not interfere with the rights of the other Party to such
intellectual property as provided in this Agreement or any agreement supplementary to this
Agreement, including any right to obtain such intellectual property (or such embodiment or
duplicates thereof) from a Third Party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->64<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>12.4 Effect of Expiration or Termination.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;By Indevus. </B>In the event of termination of this Agreement by Indevus pursuant to
Section&nbsp;12.2(a), 12.2(b) or 12.2(d) (<U>provided</U> that Allergan does not exercise its right
under Section&nbsp;12.2(c) and Indevus and Allergan do not enter into the agreement referred to
therein), the following shall be applicable: (i)&nbsp;Esprit shall promptly transfer to Indevus copies
of all data, reports, records and materials in Esprit&#146;s possession or Control that relate to the
Products and return to Indevus all relevant records and materials in Esprit&#146;s possession or Control
containing Proprietary Information of Indevus (<U>provided</U> that Esprit may keep one (1)&nbsp;copy
of such Proprietary Information of Indevus for archival purposes solely for the purpose of
compliance with this Agreement) and (ii)&nbsp;Esprit shall transfer to Indevus ownership of any
regulatory filings made or filed for Products in the Field in the Territory by Esprit or its
designees. Subject to the payment of all amounts required hereunder, Esprit and its Affiliates
shall have the right to sell or otherwise dispose of the stock of any Product subject to this
Agreement on hand at the time of such termination or in process of manufacture; <U>provided</U>,
<U>however</U>, that, at Indevus&#146; request, Esprit shall return to Indevus any Product that has not
been sold or used within six (6)&nbsp;months following such termination and, if such termination is
prior to the Processing Assumption Date, Indevus shall reimburse Esprit&#146;s procurement costs related
to such Product to the extent such costs have been previously been paid by Esprit to Indevus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;By Esprit. </B>In the event of termination of this Agreement by Esprit pursuant to Section
12.2(a) or 12.2(b), Indevus shall promptly return to Esprit all relevant records and materials in
Indevus&#146; possession or Control containing Proprietary Information of Esprit (provided that Indevus
may keep one (1)&nbsp;copy of such Proprietary Information of the terminating Party for archival
purposes solely for the purpose of compliance with this Agreement).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Expiration. </B>Upon expiration of this Agreement, all rights and licenses granted to Esprit
hereunder with respect to the Indevus Intellectual Property shall be deemed fully paid up and shall
survive such expiration, and Esprit shall be relieved of any
obligation to pay Indevus any royalties or other fees hereunder except those that accrued
prior to the date of expiration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Survival. </B>Expiration or termination of this Agreement shall not relieve the Parties of
any obligation accruing prior to such expiration or termination, including all accrued payment
obligations arising under Article&nbsp;6 and 14. In addition to any other provisions of this Agreement
that, by their terms continue after the expiration of this Agreement, Articles 1 and 15, Sections
2.3, 4.2(e) (last sentence only), 7.4, 7.5, 8.1, 8.2 (<U>provided</U> that the nonbreaching Party
shall have no obligations, and the breaching Party shall have no rights, under Section&nbsp;8.2 after
any termination of this Agreement by the nonbreaching Party pursuant to Section&nbsp;12.2(a)), 9.1, 9.2,
12.4(a)&#150;(c) (to the extent applicable), and this 12.4(d) shall survive the expiration or
termination of this Agreement. Additionally, the provisions of Articles 11 and 13 shall survive
the expiration or termination of this Agreement and shall continue in effect for seven (7)&nbsp;years
after the date of expiration or termination. In addition, any other provisions required to
interpret and enforce the Parties&#146; rights and obligations under this Agreement shall
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->65<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">also survive,
but only to the extent required for the full observation and performance of this Agreement. Any
expiration or early termination of this Agreement shall be without prejudice to the rights of any
Party against the other accrued or accruing under this Agreement prior to termination. Except as
expressly set forth herein, the rights to terminate as set forth herein shall be in addition to all
other rights and remedies available under this Agreement, at law, or in equity, or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Indemnification and Insurance</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.1 Indemnity. </B>For purposes of this Article&nbsp;13, &#147;<B>Indevus Indemnified Parties</B>&#148; refers to Indevus, its
Affiliates and the officers, directors, employees, shareholders, agents and successors and assigns
of Indevus and its Affiliates, and &#147;<B>Esprit Indemnified Parties</B>&#148; refers to Esprit, its Affiliates
and officers, directors, employees, shareholders, agents and successors and assigns of Esprit and
its Affiliates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.2 Esprit Indemnification. </B>Esprit shall defend the Indevus Indemnified Parties from and against all suits, claims,
actions, demands, complaints, lawsuits or other proceedings (other than Product Liability Claims,
which are covered in Section&nbsp;13.6), (collectively, &#147;<B>Claims</B>&#148;), that are brought by a Third Party,
and shall indemnify and hold harmless to the fullest extent permitted by Law the Indevus
Indemnified Parties from and against any and all Losses, that arise out of or are attributable to:
(a)&nbsp;the Promotion, marketing, advertising, importation, offer for sale, or sale of Products in the
Territory by or through Esprit or its Affiliates, or any of their respective employees, agents,
contractors, representatives or other persons or entities working on their behalf; (b)&nbsp;Esprit&#146;s
negligence, recklessness or willful misconduct in exercising or performing any of its rights or
obligations under this Agreement; (c)&nbsp;a material breach by Esprit of any of its obligations,
representations, warranties or covenants under this Agreement; or (d)&nbsp;any failure by Esprit to
comply with the Promotion Plan, including any failure to comply with the PDMA;
<U>provided</U>, <U>however</U>, that Esprit shall not be obligated under this Section&nbsp;13.2, to
the extent it is shown by evidence acceptable in a court of law having jurisdiction over the
subject matter and meeting the appropriate degree of proof for such Claim that the Claim arose out
of the negligence or wrongdoing on the part of Indevus.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.3 Indevus Indemnification. </B>Indevus shall defend the Esprit Indemnified Parties from and against all Claims, in each
case that are brought by a Third Party, and shall indemnify and hold harmless to the fullest extent
permitted by Law the Esprit Indemnified Parties from and against any and all Losses that arise out
of such Claims that are attributable to: (a)&nbsp;the Promotion, marketing, advertising, importation,
offer for sale, or sale of Products in the Territory by or through Indevus or its Affiliates, or
any of their respective employees, agents, contractors, representatives or other persons or
entities working on their behalf; (b)&nbsp;Indevus&#146; negligence, recklessness or willful misconduct in
exercising or performing any of its rights or obligations under this Agreement; (c)&nbsp;a material
breach by Indevus of any of its obligations, representations, warranties or covenants under this
Agreement; (d)&nbsp;any failure by Indevus to comply with the Promotion Plan, including any failure to
comply with the PDMA; or (e)&nbsp;any actual or alleged infringement or violation of any patent, trade
secret, copyright, trademark, or other proprietary rights of a Third Party arising from the
manufacture, use, sale, offer for sale, or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->66<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">importation in the Field of the Compound and/or any
Product obtained under the terms of this Agreement from Indevus; <U>provided</U>, <U>however</U>,
that Indevus shall not be obligated under this Section&nbsp;13.3, to the extent it is shown by evidence
acceptable in a court of law having jurisdiction over the subject matter and meeting the
appropriate degree of proof for such Claim that the Claim arose out of the negligence or wrongdoing
on the part of Esprit.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.4 Indemnification Procedure.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Each Party shall promptly notify the other Party in writing of any Claim or Losses for
which it is entitled to indemnification pursuant to Section&nbsp;13.2 or 13.3, as applicable.
Concurrent with the provision of notice pursuant to this section, the Indemnified Party shall
provide to the other Party copies of any complaint, summons, praecipe, subpoena or other court
filings or correspondence related to such Claim and will give such other information with respect
thereto as the other Party shall reasonably request. The Indemnifying Party and Indemnified Party
shall meet to discuss how to respond to such Claim. Failure to provide prompt notice shall not
relieve any Party of the duty to defend or indemnify except to the extent such failure materially
prejudices the defense of any matter. Each Party agrees that it will take reasonable steps to
minimize the burdens of the litigation on witnesses and on the ongoing business of the Indemnified
Parties, including making reasonable accommodations to witnesses&#146; schedules when possible and
seeking appropriate protective orders limiting the duration and/or location of depositions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Should either Party dispute that any Claim or portion of a Claim (&#147;<B>Disputed Claim</B>&#148;) of
which it receives notice pursuant to Section&nbsp;13.4(a), is an indemnifiable Claim, it shall so notify
the other Party providing written notice in sufficient time to permit such other Party to retain
counsel and timely appear, answer and/or move in any such action. In such event, such other Party
shall defend against such Claim; <U>provided</U>, <U>however</U>, that such other Party shall not
settle any Claim that it contends is an indemnified Claim without providing the Indemnifying Party
ten (10)&nbsp;Business Days&#146; notice prior to any such settlement and an opportunity to assume the
defense and indemnification of such Claim pursuant to this Agreement. If it is determined that a
Disputed Claim is subject to indemnification, the Indemnifying Party will reimburse the costs and
expenses, including reasonable attorneys&#146; fees, of the Indemnified Party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.5 Defense of Claims. </B>Esprit shall undertake the defense of any Claims that are not subject to indemnification by
Indevus under Section&nbsp;13.3 (<U>provided</U> that, if Esprit declines or fails to assume such role,
Indevus shall be entitled to assume such role). The Parties shall bear equally all defense costs,
including reasonable fees of attorneys, accountants or other experts, as incurred. Indevus shall
have the right to participate in the defense of any such Claim utilizing attorneys of its choice,
at its own expense. Indevus shall have a reasonable opportunity to participate in decision-making
with respect to the strategy of such defense, and the Parties shall reasonably cooperate with each
other in connection with the implementation thereof. Esprit shall keep any counsel selected by
Indevus reasonably informed of the status and progress of the defense and shall consult with any
counsel selected by Indevus on all material aspects of the defense, including settlement, of such
Claim, <U>provided</U>, <U>however</U>, that (a)&nbsp;Indevus shall have
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->67<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">exclusive control of the
defense of any Claim for which an Esprit Indemnified Party seeks indemnification from Indevus under
Section&nbsp;13.3, (b)&nbsp;any Indevus Indemnified Party shall be entitled to assume the defense of any
Claim with respect to such Indevus Indemnified Party, upon written notice to Esprit pursuant to
this Article&nbsp;13, in which case Esprit shall be relieved of liability under Section&nbsp;13.2 for such
Claim; and (c)&nbsp;in the event of a Claim brought against one Party containing allegations of
liability based on such Party&#146;s exercise or performing, or failure to exercise or perform any of
its rights or obligations under this Agreement, such Party shall control and bear financial
responsibility for its own defense, unless the other Party agrees to control and bear financial
responsibility of such defense and Claim.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.6 Settlement of Indemnified Claims. </B>The Indemnifying Party under Section&nbsp;13.2 or 13.3, as applicable, shall have the sole
authority to settle any Indemnified Claim without the consent of the other Party; <U>provided</U>,
<U>however</U>, that an Indemnifying Party shall not, without the written consent of the other
Party, as part of any settlement or compromise (a)&nbsp;admit to liability on the part of the other
Party; (b)&nbsp;agree to an injunction against the other Party; or (c)&nbsp;settle any matter in a manner
that separately apportions fault to the other Party. The Parties further agree that as part of the
settlement of any Indemnified Claim, an Indemnifying Party shall obtain a full, complete and
unconditional release from the claimant on behalf of the Indemnified Parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.7 Product Liability Claims. </B>Other than Claims for which either Party is obligated to indemnify the other Party under
Section&nbsp;13.2 or 13.3, the following shall apply to Losses arising out of or resulting from any
Product Liability Claim, regardless of legal theory.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Each Party shall give the other prompt written notice of any Product Liability Claim, but
failure to provide such prompt notice shall not relieve any Party of the duty to defend or
indemnify unless such failure materially prejudices the defense of any matter. With respect to
each Product Liability Claim, the Parties shall determine by mutual agreement, within twenty (20)
days following their receipt of notice of the commencement of or assertion of such Product
Liability Claim (or such lesser period of time as may be required to properly respond to such
Product Liability Claim) which Party shall undertake the defense thereof. Should the Parties be
unable to agree on who shall undertake the defense of any Product Liability Claim, Esprit shall be
entitled to assume such role, <U>provided</U>, <U>however</U>, that absent an agreement by the
Parties to the contrary, Indevus shall reimburse Esprit for fifty percent (50%) of defense costs,
including reasonable fees of attorneys, accountants or other experts retained by Esprit, as
incurred, and if Esprit declines or fails to assume such role, Indevus shall be entitled to assume
such role and Esprit shall reimburse Indevus for fifty percent (50%) of defense costs, including
reasonable fees of attorneys, accountants or other experts retained by Indevus, as incurred.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>The Party undertaking the defense of any Product Liability Claim (the &#147;<B>Controlling Party</B>&#148;)
shall consult with the other Party on all material aspects of the defense, including settlement, of
such Product Liability Claim, and the other Party shall have a reasonable opportunity to
participate in decision-making with respect to the strategy of such defense, and the Parties shall
reasonably cooperate with each other in connection with the
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->68<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">implementation thereof. The
non-Controlling Party shall also have the right to participate in the defense of any Product
Liability Claim utilizing attorneys of its choice, at its own expense. In furtherance of the
Parties&#146; cooperation, the Controlling Party will consult with the other Party regarding strategic
decisions, including the retention of counsel for defense of any Product Liability Claim. The
Controlling Party will otherwise keep the other Party reasonably informed of the status and
progress of the defense and any settlement discussions concerning each Product Liability Claim, and
the Parties shall provide each other with all reasonably requested assistance and will reasonably
cooperate with each other in connection therewith. Each Party agrees that it will take reasonable
steps to minimize the burdens of the litigation on witnesses and on the ongoing business of the
Indemnified Parties including making reasonable accommodations to witnesses&#146; schedules when
possible and seeking appropriate protective orders limiting the duration and/or location of
depositions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>The Parties shall negotiate in good faith to enter into a joint defense agreement as soon
as reasonably practicable after the commencement of any Product Liability Claim which agreement
shall, among other things: (i)&nbsp;establish procedures to allocate between the Parties the
responsibility for Losses arising out of or resulting from Product Liability Claims (giving effect
to, among other factors, the nature of the Product Liability Claim); (ii)
establish procedures as are reasonably necessary to permit the Parties to reconcile their
actual payments for such Losses with their allocable share of responsibility for such Losses on a
quarterly basis; and (iii)&nbsp;provide for procedures with respect to any settlement of a Product
Liability Claim; <U>provided</U>, <U>however</U>, that (x)&nbsp;to the extent it is shown by evidence
acceptable in a court of law having jurisdiction over the subject matter and meeting the
appropriate degree of proof for such Product Liability Claim that the Losses resulting from such
Product Liability Claim resulted from the manufacture of Products by or through Indevus or its
Affiliates or any of their respective employees, agents, contractors, representatives or other
persons or entities working on their behalf, then Indevus shall bear financial responsibility for
all such Losses, unless Esprit agrees to control and bear financial responsibility of such defense
and Product Liability Claim; (y)&nbsp;to the extent it is shown by evidence acceptable in a court of law
having jurisdiction over the subject matter and meeting the appropriate degree of proof for such
Product Liability Claim that the Losses resulting from such Product Liability Claim resulted from
the manufacture of Products by or through Esprit or its Affiliates or any of their respective
employees, agents, contractors, representatives or other persons or entities working on their
behalf, then Esprit shall bear financial responsibility for all such Losses, unless Indevus agrees
to control and bear financial responsibility of such defense and Product Liability Claim; and (z)
if the Parties are unable to agree to a mutually acceptable joint defense agreement, the matter
shall be submitted to binding arbitration for resolution.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Product Liability Claims shall be governed exclusively by the provisions of this Section
13.6 and, except in accordance with this Section&nbsp;13.6, neither Party shall seek from the other
Party any indemnity or other recovery on account of any such Product Liability Claims;
<U>provided</U>, <U>however</U>, that nothing in this Section&nbsp;13.6 shall limit either Party&#146;s
liability to the other Party for damages on account of any breach by such Party of its
representations, warranties, covenants or agreements under this Agreement.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->69<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.8 Insurance. </B>Each Party shall maintain, commencing as of the Effective Date and for a period of three
(3)&nbsp;years after any expiration of termination of this Agreement, a Commercial General Liability
Insurance policy or policies (including coverage for Product Liability, Contractual Liability,
Bodily Injury, Property Damage and Personal Injury), with minimum limits of &#091;...***...&#093;
per occurrence and in the aggregate. Such insurance shall insure against all liability arising out
of the manufacture, use, sale, distribution, or marketing of Products in the Territory. During the
Agreement Term, each Party shall not permit such insurance to be reduced (other than by payment of
Claims), expired or canceled without reasonable prior written notice to the other Party. Upon
request each Party shall provide Certificates of Insurance to the other Party evidencing the
coverage specified herein. Except as expressly stated herein, a Party&#146;s liability to the other is
in no way limited to the extent of the Party&#146;s insurance coverage. The Parties agree that neither
Party shall be deemed to be an additional insured under the terms of their respective insurance
policies. The Parties further agree that neither Party shall be deemed to be an additional insured
vendor under such policies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Orders and Supply </B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.1 Orders and Terms of Sale. </B>In the Territory and in the Field, during the Agreement Term, Esprit shall have the sole
right to (a)&nbsp;receive, accept and fill orders for Finished Product and Samples, (b)&nbsp;control
invoicing, order processing and collection of accounts receivable for Product sales, and (c)&nbsp;book
all Net Sales and record Product sales in its books of account. Esprit shall have the sole right
and responsibility for establishing and modifying the commercial terms and conditions with respect
to the sale and distribution of Products hereunder, including matters such as the price at which
Products will be sold and whether any discounts, rebates or other deductions should be made, paid
or allowed, it being understood that certain of such matters shall be incorporated in the Promotion
Plan developed pursuant to Section&nbsp;5.2. Esprit shall notify Indevus in writing of such changes at
the time such information is provided by Esprit to its Sales Force.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.2 Misdirected Orders. </B>During the Agreement Term, except in the event specifically authorized in writing to do so
by Esprit, (a)&nbsp;Indevus will not accept or fill purchase orders for Products in the Field in the
Territory and will not process billing or returns with respect to such Products (and in any event
Indevus shall have no obligation to do so); and (b)&nbsp;at no time shall Indevus have any power or
authority to accept or reject orders on behalf of Esprit. If, for any reason, Indevus receives
orders for Products hereunder, Indevus shall forward such orders to Esprit (or if directed by
Esprit to Esprit&#146;s wholesalers) promptly, for acceptance or rejection.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.3 Product Returns. </B>If any quantities of Products are returned to Indevus during the Agreement Term, Indevus
shall notify Esprit as soon as practicable and ship them to the facility designated by Esprit, with
any reasonable or authorized shipping or other documented direct cost to be paid by Esprit.
Indevus, at its option, may advise the customer who made the return that such Products should have
been returned to Esprit, but shall take no other steps in respect of any return without the consent
of Esprit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->70<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.4 Supply Obligations. </B>Subject to the terms and conditions of this Agreement, during the period beginning on the
Execution Date and expiring on the NDA Transfer Date (&#147;<B>Supply Term</B>&#148;), Indevus (or its designees)
shall supply to Esprit quantities of Finished Products and/or Samples requested by Esprit in
accordance with this Article&nbsp;14 for use in the Territory, and Esprit shall purchase from Indevus
all its requirements of Finished Products and/or Samples at the applicable Supply Price;
<U>provided</U> that, such obligations shall terminate (a)&nbsp;as of the NDA Transfer Date with
respect to Trospium Twice-Daily, and (b)&nbsp;as of the Processing Assumption Date with respect to
Trospium Once-Daily. Notwithstanding the foregoing, Indevus shall, from and after the NDA Transfer
Date, (a)&nbsp;continue to have the right, but not the obligation to supply Esprit with Finished Product
and Samples of Trospium Twice-Daily, or (b)&nbsp;if so requested by Esprit, use commercially
reasonable efforts at any time prior to the NDA Transfer Date to assign to Esprit the Madaus Supply
Agreement and Indevus&#146; rights and obligations thereunder. The Parties acknowledge and agree that
Indevus intends to obtain such Finished Products and Samples through contractual arrangements with
Third Party Manufacturers and that Indevus&#146; obligations hereunder shall be subject to the terms of
its agreements with Madaus, Catalent, and Helsinn and any other Third Party Manufacturer approved
by the Parties. The Supply Committee will discuss and address any issues resulting from the
failure to meet the requirements of this Section&nbsp;14.4. Esprit shall place orders for the
quantities requested by its Affiliates, and either have Indevus ship directly to such Affiliates or
to Esprit for its reshipment to such Affiliates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.5 Forecasts for Products.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Trospium Twice-Daily.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>The total quantity of Finished Product and Samples of Trospium Twice-Daily forecasted for
any twelve (12)&nbsp;month period specified herein shall be the &#147;<B>Annual Forecast Amount.</B>&#148; Attached
hereto as Schedule&nbsp;14.5(a) is Esprit&#146;s forecast of its orders for Finished Products and/or Samples
of Trospium Twice-Daily for the twelve (12)&nbsp;Calendar Quarters commencing with the Calendar Quarter
ending December&nbsp;31, 2007, broken down by month for the initial Annual Forecast Amount of such
forecast (the &#147;<B>Trospium Twice-Daily Forecast</B>&#148;). Esprit shall provide Indevus on September&nbsp;1, 2008
and September 1 of each Calendar Year thereafter during the Supply Term, with an updated nonbinding
&#091;...***...&#093; Trospium Twice-Daily Forecast (broken down by month for the initial Annual
Forecast Amount of each such forecast) of its orders for Finished Products and/or Samples of
Trospium Twice-Daily. Esprit shall be required to purchase at least &#091;...***...&#093; of the
first Annual Forecast Amount included in each such forecast delivered pursuant to this Section
14.5(a). Except for the first Annual Forecast Amount included in any forecast delivered pursuant
to this Section&nbsp;14.5(a), such forecast will not be binding in any way. Each Trospium Twice-Daily
Forecast shall supersede any previous forecast of the Annual Forecast Amount for each of such
twelve (12)&nbsp;month period, except that it shall not alter or effect the &#091;...***...&#093;
minimum purchase requirement of the initial Annual Forecast Amount included in earlier forecasts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>In the event that the Annual Purchased Amount with respect to the first twelve (12)
months included in a forecast delivered pursuant to Section
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->71<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">14.5(a)(i) does not equal or exceed
&#091;...***...&#093; of the first Annual Forecast Amount included in such forecast, Esprit shall
reimburse Indevus for any Minimum Supply Fees paid by Indevus pursuant to Section&nbsp;4.1(c) of the
Madaus Supply Agreement. The Parties shall cooperate in good faith to minimize the Minimum Supply
Fee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Trospium Once-Daily.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>Attached hereto as Schedule&nbsp;14.5(b) is Esprit&#146;s forecast of its orders for Finished
Products and/or Samples of Trospium Once-Daily for the &#091;...***...&#093; Calendar Quarters
commencing with the Calendar Quarter ending December&nbsp;31, 2007, broken down on a quarterly basis
(the &#147;<B>Initial Trospium Once-Daily Forecast</B>&#148;). The Initial Trospium Once-Daily Forecast shall
provide for, with respect to the Calendar Quarter ending December&nbsp;31, 2007, orders for delivery of
&#091;...***...&#093; of Trospium Once-Daily. Esprit shall provide to Indevus, (i)&nbsp;on January&nbsp;2,
2008 for the period beginning on the first day of the third Calendar Quarter of 2008 and ending on
the last day of the second Calendar Quarter of 2009, and (ii)&nbsp;on April&nbsp;1, 2008 for the period
beginning on the first day of the fourth Calendar Quarter of 2008 and ending at the end on the last
day of the third Calendar Quarter of 2009, an updated written forecast of its orders of Finished
Products and/or Samples, broken down on a quarterly basis and stating the quantities for each of
Finished Products and/or Samples for Trospium Once-Daily (the Initial Trospium Once-Daily Forecast
and each subsequent forecast, a &#147;<B>Rolling Forecast</B>&#148;). Notwithstanding anything to the contrary, all
Rolling Forecasts shall be terminated as of the Processing Assumption Date, except that Esprit
shall continue to be responsible for the Firm Commitment portion of any Rolling Forecast submitted
by Esprit to Indevus prior to the Processing Assumption Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>The first three (3)&nbsp;Calendar Quarters with respect to the Initial Trospium Once-Daily
Forecast, and the first Calendar Quarter of each Rolling Forecast provided after the launch date of
Trospium Once-Daily, shall constitute a firm order for the aggregate quantities of Trospium
Once-Daily Finished Product and Samples specified therein and a binding commitment to submit
Purchase Orders for the aggregate quantities of Trospium Once-Daily Finished Product and Samples
specified therein (&#147;<B>Firm Commitment</B>&#148;) and the following Calendar Quarters of each Rolling Forecast
shall be non-binding, good faith estimates for planning purposes only and shall not constitute
binding commitments by Esprit to purchase Trospium Once-Daily Finished Product and Samples. Each
Rolling Forecast provided by Esprit shall supersede any previous Rolling Forecast solely with
respect to Calendar Quarters that were not previously part of the Firm Commitment portion of the
Rolling Forecast.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;Minimum Requirements. </B>During each successive twelve (12)&nbsp;month period (each, a
&#147;<B>Requirement Year</B>&#148;) commencing after the expiration of the Launch Period and expiring after Esprit
has submitted Purchase Orders for an aggregate of at least &#091;...***...&#093; of Trospium
Once-Daily, Esprit shall submit Purchase Orders for at least an aggregate of &#091;...***...&#093;
of Trospium Once-Daily (&#147;<B>Minimum Requirement</B>&#148;), subject to pro rata adjustment for any Requirement
Year that is not a full twelve (12)&nbsp;month period. If Esprit does not satisfy such Minimum
Requirement during any Requirement Year, within thirty (30)&nbsp;days after the end of such Requirement
Year, Esprit shall pay Indevus an amount equal to the
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->72<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">difference between (A)&nbsp;the total amount
Esprit would have paid to Indevus if the Minimum Requirement had been fulfilled, and (B)&nbsp;the total
amount Esprit paid Indevus based on the number of capsules of Trospium Once-Daily that were the
subject of all Purchase Orders for Trospium Once-Daily submitted to Indevus in accordance with this
Agreement during the just-concluded Requirement Year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.6 Purchase Orders</B>. Notwithstanding the terms in Section&nbsp;14.5, prior to the desired delivery date, Esprit shall
submit a firm, binding, non-cancelable purchase order on the standard purchase order forms of
Esprit of its requirements for Finished Product and Samples for the aggregate number of units of
Finished Product and Samples specified in the Firm Commitment portion of the Rolling Forecast
(&#147;<B>Purchase Order</B>&#148;) specifying delivery dates for each Batch as follows: (a)&nbsp;not later than the
Execution Date, for deliveries requested during the Calendar Quarters ending December&nbsp;31, 2007
(<U>provided</U> that the quantity of Trospium Once-Daily requested for delivery during such
Calendar Quarter shall be &#091;...***...&#093; of Trospium Once-Daily), March&nbsp;31, 2008 and June
30, 2008 (<U>provided</U> that the quantity of Trospium Once-Daily requested for delivery during
each of such Calendar Quarters shall be &#091;...***...&#093; of Trospium Once-Daily) (the &#147;<B>Initial
Purchase Orders</B>&#148;); and (b)&nbsp;at least &#091;...***...&#093; before the requested delivery dates for
deliveries of Finished Product and Samples requested during any subsequent Calendar Quarters;
<U>provided</U> that Indevus shall be authorized to order sufficient quantities of Compound based
on the Firm Commitment portions of the previously provided forecasts and Esprit shall reimburse
Indevus for its Product Procurement Costs associated with any quantities of Compound so ordered
that are not included, pursuant to this Section&nbsp;14.6 in a Purchase Order for Finished Product and
Samples. Each Purchase Order covering any Firm Commitment portion of a Rolling Forecast shall be
for &#091;...***...&#093; quantities of Finished Product and Samples constituting the applicable
binding portion, with respect to Trospium Twice-Daily, or the Firm Commitment portion, with respect
to Trospium Once-Daily, of the applicable forecasts submitted under Section&nbsp;14.5. Each Purchase
Order shall conform to the terms of this Agreement and shall be consistent with the obligations of
Helsinn and Catalent under the Helsinn Agreements and the Catalent Agreements, respectively.
Indevus will promptly confirm receipt and acceptance of each such Purchase Order. Indevus shall
use Commercially Reasonable Efforts to fulfill orders made hereunder by delivering the Finished
Products and/or Samples ordered on the specified delivery date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.7 Delivery. </B>All Finished Products and/or Samples to be delivered pursuant to this Agreement shall be
delivered in accordance with this Section&nbsp;14.7, and the Specifications and suitably packed for
shipment, and marked for shipment to the final destination point indicated in Esprit&#146;s Purchase
Order. Delivery will not be complete unless each shipment is accompanied by a Certificate of
Analysis and Compliance (as defined in this Section&nbsp;14.7) and any required export documentation.
All Finished Product and Samples supplied to Esprit hereunder (other than &#091;...***...&#093;
manufactured under &#091;...***...&#093; ) shall have the longest remaining shelf life reasonably
possible, but in any event not less than &#091;...***...&#093;, based on &#091;...***...&#093;
dating, after delivery to Esprit. The shipping packaging used in connection with deliveries of
Finished Products and/or Samples shall be in accordance with cGMP with respect to protection of the
Finished Products and/or Samples during transportation, taking into consideration the mode(s) of
transport Esprit has elected to use for each such shipment, the final destination point of each
such
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->73<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shipment and reasonable expectations as to shipment time duration and possible delays
associated therewith. Indevus will deliver or cause to be delivered all Finished Products and/or
Samples to the carrier nominated by Esprit at a point selected by Indevus. If Esprit nominates a
Third Party other than
a carrier to receive the Finished Products and/or Samples, Indevus shall be deemed to have
fulfilled its obligation to deliver the Finished Products and/or Samples when the Finished Products
and/or Samples are delivered to that Third Party. Title and risk of loss shall transfer to Esprit
upon delivery, F.O.B. to the carrier or Third Party designated by Esprit. For purposes of this
Section&nbsp;14.7, &#147;<B>Certificate of Analysis and Compliance</B>&#148; means a document as determined by mutual
agreement of the Parties, signed by the designated quality manager of Indevus or Indevus&#146; Third
Party Manufacturer, as applicable, and provided by such Person to Esprit, that sets forth the
analytical test results against the Specifications for a specified Batch or lot of Finished
Products and/or Samples and that certifies that each Batch or lot of Finished Products and/or
Samples was produced and tested in compliance with the Specifications, cGMPs, the master Batch
record and all applicable FDA Approvals.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.8 Supply Price and Payments.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Invoices and Payments. </B>Except as set forth herein, Indevus shall submit invoices to
Esprit for Finished Products and/or Samples promptly after delivery to the carrier or Third Party
designated by Esprit under Section&nbsp;14.7. Payment shall be made in accordance with Section&nbsp;14.8(b).
All relevant terms of Section&nbsp;6.4 with respect to payments to Indevus hereunder shall apply to the
payment of invoices for the supply of Finished Products and/or Samples. Payments hereunder shall
be in United States dollars.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Supply Price. </B>Prior to the Processing Assumption Date with respect to Trospium
Once-Daily, and prior to the NDA Transfer Date with respect to Trospium Twice-Daily, Esprit shall
purchase Finished Products and/or Samples from Indevus at a purchase price equal to the Product
Procurement Costs incurred by Indevus for the applicable Product (the &#147;<B>Supply Price</B>&#148;). The Supply
Price shall be established and paid as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;Initial Purchase Orders. </B>Esprit shall pay Indevus on the Effective Date by wire transfer
of immediately available funds the Forecasted Supply Price for all quantities of Trospium
Once-Daily Finished Product and Samples specified in the Initial Purchase Orders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;Forecasted Supply Price. </B>Set forth on Schedule&nbsp;14.8(b) is a forecasted Supply Price for
Finished Products and/or Samples, broken down for Trospium Twice-Daily and Trospium Once-Daily,
that shall apply for all quantities of Finished Products and/or Samples of the applicable Product
purchased by Esprit from Indevus prior to the Processing Assumption Date (the &#147;<B>Forecasted Supply
Price</B>&#148;). By August&nbsp;31 of each Calendar Year, beginning on August&nbsp;31, 2008, until the NDA Transfer
Date, Indevus shall provide Esprit with an updated Forecasted Supply Price with respect to Trospium
Twice-Daily for the following twelve (12)&nbsp;month period. The Parties acknowledge that the Forecasted
Supply Price for Finished Products and/or Samples is a good faith estimate of what Indevus believes
the average Supply Price will be for Finished Products and/or Samples to be purchased by Esprit
during the
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->74<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">applicable twelve (12)&nbsp;month period, based on the forecasts provided and to be provided
by
Esprit with respect to the applicable Finished Product and Samples for the corresponding
periods under Section&nbsp;14.5. Unless otherwise agreed by the Parties, Esprit shall be invoiced at
the Forecasted Supply Price for all Finished Products and/or Samples purchased by Esprit during the
applicable twelve (12)&nbsp;month period promptly after shipment by Indevus or its Third Party
Manufacturer. Except as set forth in subsection (i)&nbsp;above, payments of the Forecasted Supply Price
shall be made by Esprit within thirty (30)&nbsp;days after Esprit&#146;s receipt of the invoice (or, for
amounts in dispute pursuant to Section&nbsp;14.10(d), within ten (10)&nbsp;days after the date the dispute is
resolved), and shall be subject to the true-up provided for in Section&nbsp;14.8(b)(iii).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;True-up of Supply Price. </B>Within sixty (60)&nbsp;days following the Processing Assumption
Date with respect to Trospium Once-Daily, and sixty (60)&nbsp;days following August&nbsp;31, 2008 and each
subsequent twelve (12)&nbsp;month period ending August&nbsp;31 thereafter with respect to Trospium
Twice-Daily, Indevus shall provide Esprit a preliminary report estimating Indevus&#146; calculation of
the actual Supply Price for the aggregate shipments of Finished Products and/or Samples supplied to
Esprit for the period covered by such report (the &#147;<B>Actual Shipment Supply Price</B>&#148;), which
calculation shall state the amount by which the Forecasted Supply Price for the applicable Product
exceeded or was less than the Actual Shipment Supply Price for such shipments. To the extent that
volume estimates are needed for such calculation, annualized volumes shall be utilized. In
addition, with respect to Trospium Twice-Daily, the report shall include a calculation of the
actual quantity of Samples purchased by Esprit for that year as a percentage of the Annual
Purchased Amount for that year and any reconciliation caused by the difference between such actual
quantity and the quantity of Samples used to determine the Forecasted Supply Price for Trospium
Twice-Daily. In the event the Forecasted Supply Price for the applicable Product exceeds the Actual
Shipment Supply Price for such period, Esprit shall credit the amount of such deviation from the
next payment due Indevus under Section&nbsp;6.4; <U>provided</U> that Indevus shall reimburse Esprit
any amounts not so credited in the event that such amounts are greater than the payments due to
Indevus in such payment under Section&nbsp;6.4. In the event the Forecasted Supply Price for the
applicable Product was less than the Actual Shipment Supply Price for such period, Esprit shall pay
the amount of such deviation with the next payment due Indevus under Section&nbsp;6.4. Within thirty
(30)&nbsp;days following the end of the first complete Calendar Quarter ending after the date of the
preliminary reports referred to above, if there are any deviations from the amounts set forth in
the preliminary reports referred to above, Indevus shall provide Esprit with a written report
including Indevus&#146; final determination of the figures set forth in the preliminary reports referred
to above and any deviations from the Actual Shipment Supply Price shall be addressed similarly to
the deviations referred to in the preceding two sentences. Upon the expiration or any termination
of this Agreement, any then unpaid true-up payments of the Supply Price shall be made by the Party
owing such payment to the other Party within thirty (30)&nbsp;days after such expiration or termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;</B>Notwithstanding the foregoing, Esprit shall be permitted to credit against any payments
due under Sections&nbsp;14.8(b)(i)&#150;(iii), an amount equal to the Supply Price for commercial quantities
of capsules contained in the &#091;...***...&#093; of Trospium Once-Daily manufactured under
&#091;...***...&#093; to the extent previously paid with respect to such commercial
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->75<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">quantities,
which amounts will be set forth in detail in a report provided by Indevus concurrently
with the first invoice delivered to Esprit pursuant to Section&nbsp;14.8(a), and which amounts
Indevus acknowledges has been paid as of the Execution Date. For clarity, such amount shall
include the cost of any packaging and any overhead and additional quality control/quality assurance
work allocated to such commercial quantities, to the extent such amounts have been previously paid
with respect to such commercial quantities as set forth in such report.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.9 Conformity; Specifications; Quality Control.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>All quantities of Finished Products and/or Samples supplied by Indevus pursuant to this
Article&nbsp;14 will conform in all material respects to the Specifications.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Indevus shall conduct, or cause to be conducted, quality control testing of Finished
Products and/or Samples prior to shipment, in accordance with the Specifications as are in effect
from time to time and such other quality control testing procedures adopted by Indevus from time to
time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Each Party shall have the right, at reasonable times and upon reasonable notice, to
inspect and audit all facilities at which Finished Products and/or Samples are manufactured and
quality control tested pursuant to this Article&nbsp;14 for compliance with cGMP, subject to Indevus&#146;
existing agreements with Third Party Manufacturers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>The Parties agree to negotiate in good faith to enter into a mutually agreeable quality
control agreement relating to, (i)&nbsp;prior to the Processing Assumption Date, the supply by Indevus
to Esprit under this Agreement of Trospium Once-Daily Finished Products and/or Samples, (ii)&nbsp;prior
to the NDA Transfer Date, the supply by Indevus to Esprit under this Agreement of Trospium
Twice-Daily Finished Products and/or Samples, and (iii)&nbsp;after the Processing Assumption Date (A)
and prior to the NDA Transfer Date, the supply by Esprit under this Agreement of Trospium
Once-Daily Finished Products and/or Samples, and (B)&nbsp;if the Ex-US Supply Agreement is entered into,
the supply by Esprit to Indevus of Trospium Once-Daily Finished Products and/or Samples or bulk
capsules of Trospium Once-Daily prior to being in its finished, labeled and packaged form, for use
in jurisdictions outside the Territory.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.10 Inspection; Non-conformance.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Inspection Upon Delivery. </B>Upon receipt of the Finished Products and/or Samples in any
shipment, Esprit or its designee may inspect such Finished Products and/or Samples and assay
samples thereof. If Esprit finds that any Finished Products and/or Samples delivered to Esprit
hereunder fails to meet Specifications upon delivery to Esprit, then Esprit shall provide Indevus
with a written notice (the &#147;<B>Non-conformance Notice</B>&#148;) within five (5)&nbsp;days after determination of
non-conformance and within thirty (30)&nbsp;days after receipt of such Finished Products and/or Samples
by Esprit. Esprit shall retain the Finished Products and/or Samples claimed to be non-conforming
and Indevus or its designee shall have the right to inspect
such Finished Products and/or Samples. In the event Indevus does not respond in writing,
within
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->76<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">thirty (30)&nbsp;days after the date of a Non-conformance Notice, Indevus shall be deemed to be
in agreement with Esprit&#146;s determination of non-conformance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Undisputed Claims. </B>Indevus shall, if it agrees with Esprit&#146;s determination of
non-conformance, replace any such non-conforming Finished Products and/or Samples with an equal
quantity of Finished Products and/or Samples complying with the Specifications at no additional
cost to Esprit and without undue delay; <U>provided</U> that Catalent, Helsinn and Madaus have not
breached their respective obligations relating to the supply of Compound, Finished Products and/or
Samples, as applicable, under the Catalent Agreements, the Helsinn Agreements, the Madaus Supply
Agreement, respectively. Esprit shall dispose of any Finished Products and/or Samples that are not
in compliance with the Specifications at Indevus&#146; cost, except that Esprit shall follow any
reasonable instructions from Indevus to return to Indevus or its designee or otherwise dispose of
such non-conforming Finished Products and/or Samples in another manner at Indevus&#146; cost. If
Indevus is in agreement with the determination of non-conformance, Esprit may credit any amounts
representing any charges relating to such non-conforming and replacement Finished Products and/or
Samples or receive a refund of any amounts paid. In the event that any Finished Products and/or
Samples shipment or Batch thereof is ultimately agreed or found to meet the Specifications, Esprit
shall accept and pay for such shipment or Batch.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Prior to the Processing Assumption Date, Indevus will assume responsibility for all FDA
mandated tests for the Finished Products and/or Samples as described in or committed to in the
applicable Product NDA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Disputed Claims. </B>If Indevus does not agree with Esprit&#146;s determination of
non-conformance, then Indevus shall provide Esprit with a written notice of such disagreement
within thirty (30)&nbsp;days after receipt of the Non-Conformance Notice, responding to Esprit&#146;s claim.
The Supply Committee shall use commercially reasonable efforts to resolve such disagreement within
ten (10)&nbsp;Business Days after Esprit&#146;s receipt of Indevus&#146; notice of disagreement. In the event
that the Supply Committee cannot resolve the issue, the Supply Committee shall submit the disputed
Finished Products and/or Samples to an independent testing laboratory, to be agreed upon by the
Supply Committee, for testing in accordance with the Testing Methods. The findings of such
laboratory shall be binding on the Parties, absent manifest error. Expenses of such independent
testing shall be borne by either Esprit or Indevus depending on which Party&#146;s testing results were
in error. Until such time as the disagreement is resolved, no Finished Products and/or Samples
from the lot tested shall be released.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.11 Inventory Management. </B>Esprit shall maintain inventory of Finished Products and/or Samples in accordance with
Esprit&#146;s usual and customary inventory management practices that Esprit applies to its other
products.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.12 Shortages; Failure to Supply. </B>If for any reason Indevus shall be, or reasonably believes that it shall be, unable to
satisfy Esprit&#146;s ordered quantities for Finished Products and/or Samples pursuant to Purchase
Orders submitted under Section&nbsp;14.6, then Indevus shall: (a)&nbsp;give Esprit prompt notice thereof,
(b)&nbsp;if such failure to supply lasts for a
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->77<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">consecutive &#091;...***...&#093; period, implement
Commercially Reasonable Efforts to remedy such shortage, and (c)&nbsp;if such inability is partial,
fulfill firm orders with such quantities of Finished Products and/or Samples as are available and
shall continue to use its Commercially Reasonable Efforts to fulfill orders on a timely basis. If
Indevus fails to supply on a timely basis the quantities of Finished Products and/or Samples
ordered pursuant to Section&nbsp;14.6, in addition to any other remedy available to Esprit, at Esprit&#146;s
sole discretion and upon notice to Indevus, such shortfall may be carried over and added to the
quantity of such Finished Products and/or Samples forecasted for the next delivery. Absent any
such notice from Esprit, however, there shall be no such carryover, and Esprit shall not be
obligated to accept a late delivery of shortfall. If Indevus or its Third Party Manufacturer
delivers a greater quantity of Finished Products and/or Samples than has been ordered, Esprit shall
not be obligated to purchase such overage and, at Indevus&#146; option, Esprit may dispose of same or
return same to Indevus or its Third Party manufacturer at Indevus&#146; direction and expense. Esprit
shall, however, have the option to treat such overage as an advance delivery of the next quantity
to be delivered or, alternatively, to accept and pay for such overage.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.13 Assumption of Processing Activities.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>On the Processing Assumption Date, Esprit shall be required to assume responsibility for
the performance of the Processing Activities in the Territory performed as of the Processing
Assumption Date by Indevus (but not its Third Party Manufacturers) in the Territory, subject to and
in accordance with the provisions of this Section&nbsp;14.13. Esprit shall provide written notice to
Indevus of the Processing Assumption Date at least ninety (90)&nbsp;days prior to the projected
Processing Assumption Date. Thereupon, the Parties, in coordination with the Supply Committee,
shall establish a plan for Esprit to so undertake such activities, which plan shall include the
activities set forth in this Section&nbsp;14.13. Notwithstanding anything to the contrary set forth in
this Agreement, Indevus shall, prior to or after, as applicable, the Processing Assumption Date,
complete the activities set forth on Schedule&nbsp;14.13(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Notwithstanding anything to the contrary set forth in this Agreement, Esprit&#146;s assumption
of responsibility for the performance of all or any portion of any Processing Activities then being
conducted by Indevus or through Catalent and/or Helsinn shall include Esprit&#146;s assumption of
Indevus&#146; obligations under the Catalent Agreements and/or Helsinn Agreements with respect to
Trospium Once-Daily, including any minimum purchase requirements or obligations or amounts required
to be paid by Indevus to Catalent and/or Helsinn, as applicable, in the event of any early
termination of the Catalent Agreements or Helsinn Agreements, as applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Technology Transfer. </B>Promptly following Indevus&#146; receipt of Esprit&#146;s written notice of
the Processing Assumption Date and thereafter for at least one hundred
twenty (120)&nbsp;days, Indevus shall commence the transfer to Esprit or its designee, or, to the
extent permitted under the applicable agreements with Indevus&#146; Third Party Manufacturer(s), use
reasonable efforts to arrange for the applicable Third Party Manufacturer to commence the transfer
to Esprit, of all technical information, regulatory information and other information and materials
reasonably necessary for Esprit to assume responsibility for the Processing Activities
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->78<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">under
Section&nbsp;14.13(a), and the Parties shall establish such operational procedures as are reasonably
necessary for Esprit to assume such responsibility. In connection therewith, Esprit shall agree in
writing to the same confidentiality obligations to which Indevus is then subject with respect to
any such Third Party Manufacturer(s). Such transfer shall include reasonable time to consult with
Indevus&#146; technical personnel (and, to the extent available, its Third Party Manufacturer(s)&#146;
technical personnel) with respect to the Processing Activities during the transfer and for a period
of up to six (6)&nbsp;months after the Processing Assumption Date. Indevus shall use commercially
reasonable efforts to cause its Third Party Manufacturer(s) to provide Esprit with such access to
such personnel and activities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>On the Processing Assumption Date, (i)&nbsp;the license under Section&nbsp;2.1(c) shall become
effective, (ii)&nbsp;if the Ex-US Supply Agreement is entered into between the Parties, the Catalent
Agreement, and all rights and obligations thereunder, shall be assigned to and assumed by Esprit in
its entirety, (iii)&nbsp;if the Ex-US Supply Agreement is not entered into between the Parties, the
Catalent Agreement, and all rights and obligations thereunder relating to the manufacture and
supply of Finished Product and Samples of Trospium Once-Daily in the Territory, shall be assigned
to and assumed by Esprit, (iv)&nbsp;Esprit shall assume Indevus&#146; obligations under all Purchase Orders
submitted by Indevus to its Third Party Manufacturers to satisfy Trospium Once-Daily Purchase
Orders submitted by Esprit prior to the Processing Assumption Date, (v)&nbsp;if Indevus has exercised
the Ex-US Supply Option, Indevus and Esprit shall enter into the Ex-US Supply Agreement, and (vi)
either (A)&nbsp;the Helsinn Agreements, and all rights and obligations thereunder, shall be assigned to
and assumed by Esprit in its entirety, or (B)&nbsp;in the event that Helsinn reasonably withholds its
consent to assignment of the Helsinn Agreements to Esprit, Indevus will use commercially reasonable
efforts to have Esprit added as a co-party to the Helsinn Agreements or allow Espirit and Helsinn
to enter into a new supply agreement for Compound. If Esprit assumes the rights and obligations of
the Helsinn Agreements in their entirety, Espirit will be obligated to supply Indevus under the
same terms and condition of the Helsinn Agreements; <U>provided</U> that Indevus shall assign the
Helsinn Agreements to Esprit on or before the NDA Transfer Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;Payment Obligations.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;Reimbursement of Expenses. </B>Esprit shall bear and reimburse Indevus for any out of pocket
expenses actually incurred by Indevus and payable to any Third Party Manufacturer in connection
with such transfers and activities or Esprit&#146;s assumption of the Processing Activities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;Supply Price Payments. </B>In addition to any payments of the Supply Price for Products
shipped prior to the Processing Assumption Date, within thirty (30)&nbsp;days after the Processing
Assumption Date, Esprit shall reimburse Indevus for the Supply
Price to the extent incurred by Indevus with respect to supply of Products by Third Parties
prior to the Processing Assumption Date with respect to Trospium Once-Daily Purchase Orders
submitted by Esprit prior to the Processing Assumption Date but for which the Forecasted Supply
Price has not yet been paid by Esprit; <U>provided</U> that such Products are held for the
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->79<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">account
of or delivered to Esprit and/or Esprit&#146;s designee. For clarity, in no event shall a charge based
on the same inventory be required to be paid more than once.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;Unused Inventory of Compound. </B>In addition to any payments required as a result of the
true-up of the Supply Price for Finished Products and/or Samples shipped prior to the Processing
Assumption Date in accordance with Section&nbsp;14.8(b), after the Processing Assumption Date, at
Indevus&#146; request, Esprit shall purchase from Indevus all or any portion of Compound in inventory as
of the Processing Assumption Date that meets applicable specifications at a price equal to Indevus&#146;
Product Procurement Cost for such Compound. For clarity, in no event shall a charge based on the
same inventory be required to be paid more than once.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iv)&nbsp;Payments to Madaus. </B>After the Processing Assumption Date, Esprit shall continue to be
responsible for and shall pay Indevus the payments required to be paid by Indevus to Madaus under
Section&nbsp;3.7(b)(2) of the Madaus License.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;Transfer of Responsibility. </B>Unless and until transfer of the Processing Activities has
been transferred to Esprit and Esprit shall have acknowledged in writing to Indevus that Esprit is
ready to assume responsibility for such Processing Activities on a specified Processing Assumption
Date, Indevus shall remain responsible for such Processing Activities hereunder. Upon Esprit&#146;s
assumption of such Processing Activities, Indevus shall be relieved from all its obligations
hereunder as they apply to the Processing Activities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.14 Ex-US Supply Agreement. </B>Indevus shall have the option (the &#147;<B>Ex-US Supply Option</B>&#148;) to request that, commencing at
any time on or after the Processing Assumption Date, Esprit supply bulk drug product of Trospium
Once-Daily, in the form prior to being in its finished and package form and as manufactured for the
Territory, to Indevus and/or its designees for jurisdictions outside the Territory. In the event
Indevus elects to exercise the Ex-US Supply Option, it shall provide a written notice of such
election to Esprit. The Parties shall then negotiate in good faith to enter into the Ex-US Supply
Agreement, which shall in any event contain terms and conditions intended to ensure compliance with
the supply obligations of Article&nbsp;V of the Madaus License and Supply Agreement, within sixty (60)
days after the date of such election notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.&nbsp;</B><FONT style="font-variant: SMALL-CAPS"><B>Miscellaneous</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.1 Force Majeure. </B>Neither Party shall be held liable or responsible to the other Party nor be deemed to have
defaulted under or breached the Agreement for failure or delay in fulfilling or performing
any term of the Agreement during the period of time when such failure or delay is caused by or
results from a Force Majeure event or act, omission or delay in acting by the other Party. The
affected Party shall notify the other Party of such Force Majeure circumstances as soon as
reasonably practicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.2 Assignment. </B>The Agreement may not be assigned or otherwise transferred without the prior written
consent of the other Party; <U>provided</U>, <U>however</U>, that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->80<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Indevus may assign this Agreement to an Affiliate or a Third Party in connection with the
transfer or sale of its business or all or substantially all of its assets or in the event of a
merger, consolidation, change in control or similar corporate transaction, without such consent;
<U>provided</U>, <U>however</U>, that such assignment shall not relieve Indevus of its
responsibilities for performance of its obligations under this Agreement, and <U>further</U>
<U>provided</U> that, in the event of any such assignment, any payment due to Esprit under this
Agreement must be received in its full amount by Esprit in the United States without any
withholding or deduction therefrom and any payment made by Esprit to any such Indevus assignee
organized in a country outside the United States shall be net of any applicable withholding tax;
and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Esprit may assign this Agreement to any Affiliate of Esprit at the time of such assignment
or in connection with the transfer or sale of Esprit&#146;s business or all or substantially all of
Esprit&#146;s assets as a whole or in the event of a merger, consolidation, change in control or similar
corporate transaction with respect to Esprit (any of the foregoing, for purposes of this Section
15.2, a &#147;<B>Corporate Transaction</B>&#148;), without such consent; <U>provided</U>, <U>however</U>, that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>such consent shall be required in connection with the transfer or sale of all or
substantially all of Esprit&#146;s assets relating to Product or the subject matter of this Agreement,
except where such transfer or sale would constitute a transfer or sale of all or substantially all
of Esprit&#146;s assets as a whole and would constitute a Corporate Transaction;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>in the event Esprit or any of its Affiliates: (A)&nbsp;signs a definitive agreement with
respect to a Corporate Transaction by operation of which Esprit or any of its Affiliates would (1)
acquire a product which causes the Department of Justice or the Federal Trade Commission (or any
successor or other federal agency similar thereto) to require the divestiture of a product other
than a Product or of a Product (a &#147;<B>Divestiture Causing Product</B>&#148;), or (2)&nbsp;be acquired by or merge
with a Third Party who has a Divestiture Causing Product; or (B)&nbsp;as a result of any other event or
transaction or series of events or transactions, engages in a Corporate Transaction that results in
the common ownership of both Product and a Divesture Causing Product; then Esprit or its Affiliate
(or the other Party to the Corporate Transaction) shall divest the Divesture Causing Product,
<U>provided</U> that any divestiture of Product will result in the automatic termination of this
Agreement; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii)&nbsp;</B>such assignment shall not relieve Esprit of its responsibilities for performance of its
obligations under this Agreement, and <U>further</U> <U>provided</U> that, in the event of any
such assignment, any payment due to Indevus under this Agreement must be received in its full
amount by Indevus in the United States without any withholding or deduction therefrom and any
payment made by Indevus to any such Esprit assignee organized in a country outside the United
States shall be net of any applicable withholding tax.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Agreement shall be binding upon and inure to the benefit of the successors and permitted
assigns of the Parties. Any assignment not in accordance with this Agreement shall be void.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of the document filed as an Exhibit omits the confidential information subject to the
confidentiality request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document has
been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->81<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.3 Severability. </B>In the event that any of the provisions contained in this Agreement are
held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of
the remaining provisions contained herein shall not in any way be affected or impaired thereby,
unless the absence of the invalidated provision(s) adversely affects the substantive rights of the
Parties. In such event, the Parties covenant and agree to renegotiate any such term, covenant or
application thereof in good faith in order to provide a reasonably acceptable alternative to the
term, covenant or condition of this Agreement or the application thereof that is invalid or
unenforceable, it being the intent of the Parties that the basic purposes of this Agreement are to
be effectuated.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.4 Notices.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>Correspondence, reports, documentation, and any other communication in writing between the
Parties in the course of ordinary implementation of this Agreement (but not including any notice
required by this Agreement) shall be in writing and delivered by hand, sent by facsimile, or by
overnight express mail (e.g., FedEx) to any one (1)&nbsp;member of the Development Committee, Marketing
Committee, or Supply Committee as
applicable, appointed by the Party which is to receive such written communication, or any
other way as the Development Committee, Marketing Committee, or Supply Committee, as applicable,
deems appropriate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Extraordinary notices and communications (including notices of termination, force majeure,
material breach, change of address, or any other notices required by this Agreement) shall be in
writing and shall be deemed to have been given when delivered in person, or sent by overnight
courier service (e.g., FedEx), postage prepaid, or by facsimile confirmed by prepaid registered or
certified air mail letter or by overnight express mail (e.g., FedEx), or sent by prepaid certified
or registered air mail, return receipt requested, to the following addresses of the parties (or to
such other address or addresses as may be specified from time to time in a written notice), and
shall be deemed to have been properly served to the addressee upon receipt of such written
communication, to the following addresses of the Parties:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if to Indevus to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">INDEVUS PHARMACEUTICALS, INC.<BR>
33 Hayden Avenue<BR>
Lexington, MA 02421<BR>
Attention: Chief Executive Officer<BR>
Fax No.: 781-862-3859
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if to Esprit to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">ESPRIT PHARMA, INC.<BR>
2 Tower Center Boulevard<BR>
East Brunswick, NJ 08816
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->82<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">Attention: Vice President and General Counsel<BR>
Fax No.: 732-828-9954
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with a copy to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">ALLERGAN, INC.<BR>
2525 Dupont Drive<BR>
Irvine, CA 92612<BR>
Attention: General Counsel<BR>
Fax No.: 714-246-4774
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or to such other address as the Party to whom notice is to be given may have furnished to the other
Parties in writing in accordance herewith. Any such communication shall be deemed to have been
given when delivered if personally delivered or sent by facsimile on a Business Day, upon confirmed
delivery by nationally-recognized overnight courier if so delivered and on the third Business Day
following the date of mailing if sent by registered or certified mail.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.5 Specific Performance. </B>Each of the Parties acknowledges and agrees that the other Party
would be damaged irreparably in the event any of the provisions of this Agreement are not performed
in all material respects or otherwise are breached. Accordingly, and notwithstanding anything
herein to the contrary, each of the Parties agree that the other Party shall be entitled to
injunctive relief to prevent breaches of the provisions of this Agreement, and/or to enforce
specifically this Agreement and the terms and provisions hereof, in any action instituted in any
court or tribunal having jurisdiction over the Parties and the matter, without posting any bond or
other security, and that such injunctive relief shall be in addition to any other remedies to which
such Party may be entitled, at law or in equity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.6 Applicable Law and Venue. </B>This Agreement shall be governed by the laws of the State of
New York. All actions and proceedings arising out of or relating to this Agreement shall be heard
and determined in any New York State or federal court sitting in the City of New York, County of
Manhattan, and the Parties hereby irrevocably submit to the exclusive jurisdiction of such courts
in any such action or proceeding and irrevocably waive any defense of an inconvenient forum to the
maintenance of any such action or proceeding. The United Nations Convention On Contracts For The
International Sale Of Goods shall not apply in any action, suit or proceeding arising out of or
relating to this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.7 Entire Agreement. </B>This Agreement, including the schedules hereto, contains the entire
understanding of the Parties with respect to the subject matter of this Agreement. All express or
implied agreements and understandings, either oral or written, made on or before the Execution
Date, including any offering letters or term sheets, are expressly superseded by this Agreement.
This Agreement may be amended, or any term hereof modified, only by a written instrument duly
executed by all Parties. Notwithstanding the foregoing, on and after the Execution Date and prior
to the Effective Date, the provisions
of the Original Agreement shall continue to apply with
respect to all rights and obligations of the Parties, and with respect to any period(s) occurring
or ending, prior to the Effective Date; and the provisions
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->83<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of the Original Agreement will be
amended, superseded and replaced by this Agreement with respect to all rights and obligations of
the Parties, and with respect to any period(s) occurring or commencing, as of and after the
Effective Date; <U>provided</U>, <U>however</U>, that, notwithstanding the foregoing, the
provisions of Article&nbsp;14 (including all defined terms used in such provisions) shall be effective
as of, and will apply with respect to all rights and obligations of the Parties, and with respect
to any period(s) occurring or commencing, as of and after the Execution Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.8 Independent Contractors. </B>It is expressly agreed that the Parties shall be independent
contractors and that the relationship between the Parties shall not constitute a partnership, joint
venture or agency.



Neither Party shall have the authority to make any statements, representations or commitments
of any kind, or to take any action, that shall be binding on the other Party, without the prior
consent of such other Party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.9 Waiver. </B>The waiver by a Party hereto of any right hereunder or the failure to perform or
of a breach by another Party shall not be deemed a waiver of any other right hereunder or of any
other breach or failure by said other Party whether of a similar nature or otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.10 Headings; References; Interpretation. </B>The captions to the several Articles, Schedules
or Sections of this Agreement are not a part of the Agreement, but are merely guides or labels to
assist in locating and reading the several Articles, Schedules or Sections of this Agreement.
Where words and phrases are used herein in the singular, such usage is intended to include the
plural forms where appropriate to the context, and vice versa. The words &#147;including&#148;, &#147;includes&#148;
and &#147;such as&#148; are used in their non-limiting sense and have the same meaning as &#147;including without
limitation&#148; and &#147;including but not limited to&#148;. Any reference in this Agreement to an Article,
Schedule or Section shall, unless otherwise specifically provided, be to an Article, Schedule or
Section of this Agreement. &#147;Herein&#148; means anywhere in this Agreement. &#147;Hereunder&#148; and &#147;hereto&#148;
means under or pursuant to any provision of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.11 Release. </B>On the Execution Date the Esprit shall deliver to Indevus, and Indevus shall
deliver to Esprit, the mutual release in the form attached hereto as Exhibit&nbsp;15.11. As a condition
precedent to the effectiveness of this Agreement, on the Effective Date, the Parties shall deliver
a bring-down mutual release in the form attached hereto as Exhibit&nbsp;15.11.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.12 Counterparts. </B>The Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same
instrument. Signatures to the Agreement transmitted by fax, by email in &#147;portable document format&#148;
(&#147;.pdf&#148;) or by any other electronic means intended to preserve the original graphic and pictorial
appearance of the Agreement shall have the same effect as physical delivery of the paper document
bearing original signature.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>&#091;Remainder of this page intentionally left blank&#093;</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->84<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>IN WITNESS WHEREOF</B></FONT>, the Parties have executed this Agreement as of the Execution
Date.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>INDEVUS PHARMACEUTICALS, INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Glenn L. Cooper, M.D.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chairman and Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>ESPRIT PHARMA, INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
John T. Spitznagel
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE 1.47</B>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a33887a1a3388769.gif" alt="(INDEVUS PHARMACEUTICALS, INC. LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE 3.1</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Development Committee Members</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Indevus designees:</B><BR>
&#091;...***...&#093;

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Esprit designees:</B><BR>
&#091;...***...&#093;

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE 3.2</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Marketing Committee Members</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Indevus designees:</B><BR>
&#091;...***...&#093;

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Esprit designees:</B><BR>
&#091;...***...&#093;

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE 3.3</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Supply Committee Members</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Indevus designees:</B><BR>
&#091;...***...&#093;

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Esprit designees:</B><BR>
&#091;...***...&#093;

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE 14.5(a)</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;...***...&#093;

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE 14.5(b)</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;...***...&#093;

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE 14.8(b)</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Forecasted Supply Price</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Trospium Once-Daily:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;...***...&#093;

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Trospium Twice-Daily:</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;...***...&#093;

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE 14.13(a)</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Manufacturing Scale-Up Requirement</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Prior to the Processing Assumption Date, a validated scaled-up &#091;...***...&#093; for Trospium
Once-Daily Finished Product utilizing &#091;...***...&#093;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Prior to the Processing Assumption Date, successful execution means completion of a formal
validation protocol that requires at least &#091;...***...&#093; full-scale production Batches.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Prior to <B>&#091;...***...&#093; </B>after the Processing Assumption Date, Indevus shall support such
validated process until a success rate of <B>&#091;...***...&#093; </B>is achieved on a total of at least
of <B>&#091;...***...&#093; </B>production Batches.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE 15.11</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Release</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>MUTUAL RELEASE AGREEMENT</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This MUTUAL RELEASE AGREEMENT (this &#147;<B>Agreement</B>&#148;) is made as of the Execution &#091;or Effective,
for the bring-down release&#093; Date (as defined in the Amended and Restated Agreement (as defined
below)), by and between Esprit Pharma, Inc., a Delaware corporation (&#147;<B>Esprit</B>&#148;), and Indevus
Pharmaceuticals, Inc., a Delaware corporation (&#147;<B>Indevus</B>&#148;). Esprit and Indevus are also
individually referred herein as a &#147;<B>Party</B>,&#148; or collectively as the &#147;<B>Parties</B>.&#148;
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RECITALS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;Esprit (as the successor-in-interest to Odyssey Pharmaceuticals, Inc.) and Indevus are
parties to that certain License, Commercialization and Supply Agreement, effective as of April&nbsp;6,
2004, as amended by Amendment No.&nbsp;1 thereto, dated as of April&nbsp;30, 2005, as further amended by the
Amendment and Consent Agreement, dated as of May&nbsp;14, 2005 (collectively, the &#147;<B>Original Agreement</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;In connection with the acquisition of Esprit Pharma Holding Company, Inc., the parent of
Esprit, by Allergan, Inc., Esprit and Indevus believe it to be in their best interest to amend and
restate the Original Agreement by entering into an Amended and Restated License, Commercialization
and Supply Agreement (the &#147;<B>Amended and Restated Agreement</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;As a condition to entering into the Amended and Restated Agreement, each of the Parties
desire to release any and all Claims (as defined below) either Party has against the other, subject
to the terms and conditions of and except as otherwise set forth herein.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in reliance on the mutual covenants, releases, agreements and conditions
contained herein and subject to the provisions and terms of this Agreement and for other good and
valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the Parties
agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<B>Release by Esprit. </B>Effective as of the date hereof, Esprit, on behalf of itself and its
(a)&nbsp;successors, assigns, subsidiaries, predecessors, successors-in-interest and purchasers &#091;for
bring down, including Allergan&#093;; and (b)&nbsp;Affiliates, officers, directors, executives, employees,
and attorneys of Esprit, solely in their respective capacity as Affiliates, officers, directors,
executives, employees, and attorneys, of Esprit, and solely to the extent that Esprit has the
authority to legally bind such
individuals or entities (the &#147;<B>Esprit Representatives</B>&#148;), hereby generally, irrevocably,
unconditionally and completely releases and forever discharges each of
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indevus and the Indevus
Representatives (as defined in Section&nbsp;2) (but, with respect to the Indevus Representatives listed
in Section&nbsp;2(b), only in their capacity as Affiliates, officers, directors, executives, employees,
and attorneys, of Indevus) from and against any and all past and present disputes, claims,
controversies, demands, rights, actions, liabilities, suits, causes of action, obligations, duties,
debts, liens, losses, costs, expenses (including, without limitation, attorneys&#146; fees) and damages
of every nature, kind and description (including, without limitation, breaches of the Original
Agreement or the Amended and Restated Agreement), but excluding continuing obligations under the
Original Agreement or Article&nbsp;14 of the Amended and Restated Agreement that have not, as of the
Execution Date &#091;for bring down: during the period from and after the Execution Date and prior to
the Effective Date&#093;, resulted from a breach of the Original Agreement or Amended and Restated
Agreement (any and all of the above, &#147;<B>Claims</B>&#148;) that any of Esprit or such Esprit Representatives
now has against any of Indevus or such Indevus Representatives, except for those Claims set forth
on <U>Schedule&nbsp;A</U> hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<B>Release by Indevus. </B>Effective as of the date hereof, Indevus, on behalf of itself and its
(a)&nbsp;successors, assigns, subsidiaries, predecessors, successors-in-interest and purchasers; and (b)
Affiliates, officers, directors, executives, employees, and attorneys solely in their respective
capacity as Affiliates, officers, directors, executives, employees, and attorneys, of Indevus, and
solely to the extent that Indevus has the authority to legally bind such individuals and entities
(the &#147;<B>Indevus Representatives</B>,&#148; and, together with the Esprit Representatives, &#147;<B>Representatives</B>,&#148;
as applicable), hereby generally, irrevocably, unconditionally and completely releases and forever
discharges each of Esprit &#091;and Allergan &#091; to be included in Effective Date bring down release&#093;&#093; and
the Esprit Representatives (but, with respect to the Esprit Representatives listed in Section&nbsp;1(b),
only in their capacity as Affiliates, officers, directors, executives, employees, and attorneys, of
Esprit) from and against any and all Claims that any of Indevus or such Indevus Representatives now
has against any of Esprit &#091;and Allergan &#091; to be included in Effective Date bring down release&#093;&#093; or
such Esprit Representatives, except for those Claims set forth on <U>Schedule&nbsp;B</U> hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<B>Section&nbsp;1542 Waiver. </B>Each Party, on its own behalf and on behalf of its respective
Representatives, (a)&nbsp;represents, warrants and acknowledges that such Party has had, or has had and
waived, the opportunity to be advised by independent legal counsel as to the contents of Section
1542 of the Civil Code of the State of California (an any analogous law of any other state,
locality or other jurisdiction) and (b)&nbsp;hereby expressly waives the benefits and protections
thereof and any rights such Party may have thereunder. Section&nbsp;1542 of the Civil Code of the State
of California provides as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&#147;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES
NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF
EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE
MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.&#148;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Each Party, on its behalf and on behalf of its Representatives, understands and acknowledges the
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">significance and consequence of its specific waiver of Section&nbsp;1542 of the Civil Code of the State
of California and hereby assumes full responsibility for any injuries, damages, and losses which it
may incur as a result of its waiver of Section&nbsp;1542 of the Civil Code of the State of California.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<B>Agreement as Bar to Future Actions. </B>The Parties understand and agree that this Agreement
may be pleaded as a full and complete defense to, and may be used as the basis of an injunction
(without the requirement of any security or undertaking) or order of dismissal with prejudice by
any court of competent jurisdiction, against any motion, suit, or other proceeding that may be
instituted, prosecuted, or attempted by either of the Parties hereto in breach of this Agreement.
The Parties further agree that if one of them (the &#147;<B>Breaching Party</B>&#148;) should hereafter commence any
suit or otherwise assert any claim against one of the other Party (the &#147;<B>Non-Breaching Party</B>&#148;)
concerning any of the Claims released by this Agreement, the Breaching Party shall be
unconditionally obligated to pay to the Non-Breaching Party all of such Non-Breaching Party&#146;s
reasonable costs of defense against such claim, including but not limited to such Non-Breaching
Party&#146;s reasonable attorneys&#146; fees and all other costs of suit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<B>Representations and Warranties. </B>Each Party hereby represents and warrants that as of the
Execution Date &#091;to be Effective Date for bring-down release&#093;:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) neither the Party or its Representatives has assigned, transferred, conveyed or
otherwise disposed of any Claim against the other Party or its Representatives, or any
direct or indirect interest in any such Claim, in whole or in part;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) to the best of such Party&#146;s knowledge, no other person or entity has any interest
in any of the released Claims;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) this Agreement has been duly and validly executed and delivered by such Party;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) neither the execution and delivery of this Agreement nor the performance hereof
will (i)&nbsp;result in any violation or breach of any agreement or other instrument to which
such Party or any of its Representatives is a party or by which such Party or any of its
Representatives is bound, or (ii)&nbsp;result in a violation or any law, rule, regulation,
treaty, ruling, directive, order, arbitration award, judgment or decree to which such Party
or any of its Representatives is subject; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) no authorization, instruction, waiver, consent or approval of any person or entity
is required to be obtained by such Party or any of such Party&#146;s Representatives in
connection with the execution and delivery of this Agreement or the performance hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<B>Modification/Waivers. </B>This Agreement may only be modified, amended or changed by an
agreement in writing signed by both Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<B>Binding Effect. </B>This Agreement and each provision hereof shall bind and inure
to the benefit of the respective heirs, successors, transferees, assigns and personal
representatives
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of the Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<B>Governing Law. </B>This Agreement shall be deemed to have been entered into in the State of
New York and all questions concerning the validity, interpretation, or performance of any of its
terms or provisions or of any rights or obligations of the Parties hereto shall be governed by and
resolved in accordance with the laws of the State of New York.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<B>Venue and Jurisdiction. </B>Each Party, on its behalf and on behalf of its Representatives,
hereby agrees that any legal action or other legal proceeding relating to this Agreement or the
enforcement of any provision of this Agreement shall be brought or otherwise commenced by a Party
in a state or federal court located in the State of New York. Each Party, on its behalf and on
behalf of its Representatives, hereby:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) expressly and irrevocably consents and submits to the nonexclusive jurisdiction of
each state and federal court located in the State of New York in connection with any such
legal proceeding;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) agrees that each state and federal court located in the State of New York shall be
deemed to be a convenient forum;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) agrees not to assert (by way of motion, as a defense or otherwise), in any such
legal proceeding commenced in any state or federal court located in the State of New York,
any claim that it is not subject personally to the jurisdiction of such court, that such
legal proceeding has been brought in an inconvenient forum, that the venue of such
proceeding is improper or that this Agreement or the subject matter of this Agreement may
not be enforced in or by such court; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) agrees that nothing contained in this Agreement shall be deemed to limit or
otherwise affect the right of a Party to raise this Agreement as a defense in any legal
proceeding in any other forum or jurisdiction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<B>Severability. </B>Any term or provision of this Agreement that is invalid or unenforceable in
any situation in any jurisdiction shall not affect the validity or enforceability of the remaining
terms and provisions hereof or the validity or enforceability of the offending term or provision in
any other situation or in any other jurisdiction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<B>Counterparts. </B>This Agreement may be executed in one or more counterparts, each of which
shall be deemed an original for all purposes and all of which, when taken together, shall
constitute one and the same agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>signature pages follows</I>&#093;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>IN WITNESS WHEREOF,</B></FONT> the Parties have caused this Agreement to be executed as of the
Execution Date &#091;To be Effective Date for bring down release&#093;.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>INDEVUS PHARMACEUTICALS, INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Glenn L. Cooper, M.D.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chairman and Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>ESPRIT PHARMA, INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>signature pages to Mutual Release Agreement</I>&#093;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE A</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>EXCLUDED ESPRIT CLAIMS</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1. With respect to the Release dated as of the Execution Date: None.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2. With respect to the Release dated as of the Effective Date: any Claims with respect to
payments that have become due under and pursuant to the Original Agreement or Article&nbsp;14 of the
Amended and Restated Agreement on or after the Execution Date and that are unpaid as of the
Effective Date, as specifically scheduled below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>&#091;To be added in release dated as of the Effective Date.&#093;</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULE B</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>EXCLUDED INDEVUS CLAIMS</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1. With respect to the Release dated as of the Execution Date: None.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2. With respect to the Release dated as of the Effective Date: any Claims with respect to
payments that have become due under and pursuant to the Original Agreement or Article&nbsp;14 of the
Amended and Restated Agreement on or after the Execution Date and that are unpaid as of the
Effective Date, as specifically scheduled below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>&#091;To be added in release dated as of the Effective Date.&#093;</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Confidential treatment has been requested for portions of this document. This copy of
the document filed as an Exhibit omits the confidential information subject to the confidentiality
request. Omissions are designated by the symbol &#091;...***...&#093;. A complete version of this document
has been provided separately to the Securities and Exchange Commission.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT D</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ESCROW AGREEMENT</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS ESCROW AGREEMENT (this &#147;<U>Agreement</U>&#148;) dated as of October &#95;&#95;&#95;, 2007 by and among
&#091;Parent&#093;, Inc., a Delaware corporation (&#147;<U>Parent</U>&#148;), Andrew J. Einhorn as agent and
attorney-in-fact (the &#147;<U>Representative</U>&#148;) for certain stockholders of &#091;Sprite&#093;, Inc., a
Delaware corporation (the &#147;<U>Company</U>&#148; and, after the Effective Time, the &#147;<U>Surviving
Corporation</U>&#148;), and &#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;, as escrow agent (the &#147;<U>Escrow Agent</U>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>RECITALS</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Agreement and Plan of Merger dated as of September&nbsp;18, 2007 (the &#147;<U>Merger
Agreement</U>&#148;) by and among Parent, Esmeralde Acquisition, Inc., a Delaware corporation and a
wholly owned subsidiary of Parent (&#147;<U>Merger Sub</U>&#148;), the Company and the Representative,
Merger Sub will merge with and into the Company and the Company will become a wholly-owned
subsidiary of Parent. Capitalized terms used and not otherwise defined herein shall have the
meanings ascribed thereto in the Merger Agreement. All interest or other income earned from the
investment of the Escrow Funds or any portion thereof (the &#147;<U>Earnings</U>&#148;) shall not become
part of the Escrow Funds and shall not be made available to satisfy Parent Claims.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent will deliver or cause to be delivered to the Escrow Agent an amount in cash equal to
the sum of Twenty Seven Million Seven Hundred Fifty Thousand Dollars ($27,750,000) (the
&#147;<U>Indemnification Escrow Amount</U>&#148;) and One Million Dollars ($1,000,000) (the &#147;<U>Net Working
Capital Escrow Amount</U>&#148;) at the Closing pursuant to Section&nbsp;3.02 of the Merger Agreement, which
amounts (the &#147;<U>Escrow Funds</U>&#148;), are to be held in escrow by the Escrow Agent pursuant hereto
and released in accordance with the terms hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, the parties agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1. <U>Escrow Funds Subject to Agreement</U>. The Escrow Agent hereby agrees to act
as escrow agent subject to the terms of this Agreement. The Escrow Agent shall accept delivery of,
hold and safeguard the Escrow Funds in an escrow account specifically established and maintained
for the purpose outlined below (the &#147;<U>Escrow Account</U>&#148;) pursuant to the terms hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2. <U>Investment of Escrow Funds</U>. The Escrow Funds shall be invested by the
Escrow Agent in Permitted Investments. The term &#147;<U>Permitted Investments</U>&#148; means the
following investments so long as they have maturities of ninety (90)&nbsp;days or less: (a)&nbsp;obligations
issued or guaranteed by the United States or by any person controlled or supervised by or acting as
an instrumentality of the United States or by any person controlled or supervised by or acting as
an instrumentality of the United States pursuant to authority granted by Congress; (b)&nbsp;obligations
issued or guaranteed by any state or political subdivision thereof rated either AAA or higher, or
MIG 1 or higher, by Moody&#146;s Investors Service, Inc. (&#147;<U>Moody&#146;s</U>&#148;) or AAA or higher, or an
equivalent, by Standard &#038; Poor&#146;s Corporation (&#147;<U>Standard &#038; Poor&#146;s</U>&#148;), both of New York, New
York, or their successors; (c)&nbsp;commercial or finance paper which is rated either Prime-1 or higher
or an equivalent by Moody&#146;s or A-1 or higher or an equivalent by Standard &#038; Poor&#146;s or their
successors; and (d)&nbsp;certificates of deposit or time deposits of banks or trust companies, organized
under the laws of the United States and having minimum equity of $500,000,000. The
Escrow Agent shall be entitled to rely upon the written certification of Parent and the
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Representative as to the characterization of the investment as a Permitted Investment, and shall
have no liability to ascertain whether or not the investment is a Permitted Investment. In the
absence of such written directions, the Escrow Agent shall invest the Escrow Funds in the
&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;. The parties acknowledge that shares in this mutual fund are not obligations
of the Escrow Agent, are not deposits and are not insured by the FDIC. The Escrow Agent or its
affiliate may be compensated by the mutual fund for services rendered in its capacity as investment
advisor, or other service provider, and such compensation is both described in detail in the
prospectus for the fund, and is in addition to compensation, if any, paid to the Escrow Agent in
its capacity as escrow agent hereunder. Until disbursement pursuant to the terms hereof, Earnings
will be deposited into the Escrow Account and invested with the Escrow Funds. The Escrow Agent
shall not be accountable for any losses resulting from the sale or depreciation in the market value
of such investments thereof, unless such loss results from the Escrow Agent&#146;s gross negligence,
fraud or willful misconduct.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3. <U>Tax Treatment and Reporting</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The parties hereto agree to treat the Escrow Funds as owned by Parent and not received by
the Escrow Participants unless and until paid to the Escrow Participants pursuant to this
Agreement, and to file all Tax Returns on a basis consistent with such treatment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The parties hereto agree that, for Tax reporting purposes, Earnings in any Tax year shall
be treated as having been realized by the Escrow Participants for United States federal income tax
purposes. Unless otherwise required by law, the parties hereto agree that, for United States
federal income tax purposes, each Escrow Participant shall report Earnings as its income and shall
report related expenses as its expense, in each case in accordance with each Escrow Participant&#146;s
Aggregate Proceeds Contribution Fraction. Notwithstanding anything to the contrary in this
Agreement, the Escrow Agent shall, not later than five (5)&nbsp;Business Days after the end of each
calendar quarter, distribute the Earnings for the preceding calendar quarter to the Representative
by wire transfer for distribution by the Representative to the Escrow Participants (in accordance
with each Escrow Participant&#146;s Aggregate Proceeds Contribution Fraction). The Escrow Agent
annually shall file information returns (if any) with the IRS and provide payee statements to
Parent, documenting such Earnings.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Any disbursement of amounts in the Escrow Account to Escrow Participants shall be treated
for United States federal income tax purposes as consisting, in part, of imputed interest in
accordance with the Code and Treasury Regulations promulgated thereunder. The Escrow Agent shall
timely file information statements with the IRS and provide payee statements to Escrow Participants
documenting each Escrow Participant&#146;s share of the imputed interest or any payment made hereunder.
The Escrow Agent shall inform Parent that the Escrow Agent filed such information returns and
provided such payee statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Parent and the Escrow Participants agree to provide the Escrow Agent with any forms and
documents that the Escrow Agent may reasonably request to complete any information returns and
payee statements (collectively, the &#147;<U>Tax Reporting Documentation</U>&#148;), prior to any
distribution to Parent or the Escrow Participants. The parties hereto understand that, in the
event the Tax Reporting Documentation is not provided to the Escrow Agent, the Internal Revenue
Code of 1986, as amended, may require withholding of a portion of any imputed interest or other
payments made to Parent or the Escrow Participants. To the extent that
amounts are so withheld by the Escrow Agent, such withheld amounts shall be treated for all
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">purposes of this Agreement as having been paid to Parent or the Escrow Participants, as
appropriate, in respect of whom such deduction and withholding was made by the Escrow Agent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4. <U>Net Working Capital Escrow Fund</U>. Upon receipt by the Escrow Agent of a
written notice from Parent or the Representative setting forth how the Net Working Capital Escrow
Amount is to be distributed and released, accompanied by either (i)&nbsp;an executed written agreement
between Parent and the Representative with respect to such distribution and release or (ii)&nbsp;a
written decision of the Accounting Firm with respect to such distribution and release, the Escrow
Agent shall promptly pay to Parent from the Net Working Capital Escrow Amount and, to the extent
the Net Working Capital Escrow Amount is insufficient, the Indemnification Escrow Amount, the
Closing Net Working Capital Shortage, if any, and release any remaining portion of the Net Working
Capital Escrow Amount from the Escrow Account to the Representative by wire transfer for
disbursement by the Representative to each Escrow Participant based on such Escrow Participant&#146;s
Aggregate Proceeds Contribution Fraction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 5. <U>Indemnification Escrow Fund</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Notices of Claims and Dispute Notices</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) With respect to any Parent Claim that Parent reasonably believes exists, or
reasonably believes will exist, Parent may deliver to the Escrow Agent a written notice (a
&#147;<U>Notice of Claim</U>&#148;), which shall set forth in reasonable detail (to the extent known)
the nature of such Parent Claim and an estimate of the aggregate amount to which Parent
believes it is at that time, or will be, entitled to be paid out of the Indemnification
Escrow Amount pursuant to the Merger Agreement. Parent shall send a copy of the Notice of
Claim to the Representative at the same time that it sends such Notice of Claim to the
Escrow Agent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Escrow Agent may liquidate any Permitted Investment in order to make available
a sufficient portion of the Indemnification Escrow Amount, if and as necessary, and shall
pay to Parent, or such Person designated by Parent, therefrom the amount set forth in a
Notice of Claim as soon as practicable, but no earlier than thirty one (31)&nbsp;days following
receipt by the Escrow Agent of such Notice of Claim; <I>provided</I>, <I>however</I>, that if within the
period of thirty (30)&nbsp;days following receipt by the Escrow Agent of such Notice of Claim,
the Escrow Agent shall have received from the Representative a written notice (a
&#147;<U>Dispute Notice</U>&#148;) stating that the Representative disputes the validity or the
amount specified in such Notice of Claim or any portion thereof (a &#147;<U>Disputed
Amount</U>&#148;) and providing in reasonable detail the reasons therefor, the Escrow Agent shall
not pay any such Disputed Amount (but shall pay any amount specified in such Notice of Claim
that is not in dispute) to Parent, or such Person designated by Parent, other than pursuant
to Section 3(b) of this Agreement. The Representative shall send a copy of each Dispute
Notice to Parent at the same time that the Representative sends such Dispute Notice to the
Escrow Agent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) If the Escrow Agent shall not have received a Dispute Notice with respect to the
amount specified in a Notice of Claim, or a portion thereof, within the period of thirty
(30)&nbsp;days following its receipt of such Notice of Claim, the Representative and the
Escrow Participants shall be forever barred and precluded from contesting in any manner
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">or forum whatsoever the distribution of the Escrow Funds on account of such amount not so
disputed (except to dispute the delivery by Parent of a Notice of Claim to the
Representative), and the Escrow Agent shall pay such amount to Parent, or such Person
designated by Parent in writing, in accordance with the preceding paragraph (ii)&nbsp;of this
Section&nbsp;5(a).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Notwithstanding the foregoing, the Escrow Agent may pay to Parent, or any Person
designated by Parent in writing, the amount set forth in a Notice of Claim earlier than
thirty (31)&nbsp;days following receipt by the Escrow Agent of such Notice of Claim, <I>provided</I>
that the Parent delivers to the Escrow Agent a Notice of Claim executed by both Parent and
the Representative authorizing the Escrow Agent to release such specified amount of the
Escrow Funds to Parent. In the event that the Representative authorizes the Escrow Agent to
release such specified amount of the Escrow Funds by executing a Notice of Claim with
Parent, the Representative and the Escrow Participants shall be forever barred and precluded
from contesting in any manner or forum whatsoever the distribution of the Escrow Funds on
account of such amount.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Disputed Amounts</U>. Upon receipt by the Escrow Agent of a written notice (a
&#147;<U>Resolution Notice</U>&#148;) from Parent and/or the Representative with respect to a Disputed
Amount specifying the amount of such Disputed Amount to which Parent is entitled, accompanied by
either (i)&nbsp;an executed written agreement between Parent and the Representative with respect to such
Disputed Amount or (ii)&nbsp;an award, judgment, decree or order of the arbitrators pursuant to Section
5(c) below, the Escrow Agent shall pay to Parent, or such Person designated by Parent, from the
Indemnification Escrow Amount the amount to which Parent is entitled, if any.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Dispute Resolution</U>. In the event of a Disputed Amount, the Parent and the
Representative shall in good faith negotiate to settle such Disputed Amount. If no resolution is
reached within thirty (30)&nbsp;days after delivery of the Dispute Notice to the Escrow Agent, either
party may demand arbitration of the dispute pursuant to Section&nbsp;12.13 of the Merger Agreement. The
decision of the arbitrator shall be written and shall set forth the award, judgment, decree or
order of the arbitrator. Judgment upon any such award, judgment, decree or order may be entered in
any court having competent jurisdiction. The non-prevailing party in any such arbitration, as
determined by the arbitrator, shall bear all fees, costs and expenses related to such arbitration,
including the reasonable attorneys&#146; fees and costs incurred by the other party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Release of the Indemnification Escrow Fund</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) On the date that is nine (9)&nbsp;months after the date of this Agreement (the
&#147;<U>First Distribution Date</U>&#148;), the Escrow Agent will release to the Representative by
wire transfer for distribution by the Representative to the Escrow Participants (in
accordance with each Escrow Participant&#146;s Aggregate Proceeds Contribution Fraction) the
positive difference, if any, between (A)&nbsp;the Indemnification Escrow Amount and (B)&nbsp;the sum
of (i)&nbsp;the aggregate amount of the payments, if any, previously made to Parent, the Escrow
Participants or the Escrow Agent out of the Escrow Funds (other than pursuant to Section
3(b) or Section&nbsp;4) in accordance with the terms of this Agreement, (ii)&nbsp;any amounts that the
Escrow Agent is required to pay but has not yet paid to Parent or a Person designated by
Parent, pursuant to Sections 5(a) or 5(b), (iii)&nbsp;the Withheld Amounts (as defined below) as
of the First Distribution Date, and (iv)&nbsp;Thirteen Million Eight Hundred Seventy
Five Thousand Dollars ($13,875,000). As soon as practicable, after the First
Distribution
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Date, the Escrow Agent will release such funds, if any, to the Representative
by wire transfer for distribution by the Representative to each Escrow Participant in
accordance with each Escrow Participant&#146;s Aggregate Proceeds Contribution Fraction. The
term &#147;<U>Withheld Amounts</U>&#148; shall mean the aggregate amount of (x)&nbsp;all Disputed Amounts
not paid or otherwise resolved by such date and (y)&nbsp;all other amounts specified in Notices
of Claims received by the Escrow Agent as of such date and not paid as of such date from the
Escrow Funds unless, as of such date, the Escrow Agent is required to pay such amounts
pursuant to Sections 5(a) or 5(b). The amounts described in clause (B)(ii) of this Section
5(d)(i) shall be paid by the Escrow Agent to Parent, or a Person designated by Parent,
pursuant to Sections 5(a) or 5(b) as the case may be, and the amounts described in clause
(B)(iii) of this Section&nbsp;5(d)(i) shall remain Escrow Funds held by, and to be paid out by,
the Escrow Agent in accordance with the terms of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;On the date that is eighteen (18)&nbsp;months after the date of this Agreement (the
&#147;<U>Second Distribution Date</U>&#148;), the Escrow Agent will release to the Representative by
wire transfer for distribution by the Representative to the Escrow Participants (in
accordance with each Escrow Participant&#146;s Aggregate Proceeds Contribution Fraction) the
positive difference, if any, between (A)&nbsp;any amount remaining in the Escrow Account and (B)
the sum of (i)&nbsp;any amounts that the Escrow Agent is required to pay but has not yet paid to
Parent or a Person designated by Parent, pursuant to Sections 5(a) or 5(b), and (ii)&nbsp;the
Withheld Amounts as of the Second Distribution Date. As soon as practicable, after the
Second Distribution Date, the Escrow Agent will release such funds, if any, the Escrow Agent
will release such funds, if any, to the Representative by wire transfer for distribution by
the Representative to each Escrow Participant in accordance with each Escrow Participant&#146;s
Aggregate Proceeds Contribution Fraction. The amounts described in clause (B)(i) of this
Section&nbsp;5.1(d)(ii) shall be paid by the Escrow Agent to Parent, or a Person designated by
Parent, pursuant to Sections 5(a) or 5(b) as the case may be, and the amounts described in
clause (B)(ii) of this Section&nbsp;5(d)(ii) shall remain Escrow Funds held by, and to be paid
out by, the Escrow Agent in accordance with the terms of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;If, after the First Distribution Date or the Second Distribution Date, as
applicable, the Escrow Agent is required to pay all or a portion of the amounts remaining in
the Escrow Account to Parent pursuant to Section 5(a) or 5(b), then the Escrow Agent shall
make such payment to Parent in accordance with such Section 5(a) or 5(b).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Upon receipt by the Escrow Agent after First Distribution Date but prior to the
Second Distribution Date of a written notice from Parent or the Representative that any
claims as to all or any portion of the Withheld Amounts as of the First Distribution Date
have been resolved (&#147;<U>Resolved Withheld Amounts</U>&#148;), accompanied by (A)&nbsp;an executed
written agreement between Parent and the Representative with respect to such Resolved
Withheld Amounts or (B)&nbsp;an award, judgment, decree or order of the arbitrator pursuant to
Section 5(c) with respect to such Withheld Amounts, the Escrow Agent shall release such
Resolved Withheld Amounts from the Escrow Account, as instructed in the joint written notice
or order, to Parent or to the Representative by wire transfer for distribution by the
Representative to each Escrow Participant in accordance with each Escrow Participant&#146;s
Aggregate Proceeds Contribution Fraction (as set forth on the
Transaction Schedule attached hereto as <U>Schedule&nbsp;A</U>), <I>provided, however</I>, that
the Escrow
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Agent shall only release to the Representative such portion of such Resolved
Withheld Amounts due the Representative, if any, that does not exceed (X)&nbsp;Thirteen Million
Eight Hundred Seventy Five Thousand Dollars ($13,875,000) <I>minus </I>(Y)&nbsp;the sum of (i)&nbsp;the
aggregate amount of the payments, if any, previously made to Parent, the Escrow Participants
or the Escrow Agent out of the Escrow Funds (other than pursuant to Section 3(b) or Section
4) in accordance with the terms of this Agreement, (ii)&nbsp;any amounts that the Escrow Agent is
required to pay but has not yet paid to Parent (including such portion of the Resolved
Withheld Amounts, if any, and to the extent not already paid) or a Person designated by
Parent, pursuant to Sections 5(a) or 5(b), and (iii)&nbsp;any other Withheld Amounts; <I>provided</I>, .
that such portion of such Resolved Withheld Amounts due the Representative that does exceed
the foregoing calculation shall continue to be retained in the Escrow Account as Escrow
Funds.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;Upon receipt by the Escrow Agent after the Second Distribution Date of a written
notice from Parent or the Representative with respect to any Resolved Withheld Amounts,
accompanied by (A)&nbsp;an executed written agreement between Parent and the Representative with
respect to such Resolved Withheld Amounts or (B)&nbsp;an award, judgment, decree or order of the
arbitrator pursuant to Section 5(c) with respect to such Resolved Withheld Amounts, the
Escrow Agent shall release such Resolved Withheld Amounts from the Indemnification Escrow
Fund as directed in such joint notice or order to Parent or to the Representative by wire
transfer for distribution by the Representative to each Escrow Participant in accordance
with each Escrow Participant&#146;s Aggregate Proceeds Contribution Fraction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;Any amounts paid or otherwise released to the Representative hereunder, when made,
shall be deemed to have been paid in full satisfaction of the rights of the Escrow
Participants to receive such payments as set forth in the Merger Agreement and hereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;Notwithstanding any other provision herein to the contrary, in no event will
amounts be released to the Escrow Participants from the Indemnification Escrow Fund in
excess of Thirty Five Million Dollars ($35,000,000) and any amount remaining in the
Indemnification Escrow Fund in excess of such amount on termination of this Agreement shall
be distributed to Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 6. <U>Administrative Provisions</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Parent and the Representative shall have the right to inspect and obtain copies of the
records of the Escrow Agent pertaining to the Escrow Account and to receive monthly reports of the
status of the Escrow Funds. The Escrow Agent shall send to Parent and the Representative monthly
reports detailing the amount of the Escrow Funds in the Escrow Agent&#146;s possession, any release of
the Escrow Funds in the preceding month and the status of any claims pending for the release of any
of the Escrow Funds.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Escrow Agent may resign as escrow agent by notice to the other parties hereto (the
&#147;<U>Resignation Notice</U>&#148;) effective upon appointment of a successor Escrow Agent. If, prior to
the expiration of sixty (60)&nbsp;Business Days after the delivery of the Resignation Notice, the Escrow
Agent shall not have received written instructions from Parent and the
Representative designating a banking corporation or trust company organized either under the
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">laws of the United States or of any state as successor escrow agent and consented to in writing by
such successor escrow agent, the Escrow Agent may apply to a court of competent jurisdiction to
appoint a successor escrow agent. Alternatively, if the Escrow Agent shall have received such
written instructions, it shall promptly transfer the Escrow Funds to such successor escrow agent.
Upon the appointment of a successor escrow agent and the transfer of the Escrow Funds, and any
other records, including without limitation, tax-related information, relating to the Escrow Funds
or this Agreement by the resigning Escrow Agent to the successor escrow agent, the duties of such
resigning Escrow Agent hereunder shall terminate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each of Parent and the Representative hereby agrees to pay the Escrow Agent reasonable
compensation for its services hereunder in accordance with the &#147;<U>Schedule of Fees</U>&#148; attached
hereto as <U>Schedule&nbsp;A</U> and to reimburse the Escrow Agent for all expenses, disbursements and
advances incurred or made by it in the performance of its duties hereunder and to indemnify and
hold the Escrow Agent harmless from and against any and all taxes, expenses (including reasonable
counsel fees), assessments, liabilities, claims, damages, actions, suits or other charges incurred
by or assessed against it for anything done or omitted by it in the performance of its duties
hereunder, except as a result of its own gross negligence, fraud or willful misconduct. Parent and
the Representative, on behalf of the Escrow Participants, shall share equally in all payments owing
under this Section&nbsp;6(c), although liability for such payments if not paid in a timely manner shall
be the responsibility of the party responsible therefore. The Representative&#146;s portion of such
payments shall be funded from the Escrow Fund (without any requirement of any written instruction
or directive from the Representative), and Parent agrees to execute a Notice of Claim pursuant to
Section 5(a) of this Agreement authorizing the Escrow Agent to release such portion of the
Representative&#146;s payments to the Escrow Agent. The agreement contained in this Section 6(c) shall
survive any termination of the duties of the Escrow Agent hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Escrow Agent shall have no duties or responsibilities, including, without limitation,
a duty to review or interpret the Merger Agreement, except those expressly set forth herein, and no
implied duties shall be read into this Agreement. It may consult with counsel, shall be fully
protected with respect to any action taken or omitted in good faith on advice of counsel and shall
have no liability hereunder except for gross negligence, fraud or willful misconduct. The Escrow
Agent shall have no responsibility as to the validity, collectibility or value of the Escrow Funds
or for investment losses related thereto, provided the Escrow Funds have been invested in
accordance with Section&nbsp;2 above, and it may rely on any notice, instruction, certificate,
statement, request, consent, confirmation, agreement or other instrument which it reasonably
believes to be genuine and to have been signed or presented by a proper person or persons. If the
Escrow Agent shall be uncertain as to its duties or rights hereunder or shall receive instructions
from any of the undersigned with respect to the Escrow Funds, which, in its opinion, are in
conflict with any of the provisions of this Escrow Agreement, it shall be entitled to refrain from
taking any action until it shall be directed otherwise in writing by the other parties hereto or by
order of a court of competent jurisdiction. Notwithstanding any provision to the contrary
contained in any other agreement between any of the parties hereto, the Escrow Agent shall have no
interest in the Escrow Funds except as provided in this Escrow Agreement and shall hold such funds
in trust in accordance herewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;All notices, consents and other communications under this Escrow Agreement shall be in
writing and shall, except as otherwise provided herein, be deemed to have been
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">received when (i)
delivered by hand, (ii)&nbsp;sent by facsimile (with receipt confirmed), <I>provided </I>that a copy is mailed
by certified mail, return receipt requested, or (iii)&nbsp;when received by the addressee, if sent by
Express Mail, Federal Express or other express delivery service (receipt requested), in each case,
at the appropriate addresses and facsimile numbers as set forth below:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="70%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to Escrow Agent:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telephone:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wire Instructions:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Bank:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ABA#:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A/C#:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to Parent:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Allergan, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2525 Dupont Drive</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Irvine, California 92612</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: General Counsel</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 714-246-4774</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">with a copy to:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Latham &#038; Watkins LLP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">650 Town Center Drive</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Costa Mesa, CA 92626</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Jonn R. Beeson</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile: (714)&nbsp;755-8290</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to the Representative:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Andrew J. Einhorn</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">c/o Milbank, Tweed, Hadley &#038; McCloy LLP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">One Chase Manhattan Plaza</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">New York, NY 10005</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Robert S. Reder, Esq.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile: (212)-822-5680</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">with a copy to:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Milbank, Tweed, Hadley &#038; McCloy LLP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">One Chase Manhattan Plaza</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">New York, NY 10005</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Robert S. Reder, Esq.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile: (212)-822-5680</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(or to such other addresses and facsimile numbers as a party may designate as to itself by notice
to the other parties in accordance with this Section&nbsp;6(e)).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Nothing in this Agreement shall be construed to limit the right of Parent, the
Representative or any of the Escrow Participants under any provision of the Merger Agreement.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;This Agreement, including the validity hereof and the rights and obligations of the
parties hereunder, shall be construed in accordance with and governed by the laws of the State of
New York applicable to contracts made and to be performed entirely in the State of New York
(without giving effect to the conflicts of laws provisions thereof).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;This Escrow Agreement may be executed in any number of counterparts, each of which shall
be deemed to be an original instrument and all of which together shall constitute a single
agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;All covenants and agreements set forth in this Agreement and made by or on behalf of any
of the parties hereto shall bind and inure to the benefit of the successors, heirs and assigns of
such party, whether or not so expressed. None of the parties may assign or transfer any of their
respective rights or obligations under this Agreement without the consent in writing of the other
parties hereto, except as otherwise provided herein and <I>provided </I>that Parent may assign or transfer
its rights and obligations hereunder in connection with a change of control of Parent or its
permitted successors or assigns, or to any other permitted assignee under the Merger Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;In the event that any one or more of the provisions contained herein is held invalid,
illegal or unenforceable in any respect for any reason in any jurisdiction, the validity, legality
and enforceability of any such provision in every other respect and of the remaining provisions
hereof shall not be in any way impaired or affected, it being intended that each of the parties&#146;
rights and privileges shall be enforceable to the fullest extent permitted by law, and any such
invalidity, illegality and unenforceability in any jurisdiction shall not invalidate or render
unenforceable such provision in any other jurisdiction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;Except as specifically set forth or referred to herein, nothing herein expressed or
implied is intended or shall be construed to confer upon or give to any person other than Parent,
any Parent Indemnified Party, the Representative, the Escrow Participants, the Escrow Agent and
their respective permitted successors and assigns any rights or remedies under or by reason of this
Agreement or any other certificate, document, instrument or agreement executed in connection
herewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;This Agreement shall terminate upon the disbursement by the Escrow Agent of all the Escrow
Funds in accordance with this Agreement; <I>provided</I>, <I>however</I>, that the provisions of Section 6(c)
hereof shall survive such termination. This Agreement may be amended only with the written consent
of all parties hereto. No waiver of any right or remedy hereunder shall be valid unless the same
shall be in writing and signed by the party giving such waiver.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;SIGNATURE PAGE FOLLOWS&#093;
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned have executed this Escrow Agreement as of the date
first written above.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom" style="font-size:1px">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 10px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD valign="top">,&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">as Escrow Agent</TD>
    <TD valign="top">&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">ALLERGAN, INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Douglas S. Ingram</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Executive Vice President, Chief</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Administrative Officer, General Counsel and
Secretary</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">REPRESENTATIVE</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Andrew J. Einhorn</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>SCHEDULE A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>SCHEDULE OF FEES</U>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">To act as an<BR>
Escrow Agent
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Annual Administration Fee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">&#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Covers acceptance of appointment as Escrow Agent including complete study of drafts of Escrow
Agreement and all supporting documents in connection therewith, conferences until final Agreement
is agreed upon, execution to final Agreement and administrative duties in connection with the
security provision of the Agreement.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Wire Transfer of Funds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">&#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT E</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GENERAL RELEASE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>This General Release</B></FONT> (this &#147;General Release&#148;) is being executed and delivered as of
October &#95;&#95;&#95;, 2007, by the undersigned (&#147;Releasor&#148;) in its capacity as a stockholder of <FONT style="font-variant: SMALL-CAPS"><B>&#091;Sprite&#093;,
Inc.</B></FONT>, a Delaware corporation (the &#147;Company&#148;), to and in favor of, and for the benefit of, the
Company, <FONT style="font-variant: SMALL-CAPS"><B>Allergan, Inc.</B></FONT>, a Delaware corporation (the &#147;Parent&#148;), and the other Releasees
(as defined in Section&nbsp;2).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>A.&nbsp;</B>Pursuant to an Agreement and Plan of Merger dated as of September&nbsp;18, 2007 (the &#147;Merger
Agreement&#148;) among Parent, Esmeralde Acquisition, Inc., a Delaware corporation and a wholly-owned
subsidiary of Parent (&#147;Merger Sub&#148;), the Company and the Escrow Participants&#146; Representative,
Merger Sub is merging with and into the Company and the Company will become a wholly-owned
subsidiary of Parent (the merger of Merger Sub into the Company being referred to as the &#147;Merger&#148;).
Any term not otherwise defined herein shall have the meaning given such term in the Merger
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>B.&nbsp;</B>Releasor is a Key Stockholder of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>C</B>.&nbsp;In connection with the Merger any shares of capital stock of the Company held by Releasor
will be exchanged for the consideration set forth in the Merger Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>D.&nbsp;</B>Parent has required, as a condition to consummating the transactions contemplated by the
Merger Agreement, that Releasor execute and deliver this General Release.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to induce Parent to consummate the transactions contemplated by the Merger Agreement,
and for other valuable consideration (the receipt and sufficiency of which are hereby acknowledged
by Releasor), Releasor hereby covenants and agrees as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.&nbsp;Release. </B>Releasor, for itself and for each of Releasor&#146;s Associated Parties (as defined in
Section&nbsp;2), hereby generally, irrevocably, unconditionally and completely releases and forever
discharges each of the Releasees (as defined in Section&nbsp;2) from, and hereby irrevocably,
unconditionally and completely waives and relinquishes, each of the Released Claims (as defined in
Section&nbsp;2).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.&nbsp;Definitions.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>The term &#147;Releasor&#146;s Associated Parties&#148; shall mean and include: (i)&nbsp;Releasor&#146;s
predecessors, successors, and administrators; (ii)&nbsp;each entity or natural person that Releasor has
the power to bind (by Releasor&#146;s acts or signature) or over which Releasor directly or indirectly
exercises control, including, to the extent Releasor has the power to bind such, the partners,
members, shareholders, principals, directors, officers, employees, agents, attorneys and
representatives of the foregoing entities; and (iii)&nbsp;each entity of which Releasor owns, directly
or indirectly, at least 50% of the outstanding equity, beneficial, proprietary, ownership or voting
interests.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>The term &#147;Releasees&#148; shall mean and include: (i)&nbsp;the Company; (ii)&nbsp;each of the direct and
indirect subsidiaries of the Company; (iii)&nbsp;each other Affiliate of the Company; and (iv)&nbsp;the
successors and past, present and future assigns, directors, officers and employees of
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the
respective entities identified or otherwise referred to in clauses &#147;(i)&#148; through &#147;(iii)&#148; of this
sentence, other than Releasor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>The term &#147;Claims&#148; shall mean and include all past and present disputes, claims,
controversies, demands, rights, obligations, liabilities, actions and causes of action of every
kind and nature including: (i)&nbsp;any unknown, unsuspected or undisclosed claim and (ii)&nbsp;any claim,
right or cause of action based upon any breach of any express, implied, oral or written contract or
agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d) </B>The term &#147;Released Claims&#148; shall mean and include each and every Claim that (i)&nbsp;Releasor
or any of Releasor&#146;s Associated Parties may have had in the past, may now have or may have in the
future against any Releasee and (ii)&nbsp;has arisen or arises directly or indirectly out of, or relates
directly or indirectly to, any circumstance, agreement, activity, action, omission, event or matter
occurring or existing on or prior to the date of this General Release, but shall exclude any rights
of Releasor under the Merger Agreement and the Escrow Agreement and shall exclude, to the extent
applicable with respect to any Releasor&#146;s Associated Parties who is a director, officer or employee
of the Company, (i)&nbsp;compensation and benefits not yet paid (including amounts payable in connection
with the consummation of the Transactions, (ii)&nbsp;reimbursement for expenses incurred by any such
Person in the ordinary course of his or her employment, which are reimbursable under the Company&#146;s
reimbursement policies, (iii)&nbsp;accrued vacation, subject to the Company&#146;s policies on accrual and
carryforward, and (iv)&nbsp;rights to indemnification under the Acquired Companies&#146; certificates of
incorporation and bylaws or the indemnification agreements listed on Section&nbsp;6.01 of the Company
Disclosure Schedule.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.&nbsp;Representations and Warranties. </B>Releasor represents and warrants that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>neither Releasor nor any of Releasor&#146;s Associated Parties has assigned, transferred,
conveyed or otherwise disposed of any Claim against any of the Releasees, or any direct or indirect
interest in any such Claim, in whole or in part;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>to the best of such Releasor&#146;s knowledge, no other Person has any interest in any of the
Released Claims;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>this General Release has been duly and validly executed and delivered by Releasor;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d) </B>this General Release is a valid and binding obligation of Releasor and each of Releasor&#146;s
Associated Parties, and is enforceable against Releasor and each of Releasor&#146;s Associated Parties
in accordance with its terms, subject to (i)&nbsp;laws of general application relating to bankruptcy,
insolvency, reorganization, moratorium and the enforcement of creditors&#146; rights generally, and (ii)
rules of law governing specific performance, injunctive relief and other equitable remedies;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e) </B>there is no Action, complaint or investigation by or before any Governmental Authority or,
to the best of Releasor&#146;s knowledge, threatened against Releasor or
any of Releasor&#146;s Associated Parties that challenges or would challenge the execution and
delivery of this General Release or the taking of any of the actions required to be taken by
Releasor under this General Release;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f) </B>neither the execution and delivery of this General Release nor the performance hereof will
(i)&nbsp;result in any violation or breach of any agreement or other instrument to which Releasor or any
of Releasor&#146;s Associated Parties is a party or by which Releasor or any of Releasor&#146;s Associated
Parties is bound, or (ii)&nbsp;result in a violation or any law, rule, regulation, treaty, ruling,
directive, order, arbitration award, judgment or decree to which Releasor or any of Releasor&#146;s
Associated Parties is subject; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g) </B>no authorization, instruction, waiver, consent or approval of any person or entity is
required to be obtained by Releasor or any of Releasor&#146;s Associated Parties in connection with the
execution and delivery of this General Release or the performance hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.&nbsp;Indemnification. </B>Without in any way limiting any of the rights or remedies otherwise
available to any Releasee, Releasor shall indemnify and hold harmless each Releasee against and
from any loss, damage, injury, harm, detriment, lost opportunity, liability, exposure, claim,
demand, settlement, judgment, award, fine, penalty, tax, fee, charge or expense (including
attorneys&#146; fees) that is directly or indirectly suffered or incurred at any time by such Releasee,
or to which such Releasee otherwise becomes subject at any time, and that arises directly or
indirectly out of or by virtue of, or relates directly or indirectly to, (a)&nbsp;any failure on the
part of Releasor to observe, perform or abide by, or any other breach of, any restriction,
covenant, obligation, representation, warranty or other provision contained herein, or (b)&nbsp;the
assertion or purported assertion of any of the Released Claims by Releasor or any of Releasor&#146;s
Associated Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.&nbsp;California Civil Code &#167;1542. </B>Releasor, on its behalf and on behalf of Releasor&#146;s
Associated Parties, (a)&nbsp;represents, warrants and acknowledges that Releasor has had, or has had and
waived, the opportunity to be advised by independent legal counsel as to the contents of Section
1542 of the Civil Code of the State of California (and any analogous law of any other state,
locality or other jurisdiction), and (b)&nbsp;hereby expressly waives the benefits thereof and any
rights Releasor and/or Releasor&#146;s Associated Parties may have thereunder. Section&nbsp;1542 of the
Civil Code of the State of California provides as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">&#147;A general release does not extend to claims which the creditor does not
know or suspect to exist in his or her favor at the time of executing the
release, which if known by him or her must have materially affected his or
her settlement with the debtor.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Releasor, on its behalf and on behalf of Releasor&#146;s Associated Parties, also hereby waives the
benefits of, and any rights Releasor and/or any of Releasor&#146;s Associated Parties may have under,
any statute or common law principle of similar effect in any jurisdiction with respect to the
Released Claims.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.&nbsp;Miscellaneous.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>Releasor acknowledges that this General Release sets forth the entire
understanding of Releasor and Releasees relating to the subject matter hereof and supersedes
all prior agreements and understandings among or between Releasor and Releasees relating to the
subject matter hereof.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>Any term or provision of this General Release that is invalid or unenforceable in any
situation in any jurisdiction shall not affect the validity or enforceability of the remaining
terms and provisions hereof or the validity or enforceability of the offending term or provision in
any other situation or in any other jurisdiction. If the final judgment of a court of competent
jurisdiction declares that any term or provision of this General Release is invalid or
unenforceable, it is agreed that the court making such determination shall have the power to limit
the term or provision, to delete specific words or phrases, or to replace any invalid or
unenforceable term or provision with a term or provision that is valid and enforceable and that
comes closest to expressing the intention of the invalid or unenforceable term or provision, and
this General Release shall be enforceable as so modified. In the event such court does not
exercise the power granted to it in the prior sentence, the parties hereto agree to replace such
invalid or unenforceable term or provision with a valid and enforceable term or provision that will
achieve, to the extent possible, the economic, business and other purposes of such invalid or
unenforceable term.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>This General Release shall be construed in accordance with, and governed in all respects
by, the laws of the State of New York (without giving effect to principles of conflicts of laws).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d) </B>Releasor, on its behalf and on behalf of Releasor&#146;s Associated Parties, and each Releasee
hereby agree that any legal action or other legal proceeding relating to this General Release or
the enforcement of any provision of this General Release shall be brought or otherwise commenced by
any Releasee in a state or federal court located in New York. Releasor, on its behalf and on
behalf of Releasor&#146;s Associated Parties, and each Releasee:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i) </B>expressly and irrevocably consents and submits to the nonexclusive jurisdiction of
each state and federal court located in the State of New York in connection with any such
legal proceeding;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii) </B>agrees that each state and federal court located in the State of New York shall be
deemed to be a convenient forum; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(iii) </B>agrees not to assert (by way of motion, as a defense or otherwise), in any such
legal proceeding commenced in any state or federal court located in the State of New York,
any claim that it is not subject personally to the jurisdiction of such court, that such
legal proceeding has been brought in an inconvenient forum, that the venue of such
proceeding is improper or that this General Release or the subject matter of this General
Release may not be enforced in or by such court.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Nothing contained in this General Release shall be deemed to limit or otherwise affect the right of
any Releasee to raise this General Release as a defense in any legal proceeding in any other forum
or jurisdiction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e) </B>The exchange of a fully executed General Release by facsimile transmission or email in a
pdf (or similar) format shall be sufficient to bind Releasor to the terms and conditions of this
General Release.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f) </B>Releasor shall execute and/or cause to be delivered to each Releasee such instruments and
other documents, and shall take such other actions, as a Releasee may reasonably request for the
purpose of carrying out or evidencing any of the actions contemplated by this General Release.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g) </B>If any legal action or other legal proceeding relating to this General Release or the
enforcement of any provision hereof is brought by Releasor or any Releasee, the prevailing party
shall be entitled to recover reasonable attorneys&#146; fees, costs and disbursements to the extent
actually incurred (in addition to any other relief to which the prevailing party may be entitled).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(h) </B>Whenever required by the context, the singular number shall include the plural, and vice
versa; the masculine gender shall include the feminine and neuter genders; and the neuter gender
shall include the masculine and feminine genders.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i) </B>Any rule of construction to the effect that ambiguities are to be resolved against the
drafting party shall not be applied in the construction or interpretation of this General Release.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(j) </B>As used in this General Release, the words &#147;include&#148; and &#147;including,&#148; and variations
thereof, shall not be deemed to be terms of limitation, and shall be deemed to be followed by the
words &#147;without limitation.&#148;
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>&#091;Signature page follows&#093;</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>In Witness Whereof,</B></FONT> Releasor has caused this General Release to be executed as of the
date first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="37%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Releasor:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><DIV style="margin-left: 30px; font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Print Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"> <!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><DIV style="margin-left: 35px; font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV></td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>General Release Signature Page</I>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT F</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">AMENDED AND RESTATED<BR>
CERTIFICATE OF INCORPORATION
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">OF

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">ESPRIT PHARMA HOLDING COMPANY, INC.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 18pt">ARTICLE I

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The name of the corporation is ESPRIT PHARMA HOLDING COMPANY, INC. (hereinafter called the
&#147;<U>Corporation</U>&#148;).
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 18pt">ARTICLE II

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The address of the Corporation&#146;s registered office in the State of Delaware is 2711
Centerville Road, Suite&nbsp;400, Wilmington, New Castle County, Delaware 19808. The name of the
registered agent at such address is Corporation Service Company.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 18pt">ARTICLE III

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the Corporation is to engage in any lawful act or activity for which
corporations may be organized under the General Corporation Law of the State of Delaware.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IV

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The total number of shares of all classes of stock that the Corporation shall have authority
to issue is 100 shares of Common Stock having the par value of $0.001 per share.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 18pt">ARTICLE V

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of directors of the Corporation shall be fixed from time to time by the Board of
Directors of the Corporation.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VI

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In furtherance and not in limitation of the powers conferred upon it by law, the Board of
Directors of the Corporation is expressly authorized to adopt, amend or repeal the Bylaws of the
Corporation.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VII

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless and except to the extent that the Bylaws of the Corporation so require, the election of
directors of the Corporation need not be by written ballot.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VIII

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent from time to time permitted by law, no director of the Corporation shall
be personally liable to any extent to the Corporation or its stockholders for monetary damages for
breach of his fiduciary duty as a director.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IX

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each person who is or was or had agreed to become a director or officer of the Corporation,
and each such person who is or was serving or who had agreed to serve at the request of the
Corporation as a director, officer, partner, member, employee or agent of another corporation,
partnership, limited liability company, joint venture, trust or other enterprise (including the
heirs, executor, administrators or estate of such person), shall be indemnified by the Corporation
to the fullest extent permitted from time to time by applicable law. Any repeal or modification of
this Article&nbsp;IX shall not adversely affect any right to indemnification of any person existing at
the time of such repeal or modification with respect to any matter occurring prior to such repeal
or modification.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT&nbsp;G</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LETTER OF TRANSMITTAL</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>for shares of capital stock of</B><BR>
<FONT style="font-variant: SMALL-CAPS"><B>&#091;Sprite&#093;, Inc. </B></FONT>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>Delivery Instructions:</I><BR>
<B>&#091; </B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><B>&#093;</B><BR>
(the &#147;<B>Payment Agent</B>&#148;)

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>By Overnight Courier or By Hand:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>By Mail:</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Attn: &#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Attn: &#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>For Information With Respect to the Payment Agent, Contact <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (XXX)&nbsp;XXX-XXXX.</I>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>For questions regarding this Letter of Transmittal call <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> at (XX)&nbsp;XXX-XXXX.</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with the terms of that certain Agreement and Plan of Merger, dated as of
September&nbsp;18, 2007 (the &#147;<B>Merger Agreement</B>&#148;) by and among &#091;Parent&#093;, Inc, a Delaware corporation
(&#147;<B>Parent</B>&#148;), Esmeralde Acquisition, Inc., a Delaware corporation (&#147;<B>Merger Sub</B>&#148;), &#091;Sprite&#093;, Inc., a
Delaware corporation (the &#147;<B>Company</B>&#148;), and Andrew Einhorn, solely in his capacity as the Escrow
Participants&#146; Representative (as defined in the Merger Agreement), Merger Sub will be merged with
and into the Company (the merger of Merger Sub into the Company being referred to as the &#147;<B>Merger</B>&#148;).
Capitalized terms used (but not defined) in this Letter of Transmittal have the meanings given to
such terms in the Merger Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of the Merger, the Company will become a wholly-owned subsidiary of Parent and
outstanding shares of the Company&#146;s capital stock will be converted into the right to receive the
cash consideration set forth in the Merger Agreement in exchange for such shares. The amount of
cash to be paid for each share of the Company&#146;s Common Stock, par value $.0001 per share (the
&#147;<B>Common Stock</B>&#148;), Series&nbsp;A Preferred Stock, par value $.0001 per share (the &#147;<B>Series&nbsp;A</B>&#148;) and Series&nbsp;B
Preferred Stock, par value $.0001 per share (the &#147;<B>Series&nbsp;B</B>,&#148; and together with the Series&nbsp;A, the
&#147;<B>Preferred Stock</B>&#148;) is described in the Merger Agreement and the Information Statement that was
previously provided to the Company Stockholders. To the extent a Company Stockholder is an Escrow
Participant, a portion of the aggregate consideration to which such Company Stockholder is
otherwise entitled for such Company Stockholder&#146;s shares of Common Stock and/or Preferred Stock
will be withheld from such Company Stockholder and will be placed in escrow to secure certain (i)
indemnification, compensation and reimbursement obligations of the Company Stockholders and (ii)
adjustments with respect to the Company&#146;s Net Working Capital, as described in the Merger Agreement
and the Information Statement previously provided to the Company Stockholders. <B>You are encouraged
to read the Merger Agreement and the Information Statement previously provided to you very
carefully</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Merger has been approved by the written consent of a majority of the Company Stockholders
and thus no further action is required on the part of Company Stockholders to approve the Merger.
However, you will not receive the consideration payable to you in connection with the Merger until
after the Merger is completed and you return this Letter of Transmittal to the Payment Agent.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To obtain payment of the consideration payable to you pursuant to the Merger Agreement in
exchange for your shares of Company Stock, please complete this Letter of Transmittal and forward
it by mail, overnight delivery, courier or hand delivery, to &#091;&#95;&#95;&#95;&#093; (the &#147;<B>Payment Agent</B>&#148;),
at the address set forth above. Each Company Stockholder must also deliver each original stock
certificate representing the Company Stock held by such Company Stockholder with the delivery of
this Letter of Transmittal to the Paying Agent. Instructions regarding the completion of the
Letter of Transmittal are set forth on the following pages.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>DO NOT SEND STOCK CERTIFICATES DIRECTLY TO<BR>
MERGER SUB OR PARENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>DELIVERY OF THIS INSTRUMENT TO AN ADDRESS OTHER THAN<BR>
AS SET FORTH ABOVE DOES NOT CONSTITUTE VALID DELIVERY.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>PLEASE READ THE ACCOMPANYING INSTRUCTIONS ON PAGE 7 CAREFULLY.</B>

</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the Merger, the undersigned (or, if two or more persons have signed this
Letter of Transmittal as the registered holders of a certificate representing Company Stock, each
of the undersigned), the registered holder of the certificate or certificates described below
representing shares of Company Stock (such certificates, the &#147;<B>Surrendered Certificate(s)</B>,&#148; and the
shares of Company Stock represented by the Surrendered Certificate(s) the &#147;<B>Surrendered Securities</B>&#148;)
that will be converted into the right to receive cash consideration upon the consummation of the
Merger, or the transferee or assignee of such registered holder, hereby surrenders the Surrendered
Certificate(s) in exchange for a check or wire transfer to the account specified by the undersigned
in this Letter of Transmittal representing a portion of the merger consideration payable pursuant
to the Merger Agreement (less the amounts placed in escrow pursuant to the Merger Agreement to the
Extend the undersigned is an Escrow Participant), in respect of the shares of Company Stock
represented by the Surrendered Certificate(s) (the cash consideration payable to the undersigned in
connection with the Merger being referred to as the &#147;<B>Payment</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The name(s) and address of the registered holder(s), as they appear on the Surrendered
Certificate(s) and the Company&#146;s stock records, are printed under &#147;Description of Surrendered
Securities.&#148; The number(s) and class(es) of the Surrendered Certificate(s) are indicated in the
appropriate boxes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Each Company Stockholder is required to give the Payment Agent such Company Stockholder&#146;s
taxpayer identification number (&#147;TIN&#148;). If the Payment Agent is not provided with the correct TIN,
payments that are made to such Company Stockholder or other payee will be subject to 28% backup
withholding. Enclosed in this packet is a Substitute W-9 Form which must be completed by the
presenting Company Stockholder.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned (or, if applicable, each of the undersigned) hereby represents and warrants
that: (a)&nbsp;he, she or it (i)&nbsp;is the true and lawful owner of, and has legal and valid title to, the
Surrendered Certificate(s) free and clear of any liens, claims or encumbrances, and (ii)&nbsp;has full
capacity, power and authority to execute and deliver this Letter of Transmittal and to surrender
the Surrendered Certificate(s) for exchange as specified above; and (b)&nbsp;when such Surrendered
Securities and Surrendered Certificate(s) are delivered to the Surviving Corporation neither the
Surviving Corporation nor Parent will be subject to any adverse claim with respect thereto. The
undersigned (or, if applicable, each of the undersigned) (x)&nbsp;acknowledges having received a copy of
the Merger Agreement from Parent, (y)&nbsp;agrees to be bound by the merger consideration adjustment
provisions set forth in Article&nbsp;II of the Merger Agreement, and (z)&nbsp;if the undersigned is an Escrow
Participant, approves the appointment of and hereby appoints the Escrow Participants&#146;
Representative as the representative of the undersigned and as the attorney-in-fact and agent for
and on behalf of the undersigned with respect to the Merger Agreement, and the taking by such
representative of any and all actions (including the incurring of expenses) and the making of any
decisions required or permitted to be taken by the representative under the Merger Agreement in
accordance with terms and provisions thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned (or, if applicable, each of the undersigned) further agrees that: (i)&nbsp;by
tendering the Surrendered Securities he, she or it shall, upon Surviving Corporation&#146;s or Parent&#146;s
request, execute any additional documents reasonably necessary or desirable to perfect the
surrender of the Surrendered Certificate(s) and (ii)&nbsp;by executing the Letter of Transmittal the
undersigned hereby forever waives any dissenter&#146;s or appraisal right it may have under any
applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned (or, if applicable, each of the undersigned) surrenders to the Surviving
Corporation all right, title and interest in and to the Surrendered Securities represented by the
Surrendered Certificate(s) and irrevocably constitutes and appoints Surviving Corporation the
lawful attorney-in-fact of the undersigned, with full power of substitution (such power of attorney
being deemed to be an irrevocable power coupled with an interest), to deliver the Surrendered
Certificate(s), together with all accompanying evidence of authority, to Payment Agent, and to
effect the cancellation of the Surrendered Certificate(s) on the books of the Company. All
authority herein conferred or agreed to be conferred shall survive the death, dissolution or
incapacity of the undersigned and any obligations of the undersigned hereunder shall be binding
upon the heirs, personal representatives, successors and assigns of the undersigned. The
representations, warranties, covenants and agreements of the undersigned contained in this Letter
of Transmittal shall survive the delivery of the Payment to the undersigned and are in addition to
any other representations, warranties, covenants or obligations of the undersigned, including any
such representations, warranties, covenants and obligations contained in the Merger Agreement.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned understands that the surrender of the Surrendered Certificate(s) will not be
deemed to have been made in acceptable form until receipt by Payment Agent of this Letter of
Transmittal, or a reproduction hereof, duly completed and signed, together with all requisite
evidence of authority in form satisfactory to Parent or Surviving Corporation. All questions as to
validity, form and eligibility of a surrender of Surrendered Certificate(s) hereunder will be
determined by Payment Agent and such determination shall be final and binding upon the undersigned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless the undersigned indicates otherwise under &#147;Special Payment Instructions,&#148; the Payment
will be made payable to the registered holder(s) appearing under &#147;Description of Surrendered
Securities.&#148; Similarly, unless otherwise indicated herein under &#147;Special Delivery Instructions,&#148;
the Payment will be mailed to the address of the registered holder(s) of the Surrendered
Certificate(s) appearing under &#147;Description of Surrendered Securities&#148; in this Letter of
Transmittal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned shall timely pay all transfer, documentary, sales, use, stamp, registration
and other taxes and charges arising from or relating to the transactions contemplated by the Merger
Agreement, and the undersigned shall, at his, her or its own expense, file all necessary tax
returns and other documentation with respect to all such transfer, documentary, sales, use, stamp,
registration, and other taxes and charges.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law will govern all questions concerning the relative rights
of the Company and the undersigned, as applicable, with respect to the Merger and all other
questions concerning the construction, validity and interpretation of this Letter of Transmittal.
All authority conferred pursuant to this Letter of Transmittal shall be binding upon the
successors, assigns, heirs, executor, administrator and legal representatives of the undersigned
and shall not be affected by, and shall survive, the dissolution, death or incapacity of the
undersigned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned understands, acknowledges and agrees that in signing this instrument, the
undersigned hereby absolutely, unconditionally and irrevocably (A)&nbsp;waives any objection or claim of
invalidity relating to the Company&#146;s Amended and Restated Certificate of Incorporation filed with
the Delaware Secretary of State on &#95;&#95;&#95;, 200&#95;&#95;&#95;as amended by the Certificate of Amendment
filed with the Delaware Secretary of State on September &#95;&#95;&#95;, 2007 (the &#147;<B><I>Certificate of
Incorporation</I></B>&#148;) and accepts the applicable merger consideration for the undersigned&#146;s Company Stock
as set forth in the Merger Agreement, as full satisfaction of all rights that the undersigned may
have pursuant to such Certificate of Incorporation in respect of the undersigned&#146;s shares of
Company Stock; (B)&nbsp;terminates, and waives any right that the undersigned may have (whether now or
in the future) under, all investor rights agreements, right of first refusal and co-sale
agreements, stockholders&#146; agreements, voting agreements and similar agreements to which the
undersigned is a party (if any); (C)&nbsp;consents (to the extent that the undersigned has not already
consented) to the consummation of the Merger without regard to, and prior to the expiration of, any
notice periods that may be required by the terms of any instrument or agreement for the benefit of
the undersigned; (D)&nbsp;to the extent the undersigned is an Escrow Participant, consents to the
appointment of the Escrow Participant&#146;s Representative and as attorney-in-fact for and an behalf of
the undersigned to give and receive notices and communications, to authorize delivery to Parent of
cash from the Escrow Fund in satisfaction of claims by Parent to object to such claims, to agree
to, negotiate and enter into settlements and compromises of claims, to demand, prosecute and defend
arbitration and to comply with order of courts and determinations and awards of arbitrators with
respect to claims and to take all actions necessary or appropriate in the judgment of the Escrow
Participants&#146; Representative for the accomplishment of any of the foregoing; (E)&nbsp;to the extent the
undersigned is an Escrow Participant, consents to and accepts the indemnify obligations and the
limitations on liability with respect to the Escrow Participant&#146;s Representative set forth in the
Merger Agreement and (F)&nbsp;to the extent the undersigned is an Escrow Participant, consents to the
establishment of the Indemnification Escrow Fund and the Net Working Capital Escrow Fund as
contemplated in the Merger Agreement (the acknowledgements, agreements, consents and waivers
contained in (A), (B), (C), (D), (E)&nbsp;and (F)&nbsp;are collectively referred to herein as the <B><I>&#147;Waivers
and Acknowledgements&#148;</I></B>).
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver of Rights Under Section&nbsp;1542 of the California Civil Code</U>. In connection with
the foregoing Waivers and Acknowledgements, the undersigned expressly acknowledges that the
undersigned has been advised by legal counsel or has had the opportunity to consult with legal
counsel and has chosen not to do so, and that the undersigned is familiar with the provisions of
section 1542 of the California Civil Code, which provides as follows:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><B>&#147;A general release does not extend to claims which the creditor does not know or suspect to
exist in his favor at the time of executing the release, which if known by him must have
materially affected his settlement with the debtor.&#148;</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent set forth in the Waivers and Acknowledgments, the undersigned hereby expressly
waives and relinquishes any and all rights that the undersigned may have under section 1542 of the
California Civil Code as well as any and all similar rights, rules, regulations, and provisions of
the laws of other states and other jurisdictions of the United States and other countries. To the
extent set forth in the Waivers and Acknowledgments, the undersigned understands and agrees that
this letter will act as a waiver and release of all future claims that may arise from such Waivers
and Acknowledgements, whether such claims are currently known, unknown, foreseen, unforeseen,
suspected or unsuspected, and agree that this release is intended to and shall constitute a full,
complete, absolute and general release of all such claims. The undersigned represents and warrants
to Parent that the effect and import of the provisions of section 1542 have been fully explained to
the undersigned by the undersigned&#146;s attorneys and the undersigned expressly acknowledges the
undersigned&#146;s understanding of the same.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="78%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="white-space: nowrap"><FONT style="font-variant: SMALL-CAPS"><B>Name of Registered Holder(s): </B></FONT></FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap valign="top"><DIV style="margin-left:0px; text-indent:-0px">
<FONT style="font-variant: SMALL-CAPS"><B>Signature(s):</B></FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="78%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap valign="top"><DIV style="margin-left:0px; text-indent:-0px">Print name of individual whose<BR>
signature appears above<BR>
(if the registered holder is an entity):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="78%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title of individual whose<BR>
signature appears above<BR>
(if the registered holder is an entity):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Date: ___________, 2007
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>COMPLETE THE INFORMATION AND SIGN WHERE INDICATED BELOW</B>
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">






<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a33887a1a3388701.gif" alt="(FORM)">
</DIV>

<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>DESCRIPTION OF SURRENDERED SECURITIES</B>
(See Instruction No.&nbsp;1 to this Letter of Transmittal)
Name(s) and Address(es) of Registered Owner(s) of Surrendered Securities
(as shown on the Surrendered Certificate(s)):
<B>Name</B>:
<B>Address</B>:
<B>SHARES SURRENDERED</B>:
(Attach separate schedule if needed.
Under &#147;Class of Shares,&#148; please indicate &#148; &#147;Common,&#148; &#147;Series&nbsp;A,&#148; or &#147;Series&nbsp;B&#148;)
Number of Shares
Certificate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represented
Number(s) Class of Shares&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by Certificate
<FONT style="font-family: Wingdings">&#168;</FONT> Check here if you were issued any certificate(s) and your certificate(s) has been lost, stolen or
destroyed. Upon receipt of notification on this Letter of Transmittal, the Company will contact you directly
regarding completing an affidavit of loss and indemnification agreement and with further instructions. See
Instruction No.&nbsp;10 to this Letter of Transmittal.
<FONT style="font-family: Wingdings">&#168;</FONT> Check here if you elect to receive your Payment in exchange for the Surrendered Securities by wire
transfer.
<FONT style="font-family: Wingdings">&#168;</FONT> Check here if you elect to receive your Payment in exchange for the Surrendered Securities by check.
<B>IF NO INSTRUCTION IS GIVEN, ANY PAYMENT SHALL BE PAID BY CHECK AND MAILED TO THE ADDRESS(ES) OF THE REGISTERED
HOLDERS(S) APPEARING UNDER &#147;DESCRIPTION OF SURRENDERED SECURITIES&#148; ABOVE.
SPECIAL PAYMENT INSTRUCTIONS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SPECIAL DELIVERY INSTRUCTIONS</B>
Complete ONLY if the checks
representing the Payment are to be
issued in a name other than the
name(s) on the Surrendered
Certificate(s) or the Company&#146;s stock
records.* Pay to: Complete ONLY if the checks
Name: representing the Payment are to be
Address: mailed to the undersigned at an
TIN**: address other than the address
*Requires signature guarantee. See&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reflected above.* Mail to:
Instruction No.&nbsp;2 to this Letter of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:
Transmittal. Address:
** Fill in Taxpayer Identification *Requires signature guarantee.
Number of Payee. See Instruction 9 to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See Instruction No.&nbsp;2 to this
this Letter of Transmittal. Letter of Transmittal.</TD>
</TR>
</TABLE>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a33887a1a3388702.gif" alt="(FORM)">
</DIV>

<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>PAYMENT BY WIRE TRANSFER (to be completed only if the Payment is to be made by wire transfer):
WIRE TRANSFER INSTRUCTIONS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SPECIAL PAYMENT INSTRUCTIONS</B>
Complete ONLY if the wire transfers representing
the Payment are to be made to an account name that
differs from the name(s) on the Surrendered
Certificate(s) or the Company&#146;s stock records.*
Transfer to:
Bank Name/Address:
ABA No./Swift Code:
Account Name:
Bank Name: Account No.:
&#151;&#151;  Reference:
Bank Address: * Requires signature guarantee. See Instruction 2.
ABA No./Swift Code: ** Fill in Taxpayer Identification Number of
Account Name: Payee. See Instruction 9 to this Letter of
Account No.: Transmittal on page 8.
Reference:
<B>SIGN HERE</B>
(By signing, the undersigned acknowledges and agrees to the terms of the Letter of Transmittal)
(Signature(s) of Registered Holder(s) of Surrendered Securities)
(Signature(s) of Spouse(s) of Registered Holder(s) of Surrendered Securities)
(Must be signed by Registered Holder(s) exactly as name(s) appear on Surrendered Certificate(s)
and the Company&#146;s stock records. If you are an individual resident of California, your spouse
must sign. See Instructions No.&nbsp;1, 2 and 4 to this Letter of Transmittal.)
Dated: &#95;&#95;&#95;, 2007
(Print or Type Area Code and Telephone Number Above) (Print or Type Taxpayer Identification or
Social Security Number Above)
If signing is by an officer on behalf of a corporation or by an attorney, executor, administrator,
trustee, guardian, agent or other person acting in a fiduciary or representative capacity, please
provide the information requested below:
(Print or Type Name(s) Above) (Print or Type Full Title(s) Above)
(Print or Type Address Above)
<B>GUARANTEE OF SIGNATURE(S)</B>
(See Instruction No.&nbsp;2 to this Letter of Transmittal &#150; Complete Only if Required)
X
- (Authorized Signature)
Dated:
(Print or Type Name(s) Above) (Print or Type Full Title(s) Above)
(Print or Type Area Code and Telephone Number Above)
(Print or Type Name of Firm Above)
(Print or Type Address Above)
<B>PLEASE COMPLETE SUBSTITUTE FORM W-9 ON PAGE 11 OF THIS DOCUMENT.</B></TD>
</TR>
</TABLE>





<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INSTRUCTIONS FOR COMPLETING LETTER OF TRANSMITTAL</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1. Delivery of Letter of Transmittal. </B>The properly completed and duly executed Letter of
Transmittal and any other documents required by this Letter of Transmittal, including the
Surrendered Certificate(s) must be received by Payment Agent for delivery to be effected and the
appropriate person to be entitled to receive the consideration set forth in the Merger Agreement.
Notwithstanding any other provisions hereof, Payment will be delivered in exchange for Surrendered
Certificate(s) only after receipt by Payment Agent of a properly completed and duly executed Letter
of Transmittal and all other required documents, including the Surrendered Certificate(s).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All questions as to validity, form and eligibility of any surrender of the Surrendered
Securities hereunder or delivery by the holder(s) of this Letter of Transmittal shall be determined
by Payment Agent and Parent. Parent reserves the absolute right to reject any Surrendered
Certificate or Letter of Transmittal not in proper form or the acceptance of which may, in the
judgment of counsel for Parent, be unlawful. Parent also reserves the absolute right to waive any
defect or irregularity in the surrender of any Surrendered Certificate or delivery of any Letter of
Transmittal, and its interpretations of other terms and conditions of the Merger Agreement and this
Letter of Transmittal (including these instructions) with respect to such irregularities or defects
shall be final and binding. Neither Parent (nor any of its affiliates) nor any other person will
be under any duty to give notice of any defects or irregularities in any Letter of Transmittal or
Surrendered Certificate nor will such parties incur any liability for failure to give any notice to
any person (even if such notice is given to other persons).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The method of delivery of the Letter of Transmittal and all other required documents,
including any Surrendered Certificate(s), is at the election of the surrendering holder(s), but
risk of loss and title to the Surrendered Certificate(s) will pass only upon delivery of the
Surrendered Certificate(s) to Payment Agent. If delivery is by mail, registered mail with return
receipt requested, properly insured, is recommended.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2. Guarantee of Signatures. </B>No signature on this Letter of Transmittal is required to be
guaranteed if (i)&nbsp;this Letter of Transmittal (or a reproduction hereof) is signed by the registered
holder(s) of the Surrendered Securities and the signature(s) correspond exactly with the name(s) as
written on the face(s) of the Surrendered Certificate(s) <U>unless</U> such holder(s) have
completed the box entitled &#147;Special Payment Instructions&#148; or the box entitled &#147;Special Delivery
Instructions,&#148; or (ii)&nbsp;the Surrendered Securities are tendered for the account of a firm that is a
member of a registered national securities exchange or of the National Association of Securities
Dealers, Inc. or by a commercial bank or trust company having an office or correspondent in the
United States (each of the foregoing firms, banks and trust companies being referred to as an
&#147;Eligible Institution&#148;). In all other cases, all signatures on this Letter of Transmittal must be
guaranteed by an Eligible Institution that is a participant in the Securities Transfer Agents
Medallion such as STAMP, SEMP or MSP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3. Inadequate Space. </B>If the space provided in this Letter of Transmittal is inadequate, the
Surrendered Certificate number(s) or number of shares should be listed on a separate signed
schedule and attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4. Signatures on Letter of Transmittal, Stock Powers and Endorsements. </B>If this Letter of
Transmittal is signed by the registered holder(s) of the Surrendered Securities, the signature(s)
must correspond exactly with the name(s) as written on the face(s) of the Surrendered
Certificate(s) without alteration, enlargement or any change whatsoever.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, for a correction of name or for a change in name which, in
either case, does not involve a change of ownership, proceed as follows: (a)&nbsp;for a change in name
by marriage, etc. the Surrendered Certificate(s) should be endorsed, e.g., &#147;Mary Doe, now by
marriage Mrs.&nbsp;Mary Jones,&#148; with the signature guaranteed by an Eligible Institution, and (b)&nbsp;for a
correction in name, the Surrendered Certificate(s) should be endorsed, e.g., &#147;James E. Brown,
incorrectly inscribed as J.E. Brown,&#148; with the signature guaranteed by an Eligible Institution.
See Instruction 2 above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any Surrendered Certificate is owned of record by two or more joint owners, all such owners
must sign this Letter of Transmittal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Letters of Transmittal executed by trustees, executors, administrators, guardians, officers of
corporations, attorneys-in-fact, or other person acting in a representative or fiduciary capacity
must be accompanied by proper evidence of the signer&#146;s authority to act.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When this Letter of Transmittal is signed by the registered holder(s) of the Surrendered
Securities, no endorsements of the Surrendered Certificate(s) or separate stock powers for the
Surrendered Certificate(s) are required.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Letter of Transmittal is signed by a person other than the registered holder(s) of the
Surrendered Securities, the Surrendered Securities must be endorsed (in the case of Surrendered
Certificate(s)) or accompanied by appropriate stock powers for the Surrendered Certificate(s)
signed exactly as the name(s) of the registered holder(s) appear(s) on such Surrendered
Certificate(s). Signature on any such Surrendered Certificate(s) or stock powers must be
guaranteed by an Eligible Institution. See Instruction 2 above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the registered holder(s) has completed the box entitled &#147;Special Payment Instructions&#148; or
the box entitled &#147;Special Delivery Instructions,&#148; the signature(s) on this Letter of Transmittal
must be guaranteed by an Eligible Institution. See Instruction 2 above.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5. No Conditional Surrender. </B>No alternative, conditional, irregular or contingent surrender of the
Surrendered Securities or transmittal of this Letter of Transmittal will be accepted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6. Multiple Registration. </B>If a holder&#146;s shares of Company stock to be surrendered are registered
in different names or with different addresses on several Surrendered Certificates, it will be
necessary for the holder to complete, sign and submit as many separate Letters of Transmittal as
there are different registrations for the holder&#146;s Company shares, or provide appropriate stock
power forms with the signatures thereon guaranteed. See Instructions 1, 2 and 4 above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7. Special Payment and Delivery Instructions. </B>If the Payment is to be payable to someone other
than the registered holder(s) of the Surrendered Securities, or the Payment is to be mailed to
either (i)&nbsp;someone other than the person(s) signing this Letter of Transmittal, or (ii)&nbsp;to the
person(s) signing this Letter of Transmittal at an address other than that under &#147;Description of
Surrendered Securities&#148; above, then the appropriate boxes on this Letter of Transmittal should be
completed and the signature(s) on this Letter of Transmittal must be guaranteed by an Eligible
Institution. See Instruction 2 above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8. Requests for Assistance or Additional Copies</B>. Requests for assistance may be directed to, and
additional copies of this Letter of Transmittal may be obtained from
&#95;&#95;&#95; by contacting
&#95;&#95;&#95; at (XXX)&nbsp;XXX-XXXX or &#95;&#95;&#95; at (XXX)&nbsp;XXX-XXXX.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>9. Substitute Form W-9; Form W-8. </B>Under federal income tax laws, each Company Stockholder
surrendering any Surrendered Securities is required to provide Parent with a correct Taxpayer
Identification Number (&#147;<B>TIN</B>&#148;) on Substitute Form W-9, which is provided under &#147;Important Tax
Information,&#148; and to indicate if such Company Stockholder is not subject to backup withholding by
signing and dating the Substitute Form W-9. Failure to provide the information on the form may
subject the surrendering holder(s) to a $50 penalty imposed by the Internal Revenue Service and the
Payment will be subject to backup withholding taxes of 28%. See &#147;Important Tax Information&#148; below.
<B>Please consult your accountant or tax advisor for further guidance in completing the Substitute
Form&nbsp;W-9. </B>A non-U.S. Company Stockholder that certifies its non-U.S. status by completing an
appropriate IRS Form W-8 will not be subject to backup withholding and will not need to complete a
Form&nbsp;W-9. Non-U.S. holders should consult their tax advisors regarding the appropriate Form W-8
(which can be obtained from the Internal Revenue Service web site at <U>http://www.irs.gov</U> or
by contacting the Payment Agent) and any other forms that may be required.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>10. Lost, Destroyed or Stolen Certificates. </B>If the Company issued to you any certificate(s)
representing your shares of Company stock and any such certificate has been lost, mutilated,
destroyed or stolen (the &#147;<B>Lost Certificate</B>&#148;), the holder should promptly notify the Payment Agent
in writing, at the address set forth on the first page of this Letter of Transmittal. An affidavit
of that fact, a completed Letter of Transmittal and any related documents should accompany the
written notice of a lost, mutilated, destroyed or stolen Company stock certificate; however, it
cannot be processed until the procedures for replacing the lost, mutilated, destroyed or stolen
certificate have been followed. The holder will then be instructed as to the steps that must be
taken in order to replace such certificate. In order to receive Payment, the Payment Agent will
require holders who have lost their certificate(s) to post a bond as an indemnity against any claim
that may be made against the Payment Agent with respect to such Lost Certificate. The bond fee is
2% of the cash value of the Company stock plus a $60 handling fee.
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>11. Important Tax Information. </B>Under federal income tax law, a Company Stockholder surrendering
any Surrendered Securities is required to provide Parent with such Company Stockholder&#146;s correct
Taxpayer Identification Number (TIN)&nbsp;on Substitute Form W-9 below. If such Company Stockholder is
an individual, the TIN is the Company Stockholder&#146;s social security number. If Parent is not
provided with the correct TIN, the Company Stockholder may be subject to a $50 penalty imposed by
the Internal Revenue Service. In addition, any Payment made to such Company Stockholder may be
subject to backup withholding. Certain Company Stockholders (including, among others, all
corporations and certain foreign individuals) are not subject to these backup withholding and
reporting requirements. In order for a foreign individual to qualify as such an exempt recipient,
such Company Stockholder must submit a statement signed under penalties of perjury, attesting to
such Company Stockholder&#146;s exempt status. Such statements can be obtained from the Payment Agent,
attention: &#95;&#95;&#95; (XXX)&nbsp;XXX-XXXX or from the Internal Revenue Service at
http://www.irs.gov. See the enclosed Guidelines for Certification of Taxpayer Identification Number
on Substitute Form W-9 for additional information. If backup withholding applies, Parent is
required to withhold 28% of any cash amounts otherwise payable to the applicable Company
Stockholder. Backup withholding is not an additional tax; rather, the tax liability of persons
subject to backup withholding will be reduced by the amount of tax withheld. If withholding
results in an overpayment of taxes, a refund may be obtained from the Internal Revenue Service.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Please consult your accountant or tax advisor for further guidance</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>in completing the Substitute Form W-9.</B></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Purpose of Substitute Form&nbsp;W-9</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To prevent backup withholding on cash payments that are made to a Company Stockholder with
respect to Surrendered Securities surrendered for payment, the Company Stockholder is required to
notify Payment Agent of his or her current TIN by completing the form below certifying that such
holder is a U.S. person (including a U.S. resident alien), that the TIN provided on Substitute Form
W-9 is correct (or that such holder is awaiting a TIN) and that (i)&nbsp;such Company Stockholder is
exempt from backup withholding, (ii)&nbsp;such Company Stockholder has not been notified by the Internal
Revenue Service that he or she is subject to backup withholding as a result of failure to report
all interest or dividends or (iii)&nbsp;the Internal Revenue Service has notified such Company
Stockholder that he or she is no longer subject to backup withholding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>What Number to Give</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Company Stockholder is required to give Parent the social security number or employer
identification number of the record holder(s) of the Surrendered Securities. If a Surrendered
Certificate is in more than one name or is not in the name of the actual holder, consult the
enclosed Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9 for
guidance on which number to report.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>IRS Circular 230 Disclosure</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. tax
advice contained in this communication (including any attachments) is not intended or written to be
used, and cannot be used, for the purpose of (i)&nbsp;avoiding penalties under the Internal Revenue
Code, or (ii)&nbsp;promoting, marketing or recommending to another party any matters addressed herein.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a33887a1a3388703.gif" alt="(FORM)">
</DIV>

<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">
<B>Substitute Form W-9 Request for Taxpayer Identification Number and Certification
PAYER&#146;S NAME: ALLERGAN, INC.</B>
Name as shown on account (if joint,
list first and circle name of the person or entity whose number you enter below)
Name:
Address:
City, State, and Zip Code:

<B>TAXPAYER IDENTIFICATION NO. FOR ALL
ACCOUNTS</B>
Enter your taxpayer identification number
in the appropriate box.
For most individuals this is your social
<B>SUBSTITUTE </B>security number. If you do not have a
<B>Form&nbsp;W-9 </B>number, see the enclosed Guidelines.
<B>Department of the Treasury&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note</B>:
If the account is in more than one <B>Social Security Number
Internal Revenue Service </B>name, see the chart in the enclosed <B>&#95;&#95;&#95;
Payer&#146;s Request for </B>Guidelines on which number to give the <B>Employer Identification Number
Taxpayer Identification Number (TIN) </B>payer. <B>&#95;&#95;&#95;
Certification </B>&#150; Under penalties of perjury, I certify that:
(1)&nbsp;the number shown on this form is my correct Taxpayer Identification Number (or I am waiting for a number to be issued to me),
(2)&nbsp;I am not subject to backup withholding because (a)&nbsp;I am exempt from backup withholding, or (b)&nbsp;I have not been notified by the Internal
Revenue Service (&#147;IRS&#148;) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c)&nbsp;the IRS
has notified me that I am no longer subject to backup withholding, and
(3)&nbsp;I am a U.S. person (including a U.S. resident alien)<B>.
Certification Instructions </B>&#150; You must cross out Item (2)&nbsp;above if you have been notified by the IRS that you are subject to backup
withholding because of under reporting interest or dividends on your tax returns. However, if after being notified by the IRS that you were
subject to backup withholding you received another notification from the IRS that you are no longer subject to backup withholding, do not
cross out Item (2). Also see &#147;Signing the Certification&#148; under &#147;Specific Instructions&#148; in the enclosed Guidelines.
<B>SIGNATURE DATE
NOTE: FAILURE TO COMPLETE AND RETURN THIS FORM MAY RESULT IN BACKUP WITHHOLDING. PLEASE REVIEW
THE ENCLOSED GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION NUMBER ON SUBSTITUTE FORM
W-9 FOR ADDITIONAL DETAILS.</B>
</TD>
</TR>
</TABLE>





<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="right" style="font-size: 10pt"><B>EXHIBIT&nbsp;H</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LETTER OF TRANSMITTAL</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>for Warrant to Purchase Common Stock of</B><BR>
<FONT style="font-variant: SMALL-CAPS"><B>&#091;Sprite&#093;, Inc. </B></FONT>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>Delivery Instructions:</I><BR>
<B>&#091; <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> &#093;</B><BR>
(the &#147;<B>Payment Agent</B>&#148;)

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>By Overnight Courier or By Hand:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>By Mail:</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Attn: &#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Attn: &#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>For Information With Respect to the Payment Agent, Contact <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (XXX)&nbsp;XXX-XXXX.</I>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>For questions regarding this Letter of Transmittal call <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> at (XX)&nbsp;XXX-XXXX.</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with the terms of that certain Agreement and Plan of Merger, dated as of
September&nbsp;18, 2007 (the &#147;<B>Merger Agreement</B>&#148;) by and among &#091;Parent&#093;, Inc, a Delaware corporation
(&#147;<B>Parent</B>&#148;), Esmeralde Acquisition, Inc., a Delaware corporation (&#147;<B>Merger Sub</B>&#148;), &#091;Sprite&#093;, Inc., a
Delaware corporation (the &#147;<B>Company</B>&#148;), and Andrew Einhorn, solely in his capacity as the Escrow
Participants&#146; Representative (as defined in the Merger Agreement), Merger Sub will be merged with
and into the Company (the merger of Merger Sub into the Company being referred to as the &#147;<B>Merger</B>&#148;).
Capitalized terms used (but not defined) in this Letter of Transmittal have the meanings given to
such terms in the Merger Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of the Merger, the Company will become a wholly-owned subsidiary of Parent and
outstanding shares of the Company&#146;s capital stock will be converted into the right to receive the
cash consideration set forth in the Merger Agreement in exchange for such shares. The amount of
cash to be paid for each share of the Company&#146;s Common Stock, par value $.0001 per share (the
&#147;<B>Common Stock</B>&#148;), Series&nbsp;A Preferred Stock, par value $.0001 per share (the &#147;<B>Series&nbsp;A</B>&#148;) and Series&nbsp;B
Preferred Stock, par value $.0001 per share (the &#147;<B>Series&nbsp;B</B>,&#148; and together with the Series&nbsp;A, the
&#147;<B>Preferred Stock</B>&#148;) is described in the Merger Agreement and the Information Statement that was
previously provided to the Company Securityholders. To the extent a Company Securityholder is an
Escrow Participant, a portion of the aggregate consideration to which such Company Stockholder is
otherwise entitled for such Company Stockholder&#146;s shares of Common Stock and/or Preferred Stock
will be withheld from such Company Stockholder and will be placed in escrow to secure certain (i)
indemnification, compensation and reimbursement obligations of the Company Stockholders and (ii)
adjustments with respect to the Company&#146;s Net Working Capital, as described in the Merger Agreement
and the Information Statement previously provided to the Company Stockholders. <B>You are encouraged
to read the Merger Agreement and the Information Statement previously provided to you very
carefully</B>. Pursuant to the terms of the Merger Agreement, the Warrant (to the extent outstanding
and unexercised as of the Effective Time) shall be, at the Effective Time, terminated and upon
termination thereof shall be converted into the right to receive, in respect of each share of
Common Stock issuable upon the automatic exercise of the Warrant in accordance with its terms, the
amount of cash set forth in the Merger Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To obtain payment of the consideration payable to you pursuant to the Merger Agreement in
exchange for the Warrant, please complete this Letter of Transmittal and forward it by mail,
overnight
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">delivery, courier or hand delivery, to &#091;&nbsp;&nbsp;&nbsp;&nbsp;&#093; (the &#147;<B>Payment Agent</B>&#148;), at the address
set forth above. You must also deliver the original Warrant with the delivery of this Letter of
Transmittal to the Paying Agent. Instructions regarding the completion of the Letter of
Transmittal are set forth on the following pages.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>DO NOT SEND THE WARRANT DIRECTLY TO<BR>
MERGER SUB OR PARENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>DELIVERY OF THIS INSTRUMENT TO AN ADDRESS OTHER THAN<BR>
AS SET FORTH ABOVE DOES NOT CONSTITUTE VALID DELIVERY.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>PLEASE READ THE ACCOMPANYING INSTRUCTIONS CAREFULLY.</B>

</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the Merger, the undersigned (or, if two or more persons have signed this
Letter of Transmittal as the registered holders of the Warrant, each of the undersigned), the
registered holder of the Warrant that will be converted into the right to receive cash
consideration upon the consummation of the Merger, or the transferee or assignee of such registered
holder, hereby surrenders the Warrant in exchange for a check or wire transfer to the account
specified by the undersigned in this Letter of Transmittal representing a portion of the merger
consideration payable pursuant to the Merger Agreement (less the applicable withholding amounts
required by law), in respect of the shares of Company Stock represented by the Warrant (the cash
consideration payable to the undersigned in connection with the Merger being referred to as the
&#147;<B>Payment</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Each Company Securityholder is required to give the Payment Agent such Company
Securityholder&#146;s taxpayer identification number (&#147;TIN&#148;). If the Payment Agent is not provided with
the correct TIN, payments that are made to such Company Securityholder or other payee will be
subject to 28% backup withholding. Enclosed in this packet is a Substitute W-9 Form which must be
completed by each Company Securityholder.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned (or, if applicable, each of the undersigned) hereby represents and warrants
that: (a)&nbsp;he, she or it (i)&nbsp;is the true and lawful owner of, and has legal and valid title to, the
Warrant free and clear of any liens, claims or encumbrances, and (ii)&nbsp;has full capacity, power and
authority to execute and deliver this Letter of Transmittal and to surrender the Warrant for
exchange as specified above; and (b)&nbsp;when the Warrant is delivered to the Surviving Corporation
neither the Surviving Corporation nor Parent will be subject to any adverse claim with respect
thereto. The undersigned (or, if applicable, each of the undersigned) (x)&nbsp;acknowledges having
received a copy of the Merger Agreement from Parent, (y)&nbsp;agrees to be bound by the merger
consideration adjustment provisions set forth in Article&nbsp;II of the Merger Agreement, and (z)
approves the appointment of and hereby appoints the Escrow Participants&#146; Representative as the
representative of the undersigned and as the attorney-in-fact and agent for and on behalf of the
undersigned with respect to the Merger Agreement, and the taking by such representative of any and
all actions (including the incurring of expenses) and the making of any decisions required or
permitted to be taken by the representative under the Merger Agreement in accordance with terms and
provisions thereof, as such relates to the Post-Closing Cash Consideration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned (or, if applicable, each of the undersigned) further agrees that: (i)&nbsp;by
tendering the Warrant he, she or it shall, upon Surviving Corporation&#146;s or Parent&#146;s request,
execute any additional documents reasonably necessary or desirable to perfect the surrender and
cancellation of the Warrant and (ii)&nbsp;by executing the Letter of Transmittal the undersigned hereby
waives any notice or other such rights set froth in the Warrant (and related documents).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The representations, warranties, covenants and agreements of the undersigned contained in this
Letter of Transmittal shall survive the delivery of the Payment to the undersigned and are in
addition to any other representations, warranties, covenants or obligations of the undersigned,
including any such representations, warranties, covenants and obligations contained in the Merger
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless the undersigned indicates otherwise under &#147;Special Payment Instructions,&#148; the Payment
will be made payable to the registered holder(s) of the Warrant. Similarly, unless otherwise
indicated herein under &#147;Special Delivery Instructions,&#148; the Payment will be mailed to the address
of the registered holder(s) set forth in the signature block of this Letter of Transmittal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned shall timely pay all transfer, documentary, sales, use, stamp, registration
and other taxes and charges arising from or relating to the transactions contemplated by the Merger
Agreement, and the undersigned shall, at his, her or its own expense, file all necessary tax
returns and other documentation with respect to all such transfer, documentary, sales, use, stamp,
registration, and other taxes and charges.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law will govern all questions concerning the relative rights
of the Company and the undersigned, as applicable, with respect to the Merger and all other
questions concerning the construction, validity and interpretation of this Letter of Transmittal.
All authority conferred pursuant to this Letter of Transmittal
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shall be binding upon the successors, assigns, heirs, executor, administrator and legal
representatives of the undersigned and shall not be affected by, and shall survive, the
dissolution, death or incapacity of the undersigned.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="78%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS"><B>Name of Warrant Holder(s): </B></FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
    <TD valign="top" align="right"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="width: 70%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS"><B>Signature(s):</B></FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
    <TD valign="top" align="right"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="width: 86%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Print name of individual whose</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">signature appears above</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(if the registered holder is an entity):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
    <TD valign="top" align="right"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="width: 67%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title of individual whose</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">signature appears above</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(if the registered holder is an entity):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
    <TD valign="top" align="right"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="width: 67%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2007</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>COMPLETE THE INFORMATION AND SIGN WHERE INDICATED BELOW</B>
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a33887a1a3388704.gif" alt="(FORM)">
</DIV>

<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>SPECIAL PAYMENT INSTRUCTIONS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SPECIAL DELIVERY INSTRUCTIONS</B>
Complete ONLY if the checks
representing the Payment are to be
issued in a name other than the
name(s) on the registered holder of
the Warrant.* Pay to: Complete ONLY if the checks
Name: representing the Payment are to be
Address: mailed to the undersigned at an
TIN**: address other than the address
*Requires signature guarantee. See&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reflected below.* Mail to:
Instruction No.&nbsp;2 to this Letter of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:
Transmittal. Address:
** Fill in Taxpayer Identification *Requires signature guarantee.
Number of Payee. See Instruction 9 to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See Instruction No.&nbsp;2 to this
this Letter of Transmittal. Letter of Transmittal.
<B>PAYMENT BY WIRE TRANSFER (to be completed only if the Payment is to be made by wire transfer):
WIRE TRANSFER INSTRUCTIONS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SPECIAL PAYMENT INSTRUCTIONS</B>
Complete ONLY if the wire transfers representing
the Payment are to be made to an account name that
differs from the name(s) of the holder of the
Warrant.* Transfer to:
Bank Name/Address:
ABA No./Swift Code:
Bank Name: Account Name:
&#151;&#151;  Account No.:
Bank Address: Reference:
ABA No./Swift Code: * Requires signature guarantee. See Instruction 2.
Account Name: ** Fill in Taxpayer Identification Number of
Account No.: Payee. See Instruction 9 to this Letter of
Reference: Transmittal on page 8.
<B>SIGN HERE</B>
(By signing, the undersigned acknowledges and agrees to the terms of the Letter of Transmittal)
(Signature(s) of Registered Holder(s) of the Warrant)
(Signature(s) of Spouse(s) of Registered Holder(s) of the Warrant)
(Must be signed by Registered Holder(s) exactly as name(s) appear on the Warrant. If you are an
individual resident of California, your spouse must sign. See Instructions No.&nbsp;1, 2 and 4 to this
Letter of Transmittal.)
Dated: &#95;&#95;&#95;, 2007
(Print or Type Area Code and Telephone Number Above) (Print or Type Taxpayer Identification or
Social Security Number Above)
If signing is by an officer on behalf of a corporation or by an attorney, executor, administrator,
trustee, guardian, agent or other person acting in a fiduciary or representative capacity, please
provide the information requested below:
(Print or Type Name(s) Above) (Print or Type Full Title(s) Above)
(Print or Type Address Above)
<B>PLEASE COMPLETE SUBSTITUTE FORM W-9 ON PAGE 9 OF THIS DOCUMENT.</B></TD>
</TR>
</TABLE>






<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INSTRUCTIONS FOR COMPLETING LETTER OF TRANSMITTAL</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1. Delivery of Letter of Transmittal. </B>The properly completed and duly executed Letter of
Transmittal and any other documents required by this Letter of Transmittal, including the original
Warrant must be received by Payment Agent for delivery to be effected and the appropriate person to
be entitled to receive the consideration set forth in the Merger Agreement. Notwithstanding any
other provisions hereof, Payment will be delivered in exchange for the Warrant only after receipt
by Payment Agent of a properly completed and duly executed Letter of Transmittal and all other
required documents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All questions as to validity, form and eligibility of the surrender of the Warrant hereunder
or delivery by the holder(s) of this Letter of Transmittal shall be determined by Payment Agent and
Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The method of delivery of the Letter of Transmittal and all other required documents,
including the Warrant, is at the election of the surrendering holder(s), but risk of loss and title
to the Warrant will pass only upon delivery of the Warrant to Payment Agent. If delivery is by
mail, registered mail with return receipt requested, properly insured, is recommended.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2. Special Payment and Delivery Instructions. </B>If the Payment is to be payable to someone
other than the registered holder(s) of the Warrant, or the Payment is to be mailed to someone other
than the person(s) signing this Letter of Transmittal, then the appropriate boxes on this Letter of
Transmittal should be completed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3. Requests for Assistance or Additional Copies</B>. Requests for assistance may be directed
to, and additional copies of this Letter of Transmittal may be
obtained from &#95;&#95;&#95; by
contacting &#95;&#95;&#95; at (XXX)&nbsp;XXX-XXXX or &#95;&#95;&#95; at (XXX)&nbsp;XXX-XXXX.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4. Substitute Form W-9; Form W-8. </B>Under federal income tax laws, each Company
Securityholder is required to provide Parent with a correct Taxpayer Identification Number (&#147;<B>TIN</B>&#148;)
on Substitute Form W-9, which is provided under &#147;Important Tax Information,&#148; and to indicate if
such Company Securityholder is not subject to backup withholding by signing and dating the
Substitute Form W-9. Failure to provide the information on the form may subject the surrendering
holder(s) to a $50 penalty imposed by the Internal Revenue Service and the Payment will be subject
to backup withholding taxes of 28%. See &#147;Important Tax Information&#148; below. <B>Please consult your
accountant or tax advisor for further guidance in completing the Substitute Form W-9. </B>A non-U.S.
Company Stockholder that certifies its non-U.S. status by completing an appropriate IRS Form W-8
will not be subject to backup withholding and will not need to complete a Form&nbsp;W-9. Non-U.S.
holders should consult their tax advisors regarding the appropriate Form W-8 (which can be obtained
from the Internal Revenue Service web site at http://www.irs.gov or by contacting the Payment
Agent) and any other forms that may be required.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Please consult your accountant or tax advisor for further guidance<BR>
in completing the Substitute Form&nbsp;W-9.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Purpose of Substitute Form&nbsp;W-9</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To prevent backup withholding on cash payments that are made to a Company Stockholder with
respect to Surrendered Securities surrendered for payment, the Company Stockholder is required to
notify Payment Agent of his or her current TIN by completing the form below certifying that such
holder is a U.S. person (including a U.S. resident alien), that the TIN provided on Substitute Form
W-9 is correct (or that such holder is awaiting a TIN) and that (i)&nbsp;such Company Stockholder is
exempt from backup withholding, (ii)&nbsp;such Company Stockholder has not been notified by the Internal
Revenue Service that he or she is subject to backup withholding as a result of failure to report
all interest or dividends or (iii)&nbsp;the Internal Revenue Service has notified such Company
Stockholder that he or she is no longer subject to backup withholding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>What Number to Give</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Company Stockholder is required to give Parent the social security number or employer
identification number of the record holder(s) of the Surrendered Securities. If a Surrendered
Certificate is in more than one name or is not in the name of the actual holder, consult the
enclosed Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9 for
guidance on which number to report.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>IRS Circular 230 Disclosure</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. tax
advice contained in this communication (including any attachments) is not intended or written to be
used, and cannot be used, for the purpose of (i)&nbsp;avoiding penalties under the Internal Revenue
Code, or (ii)&nbsp;promoting, marketing or recommending to another party any matters addressed herein.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a33887a1a3388705.gif" alt="(FORM)">
</DIV>

<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF"><B>Substitute Form W-9 Request for Taxpayer Identification Number and Certification
PAYER&#146;S NAME: ALLERGAN, INC.</B>
Name as shown on account (if joint, list first and circle name of the person or entity whose number you enter below)
Name:
Address:
City, State, and Zip Code:
<B>TAXPAYER IDENTIFICATION NO. FOR ALL
ACCOUNTS</B>
Enter your taxpayer identification number
in the appropriate box.
For most individuals this is your social
<B>SUBSTITUTE </B>security number. If you do not have a
<B>Form&nbsp;W-9 </B>number, see the enclosed Guidelines.
<B>Department of the Treasury&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note</B>: If the account is in more than one <B>Social Security Number
Internal Revenue Service </B>name, see the chart in the enclosed <B>&#95;&#95;&#95;
Payer&#146;s Request for </B>Guidelines on which number to give the <B>Employer Identification Number
Taxpayer Identification Number (TIN) </B>payer. <B>&#95;&#95;&#95;
Certification </B>&#150; Under penalties of perjury, I certify that:
(1)&nbsp;the number shown on this form is my correct Taxpayer Identification Number (or I am waiting for a number to be issued to me),
(2)&nbsp;I am not subject to backup withholding because (a)&nbsp;I am exempt from backup withholding, or (b)&nbsp;I have not been notified by the Internal
Revenue Service (&#147;IRS&#148;) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c)&nbsp;the IRS
has notified me that I am no longer subject to backup withholding, and
(3)&nbsp;I am a U.S. person (including a U.S. resident alien)<B>.
Certification Instructions </B>&#150; You must cross out Item (2)&nbsp;above if you have been notified by the IRS that you are subject to backup
withholding because of under reporting interest or dividends on your tax returns. However, if after being notified by the IRS that you were
subject to backup withholding you received another notification from the IRS that you are no longer subject to backup withholding, do not
cross out Item (2). Also see &#147;Signing the Certification&#148; under &#147;Specific Instructions&#148; in the enclosed Guidelines.
<B>SIGNATURE DATE
NOTE: FAILURE TO COMPLETE AND RETURN THIS FORM MAY RESULT IN BACKUP WITHHOLDING. PLEASE REVIEW
THE ENCLOSED GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION NUMBER ON SUBSTITUTE FORM
W-9 FOR ADDITIONAL DETAILS.</B></TD>
</TR>
</TABLE>






<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
